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With the introduction of the immune checkpoint inhibitors (ICIs), a novel category of 
cancer therapy was created that leads to a cytotoxic immune response against cancer 
cells. While cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors have been 
introduced in 2011 for the treatment of patients with metastatic melanoma1, inhibitors 
targeting the programmed cell death protein 1 (PD-1) receptor or its ligand (PD-L1) are 
now standard of care for many types of cancer. Durable tumor responses after treatment 
with ICIs have been observed in metastatic melanoma2, renal cell cancer (RCC)3 as well 
as in non-small cell lung cancer (NSCLC)4,5. In this Introduction, an overview is given of 
the available evidence in regard to pharmacokinetics (PK) and predictive markers at the 
start of this thesis, being March 2017,  and which is updated in the Summary and Future 
Perspectives (Chapter 17).
Essentially, the clinical implementation of ICIs has differed from strategies traditionally 
used for cytotoxic drugs in oncology. ICIs are well-tolerated with a high maximum tolerated 
dose (MTD), whereas chemotherapeutic agents generally have a small therapeutic 
range and a low MTD. Dose-limiting toxicities are rarely reported. Only one of the main 
phase 1 trials of ICI monotherapy across several tumor types has identified dose-limiting 
toxicities6, as reviewed by Postel-Vinay7. Moreover, a profound dose-response relationship 
has been lacking for ICIs in advanced-stage melanoma or NSCLC (Table 1). Previously, a 
dose-response relationship has not been observed in larger patient cohorts8,9, with the 
exception of a phase I trial for ipilimumab (0.3 – 10 mg/kg)10. Here, only a small subset 
of all included metastatic melanoma patients (5%) displayed therapy response, and may 
consequently be explained by a lack of power. Based on the available trial data, there is a 
consensus that the serum trough levels achieved with the recommended dosage is well-
tolerated and much higher than the required serum concentrations. 
Although no efficacy of very low dosing schemes can be expected, a dose-response 
relationship is lacking in present ICI dosing schemes11, paving the way for dose optimization. 
In this context, population PK modeling may support rational dosing across tumor types. 
Population PK modeling is used to describe the time course of drug exposure in patients 
and investigates the sources of its variability, which is of particular interest in the real-
world setting. Real-world patients, being treated as standard of care, are not identical to 
trial patients who are subjected to strict inclusion and exclusion criteria. Therefore, we 
believe that investigation of the source of variability of PK is particularly informative in a 
real-world setting where physicians are often challenged by patients with a higher age, 
comorbidities, advanced progression, worse clinical performance or brain metastases.
PK modeling aims to integrate data, knowledge and biological mechanisms to guide 
rational decisions regarding drug dosing.12 
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Table 1. Therapeutic response in different dose levels of PD-1 or CTLA-4 inhibitors
ICI 
monotherapy
Indication Dose ORR (%) Reference
CTLA-4 MM
Ipilimumab Pretreated MM 0.3 mg/kg Q3W 0 Wolchok et al., Lancet Oncol 
201010
3 mg/kg Q3W 4.2
10 mg/kg Q3W 11.1





2 mg/kg Q3W 26 Robert et al., Lancet 201413
10 mg/kg Q3W 26
Pembrolizumab Pretreated MM 10 mg/kg Q2W 33.7 Robert et al., N Engl J Med 
20158
10 mg/kg Q3W 32.9
Nivolumab Pretreated MM 0.1 mg/kg Q2W 35.3 Topalian et al., J Clin Oncol 
201414
0.3 mg/kg Q2W 27.8
1 mg/kg Q2W 31.4
3 mg/kg Q2W 41.2
10 mg/kg Q2W 20
Nivolumab Previously 
untreated MM
2 mg/kg Q3W 40 Robert et al., N Engl J Med 
20152
PD-1 NSCLC
Pembrolizumab Pretreated stage 
IV NSCLC
2 mg/kg Q3W 18 Herbst et al., Lancet 201615
10 mg/kg Q3W 18.5






Topalian et al., N Engl J Med 
201216
10 mg/kg Q2W 18
 
Summary of the objective response rate (ORR) in different dose levels for CTLA-4 and PD-1 inhibitors 
derived from phase I/II/III trials in metastatic melanoma (MM) and non-small cell lung cancer (NSCLC). 
ORR was based on best overall response (CR or PR defining radiological response) using RECIST v1.117. 
Selection of patients is essential as ICIs come with high costs, relatively low response rates 
and high rates of immune-related adverse events (irAEs). Up to the beginning of this thesis, 
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efforts to predict response (Box 1) have yielded various markers for NSCLC and melanoma, 
including peripheral blood cells, soluble blood-based molecules, characteristics of the 
tumor genome or microenvironment (TME) and commensal microbiome (Table 2). 
Box 1 Understanding biomarkers Generally, misunderstanding occurs for the terms 
prognostic, predictive and (early) monitoring biomarkers in this immune-oncology 
setting. To clarify, an example about the difference between prognostic and predictive 
biomarkers is shown in the figure. Additional categories of biomarkers (e.g. susceptibility, 
diagnostic or safety biomarkers) are out of the scope of this thesis.
Figure Box 1. A) example of a biomarker that is prognostic. Assume that patients have received 
either immune checkpoint inhibition (ICI) or chemotherapy (chemo). The survival outcomes of 
both groups are similar, illustrating prognostic value. In contrast, B) illustrates a negative predictive 
biomarker reflected in worse survival in patients who received ICI and who are positive for the 
biomarker. Figure adapted from the BEST (Biomarkers, EndpointS, and other Tools) Resource18.
Prognostic biomarkers are generally used to identify the likelihood of a clinical event 
(death, progressive disease) in a patient population, while predictive or early biomarkers 
are utilized to predict clinical outcome after treatment or are monitored during treatment 
to evaluate the efficacy.
Biologically, the binding of PD-L1 to the inhibitory immune checkpoint PD-1 aids cancer 
cells to evade the host immune system. PD-L1 expression in cancer tissue has emerged in 
2010 as a predictive biomarker to select patients who are more likely to have an objective 
response to PD-1 inhibitors19. PD-L1 negative tumors have shown a lower probability 
of therapy response and higher PD-L1 expression has been correlated with improved 
efficacy16. Hence, some clinical trials used PD-L1 positivity as an inclusion criteria. This 
has led to approval of a PD-1 inhibitor for NSCLC patients whose tumors are positive for 
PD-L120. Nonetheless, PD-L1 expression in tumor as a predictive biomarker has many 
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drawbacks. PD-L1 expression in tumor have proven to be variable among different assays21 
or cutoffs, inter-tumoral22 or intra-tumor heterogeneity23, and variability after exposure to 
prior therapies24. Therefore, PD-L1 expression in tumor tissue is considered unreliable to 
properly guide treatment decisions.
Up to March 2017, a number of blood parameters have been associated with clinical 
outcome after ICI therapy. For instance, myeloid-derived suppressor cells (MDSCs), 
discriminated from other immune cells of the myeloid lineage by immunosuppressive 
activity, were consistently negatively correlated with clinical outcome25-28. Moreover, the 
absolute numbers of peripheral monocytes have been related to resistance to CTLA-4 
inhibitors25, and peripheral eosinophils were predominantly associated with response to 
PD-1 inhibition in metastatic melanoma29. 
Serum lactate dehydrogenase (LDH) has been proposed as a negative predictor for ICIs 
in metastatic melanoma29-32. However, LDH is generally recognized a negative prognostic 
factor of metastatic melanoma33, and no differences in ICI efficacy have been observed 
in a subgroup analysis between patients with normal and elevated LDH34, supporting 
prognostic value for LDH. In the same way, preliminary data from a proteomic study 
have indicated that serum of PD-1 resistant patients is characterized by acute phase, 
complement and wound healing molecules35, but failed to distinguish a predictive rather 
than a prognostic biomarker. 
The potential impact of the microbiome was demonstrated by early findings that the 
antitumor effects of CTLA-4 inhibition relies on distinct gut bacteria, and may be overcome 
by fecal microbial transplantation in mice36.
Essentially, higher rates of proliferating cytotoxic T cells recognizing tumor antigens have 
been detected in blood from patients with clinical benefit after ICIs in patients with NSCLC 
and melanoma37, as well as its density in the TME38-40. Recognition of tumor antigens by 
tumor-infiltrating lymphocytes (TILs) is proposed to be a prerequisite for the efficacy of ICI, 
when presented at the tumor cell surface in the context of classical HLA. Firstly, preliminary 
data has indicated a relation of T cell receptor (TCR) diversity in blood with response to 
CTLA-4 inhibitors41. A more diverse TCR repertoire was related to clinical benefit, suggesting 
that in those patients an antitumor T cell population is present that can proliferate and 
recognize tumor antigens. Secondly, the tumor mutation burden (TMB) was strongly 
associated with improved clinical outcome after ICIs in advanced-stage NSCLC37,42,43 and 
melanoma44,45. TMB is a measurement of the frequency of mutations in tumor cells, and 
relates to the number of tumor antigens that can be recognized by cytotoxic T cells37,46. 
Consistently, thirdly, solid tumors with defects in DNA damage repair (DDR) genes are 
more likely to benefit from ICIs47. This may be illustrated by the observations that defects 
of the mismatch repair (MMR) machinery lead to hypermutation48 and associate to higher 
density of TILs in the TME49. Fourthly, mutations related to attenuated presentation of 
tumor antigens at the cell surface (e.g. B2M mutation or HLA homozygosity) have been 
related with resistance mechanisms of ICIs50,51. Although other genes have also been 
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suggested to impact response and resistance to ICIs (e.g. mutations in STK11, BRAF, EGFR, 
NF1 or JAK1/2)51-54, their predictive value remains uncertain. Lastly, an interferon-γ gene 
signature was associated with improved clinical outcome after PD-L1 inhibition (and not 
for the chemotherapy arm of this trial)55. Taken together, the above five lines of evidence 
emphasize the key role for cytotoxic functions of lymphocytes in ICI therapy.
Table 2. Literature overview (up to March 2017) of proposed biomarkers for immune 
checkpoint inhibitors
Agent Tumor Marker Association Reference
Peripheral blood cells
CTLA-4 inhibitors MM MDSCs Negative Meyer et al., Cancer Immunol 
Immunother 201426
CTLA-4 inhibitors MM MDSCs Negative Kitano et al., Cancer Immunol Res 
201427
CTLA-4 inhibitors MM MDSCs Negative Gebhardt et al., Clin Cancer Res 
201528




Postow et al., J Immunother Cancer 
201541




Martens et al., Clin Cancer Res 
201625
PD-1 inhibitors MM AEC Positive Weide et al., Clin Cancer Res 201629
PD-1 inhibitors MM Th9 cells Positive Nonomura et al., Oncoimmunology 
201656
Blood-based molecules
CTLA-4 inhibitors MM LDH Negative Kelderman et al., Cancer Immunol 
Immunother 201432
PD-1 inhibitors MM LDH Negative Diem et al., Br J Cancer 201631
PD-1 inhibitors MM LDH Negative Weide et al., Clin Cancer Res 201629
PD-1 inhibitors MM LDH Negative Ribas et al., JAMA 201630
PD-1 inhibitors MM Serum signaturea Positive Weber et al., Cancer Immunol Res 
201635
PD-1 inhibitors MM TGF-β Positive Nonomura et al., Oncoimmunology 
201656
Tumor genome
CTLA-4 inhibitors MM TMBb Positive Van Rooij et al., J Clin Oncol 201357
PD-1 inhibitors NSCLC TMB Positive Rizvi et al., Science 201542





Johnson et al., Cancer Immunol Res 
201552
CTLA-4 inhibitors MM BRAF mutation Uncertain Mangana et al., PLos One 201558
PD-1 inhibitors Solid 
tumors
MMR deficiency Positive Le et al., N Engl J Med 201547
PD-1 inhibitors NSCLC TMB Positive Campesato et al. Oncotarget 201643
PD-1 inhibitors NSCLC TMBc Positive McGranahan et al. Science 201637
NSCLC EGFR mutation Negative Peng et al., Cancer Discov 201654
16   |   Chapter 1
PD-1 inhibitors MM TMB Positive Hugo et al., Cell 201644
PD-1 inhibitors MM/
NSCLC
TMB Positive Roszik et al., BMC Med 201645
PD-(L)1 inhibitors MM HLA 
homozygosity
Negative Inoue et al., OncoImmunology 
201650




Zaretsky et al., N Engl J Med 201651
Tumor microenvironment
PD-1 inhibitors MM IHC signatured Positive Tumeh et al., Nature 201459
PD-L1 inhibitors NSCLC PD-L1 
expression





Positive Larkin et al., N Engl J Med 201561
PD-1 inhibitors NSCLC PD-L1 
expression







Chen et al., Cancer Discov 201662
PD-L1 inhibitors NSCLC PD-L1 
expression
Positive Fehrenbacher et al., Lancet 201655
PD-1 inhibitors NSCLC PD-L1 
expression
Positive Herbst et al., Lancet 201663
PD-1 inhibitors NSCLC PD-L1 
expression
Positive Reck et al., N Engl J Med 201664
PD-1 inhibitors NSCLC PD-L1 
expression
Positive Roach et al., Appl IHC Mol Morphol 
201665




CD8+ T cellsg Positive McGranahan et al., Science 201637
PD-L1 inhibitors NSCLC IFN-γ signatureh Positive Fehrenbacher et al., Lancet 201655
Commensal microbiotica
CTLA-4 inhibitors MM Bacteroides 
species 
Uncertain Vetizou et al., Science 201536
Literature overview of markers that correlate with clinical outcome after immune checkpoint 
inhibitors for metastatic melanoma (MM) or non-small cell lung cancer (NSCLC). Data cutoff was 
set at March 2017, at the start of this thesis. An update is provided in the discussion and future 
perspectives of this thesis, including an extended overview of biomarkers after March 2017. 
Abbreviations: tumor mutation burden (TMB), absolute monocyte count (AMC), myeloid-derived 
suppressor cell (MDSC), absolute eosinophil count (AEC), lactate dehydrogenase (LDH), T cell 
receptor (TCR), not applicable (NA), immunohistochemistry (IHC). aSerum protein profile consisting 
of molecules involved in wound healing, acute phase reactants and complement system.  bTMB and 
neo-antigen-specific T cell reactivity. cTMB and clonal neo-antigens. dHigher numbers of CD8, PD1, 
and PD-L1 expressing cells and clonal TCR repertoire in tumor. Early on-treatment tumor biopsies 
revealed a distinct IHC signature consisting of eCD8 for CTLA-4 and of fCD4, CD8, CD3, PD-1, PD-
L1, LAG3, FOXP3 and granzyme B for PD-1 inhibition. gProliferating CD8+ T cells. hInterferon-γ gene 
signature defined by expression of CD8A, GZMA, GZMB, IFNG, EOMES, CXCL9, CXCL10, and TBX21.
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This thesis is divided in five parts. Part I describes the pharmacology of ICIs, where we 
studied the relationship between pharmacokinetic parameters (such as drug exposure, 
drug clearance) and efficacy. We developed a PK model in a real-world cohort to assess 
the impact of patient factors on the pharmacokinetics of nivolumab and pembrolizumab. 
Part II and III involve treatment selection of immunotherapy of predominantly NSCLC 
and melanoma, among other tumor types. Part IV provides a summary of all findings and 
the future perspectives of the pharmacology and treatment selection of ICIs, including an 
updated literature overview. Part V contains the appendix.
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Introduction: Nivolumab treatment is subject to large interpatient variability 
in both efficacy and toxicity, which may partly be explained by differences in 
nivolumab exposure. Exposure-response relationships in regular healthcare have 
not been extensively investigated for nivolumab. Therefore, we aimed to identify 
possible exposure-response relationships in nivolumab treated non-small cell lung 
cancer (NSCLC) patients.
Materials and Methods: NSCLC patients who started 2nd line nivolumab therapy 
(3 mg/kg Q2W) between May 5th 2016 and August 1st 2017, and from whom serial 
blood samples, toxicity data, and outcome data were prospectively collected, were 
included. Follow-up was carried out until November 1st 2017. Patients were classified 
according to best objective response (BOR) based on RECIST v1.1, and toxicities 
according to CTCAE. Nivolumab trough concentrations were measured after 2, 4, 
and 10 weeks of treatment, excluding dose delays, and calculated geometric means 
were tested versus BOR or toxicity using ANOVA and an independent samples t-test, 
respectively. Overall survival (OS) and progression free survival were compared 
between high and low trough concentration groups.
Results: Seventy-six patients were evaluable for analyses. Responders (n=15) had 
higher mean trough concentrations than patients with progression (n=33): 47% 
higher after 2 weeks (p=0.001), 53% higher after 4 weeks (p=0.008), and 73% higher 
after 10 weeks (p=0.002). Higher trough concentrations were associated with longer 
OS (p=0.001).
Discussion: This study shows that NSCLC patients with a response to nivolumab had 
a higher nivolumab exposure than patients with progression, indicating a potential 
exposure-response relationship. Further clinical research should focus on clarifying 
these exposure-response relationships.
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INTRODUCTION
Nivolumab is a human immunoglobin G4 monoclonal antibody directed against 
programmed death 1 (PD-1) protein, reinvigorating intratumoral T-cells, which often have 
become inactivated in a T-cell co-stimulation-deprived micro-environment.{Nishimura, 
1999 #1}1 Nivolumab is currently approved for the treatment of various solid and 
hematological malignancies. 
PD-1 receptor occupancy on circulating CD3+ T cells in nivolumab treated melanoma 
patients has been demonstrated to be saturated at doses above 0.3 mg/kg, as patients 
receiving higher doses did not achieve a higher PD-1 receptor occupancy. However, 
response rates in these patients were higher in doses > 0.3 mg/kg,2,3 indicating the 
presence of unexplored mechanisms which determine response to nivolumab treatment. 
Comparable results are reported for nivolumab treated NSCLC patients: response rates 
in patients dosed at 3 mg/kg Q2W were higher than those dosed at 1 mg/kg Q2W (24% 
versus 3%). However, no increase in response rates was observed in patients receiving 10 
mg/kg Q2W compared to 3 mg/kg Q2W.2,3 Moreover, the occurrence of serious adverse 
events did not increase in patients who received nivolumab doses of 1.0 mg/kg or 
higher.3 Therefore, the dose of 3 mg/kg Q2W was used in consecutive phase 3 trials.4,5 As 
a consequence, subtle exposure-response relationships in NSCLC patients receiving the 
nivolumab dose of 3 mg/kg may have been overlooked. 
So far, exposure-response relationships in nivolumab treated patients have not been 
reported,6 whereas various other monoclonal antibodies used for the treatment of solid 
tumors and hematologic malignancies have shown exposure-response relationships.7-11 
For example, breast cancer patients treated with trastuzumab with an exposure in the 
lowest quartile after cycle 1, had 8 months shorter median overall survival than patients 
in other quartiles, without a difference in the occurrence of toxicities. Colorectal cancer 
patients with a below median cetuximab exposure, experienced significantly shorter 
median progression free survival (PFS) than other patients (3.3 versus 7.8 months). 
Furthermore, in patients with advanced melanoma, ipilimumab 10 mg/kg resulted in 
significantly longer median overall survival (OS) than ipilimumab 3 mg/kg (15.7 versus 
11.5 months).12 For the first time, we studied exposure-response relationships in standard 
of care nivolumab treated NSCLC patients, treated with a dosing regimen of 3 mg/kg Q2W.
MATERIALS AND METHODS
Design
Stage IV NSCLC patients who started nivolumab treatment between May 5th 2016 and 
August 1st 2017 at the Erasmus MC Cancer Institute, were included prospectively in this 
study (Dutch Trial Registry number NTR7015), allowing for serial sampling during standard 
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of care nivolumab treatment. Data cut-off was at November 1st 2017. Blood was drawn 
prior to every 2-weekly nivolumab infusion to measure nivolumab trough concentrations 
(i.e. concentration immediately prior to following infusion). Patient characteristics and 
clinical data were included from the hospital’s electronic patient record system. Best overall 
response (BOR) was assessed according to RECIST v1.1 with a minimal follow-up time of 
90 days.13 If treatment was discontinued before 90 days due to rapid progression or death, 
BOR was classified as progressive disease (PD). A minimum duration of 90 days for stable 
disease (SD) was necessary. Confirmation of partial response (PR) or complete response 
was not required for best response determination. In patients treated beyond radiologic 
progression, subsequent response assessments accounted for BOR. Adverse events were 
registered from start of treatment until end of follow-up according to National Cancer 
Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v4.03. 
Nivolumab serum measurements
Four mL of serum was obtained before every nivolumab infusion, of which 5 µL was used to 
measure nivolumab serum concentrations. All nivolumab concentrations were measured 
with an in-house developed and validated ELISA.14 Measurements were performed as 
follows: 96-well EIA/RIA microtiter plates (Corning, NY, USA) were coated overnight at 4° 
C with 100 µL/well of 0.1 µg/mL capture antigen (recombinant human PD-1 Fc chimera, 
R&D, Minneapolis, MN, USA), diluted in PBS (BioWhittaker Inc, Walkersville, MD, USA), pH 
7.4. The plates were washed three times in washing buffer (0.05% Tween 20 in PBS, pH 7.4) 
and incubated for 1 hour at room temperature (RT) with 300 µL/well blocking solution (1% 
BSA/0.05% Tween20 in PBS, pH 7.4). After three washes, nivolumab calibration standards, 
ranging from 25 to 0.20 ng/mL and serum samples, 1:4000 diluted in blocking solution 
were added in duplicate to the wells and subsequently, the plates were incubated for 2 
hours at RT on a shaker set at 300 rpm. After three additional washes, 100 µl/well of 0.2 µg/
mL detection antibody (Human IgG4-HRP, BioRad, Hercules, CA, USA), diluted in blocking 
solution, was added to the plates, followed by incubation for 2 hours at RT on a shaker. 
Subsequently, plates were washed three times and 100 µl/well tetramethylbenzidine 
peroxidase substrate was added. Plates were incubated for 15 minutes in the dark and 
the reaction was stopped with 2 M H2SO4. Results were read using VersaMax Tunable 
microplate reader (Molecular Devices) at an optical density of 450 nm, corrected at 
wavelength of 570 nm. Results were calculated by averaging all duplicate readings and 
using a standard curve, generated by a 5 parameter logistic curve-fit.    
Statistics and data analysis
Patients were divided according to BOR in PD, SD and PR, and according to toxicity 
(occurrence of grade ≥3 or grade ≤2 adverse events). Trough concentrations were compared 
on the log-scale at week 2, 4, and 10 between BOR groups with ANOVA and between toxicity 
groups with an independent samples t-test. Patients with dose-delays until time point of 
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analysis were excluded for that particular --and following-- time points. If significant, a post 
hoc analysis with Tukey HSD test was performed between BOR groups. The assumption of 
equal variances in log transformed trough concentrations between groups was assessed 
with Levene’s test. A Log Rank test was performed to assess potential differences in OS and 
PFS between the groups with 50% lowest trough concentrations (low exposure) and 50% 
highest trough concentrations (high exposure). Patients dying without progression were 
censored. Data collection and statistical analysis were performed using R v3.3.1 and IBM 
SPSS Statistics v24 (Chicago, IL). A two-sided p value <0.05 was considered significant. 
Table 1. Patient characteristics







Male 46 (61%) 21 (64%) 6 (40%)
Female 30 (40%) 12 (36%) 9 (60%)
Age at start (years)
Mean (±SD) 63 (±8.9) 60 (±9.7) 65 (±6.6)
WHO performance status
0 17 (22%) 5 (15%) 3 (20%)
1 39 (51%) 20 (61%) 10 (67%)
2 1 (1%) 1 (3%) 0 (0%)
Unknown 19 (25%) 7 (21%) 2 (13%)
Primary lung tumor
Adenocarcinoma 50 (66%) 22 (67%) 12 (80%)
Squamous cell carcinoma 23 (30%) 10 (30%) 2 (13%)
Large cell carcinoma 3 (4%) 1 (3%) 1 (7%)
Number of pre-treatment linesa
1 60 (79%) 23 (70%) 14 (93%)
2 14 (18%) 10 (30%) 0 (0%)
3 2 (3%) 0 (0%) 1 (7%)
aAll patients with pre-treatment received a platinum containing regimen.
 
RESULTS
Out of 84 patients, 76 were evaluable (see table 1), since 4 patients were non-evaluable 
according to RECIST and 4 patients had no follow-up blood samples available as their 
treatment was discontinued after the first cycle (3 patients because of rapid clinical 
deterioration and 1 patient because of grade 3 skin toxicity). According to BOR, 33, 28, and 
15 patients had PD, SD and PR, respectively. Grade ≥3 toxicities occurred in 15 patients. 
Median follow-up time was 246 days (IQR 127–379 days).
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Figure 1. Median nivolumab trough concentrations 
Nivolumab trough concentrations for each response category, measured prior to every nivolumab 
infusion and 2 weeks after a previous infusion. Lines represent median values for PR (green), SD 
(blue), and PD (red), respectively. Shaded area represents interquartile ranges for partial responders 
(green) and patients with progressive disease (red).
 
The courses of median nivolumab trough concentrations per response group until 20 
weeks after treatment start are shown in figure 1. Comparisons of median trough levels 
and the number of evaluable patients per response group at week 2, 4, and 10 are shown 
in figure 2. In figure 3a and 3b Kaplan-Meier curves are shown for OS and PFS per group 
of trough concentration, whereas median trough concentrations and the number of 
evaluable patients per toxicity group are shown in figure 4. For each time point, geometric 
mean trough concentrations were significantly different between response groups: at 
week 2: p=0.001; at week 4: p=0.01; at week 10: p=0.002. Post hoc comparisons showed 
that at week 2, PR patients (27.4 µg/mL, 95%CI: 22.3-33.6 µg/mL) had 47% (95%CI: 34-
61%) higher geometric mean trough concentrations than PD patients (18.7 µg/mL, 95%CI: 
16.7-20.9 µg/mL; p=0.001), and 30% (95%CI: 20-42%) higher trough concentrations than 
SD patients (21.0 µg/mL, 95%CI: 18.6-23.7 µg/mL; p=0.034). At week 4, PR patients (46.2 
µg/mL, 95%CI: 37.4-57.0 µg/mL) had 53% (95%CI: 50-57%) higher trough concentrations 
than PD patients (30.2 µg/mL, 95%CI: 25.0-36.4 µg/mL; p=0.008), and 40% (95%CI: 32-
48%) higher trough concentrations than SD patients (33.0 µg/mL, 95%CI: 28.3-38.5 µg/
mL; p=0.047). At week 10, PR patients (79.4 µg/mL, 95%CI: 60.7-103.8 
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Figure 2. Nivolumab trough concentrations per time point according to BOR
Nivolumab trough concentrations per response category per time point. Red, blue, and green boxes 
represent the median and interquartile ranges for the PD, SD, and PR groups, respectively. Whiskers 
show 5 - 95% percentile. *Indicates significant difference (p<0.05); aOne missing sample. 
Figure 3. OS and PFS versus nivolumab trough concentrations
Kaplan-Meier curve for overall survival (a) and progression free survival (b) stratified for the groups 
with 50% lowest trough concentrations (Q1Q2) and 50% highest trough concentrations (Q3Q4).
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Figure 4. Nivolumab trough concentrations per time point according to toxicity
Nivolumab trough concentrations per toxicity category per time point. Green and red boxes 
represent the median and interquartile ranges for the grade ≤2 toxicity and grade ≥3 toxicity 
groups, respectively. Whiskers show 5 - 95% percentile.
µg/mL) had 73% (95%CI: 71-76%) higher trough concentrations than PD patients (45.8 
µg/mL, 95%CI: 35.6-58.9 µg/mL; p=0.002), whereas trough concentrations in SD patients 
were 36% (95%CI: 21-54%) higher than in PD patients (62.5 µg/mL, 95%CI: 54.9-71.3 µg/
mL; p=0.048). The high exposure group experienced significant longer OS (median: not 
reached versus 306 days; p=0.001), whereas no significant difference was found for PFS 
(median: 189 versus 77 days; p=0.061). 
No difference in exposure was found when comparing patients with and without grade 
≥3 toxicity during all time points: 4% (95%CI: 3–5%) difference at week 2 (p=0.732), 21% 
(95%CI: 20–23%) difference at week 4 (p=0.216, and 20% (95%CI: 12–32%) difference at 
week 10 (p=0.413). Assumption of equal variances between BOR groups and between 
toxicity groups was met at each investigated time point.
Only after 4 weeks of treatment, a difference in exposure between males and females was 
found (30.4 µg/mL versus 41.3 µg/mL; p=0.005).
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DISCUSSION
In this study, we aimed to assess the relationship between nivolumab exposure and 
clinical outcome in NSCLC patients. We demonstrated for the first time that patients, 
treated with an equivalent dose per kg and with an objective radiographical response 
to nivolumab therapy, have a significantly higher exposure than non-responders at all 
the time points measured (i.e. after 2, 4, and 10 weeks of treatment). The high exposure 
group experienced longer OS, whereas no difference was found for PFS. No association 
was found between the occurrence of grade ≥3 adverse events and drug exposure, which 
is in line with earlier phase I studies, where no maximum tolerated dose could be defined 
for nivolumab in the dose range of 0.3 to 10 mg/kg.15 
These observations might reflect a true exposure-response relationship for nivolumab. 
On the other hand, a target concentration of 10 µg/mL was sufficient in an ex vivo model 
for reaching >90% of the maximum achievable receptor occupancy,16 which is already 
reached after the first cycle in all treatment groups. Furthermore, it has recently been 
suggested that the exposure-response relationship for immune checkpoint inhibitors is 
confounded by the catabolic state due to cancer cachexia, which would lead to lower 
nivolumab concentrations due to accelerated IgG breakdown and would shorten survival.17 
In that study, however, the exposure-response relationship could not be explained by 
cachexia alone and other factors than only peripheral PD-1 receptor occupancy are likely 
involved in a response to treatment too, as has been suggested earlier.2 Moreover, our 
primary endpoint (i.e. best objective response) is less likely to be affected by cachexia 
than overall survival is. Currently available evidence is therefore not sufficient to rule out 
an exposure-dependent anti-cancer effect of nivolumab and it remains vital to further 
elucidate the relationship between exposure and response. Additionally, an increasing 
response rate until a nivolumab dose of 3.0 mg/kg Q2W in NSCLC patients2,3 supports a 
possible exposure-response relationship in patient groups receiving 3.0 mg/kg Q2W.  
If exposure appears to determine response (at least partially), we hypothesize that PD 
and SD patients would have had a better response if they had reached higher systemic 
exposure at an earlier moment, since nivolumab trough concentrations are higher in PR 
patients in an early phase of treatment. To achieve this a loading dose could be considered, 
e.g. by doubling the first dose of nivolumab. The long terminal half-life of the nivolumab 
IgG antibody, leading to a long time until steady-state is reached, supports such a loading 
dose, which is applied for many other therapeutic IgG antibodies too.18 Many factors have 
been demonstrated or are thought to influence the pharmacokinetics of monoclonal 
antibodies. Along with cachexia, the influence of other parameters on monoclonal 
antibody exposure needs to be quantified, body weight has been correlated with the 
clearance of monoclonal antibodies.19 And clearance itself is associated with overall 
survival in pembrolizumab treated patients.17 Also, it is thought that endothelial wall 
inflammation may influence the distribution of monoclonal antibodies.20 Furthermore, 
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(epi)genetic variation in the neonatal Fc-receptor (FcRn) may influence pharmacokinetics 
of certain antibodies.21 Target-mediated clearance and thus PD-1 expression may affect 
exposure too.22,23 Furthermore, the formation of antidrug antibodies (ADA) influences 
pharmacokinetics of administered antibodies.21 Although a negligible effect was seen 
on efficacy, and no effect was seen on clearance, 12.7% of nivolumab treated patients 
experience ADA formation.24
In our analysis, the high exposure group experienced longer OS, whereas no difference was 
found for PFS. This may indicate that trough concentrations are affected by mechanisms 
influencing OS, but less PFS, such as cachexia. However, subsequent treatment lines after 
nivolumab may also influence OS, whereas PFS is not affected.
Male patients experienced lower exposure only after 4 weeks of treatment, this is in line 
with earlier findings, reporting higher clearance in males.17,25
Serial sampling of blood allowed us to include time points prior to a radiologic assessment, 
and therefore to study a high number of patients treated with an equivalent dose per 
kg. The prospective character of this study, the inclusion of a uniform cohort treated 
with a similar nivolumab dosage, the distribution of the response groups comparable to 
earlier reported trials and intensive sampling prior nivolumab administration provide a 
solid background for interpretation of results. Intensive measurements of Ctrough levels are 
--to our opinion-- excellent means to study exposure response relationship because it is 
relatively convenient for patients and it is the most informative pharmacokinetic sample 
to quantify exposure in a single pharmacokinetic sample strategy. Moreover, minimum 
and median follow-up time (3 and 8.1 months, respectively) well exceeded median time 
to response (2.1-2.2 months)4,5 and toxicity, that generally occurs within 3 months.26 
Therefore, only few data on the clinical endpoints is lacking in this analysis. In a real world 
setting, physicians occasionally decide for treatment beyond progression, two patients 
had ‘pseudo-progression’. Both patients eventually achieved PR during nivolumab therapy, 
and were therefore classified accordingly. Regarding the PK data, one should notice that 
patients with serious adverse events or progressive disease were excluded from analysis 
at week 4 and 10 relatively more frequent because of interruption or discontinuation 
of treatment, respectively, which may lead to a higher decrease of included patients at 
later time points in those subgroups. Some caution when interpreting the data should 
be taken, since potential factors associated with treatment outcome, such as tumor load, 
the occurrence of pre-existent cachexia or clearance17, and their influence on exposure, 
are not included in this analysis. Also, the included number of patients in this analysis is 
relatively low. We did not perform a multivariable analysis due to potential sparse-data 
bias. Although it has been noted that exposure-response relationships in nivolumab 
treated patients may be biased by decreased clearance in responding patients, this finding 
is shown to be of less relevance in an early stage of treatment.27 This emphasizes the need 
for further research following our results, despite earlier analysis showing a relatively flat 
exposure-response relationship over various nivolumab doses.28
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This is the first study showing an exposure-response relation for nivolumab. We argue 
that further clarification of exposure-response relationships and its covariates in patients 
treated with nivolumab is highly warranted, and new dosing strategies or combination 
therapies aiming at increasing the dosage should be explored. In particular, as toxicity 
does not increase with a higher systemic exposure, future nivolumab dosing adjustments 
based on exposure may improve treatment outcome.
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Background: Nivolumab is administered in a weight-based or fixed-flat dosing 
regimen. For patients with non-small cell lung cancer (NSCLC), a potential exposure-
response relationship has recently been reported and may argue against the 
current dosing strategies. The primary objectives were to determine nivolumab 
pharmacokinetics (PK) and to assess the relationship between drug clearance and 
clinical outcome in NSCLC, melanoma, and renal cell cancer (RCC). 
Materials and Methods: In this prospective observational cohort study, individual 
estimates of nivolumab clearance and the impact of baseline covariates were 
determined using a population-PK model. Clearance was related to best overall 
response (RECISTv1.1), and stratified by tumor type.
Results: Two-hundred-twenty-one patients with metastatic cancer receiving 
nivolumab-monotherapy were included of whom 1,715 plasma samples were 
analyzed. Three baseline parameters had a significant effect on drug clearance 
and were internally validated in the population-PK model: gender, BSA, and serum 
albumin. Women had 22% lower clearance compared to men, while the threshold of 
BSA and albumin that led to >20% increase of clearance was > 2.2m2 and <37.5g/L, 
respectively. For NSCLC, drug clearance was 42% higher in patients with progressive 
disease(mean: 0.24; 95%CI: 0.22-0.27 L/day) compared to patients with partial/
complete response(0.17; 0.15-0.19). A similar trend was observed in RCC, however, 
no clearance-response relationship was observed in melanoma. 
Discussion: Based on the first real-world population-PK model of nivolumab, 
covariate analysis revealed a significant effect of gender, BSA, and albumin on 
nivolumab clearance. A clearance-response relationship was observed in NSCLC, 
with a non-significant trend in RCC, but not in melanoma. Individual pharmacology 
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BACKGROUND
Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody (MoAb) that 
inhibits the interaction between the co-inhibitory immune receptor programmed death-1 
(PD-1) and its ligands, PD-L1 and PD-L2. Nivolumab monotherapy has been approved for 
several indications, including advanced and metastatic melanoma1, advanced clear-cell 
renal cell cancer (RCC), and metastatic non-small-cell lung cancer (NSCLC)2,3. IgG4 MoAbs, 
such as nivolumab, are characterized by a relatively high molecular mass, leading to a 
slow distribution in tissues4. The elimination of nivolumab is very much alike endogenous 
immunoglobulins with a half-life of approximately 27 days5 and a steady-state at 12 weeks. 
In current clinical practice, nivolumab is administered in different schedules including 3 
mg/kg Q2W, 240 mg flat dosing Q2W, and 480 mg flat dosing Q4W. The dosing of 3 mg/
kg Q2W --approved by the Food and Drug Administration (FDA) in 2014 -- was based on 
dose-finding phase I/II studies, showing tolerability for the wide range of 0.1 to 10 mg/kg, 
and showing activity at 0.1 mg/kg Q2W and higher6. However, approval of nivolumab flat 
dosing (in March 2018), however, was solely based on in silico studies: selected flat doses 
were based on equivalence with initial dosing at median body weight of 80 kg. Population 
pharmacokinetic (PPK) modeling of data from approximately 100 clinical trials was used 
to simulate nivolumab concentrations and to compare flat dosing regimens (240 mg Q2W, 
480 mg Q4W) with 3 mg/kg Q2W dosing.7,8 It is noteworthy that a previous model-based 
PPK analysis resulted in significant but not clinically relevant covariate effects, of which 
gender and body weight were the most important9.
Few studies have assessed dose-response (D-R) and exposure-response (E-R) relationships 
of nivolumab. In a quantitative analysis10 of a phase 1b dose-escalation study in 129 patients 
with NSCLC6, a positive D-R relationship was found at 3 or 10 mg/kg versus 1 mg/kg. In 
addition, trough concentrations at steady state were correlated with objective response 
(OR) at 0.1 to 3 mg/kg in another cohort of patients with NSCLC10. A D-R relationship could 
not be demonstrated in patients with melanoma (n=107) nor RCC (n=34) at this dose 
range, but was only observed at 0.1 up to 1 mg/kg. In 221 melanoma patients treated 
in phase 1b6 and 3 studies11, absence of an E-R relationship was confirmed utilizing PPK 
modeling by relating the time-averaged nivolumab concentration to OR12. 
In a recent real-world study performed by our group, a steep positive E-R relationship 
of nivolumab was found for NSCLC (n=76). Here, patients with a partial response (PR) 
had significant higher mean trough levels during therapy than patients with progressive 
disease (PD), and high exposure correlated significantly with better overall survival (OS).13
The present study addresses the PK of nivolumab in a real-world setting. The main 
objectives were 1) to define patient parameters influencing nivolumab pharmacokinetics 
and  2) to describe the relationship of systemic nivolumab clearance with objective 
response in patients with NSCLC, melanoma, and RCC. Secondary objectives include an 
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exploratory analysis in regard to immune-related adverse events (irAEs), progression-free 
survival (PFS), and OS.
METHODS
Patients and study design
Patients with advanced cancer who were treated with nivolumab between 20th April 2016 
and 30th October 2018 at the Erasmus MC Cancer Institute (Rotterdam, The Netherlands) 
and the Amphia Hospital (Breda, The Netherlands) were included prospectively in 
this study (Dutch Trial Register number NTR7015/ NL6828), allowing for serial blood 
sampling during standard of care nivolumab treatment. The study was approved by the 
independent ethics committee (MEC 16-011) and all patients provided written informed 
consent. Blood samples were drawn prior to every 2-weekly nivolumab to measure trough 
concentrations. For those patients who gave extensive informed consent, intensive 
sampling was performed between the first and second administration of nivolumab. 
Patient characteristics and clinical data were prospectively collected. 
Pharmacokinetic measurements
For all patients (n=221), nivolumab trough concentrations were determined for a 
selection of serum samples until end of treatment. Nivolumab serum concentrations were 
determined by an in-house developed and validated enzyme-linked immune sorbent 
assay (ELISA, as described previously14. Serum samples were selected to determine trough 
concentrations prior to each administration for the first 12 weeks, thereafter at evenly 
12-weekly intervals until the end of treatment. For some patients (n=3), intensive sampling 
allowed to determine nivolumab concentrations at 2 hours, 2 days, and 1 week after the 
first administration in order to estimate a best-fit compartmental model.
Data collection
The following baseline patient parameters were collected: gender, race, tumor type, 
performance status, age, body weight, body surface area (BSA), total volumetric tumor 
burden, serum creatinine, renal function, total serum protein, serum albumin, lactate 
dehydrogenase (LD) and leucocyte count. Performance status was determined according 
to Eastern Cooperative Oncology Group15. For NSCLC patients, weight loss was recorded 
and defined as a percentage of 2.5 or higher16 during a period of three months prior to the 
first administration of nivolumab. BSA was calculated by the Mosteller equation17. Renal 
function was estimated using the Chronic Kidney Disease Epidemiology Collaboration 
(CKD-EPI) formula18.
For a subgroup of NSCLC patients (n=30), total volumetric tumor burden at baseline was 
assessed by a thoracic radiologist (A.O.) in a blinded manner using IntelliSpace Portal 
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version 8 (Philips Medical Systems Nederland B.V., The Netherlands). Only primary tumor 
lesions with a long axis >10 mm, lymph nodes with a short axis >15 mm and metastatic 
lesions with a long axis >10 mm were included. Total volumetric tumor burden was not 
assessed if the primary tumor was not identifiable or its boundaries could not be defined, 
e.g. due to surrounding atelectasis or radiation effects. 
Best overall response (BOR) was assessed according to Response Evaluation Criteria in 
Solid Tumors version 1.1 (RECIST v1.1)19. A minimum duration of 90 days for stable disease 
(SD) was required. Confirmation of PR or complete response (CR) was not required. PFS 
was defined as the time from the first administration of nivolumab until PD or death 
due to any cause, whichever occurred first. OS was defined as the time from the first 
administration of nivolumab until death due to any cause. IrAEs were registered from 
start of treatment until end of follow-up according to National Cancer Institute Common 
Terminology Criteria for Adverse Events version 4.03 (NCI-CTCAE v4.03). Data cut-off for 
these analyses was set at 1st of January 2019.
Pharmacokinetic modeling
To determine patient parameters influencing nivolumab PK (primary objective 1), 
nonlinear mixed effect modeling software, NONMEM (version 7.4; ICON, Development 
Solutions, MD) was used to analyze the PK data. The first-order conditional estimation 
method with interaction was used for parameter estimation. Pirana software version 2.9.7 
(Pirana, www.pirana-software.com) was used as a modeling environment, and data were 
further handled in the latest R desktop version 1.1.453 (R-project, www.rproject.org). 
A two-compartment PPK model was developed to best fit the nivolumab pharmacokinetics 
with individual estimates of systemic drug clearance (schematically shown in Suppl. 
Figure 1). Two-compartment PPK models have previously been described to best fit 
pharmacokinetics of monoclonal antibodies in blood20. Since we had only trough PK levels 
available, modelling of nivolumab distribution was challenging. Hence, we assumed that 
the central volume (V1) equals the peripheral volume of distribution (V2) as previously 
described for nivolumab21. 
Between-subject variability (BSV) was tested for clearance and distribution volume. The 
inclusion of BSV was evaluated according to the change of objective function value (OFV, 
P<0.05) and shrinkage. A shrinkage value below 25% was considered acceptable22. 
BSV was modelled according to equation 1:
       (1)
where Pi represents the parameter estimate for each individual patient (i), P represents 
the typical population parameter estimate and ηi represents BSV distributed according to 
N (0, ω2).
Residual errors were described by a proportional error model (equation 2):
      (2)
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where Cobs,ij and Cpred,ij represent the observed and predicted concentration for the (i)th 
subject and the (j)th measurement, respectively. εp,ij represents the proportional error 
distributed according to N (0,σ2).
Covariates were added to the PPK model (initial model Mi) to obtain a final model (final 
model Mf). Potential covariates were selected based on clinical plausibility and tested by 
a stepwise approach with forward inclusion (threshold p<0.01) and backward elimination 
(threshold p<0.005)23-25. The covariates were tested on clearance (CL) by multiplying 
a typical clearance value (CLTV) with a factor for categorical (Factorcat) and continuous 
(Factorcon) covariates (equation 3).
     (3)
Categorical covariates were scored as ‘0’ or ‘1’. Equation 4 was applied for patients who 
scored ‘1’ in which θx represents the covariate effect size estimate. Continuous variables 
were tested with the PK model using equation 5 where cov represents the covariate 
measure, covmedian the population median of the covariate, and θy the covariate effect 
measure.
       (4)
      (5)
Data analysis
Descriptive statistics included frequency and the median with range and inter-quartile 
range (IQR) of covariates. To analyze the relationship of systemic nivolumab clearance, 
which is inversely proportional to drug exposure, with treatment outcome (primary 
objective 2), patients were stratified by tumor type (NSCLC, melanoma, and RCC) and 
ranked according to BOR. To avoid potential confounding from covariates that may 
correlate with response, the initial model Mi was used to compare individual drug clearance 
estimates between different BOR groups (PD, SD, PR/CR). Equal variances among groups 
were assessed with Levene’s test, normal distribution was assessed using the skewness 
and kurtosis. Comparison of individual drug clearance was assessed for the three BOR 
groups by ANOVA and post-hoc independent samples t-tests.
To investigate the relationship of systemic nivolumab clearance with toxicity, patients were 
stratified by tumor type, grouped based on the occurrence of grade 0-2 or grade >3 irAEs, 
and analyzed by independent samples t-test. To relate systemic nivolumab clearance to 
PFS and OS, NSCLC patients were grouped into quartiles: patients with low clearance (Q1) 
were compared with patients with high clearance (Q4) by the Kaplan-Meier approach. The 
relative risk of death or death/progression was assessed by the Cox proportional hazards 
model. Additional patient characteristics were included grouped by clearance quartile 
(Q1-Q4). A two-sided p-value <0.05 was considered significant.
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Post-processing of NONMEM generated data and statistical analysis was conducted with 
R and IBM SPSS Statistics version 24.0.0.1 (Chicago, IL).
RESULTS
A total of 221 nivolumab-treated cancer patients were included in the PPK model (Mi and 
Mf): NSCLC (71.4%), melanoma (21.7%), RCC (6.3%), and one mesothelioma patient. The 
patient characteristics are shown in Table 1. One patient received ipilimumab after initial 
treatment with nivolumab monotherapy, and was excluded from clearance-response, 
clearance-survival and clearance-toxicity analysis. Dosing was based on body weight 
(3mg/kg Q2W), with an average dose of 240 mg per administration (IQR: 200 – 280 mg). 
The average number of nivolumab cycles administered per patient was 12. The overall 
median follow up time (from first administration of nivolumab to censoring) was 338 
days (IQR: 145 – 487 days). A total of 1,715 measurements were available for PK analysis 
(average of 8 measurements per patient). Examples of nivolumab measurements and 
administrations over time from two patients, one with and one without dose delays, are 
shown in Figure 1. 
Figure 1. Patient examples
A
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B
Example of two subjects (2010: NSCLC, 1015: melanoma patient) showing concentrations of 
nivolumab (mg/L) versus time (weeks), with received administrations of nivolumab being marked 
as open triangles. Single measurements are represented by closed circles. A) Note that patient 2010 
experienced several dose delays followed by a decrease of nivolumab concentrations that was in 
line with the approximate half-life time of 25 days, whereas B) patient 2015 has had no dose delays 
and demonstrated a time to steady state concentrations of approximately 20 weeks.
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Table 1. Patient characteristics
Demographic Covariates Categorical n (%)
Tumor Type
   NSCLC all types 158 (71.5)
      Non-Squamous 96
      Squamous 42
      Unknown NSCLC type 20
   Melanoma 48 (21.7)
   RCC 14 (6.3)
   Mesothelioma 1 (0.5)
Treatment
   Nivolumab monotherapy (3 mg/kg Q2W) 221 (100)
Gender
   Male 138 (62.4)
   Female 83 (37.6)
Race
   Caucasian 195 (88.2)
   Other 5 (2.3)
   Unknown 21 (9.5)
WHO Performance Status
   0 63 (28.5)
   1 103 (46.6)
   2 4 (1.8)
   Unknown 51 (23.1)
Weight loss prior to start therapy (only in NSCLC)
   Yes 36 (16.3)
   No  81 (36.7)
   Unknown 104 (47.1)
Demographic and Laboratory Covariates Continuous Median (IQR) n (%)
   Age (yr) 65 (59-71) 221 (100)
   Body Weight (kg) 78.5 (70-88) 220 (99.5)
   Body Surface Area (m2) 1.95 (1.81-2.09) 205 (93)
   Tumor Burden 3D (cm3; only in NSCLC) 18.6 (66-98) 25 (11)
   Creatinine (μmol/L) 81 (66-98) 203 (92)
   CKD (mL/min) 81 (62-90) 203 (92)
   Total Protein (g/L) 73 (69-90) 163 (74)
   Albumine (g/L) 42 (42-45) 174 (79)
   LD (U/L) 215 (183-275) 196 (89)
   Leucocytes (109 cells/L) 7.7 (6.3-10.2) 203 (92)
Baseline covariates of patients. Abbreviations: number of patients (n), inter-quartile range (IQR), 
CKD-EPI renal clearance (CKD), lactate dehydrogenase (LD).
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Gender, BSA and albumin influence nivolumab pharmacokinetics
Continuous and categorical clinical covariates were incorporated in the final two-
compartment model by forward inclusion and backward elimination (Suppl. Table 1), 
resulting in four covariates reaching the significance threshold, namely: gender, BSA, 
albumin, and body weight. BSA had a higher impact on nivolumab pharmacokinetics 
than weight; the latter being rejected by the backward elimination step. The parameter 
estimates according to the Mf are shown in Table 2 including the results of internal 
validation. The NONMEM model can be found Suppl. Appendix 1. Inter-individual 
variance was reduced from 37% (as indicated by Mi) to 30.7% by incorporating these three 
covariates. Women had 22% lower clearance than men, as evidenced by a mean clearance 
of 0.185 and 0.237 L/day, respectively. The thresholds of BSA and baseline serum albumin 
that led to an estimated >20% increase of systemic nivolumab clearance were > 2.2 m2 
(BSA) and <37.5 g/L (albumin), respectively (Figure 2).
Table 2. Parameter estimates





   Clearance (CL) L/day 0.211 3.5 0.211 0.196 to 0.226
   Central volume of distribution (V1) L 3.46 5.8 3.46 3.09 to 3.83
   Peripheral volume of distribution (V2) L 3.46 5.8 3.46 3.09 to 3.84
   Inter-compartmental clearance (Q) L/day 0.48 <0.1 0.48 0.48 to 0.48
Covariate effects
   Female gender on CL - -0.17 29.1 -0.17 -0.27 to -0.06
   BSA effect on CL - 0.97 24.1 0.96 0.48 to 1.45
   Albumin effect on CL - -1.34 19.8 -1.33 -1.83 to -0.86
Between-subject variability
   Clearance (CL) CV% 30.7 9 30.3 24.8 to 35.6
   Residual unexplained variability
   Proportional error CV% 31.8 8 31.8 29.1 to 34.2
Table 2. Population parameters, covariate effects and between-subject variability according to 
the final population pharmacokinetic model (Mf). Abbreviations: clearance (CL), relative standard 
error (RSE), percentage coefficient of variation (CV%), confidence interval (CI). The shrinkage of the 
between-subject variability of clearance and the proportional error was 9.2% and 4%, respectively.
Correlation between drug clearance and clinical outcome
Clinical outcome and occurrence of toxicity are shown in Suppl. Table 2. The initial model 
(Mi) was used to investigate the relationship between individual clearance of nivolumab 
and clinical response or toxicity in NSCLC, melanoma, and RCC (Figure 3B-D). A negative 
clearance-response relationship 
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Figure 2. Parameter effect on clearance
A) Estimated nivolumab clearance (L/day) as a function of A) baseline serum albumin (g/L) and B) 
body surface area (BSA; m2). Single measurements are represented by open circles. The red line 
predicts clearance according to the final PPK model (Mf). The horizontal dotted lines mark the 20% 
increase of clearance, taking the mean clearance as reference (solid line). The vertical dotted line 
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Figure 3. Clearance-response analysis 
A) Nivolumab clearance (L/day) of A) all patients receiving nivolumab monotherapy grouped 
by best overall response (BOR), and stratified by B) NSCLC, C) melanoma, and D) RCC. Single 
measurements are represented by open circles. Bars indicate the 95% confidence interval of the 
mean. Abbreviations: progressive disease (PD), stable disease (SD) and partial response/ complete 
response (PR/CR). P-values indicated by ***<0.001 (post-hoc independent samples t-test).
was found in patients with NSCLC (p<0.001), as a significantly higher clearance of 41.8% 
was observed in patients with PD (mean: 0.244; 95%CI: 0.223 – 0.265 L/day) compared 
to patients with PR/CR (0.172; 0.152 – 0.192). Patients with SD were identified as an 
intermediate group (0.211; 0.193 – 0.228). A non-significant trend similarly to NSCLC was 
observed in RCC (p=0.054). Of note, no clearance-response relationship was observed in 
melanoma (p=0.987). A clearance-irAE relationship was not found for NSCLC, melanoma, 
or RCC (respectively p=0.28, p=0.84 and p=0.92; Suppl. Figure 2B-D), nor for all three 
tumor types pooled together (p=0.31; Suppl. Figure 2A).
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There was no significant difference in drug clearance between tumor types (p=0.47; 
Figure 3A), corresponding with above-mentioned PPK modeling where tumor type as 
a categorical covariate did not reach the significance threshold. Notably, when patients 
with NSCLC were grouped by clearance, the lowest quartile of clearance was significantly 
associated with better PFS (HR 0.32; 95%CI: 0.18 – 0.57, p<0.001) and OS (HR: 0.25; 95%CI: 
0.12 – 0.51, p<0.001) compared to patients with the highest quartile of clearance (Figure 
4A-B). Additionally, the patient characteristics grouped by quartile of clearance are shown 
in Supplementary Table 3.
Figure 4. Kaplan-Meier curves
 
A) progression-free survival (PFS) and B) overall survival (OS) of NSCLC patients receiving 
nivolumab monotherapy stratified by clearance into 4 quartiles of clearance displayed by Kaplan-
Meier methodology: Q1 [first quartile (blue); lowest clearance] - Q4 [fourth quartile (red); highest 
clearance].
DISCUSSION
In the current study, we showed that gender, baseline BSA, and serum albumin had a 
significant effect on the systemic clearance of nivolumab in the two compartment PPK 
model. These three covariates partially explained the high inter-individual variance 
(~37%) of drug clearance. Secondly, we have demonstrated the relationship between 
nivolumab pharmacokinetics and radiological response to therapy. By stratifying tumor 
types, the negative clearance-response relationship was highly significant in NSCLC, and 
A       B 
 




54   |   Chapter 3
a non-significant trend was seen in RCC. The clearance-response relationship could not be 
confirmed in melanoma. 
Our developed PPK model was comparable to previously described models for different 
MoAbs and nivolumab. In a model-based meta-analysis for four different MoAbs a 
robust fit was obtained using a two-compartment model with estimates for systemic 
clearance and volume of distribution of 0.200 L/day and 3.6 L, respectively, and with 
a 31% inter-subject variability of clearance20. This was similar to recently published 
parameter estimates of a nivolumab-based two-compartment model described by Bajaj 
and colleagues (clearance 0.226 L/day; compartmental volume 3.6; 35% inter-subject 
variability of clearance)9. Although the time-varying pharmacokinetics as described by 
Liu et al.21 could not be confirmed in our analysis, our time-stationary PPK model worked 
with sufficient accuracy. Important to note is that we observed that trough levels reached 
steady state concentrations and remained stable over time in individual patients (as 
illustrated by Figure 1B).
Estimated systemic drug clearance according to the PPK model, which is inversely 
proportional to exposure, was utilized in this study to correlate clearance with response, 
survival, and occurrence of irAEs. It is important to realize that correlating systemic 
clearance to treatment outcome using a PPK model may potentially be influenced by 
those incorporated baseline covariates that are related to the efficacy of immunotherapy. 
To avoid such confounding, we utilized the initial model to demonstrate the relationship of 
systemic clearance with clinical outcome, which was further grouped by tumor type. Two 
patients were excluded from these analyses: a patient with mesothelioma and a patient 
who was treated with concomitant ipilimumab from the second cycle of nivolumab, at 
which point he was censored from the analyses. 
The differential clearance-response relationship of nivolumab in NSCLC compared to 
melanoma remains to be elucidated. This may be explained by different tumor intrinsic 
as well as extrinsic factors, such as tumor immunogenicity and patient immunity (e.g. 
microbiota, environmental factors) respectively. In addition, positive D-R relationships 
were found for NSCLC at doses from 0.1 to 3 mg/kg Q2W10, whereas for melanoma this was 
only observed at doses from 0.1 to 1 mg/kg Q2W10. In this respect it is noteworthy that the 
ORR of nivolumab in metastatic melanoma is superior compared to metastatic NSCLC1-3. 
In our study, patients with melanoma demonstrated better performance than patients 
with NSCLC before initiation of nivolumab monotherapy (WHO performance score of 0: 
76% and 23%, respectively). Taken together, we cannot exclude that nivolumab may be 
effective at lower doses for patients with melanoma than for NSCLC, and that patients 
with NSCLC may be more sensitive for changes in exposure than patients with melanoma. 
Consequently, nivolumab dosing based on weighted parameters may be relevant to 
optimize efficacy, particularly for NSCLC patients. 
Whether the inverse clearance-response relation for nivolumab in NSCLC indicate a 
true causal effect on clinical outcome remains to be clarified. The issue was discussed 
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by Badawi in a comment on our previous work showing a positive E-R relationship of 
nivolumab for NSCLC13,26. Of note, an absent E-R relationship but a strong negative 
clearance-OS association has been described for pembrolizumab, another PD-1 blocking 
monoclonal antibody, in solid tumors27. The efficacy of pembrolizumab seemed to 
be independent of absolute doses from 2 to 10 mg/kg Q2W or flat dose 200 mg Q3W. 
Turner and colleagues argued that this clearance-OS relationship was confounded by 
the cachectic state of patients, which caused more rapid protein (and thus antibody) 
turnover and worse survival.27 Given the circular reasoning in their study design, however, 
this hypothesis may not have been supported by appropriate evidence28. Although we 
did not find a covariate effect of prior weight loss or the performance score on the PPK 
model, serum albumin was inversely correlated with nivolumab clearance. Albumin may 
be considered as a surrogate marker for protein clearance, coinciding with clearance of 
endogenous immunoglobulins and nivolumab. This may provide supporting evidence to 
the hypothesis that the exposure-response (or inverse clearance-response) relationship is 
affected by the metabolic state of patients, although we cannot rule out the possibility of 
a true causal relationship.
The elimination and recycling mechanisms of nivolumab is expected to exhibit similarities 
to those of endogenous immunoglobulins with a central role for the neonatal Fc receptor 
(FcRn)29. The FcRn is being widely expressed in human tissue (www.proteinatlas.org), 
particularly in myeloid cells, and reported to play a key role in the metabolism of albumin 
in blood30. Interestingly, myeloid cells have emerged as major regulators of cancer immune 
response by presenting tumor antigens to T cells and controlling the activity of cytotoxic 
cells, where myeloid-derived suppressor cells (MDSCs) suppress T cell responses and are 
implicated in tumor metastasis31,32. In fact, MDSCs were negatively associated with response 
to treatment and survival in NSCLC33,34. Monocytic myeloid cells in peripheral blood prior 
to anti-PD-1 nivolumab and pembrolizumab are associated with inferior PFS and OS35. We 
expect that by further exploring the interaction between the peripheral immune system, 
e.g. FcRn in the myeloid lineage, and nivolumab pharmacokinetics, understanding of 
immune checkpoint inhibitor treatment could be significantly enhanced.
CONCLUSIONS
In oncology, pharmacokinetic modeling is widely used to optimize drug dosing. For 
immune checkpoint inhibitors, approved flat dosing regimens for nivolumab have been 
solely based on simulations from dose-finding clinical trials. In this prospective real-life 
patient cohort study, we observed an effect of gender, body surface area, and baseline 
serum albumin on systemic drug clearance, thereby providing understanding of the 
high inter-individual variance of clearance. We demonstrate a strong inverse correlation 
of drug clearance and response in NSCLC, and a similar trend in RCC, but a clearance-
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response relationship was not observed in melanoma. Considering the recent approval 
of nivolumab fixed dosing regimens --which was solely based on simulating PK data from 
clinical studies-- this real-world study suggests that dosing regimens based on patient 
parameters may be considered to improve efficacy, particularly in NSCLC, and should be 
prospectively studied.
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SUPPLEMENTARY MATERIALS
Supplementary Figure 1. PPK model
Schematic overview of the two-compartmental PPK model of nivolumab. 
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Supplementary Figure 2. Clearance-toxicity analysis
A) Drug clearance (L/day), according to initial model Mi, grouped by toxicity (irAEs; grade 0-2 vs. 
grade >3) of A) all patients, B) NSCLC (in red), C) melanoma (in blue) and D) renal cell cancer (RCC; 
in green) receiving nivolumab monotherapy. Single measurements are represented by open circles. 
Bars indicate the 95% confidence interval of the mean.
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Supplementary Figure 3. Goodness of fit
Standard goodness of fit of the A) initial (Mi) and B) final model (Mf). Single observations are represented 
by open circles. Red and black lines mark locally estimated scatterplot smoothing lines, lines of identity 
(diagonal) or ordinate value of 0 (horizontal), respectively. The figures include observations versus 
individual predictions (a), observations vs population predictions (b), conditional weighted residuals 
(CWRES) versus population predictions (c) and CWRES versus time after dose (d).
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Supplementary Table 1. Parameter estimates
Categorical Covariates Estimates dOFD
NSCLC vs. other tumor types -0.03 -0.251
Melanoma vs. other tumor types 0.05 -0.449
Female vs. Male -0.26 -29.685
WHO=0 vs. Rest (including unknowns) 0.08 -1.682
Weight Loss Present vs. Rest (including unknowns) 0.09 -1.406
Continuous Covariates Estimates dOFD
   Age (yr) 0.12 -0.604
   Body Weight (kg) 0.60 -18.716
   Body Surface Area (m2) 1.22 -25.519
   Tumor Burden 3D (cm3) 0.09 -2.252
   Creatinine (μmol/L) -0.01 -0.003
   CKD (mL/min) 0.01 -0.307
   Total Protein (g/L) 0.25 -0.300
   Albumine (g/L) -1.31 -18.989
   LD (U/L) 0.0004 -
   Leucocytes (109 cells/L) 0.07 -0.648
Categorical and continuous covariates shown as estimates and difference in objective function 
value according to initial model Mi (dOFD). Abbreviations: CKD-EPI renal clearance (CKD), lactate 
dehydrogenase (LD).
Supplementary Table 2. Clinical outcome and toxicity
Total n(%) NSCLC n(%) Mel n(%) RCC n(%)
BOR (RECIST v1.1)
   PR/CR 53 (24.2) 28 (17.7) 22 (46.8) 3 (21.4)
   SD 57 (26.0) 47 (29.7) 7 (14.9) 3 (21.4)
   PD 97 (44.3) 73 (46.2) 18 (38.3) 6 (42.9)
   Non-evaluable 12 (5.5) 10 (6.3) - 2 (14.3)
IrAEs (CTCAE 4.03)
   Grade 0-2 175 (79.9) 127 (80.4) 35 (74.5) 13 (92.9)
   Grade >3 43 (19.6) 31 (19.6) 11 (23.4) 1 (7.1)
   Unknown 1 (0.5) - 1 (2.1) -
 
Distributions of best overall response (BOR) by RECIST v1.1 and irAEs by CTCAE v4.03 for all patients 
receiving nivolumab monotherapy and grouped by tumor type. Abbreviations: melanoma (Mel), renal 
cell carcinoma (RCC).
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Supplementary Table 3. Patient characteristics by quartiles of drug clearance
Q1 Q2 Q3 Q4
Tumor type n (% within 
quartile)
NSCLC n=39 n=40 n=40 n=39
   Adenocarcinoma 23 (59) 30 (75) 23 (57.5) 20 (51)
   Squamous cell carcinoma 11 (28) 7 (17.5) 10 (25) 14 (36)
   Unknown 5 (13) 3 (7.5) 7 (17.5) 5 (13)
WHO performance score  
n (% within quartile)
   0 5 (13) 8 (20) 7 (17.5) 5 (13)
   1 25 (64) 16 (40) 19 (47.5) 23 (59)
   2 - 1 (2.5) - 1 (2.5)
   Unknown 9 (23) 15 (37.5) 14 (35) 10 (25.5)
Weight loss prior to start 
therapy  
n (% within quartile)
   Yes 12 (31) 12 (30) 5 (12.5) 7 (18)
   No 17 (43.5) 19 (47.5) 21 (52.5) 23 (59)
   Unknown 10 (25.5) 9 (22.5) 14 (35) 9 (23)
Gender n (% within quartile)
   Male 11 (28) 23 (57.5) 29 (72.5) 35 (90)
   Female 28 (72) 17 (42.5) 11 (27.5) 4 (10)
Body Surface Area (m2) 
median (IQR)
1.81 (1.55-1.97) 1.85 (1.76-2.06) 1.95 (1.84-2.10) 2.00 (1.91-2.13)
Albumin (g/L) median (IQR) 42 (41-44) 43 (40-45) 42 (40-45) 39 (34-43)
Patient characteristics including important patient parameters (gender, BSA and serum albumin) 
grouped by quartile of drug clearance (Q1-Q4), which was utilized for the clearance-survival analysis. 
The percentage within the quartiles is shown, leaving out the unknown parameters. Abbreviations: 
Q1-4 (quartile 1-4), IQR (inter-quartile range).
Supplementary Appendix 1.
The final and initial models were internally validated using VPC (Suppl. Figure 3) and a 
bootstrap procedure. Bootstrap analysis was performed with replacement by randomly 
selecting patients from the dataset. 
Syntax of initial PPK model Mi:
$PROBLEM PK
$INPUT DROP ID CYCLE TIME DV AMT RATE MDV EVID CMT DAY WEEK TAD RESPONS GRTT 
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CL = THETA(1)*EXP(ETA(1))












(0, 0.01) ; CL
(0, 5) ; V1
0.02 FIX; Q
$OMEGA
(0.1) ; IIV CL
$SIGMA
0.05  ;   prop paz
$EST METHOD=1 INTER MAXEVAL=2000 NOABORT SIG=3 PRINT=1 POSTHOC
$COV
Syntax of final PPK model Mf:
$PROBLEM PK
$INPUT DROP ID CYCLE TIME DV AMT RATE MDV EVID CMT DAY WEEK TAD RESPONS 
       GRTT SEX RACE DISEASE AGE WHO LGT WGT BSA TWOD THREED CREAT CKD TPRO ALB 
       LD LEU GRAN EOS NEUIMM NEUMAT BC MON DC TC CDF CDE CDFP CDEP WLB WLP
$DATA FINAL_PK_MULTOMAB_NSCLC_RCC_MEL.csv IGNORE=#;concentration mg/L
$SUBROUTINES ADVAN3 TRANS4
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$PK
;CLSEX-DEFINITION START
IF(SEX.EQ.0) CLSEX = 1 ; Most common










































(0.1) ; IIV CL
$SIGMA
0.05  ;   prop paz
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Introduction: Pretreatment selection of patients with non–small cell lung cancer 
(NSCLC) who would derive clinical benefit from treatment with immune checkpoint 
inhibitors (CPIs) would fulfill an unmet clinical need by reducing unnecessary 
toxicities from treatment and result in substantial health care savings.
Material and Methods: In a retrospective study, mass spectrometry (MS)-based 
proteomic analysis was performed on pretreatment sera derived from patients 
with advanced NSCLC treated with nivolumab as part of routine clinical care (n = 
289). Machine learning combined spectral and clinical data to stratify patients into 
three groups with good (“sensitive”), intermediate, and poor (“resistant”) outcomes 
following treatment in the second-line setting. The test was applied to three 
independent patient cohorts and its biology was investigated using protein set 
enrichment analyses (PSEA).
Results: A signature consisting of 274 MS features derived from a development set of 
116 patients was associated with progression-free survival (PFS) and overall survival 
(OS) across two validation cohorts (N = 98 and N = 75). In pooled analysis, significantly 
better OS was demonstrated for “sensitive” relative to “not sensitive” patients treated 
with nivolumab; HR, 0.58 (95% confidence interval, 0.38–0–87; P = 0.009). There was 
no significant association with clinical factors including PD-L1 expression, available 
from 133 of 289 patients. The test demonstrated no significant association with 
PFS or OS in a historical cohort (n = 68) of second-line NSCLC patients treated with 
docetaxel. PSEA revealed proteomic classification to be significantly associated with 
complement and wound-healing cascades.
Discussion: This serum-derived protein signature successfully stratified outcomes 
in cohorts of patients with advanced NSCLC treated with second-line PD-1 CPIs and 
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STATEMENT OF TRANSLATIONAL RELEVANCE
Predictive biomarkers for the efficacy of PD-(L)1 inhibition in non-small cell lung cancer 
54 (NSCLC) beyond PD-L1 are lacking. We retrospectively developed a pretreatment 
proteomic 55 signature derived from peripheral blood that was able to stratify patients 
for benefit of 56 Nivolumab in treatment of relapsed NSCLC. A signature consisting of 274 
mass spectral 57 features derived from a development set of 116 patients was associated 
with progression 58 free survival (PFS) and overall survival (OS) across 2 validation cohorts 
(N=98 and N=75). 59 In pooled analysis, a significantly better OS was demonstrated for 
“sensitive” relative to “not 60 sensitive” patients, hazard ratio (HR) 0.58 (95% CI 0.38-0-87, 
P=0.009). There was no 61 significant association with clinical factors including PD-L1 
immunohistochemistry. Further 62 prospective exploration of the predictive capabilities 
of this assay is underway.
INTRODUCTION
The addition of immune checkpoint inhibitors (CPIs) to the armamentarium of medical 
treatment of advanced non–small cell lung cancer (NSCLC) has increased survival for a 
minority of patients. Historically, in patients with metastatic disease, 2-year survival rates 
following platinum-based chemotherapy were 10%–20% (1). In recent phase III studies, 
either comparing CPIs alone or CPI chemotherapy to chemotherapy (2), 2-year survival 
rates in the CPI arms range from 32% to 67%. In addition, long-term follow-up of patients 
treated in early single-agent CPI studies indicates that 5-year survival of 15%–20% may be 
expected, even in heavily pretreated patients (3, 4).
At the same time, it is clear that not all patients benefit from treatment with CPIs. Indeed, 
response rates and survival times can be augmented by pretreatment selection based on 
tumor characteristics
such as PD-L1 expression (5), staining of CD8-positive cells (6), tumor mutational burden 
(TMB; ref. 7), and other genomic markers (8, 9). The predictive power of the best studied 
of these PD-L1 IHC is far from perfect. For example, in patients with previously treated 
NSCLC with PD-L1 staining of at least 50%, the objective response rate to pembrolizumab 
was 44% (5). Thus, alternative predictive biomarkers for response and clinical benefit are 
needed. We sought to develop a serum-based, pretreatment protein test to avoid the 
need for tissue biopsies, which are typically required to analyze tumor-related biomarkers. 
Here, we report on the development of such a test in advanced NSCLC treated with single-
agent CPI in the second-line setting.
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MATERIALS AND METHODS
Patient cohorts and sample sets
Pretreatment serum samples, collected within 1 month of immunotherapy initiation, were 
available from four cohorts of patients. The development set consisted of 116 samples 
from patients treated at the Netherlands Cancer Institute (Amsterdam, the Netherlands) 
between May 2015 and March 2017. Validation set 1 consisted of 98 samples from 
patients treated at the Vrije Universiteit Medical Center (Amsterdam, the Netherlands) or 
the Netherlands Cancer Institute (Amsterdam, the Netherlands) between June 2015 and 
July 2018. Validation set 2 comprised samples from 75 patients treated at the Erasmus 
University Medical Centre (Rotterdam, the Netherlands) between April 2016 and July 2017. 
Patients, identified according to criteria established in the phase III trials demonstrating 
benefit for nivolumab over docetaxel (10, 11), received nivolumab 3 mg/kg, administered 
as an intravenous infusion, every 2 weeks, for advanced NSCLC after platinum-containing 
chemotherapy as part of routine clinical care. Patients in the development cohort and 
validation set 2 were treated in second-line. Validation set 1 contained 58 patients treated 
in second-line and 40 patients treated in higher lines. The cohorts comprised all patients 
in the respective institutions who provided pretreatment serum samples available for 
analysis, were eligible for immunotherapy as routine care, and who received at least one 
dose of nivolumab. Response to treatment was evaluated according to RECIST v1.1 every 
6 weeks for the first 12 weeks and every 3 months thereafter. In addition, a fourth cohort 
of pretreatment serum samples (chemotherapy cohort) was collected from patients 
with advanced NSCLC treated in second-line with chemotherapy while enrolled in a 
clinical trial (NCT00989690; ref. 12). Samples were available for 68 of the 74 patients who 
received docetaxel (75 mg/ m2 every 21 days) in this study. Trial inclusion and exclusion 
criteria have been published elsewhere (12). All samples were obtained in the context 
of biobanking protocols or a clinical trial for which institutional review board approval 
was sought and obtained. All patients provided written informed consent according to 
local ethical standards and adhered to standards set out in the Declaration of Helsinki. 
Progression-free survival (PFS) was measured from start of treatment until progression of 
disease, death, or loss to follow-up. Overall survival (OS) was defined as time from start of 
therapy until death or loss to follow-up.
PD-L1 IHC
Tumor PD-L1 expression scoring was performed according to the instruction manual of 
the qualitative IHC assay developed as a complementary diagnostic tool for nivolumab 
(PD-L1 IHC 22C3 pharmDx, Dako). PD-L1 expression levels were determined by observing 
complete circumferential or partial linear expression (at any intensity) of PD-L1 on the 
plasma cell membrane of viable tumor cells. In parallel, the pattern of staining in CD4-
stained slides, which also stain CD4þ lymphocytes and macrophages, was evaluated and 
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compared with PD-L1-stained slides to avoid false positive assessment due to PD-L1–
expressing macrophages in between tumor cells. Assessment of expression levels was 
performed in sections that included at least 100 tumor cells that could be evaluated.
Spectral acquisition and processing
Samples were processed using standardized operating procedures. We used the Deep 
matrix-assisted laser desorption/ionization (MALDI) method of mass spectrometry on a 
MALDI Time-ofFlight Mass Spectrometer (SimulTof Systems) to generate reproducible 
mass spectra from small amounts of serum (3 mL; ref. 13). This approach reveals mass 
spectral (MS) peaks with a greater dynamic range than previously possible by exposing 
the samples to 400,000 MALDI laser “shots,” rather than the several thousand used in 
standard applications. The spectra were processed to render them comparable between 
patients, and 274 MS features (peaks) were selected for further analysis for their known 
reproducibility and stability (listed in Supplementary Data). Sample processing and 
MS analysis followed methods presented previously (14, 15) and are outlined in the 
Supplementary Materials and Methods. Parameters for these procedures were established 
using only the 116-sample development set, and this fixed procedure was applied to all 
other sample sets without modification.
Test development
Test development was carried out using the Diagnostic Cortex platform (16), which has 
been used previously to design tests that were able to stratify patients by outcome in 
various settings, for example, to identify patients with advanced melanoma likely to be 
sensitive to CPIs (14, 15). The approach incorporates machine learning concepts and 
elements of deep learning (17) to facilitate test development in cases where there are 
more measured attributes than samples. The potential for overfitting was minimized, thus 
allowing the creation of tests that can generalize to unseen datasets. Tests were created 
averaging over many splits of the development set into training and test sets, and reliable 
test performance estimates can be obtained from the development set by restricting 
averages to the test set evaluations (“out-of-bag estimates”; ref. 18).
For successful supervised learning, suitable training class labels are required. We used a 
semisupervised approach (19) that does not require accurate prespecification of patients 
into better or worse outcome training classes and allows us to be guided by the gold 
standard time-to-event outcomes of OS and PFS. An approximation was made for 
training classes, with patients with the lowest time-to-event outcome times assigned to 
the “negative” class and those with the highest time-to-event outcome times assigned 
to the “positive” class. A classifier was constructed using these training classes and used 
to generate classifications for all samples in the development set using out-of-bag 
evaluations. These resulting classifications were then used as improved training class labels 
for a second iteration of classifier construction. This simultaneous iterative refinement of 
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the classifier and the classes used in training generally converges quickly and reveals the 
underlying structure of the MS data and its association with clinical outcomes (19). Full 
details of the application of the method in this setting are provided in the Supplementary 
Materials and Methods
One classifier previously developed with the Diagnostic Cortex platform was used as part 
of the developed test. BDX008 was created to stratify patients with advanced melanoma 
into groups with better and worse outcomes when treated with nivolumab (15). It has 
been validated in multiple independent cohorts of patients with melanoma treated 
with CPIs (15, 20). Also, it has demonstrated some ability to stratify OS of patients with 
advanced NSCLC treated with nivolumab (21). A version of BDX008, adapted for the 
spectral preprocessing parameters and feature definitions in this project, was created (see 
Supplementary Data: Supplementary Materials and Methods for details).
Preliminary statistical considerations showed a binary split of the development set into 
equal-sized groups would allow detection of a HR between the groups of 0.55 with 
90% power, assuming fully mature clinical data and a significance level of 95%. Similar 
considerations for a ternary split into equal size subgroups would allow detection of an 
HR of 0.48 under the same specifications.
All reference data and test parameters were generated solely using the development 
set. Validation sets and the chemotherapy cohort were never used in the creation of any 
components of the test. All elements of the classification algorithms were locked prior to 
running the test on the validation sets and chemotherapy cohort
Protein set enrichment analysis
This analysis applies the gene set enrichment analysis (GSEA) method (22) to protein 
expression data. The method identifies expression differences that are consistent across 
prespecified groups or sets of attributes, in this case, sets of proteins that are associated 
with particular biological processes. Two additional independent reference sets of serum 
samples with matched MS data and protein expression data were used for this set 
enrichment analysis. One sample set was composed of 49 samples with protein expression 
data from a panel of 1,129 proteins; the second set had 100 samples with protein expression 
data from a panel of 1,305 proteins (protein expression measurements were generated 
by SomaLogic). Specific protein sets were created as the intersection of the list of the 
panel targets and results of queries for biological functions from gene ontology, using 
AmiGO2 tools (http:// amigo.geneontology.org/amigo) and UniProt databases (https://
www. uniprot.org/). The protein set enrichment analyses (PSEA) method associated test 
classification with these biological functions via a rankbased correlation of the measured 
protein expressions with the test classifications of the reference samples (23). The mass 
spectral features associated with biological processes (in particular immune response 
type 2) were determined using Spearman correlation of the measured protein expressions 
with the mass spectral features (23) using the 49- sample reference set only. While the 
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implementation closely follows the GSEA approach, we employed an extension of the 
standard method that increases the statistical power to detect associations between 
phenotype (test classification subgroup) and biological process (24). The PSEA was carried 
out using a C# implementation and MATLAB (MathWorks). PSEA P values were defined 
as described by Subramanian and colleagues (20). FDRs for the PSEA calculations were 
assessed using the method of Benjamini and Hochberg (25).
Other statistical analysis
All analyses, except the PSEA, were carried out using SAS9.3 (SAS Institute) or PRISM 
(GraphPad). Survival/PFS plots and medians were generated using the Kaplan–Meier 
method. Association between test classification and categorical or continuous variables 
was assessed using Fisher exact test and Mann–Whitney test, respectively. All P values are 
two-sided.
RESULTS
Patient characteristics and overall outcomes for all four cohorts are summarized in Table 
1 and were typical of patients with advanced NSCLC treated predominantly in the second-
line setting. Clinicopathologic characteristics were generally similar between the four 
cohorts, although the proportion of patients with performance status 2 or higher was 
larger in the development cohort and validation set 1, and the proportion of patients 
with performance status 0 was higher in the chemotherapy cohort. PD-L1 status was not 
available for the chemotherapy cohort and was missing for at least one-third of patients 
in the other three cohorts.
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Development of the test
A ternary test was developed that was able to stratify the development set of 116 samples 
into three groups with different outcomes after anti-PD-1 treatment, that is, the resistant 
group (with poor outcomes), the intermediate group (with intermediate outcomes), 
and the sensitive group (with good outcomes). The ternary test result was generated by 
combining the results of three binary classification algorithms (classifiers). Each of the 
three classifiers stratified patients into two groups: “positive” with better outcomes and 
“negative” with worse outcomes. The binary results were integrated as shown in Fig. 1 to 
yield the final test result. First, classifications were generated for all samples by classifier 
A, the version of the preexisting BDX008 test adapted to the spectral processing used 
in this project. To identify a group of patients least likely to have good outcomes, the 
patients classified as negative by classifier A were subsequently classified by classifier C. 
This classifier was developed using the subset of MS features found to be associated with 
immune response type 2 by PSEA and a subset of the development cohort enriched for 
inferior outcomes, by excluding patients designated as BDX008þ and having performance 
status 0 (the MS features in this subset are listed in the Supplementary Materials and 
Methods). Samples designated as negative by both classifier A and classifier C were 
classified as “resistant.” To identify a group of patients likely to have the best outcomes, 
the patients classified as positive by classifier A were further classified by classifier 
B. This classifier was developed using all 274 mass spectral features on a subset of the 
development set enriched for better outcomes, by excluding patients who were classified 
both as BDX008 and negative by classifier C. Samples designated positive by both classifier 
A and classifier B were classified as “sensitive.” All samples not classified as “sensitive” or 
“resistant” were classified as “intermediate.” More details of the test development process 
and parameters are provided in the Supplementary Data. Reproducibility was assessed 
by running the test on the 98 serum samples of validation set 1 twice, 13 months apart. 
Concordance between classifications was 85%. For identification of patients with resistant 
outcomes (resistant vs. not resistant, i.e., sensitive and intermediate), concordance was 
91% and for identification of patients with sensitive outcomes (sensitive vs. not sensitive, 
i.e., resistant and intermediate), concordance was 93%. 
The test was able to stratify patients into three groups (sensitive, intermediate, and resistant) 
with different OS and PFS. Of the 116 samples in the development set, 41 (35%) were classified 
as resistant, 43 (37%) as intermediate, and 32 (28%) as sensitive. Kaplan–Meier plots of OS 
and PFS by classification groups are shown in Fig. 2A and B. PFS for the resistant subgroup 
was significantly shorter than for the other groups [resistant vs. sensitive: HR, 0.33 (95% 
confidence interval (CI), 0.19–0.58); P < 0.001 and resistant vs. intermediate: HR, 0.59 (95% CI, 
0.37–0.96); P = 0.035]. Median PFS was 1.4 (95% CI, 1.3–2.3) months for the resistant group, 
4.3 (95% CI, 1.4–5.7) months for the intermediate group, and 9.1 (95% CI, 2.5–undefined) 
months for the sensitive group. OS for the resistant subgroup was significantly shorter than 
for the sensitive subgroup and numerically shorter than for the intermediate group (resistant 
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vs. sensitive: HR, 0.34 (95% CI, 0.19–0.64); P < 0.001 and resistant vs. intermediate: HR, 0.63 
(95% CI, 0.38–1.06); P = 0.083]. Median OS was 4.3 (95% CI, 2.0–7.9) months for the resistant 
subgroup, 10.4 (95% CI, 5.9–11.4) months for the intermediate group, and 17.3 (95% CI, 
8.5–undefined) months for the sensitive group. Test classification was also associated with 
response (P < 0.001, see Supplementary Data: Supplementary Results; Supplementary Table 
S12). Eighty-five percent of patients classified as resistant experienced progressive disease 
as best response and only 10% had a response (all partial). In the sensitive group, only 28% 
of patients had progressive disease as best response and 28% achieved a response [one 
complete response (CR) and eight partial responses (PR) as best response of 32 patients].
Figure 1. 
Heatmaps within the schema show log10 values of features used in each classifier (x-axis) for the 
development cohort of 116 samples, grouped by individual classifier results, negative or positive. 
The heatmap below the schema shows the log10 values of all 274 features used within the test for 
all samples in the development cohort, grouped by test classification (resistant, intermediate, or 
sensitive). Larger versions of the heatmaps are in the Supplementary Data.
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Figure 2.
Outcomes by test classification for the development cohort.
For differentiating patients with the worst outcome from the remainder of the cohort, we 
compared the resistant subgroup with the “not resistant” group, that is, the combination 
of intermediate and sensitive subgroups, see Fig. 2C and D. The resistant subgroup had 
significantly inferior OS and PFS than the other subgroups [HR, 0.48 (95% CI, 0.30–0.77); 
P = 0.002 for OS and HR, 0.46 (95% CI, 0.30– 0.71); P < 0.001 for PFS]. These differences 
remained significant for PFS (P = 0.015) and trended to significance for OS (P = 0.062) 
in multivariate analysis when adjusted for other baseline characteristics, including 
performance status and PD-L1 expression.
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The patients with the best outcomes (sensitive subgroup) were compared with the ”not 
sensitive” group, that is, the remainder of the cohort (resistant þ intermediate subgroups; 
Fig. 2E and F). Patients classified as sensitive had significantly better OS and PFS than 
patients classified as not sensitive [HR, 0.45 (95% CI, 0.25– 0.79); P = 0.006 for OS and HR, 
0.45 (95% CI, 0.27–0.76); P = 0.003 for PFS]. Median OS was 17.3 (95% CI, 8.5–undefined) 
months for the sensitive group, compared with 6.0 (95% CI, 4.3–9.2) months for the not 
sensitive group; median PFS was 9.1 (95% CI, 2.5–undefined) months for the sensitive 
group, compared with only 1.8 (95% CI, 1.4–2.7) months for the not sensitive group. In 
multivariate analyses, while the effect sizes for OS and PFS remained substantial (HR, 
0.60 and 0.63, respectively), classification of sensitive versus not sensitive did not retain 
its independent significance as a predictive factor (Supplementary Data: Supplementary 
Results; Supplementary Tables S13 and S14).
Baseline patient characteristics showed no association with test classification for P < 0.05 
(Supplementary Data: Supplementary Results; Supplementary Table S15). In particular, 
PD-L1 expression was not significantly correlated with test classification (P < 0.387 for 
ternary classification vs. PD-L1+/PD-L1-/NA).
Validation
The locked test was applied to samples from validation sets 1 and 2 and the chemotherapy 
cohort. Validation set 1 had been used in a previous investigation (26) and, therefore, 
while it was not used in test development, validation set 1 could not be run blinded to 
clinical data. The chemotherapy cohort was a subset of a previously analyzed clinical 
trial comparing chemotherapy and targeted therapy, and hence, could also not be 
tested blinded to clinical data. Testing of validation set 2 was completely blinded to all 
clinical data. Statistical consideration of power to detect the effect sizes observed in the 
development cohort for each validation set and the chemotherapy cohort is outlined in 
the Supplementary Data.
Within the validation sets, the number and proportions of patients assigned to each 
classification group were 37 (38%)/32 (43%) resistant, 30 (31%)/19 (25%) intermediate, 
and 31 (32%)/24 (32%) sensitive for set 1/set 2, respectively. Kaplan–Meier plots of OS 
by test classification, resistant versus not resistant and sensitive versus not sensitive, are 
shown for the validation sets in Fig. 3A–D. In validation set 1, Fig. 3A and B, patients 
classified as resistant had significantly worse OS than not resistant patients [HR, 0.60 (95% 
CI, 0.37–0.97); P = 0.037] and patients classified as sensitive had significantly better OS 
than not sensitive patients [HR, 0.56 (95% CI, 0.33–0.97); P = 0.038]. One-year survival 
for the sensitive group was 65% and the corresponding median was 15.3 (95% CI, 8.8– 
undefined) months. In contrast, median OS was only 4.8 (95% CI, 2.9–9.3) months in the 
resistant group, with 29% OS at 1 year. PFS was numerically superior in the sensitive 
group and inferior in the resistant group, but the differences in outcome were smaller 
and did not reach statistical significance (see Supplementary Data: Supplementary 
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Results; Supplementary Figs. S1 and S2). Analysis of the subgroup of patients treated with 
nivolumab in third- or higher line (N = 40), showed similar behavior in OS and PFS, with 
resistant patients showing a trend to shorter outcomes [HR, 0.49 (95% CI, 0.23–1.04); P 
= 0.062 for OS and HR, 0.50 (95% CI, 0.25–1.02); P = 0.057 for PFS] and sensitive patients 
showing numerically longer survival [HR, 0.48 (95% CI, 0.21–1.10); P = 0.082 for OS and 
HR, 0.62 (95% CI, 0.31–1.23); P = 0.172 for PFS]. Kaplan–Meier plots for this subgroup are 
shown in the Supplementary Data.
Figure 3.
Kaplan–Meier plots of OS for the validation sets and the chemotherapy cohort. A, Validation set 
1 resistant versus not resistant. B, Validation set 1 sensitive versus not sensitive. C, Validation set 
2 resistant versus not resistant. D, Validation set 2 sensitive versus not sensitive. E, Chemotherapy 
cohort sensitive versus not sensitive. F, Chemotherapy cohort resistant versus not resistant.
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Results for validation set 2 are shown in Fig. 3C and D. Patients classified as resistant 
had worse OS than not resistant patients [HR, 0.39 (95% CI, 0.19–0.77); P = 0.007]. The 
comparison of OS between the sensitive group and the not sensitive patients yielded 
an HR of 0.58, but did not show a significant difference (P = 0.179). However, for ternary 
test classifications, the sensitive group had longer OS than the resistant group [HR, 
0.41 (95% CI, 0.18–0.94); P = 0.036]. Full analysis for the sensitive/intermediate/resistant 
classifications can be found in Supplementary Data: Supplementary Results. Analysis of 
PFS showed only numerical differences between classification groups.
As results were consistent across cohorts, within the limits of relatively small subgroup 
sizes, a pooled analysis of all patients treated in second-line setting with nivolumab was 
carried out stratified by cohort (N = 249). There was no indication of any correlation of 
PD-L1 expression with test classification (P = 0.292, 0.810, and 0.337 for ternary, resistant 
vs. not resistant, and sensitive vs. not sensitive test classifications), although positive PD-
L1 expression was a predictor of improved OS and PFS in the pooled analysis [HR, 1.60 
(95% CI, 1.01–2.54); P = 0.046 for OS and HR, 1.61 (95% CI, 1.07–2.44); P = 0.023 for PFS]. 
Indeed, analysis including test classification and PD-L1 expression demonstrated both to 
be independent predictors of PFS (see Supplementary Data). Within the pooled second-
line population, multivariate analysis showed that the resistant versus not resistant 
stratification was a significant independent predictor of OS (P < 0.001) and PFS (P = 0.006) 
when adjusted for multiple baseline factors (Table 2). The sensitive versus not sensitive 
stratification was a significant independent predictor of OS (P = 0.009) and showed a 
trend for prediction of PFS (P = 0.079).
Figure 3E and F show OS for classification groups obtained by applying the test to 
pretreatment samples of the chemotherapy cohort, in which patients received docetaxel 
as second-line therapy. There was no indication that the test was able to stratify patients 
by outcome following this single-agent chemotherapy (P = 0.471 and P = 0.165 for OS 
comparison of resistant vs. not resistant and sensitive vs. not sensitive, respectively).
6
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Protein set enrichment
To examine the potential biological mechanisms underlying the test, the association of 
test classification with various biological processes was assessed using PSEA methods 
(22–24). The results are summarized in Table 3. Acute phase response, acute inflammatory 
response, wound healing, and complement activation were identified as associated 
with test classification with P < 0.001. In addition, innate immune response and chronic 
inflammatory response were identified as associated with P < 0.01. Similar analysis was 
performed comparing the sensitive subgroup with the remaining patients. Only immune 
tolerance and suppression were identified as associated with test classification with P < 
0.01 (FDR < 0.1). Full results for sensitive versus not sensitive phenotype are contained in 
the Supplementary Data: Supplementary Results; Supplementary Table S21.
Table 3. Results of PSEA of test classifications resistant versus not resistant
Abbreviation: NK, natural killer.
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DISCUSSION
Here, we report the establishment of a pretreatment serum proteomic classifier that 
separates those patients who obtain little from those that obtain durable clinical benefit 
from treatment with the PD-1 inhibitor, nivolumab, as second-line treatment for advanced 
NSCLC. On the basis of 274 MS features, patients could be classified as being resistant, 
intermediate, or sensitive. The difference in OS between resistant and not resistant 
patients was highly significant: the HR was 0.48, and median survival times were 4.3 
months versus 11.1 months, respectively. The test was validated while blinded to clinical 
outcome data with an independent set of patients with advanced NSCLC, treated at a 
different institution. The classifier failed to stratify outcomes within a historical cohort of 
patients with advanced NSCLC treated with docetaxel as second-line therapy. Moreover, 
test classification, as expected, was independent of well-established clinical factors and 
notably showed no evidence of association with PD-L1 expression.
A serum test would have obvious advantages, such as ease of detection using one blood 
draw. Also, the test may avoid the issue of intrapatient tumor heterogeneity and could 
assess host factors that are not captured by examination of the tumor microenvironment 
in histologic samples. Further characterization of the classifier revealed that the 
classification phenotypes identified are associated with biological processes known to 
confer a poor prognosis in lung cancer. Several lines of research indicate that complement, 
as a member of a diverse family of innate immune proteins, is involved in dysregulation 
of mitogenic signaling and escape from immune surveillance (27, 28). Complement 
activation, as measured by Cd4, a stable complement degradation product, in serum of 
patients with early-stage NSCLC was significantly associated with poor prognosis (29). A 
number of authors have identified the ratio of the acute phase protein, serum C-Reactive 
protein, to albumin as a negative prognostic factor in both early and advanced NSCLC 
(30). Intratumoral wound-healing signatures, as measured by mRNA expression arrays, 
are considered to be T-cell suppressive and have been observed in several tumor types, 
among them NSCLC (31). Interestingly, sera derived from patients with tumors exhibiting 
woundhealing signatures elicited identical signatures from nontumorassociated 
fibroblasts, which were found to be a powerful predictor of an unfavorable clinical course 
(32). These observations may provide the biological basis of our findings, although a direct 
link between the abundance of these circulating proteins and absence of a response to 
PD-1 inhibitors remains to be established.
The results obtained in this study do not stand alone. Weber and colleagues identified 
a protein classifier from sera of patients with melanoma treated with PD-1 inhibitors, 
employing the same technology that was used in our study. This was validated in multiple 
patient cohorts treated with PD-1 inhibitors and CTLA4 antagonists. (14) As here, they 
were able to identify, prior to initiation of treatment, patients who had a favorable 
outcome following treatment. Biological processes associated with that classifier included 
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complement, wound healing, and acute phase pathways, all upregulated in the poor 
prognosis group, corroborating our results. Further evidence that the pretreatment 
circulating proteome provides important information on checkpoint efficacy was provided 
in the context of a phase II study where atezolizumab was compared with docetaxel as 
second-line treatment in 272 patients with advanced NSCLC (33). Similar to our results, 
a serum protein classifier was established that identified patients with poor [median OS, 
7.3 months; n ¼ 60 (45%)] and good [median OS, not reached; n = 73 (55%)] outcomes. 
This classifier was shown in blinded validation to be predictive for atezolizumab versus 
docetaxel for OS and PFS (Pinteraction < 0.01). In that study, as in our own, there was no 
association between test classification and tumor PD-L1 expression; there was also no 
association with TMB. Also, among the biological processes that were most significantly 
associated with classification by PSEA, acute inflammation and complement activation 
ranked in the top three.
There are some limitations to our results. Obviously, the number of patients was low 
and all three immunotherapy-treated cohorts came from one geographic area and were 
investigated retrospectively. Also, for historical reasons, validation blinded to all clinical 
data was only possible for validation set 2. Although we made strong efforts to obtain 
sufficient tumor tissue samples, we were not able to obtain PD-L1 expression data on all 
patients. Several factors contributed to this: many patients are diagnosed on the basis of 
cytology alone and so have no tissue available for PD-L1 analysis; at the time of treatment 
initiation for these patients, use of PD-L1 expression was still somewhat investigational; 
and positive PD-L1 expression status was not mandatory for administration of nivolumab 
in the second- and higher-line setting. Unfortunately, TMB data were not collected. 
Investigation of larger cohorts with more complete information on TMB and PD-L1 
expression would be useful to examine with more precision the level of association of 
these markers and how much complementary information each can provide to predict 
outcome. The nonimmunotherapy-treated control set was small and restricted to one 
therapy. It would be of interest to study the performance of the test in larger control 
cohorts in other standard-of-care nonimmunotherapy regimens to be able to explore the 
test’s predictive potential.
Additional validation of the test in other larger cohorts of patients treated with CPIs is 
necessary. So far, we have investigated the ability of the test to stratify outcome for patients 
receiving checkpoint blockade monotherapy in the second- and higher-line setting, after 
platinum-based chemotherapy. However, now immunotherapy is moving into the first-
line setting, either as monotherapy for patients with PD-L1 expression greater than 50%, 
or in combination with chemotherapy. It is of interest to evaluate the performance of the 
test in these first-line settings. A prospective trial, comparing outcomes between mono-
immunotherapy and the chemo-immunotherapy combination in first-line patients with 
high PD-L1 expression is in the final stages of design. Studies in earlier stage patients 
receiving durvalumab with chemoradiation would also be informative. Evaluation of 
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the test with appropriate comparator nonimmunotherapy regimens in a prospective, 
randomized setting would be required to unequivocally determine its predictive power 
and clinical utility.
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Introduction: Immune checkpoint inhibitors have emerged as a standard of care 
treatment for non-small cell lung cancer (NSCLC). To get insight into variations 
in tumor growth kinetics and their potential predictive values for outcome we 
evaluated tumor growth rate (TGR) in patients receiving PD-1 checkpoint inhibitors.
Materials and Methods: Differences in TGR before and after the start of treatment 
were calculated by entering the sum of the longest diameters from CT-scans 
before and after the initiation of therapy into a formula that assumes a volumetric 
exponential tumor growth. TGR variations, possible predictors for TGR changes and 
its relationship to overall survival (OS) were studied. For comparison tumor response 
was assessed using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 
v1.1).
Results: Among the 58 evaluable patients, 37 patients (64%) showed deceleration of 
TGR and 16 patients (27%) showed an acceleration of TGR after initiation of therapy, 
with a significant difference in median OS of 18.0 versus 6.0 months (HR=0.35; 
95%CI:0.18-0.71) between these groups. Four patients (7%) were defined as having 
HPD. In 5 patients (9%), the tumor growth remained stable. These TGR categories 
were not significantly different according to age, gender, histology, smoking or 
previous radiotherapy. Of the patients defined as having progressive disease by 
RECIST1.1 at first follow up 40% showed response to CPI by a decrease in tumor 
growth rate. 
Discussion: Tumor growth kinetics can be used as a clinically relevant predictor for 
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INTRODUCTION
In recent years, programmed cell death (PD)-(L)1 immune checkpoint inhibitors have 
emerged as a standard of care treatment option with an increase in survival and this 
has changed the way patients with cancer are managed[1]. Checkpoint inhibitor (CPI) 
treatment is associated with novel patterns of tumor response, and evidence suggests that 
treatment with these immunotherapeutic agents may even backfire in certain patients[2]. 
In current practice,  the anti-tumor activity of therapeutic agents is assessed using the 
Response Evaluation Criteria in Solid Tumors (RECIST) guidelines, originally published 
in 2000 and revised in 2009 as RECIST1.1[3]. This utilizes unidimensional diameter 
measurements for response evaluation. Progression is defined at an increase in tumor 
size (which is the summation of the longest diameter of 5 target lesions) of more than 
20% compared to the lowest determined tumor size at any point in time. The possibility 
of pseudoprogression[4–6] necessitated a second update of RECIST and in 2017 iRECIST 
was adopted as novel tumor response evaluation tool in patients with immunotherapy 
treatment[7]. Several authors have suggested that RECIST criteria may be inadequate to 
capture the response to immunotherapies[8–13].
At first, anecdotal evidence of rapid disease progression in patients treated with 
immunotherapy was reported[14, 15]. This was followed by a review of the tumor 
growth rate in 131 patients with different tumor histology upon treatment with anti-
PD-1 therapies, which revealed that 9% of patients developed accelerated tumor 
growth which was subsequently characterized as hyperprogressive disease (HPD)[16]. To 
identify tumors showing HPD, tumor growth kinetics were integrated into the response 
evaluation method and implemented in multiple recent studies[16–20]. (Table 1) In all 
five the definitions of HPD, tumor kinetics and time are taken into account, which are both 
not part of the RECIST measurements. For example, tumor growth rate (TGR) uses the 
same computed tomography (CT) measurements as RECIST but assumes that volumetric 
tumor growth follows an exponential law. Also, it integrates the time intervals between 
CT scans allowing a quantitative assessment of the dynamics and kinetics of the tumor. In 
both RECIST and TGR, each patient is used as his or her own control. TGR has already been 
successfully used to evaluate the activity of multiple agents other than CPIs and in other 
tumor types[16, 21–24] and for this study the authors believe that it can be instrumental 
to identify therapeutic effects in the treatment with immunotherapeutic agents other 
than for HPD.
In this study, it is hypothesized that tumor growth kinetics based on CT measurements 
provides clinically relevant information in CPI treatment for NSCLC and is associated with 
clinical outcome. RECIST measurements and TGR differences before and after initiation of 
CPI treatment were analyzed in NSCLC to assess the variations in tumor growth kinetics 
and their potential predictive values for outcome.
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Table 1. Definitions of Hyperprogressive disease in immunotherapy using tumor growth 
kinetics
Definition of Hyperprogressive disease Tumor type No. of 
patients
Reference
A Response Evaluation Criteria in Solid Tumors 
progression at the first evaluation with a 2-fold 
or greater increase in Tumor growth rate (TGR) 





131 Champiat et 
al. (2017)
A tumor growth kinetics ratio ≥2, being the ratio 
between the slope of tumor growth prior to 
treatment and after start of therapy





Time-to-treatment failure of less than 2 months, 
>50% increase in tumor burden compared 
with pre-immunotherapy imaging, and >2-fold 
increase in progression pace
Stage IV cancer, 
different tumor 
types
155 Kato et al. 
(2017)
A disease progression at the first evaluation 
with ΔTGR exceeding 50%. With ΔTGR being the 
variation per month between tumor growth rate 
before and during treatment.
Non-small cell lung 
cancer
406 Ferrara et al. 
(2018)
An absolute increase of delta TGR by 50%, with 
delta TGR being the variation per month of TGR 
before and after initiation of therapy
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Between June 2015 and September 2017, 196 NSCLC patients were treated with the 
anti-PD1 immune checkpoint inhibitor nivolumab as a second line therapy in an early 
access program (EAP) and as standard of care at the Erasmus MC, Erasmus University 
Medical Center (Rotterdam, The Netherlands). The Erasmus MC is a tertiary hospital to 
which patients were referred from other hospitals for CPI treatment. Nivolumab was 
administered intravenously at a dose of 3 mg/kg every two weeks. 
Out of these, 58 were eligible for inclusion (Figure 1A). These patients had: (1) a baseline 
CT-scan prior to the initiation of  therapy (< 2weeks); (2) at least one pre-baseline CT-scan 
taken before the baseline CT-scan, during which interval no treatment was provided; and 
(3) at least one follow-up CT-scan following immunotherapy available for adequate review. 
For the pre-baseline CT-scan, the last CT-scan from the referring hospitals was frequently 
used. As patients were referred for CPI treatment from other hospitals and given the EAP 
application procedure, there is a time lag between the determination of progression on 
last systemic treatment and the start of the new therapy. The median time between the 
pre-baseline and baseline CT-scan is 1.8 months, ranging from 1.3 to 6.8 months. A small 
window between the baseline CT and the start of therapy of no more than two weeks was 
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required. Follow-up scans were performed according to the treating physicians’ discretion 
as a part of clinical care without predefined intervals. There was an expected average time 
of 6 to 8 weeks between the baseline CT scan and response assessment.
Figure 1.
A: Patient selection flow chart. B: Reviewed CT scan moments. PREBA (pre-baseline to baseline) = 
time between pre-baseline and baseline CT scan. BAFFU (baseline to first follow up = time between 
baseline and first follow up CT. Red marked area = time between baseline CT and start Nivolumab 
which was < 2 weeks.
Assessment of tumor growth kinetics
The pre-baseline, baseline and first follow-up (FU) CT scans were retrospectively reviewed 
for the assessment of tumor burden and identification of target lesions (Figure 1B). 
Identification of target lesions and tumor size measurements were quantitatively assessed 
by the radiologists using RECIST v1.110. In brief, target lesions (≥10 mm in the longest 
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diameter for non-nodal lesions and ≥15 mm in short axis for nodal lesions) were selected 
on baseline scans with a slice thickness no greater than 5 mm, allowing up to 2 lesions 
per organ and up to 5 lesions in total10.  Only patients with at least one target lesion on 
baseline scan were included. Follow-up scans were performed according to the treating 
providers’ discretion as a part of clinical care without predefined intervals. 
Definitions
Tumor size was defined as the sum of the longest diameters (SLD) of the target lesions 
for pre-baseline, baseline and the first FU scan as per RECIST v1.1. According to RECIST 
v1.1, the tumor response was classified as: complete response (CR), partial response (PR), 
stable disease (SD), and progressive disease (PD)5. To report the tumor size difference 
between PREBA (pre-baseline to baseline) and BAFFU (baseline to first follow up) in a 
clinically meaningful way, time was taken into account as a factor. This was expressed as 
the percentage difference in SLD of the target lesions for the reference period of 6 weeks, 
which is the planned time between follow up CT scans (SLDdiff):
SLDdiffPREBA = ((((SLDBaseline – SLDPre-baseline)/SLDPre-baseline))*100)/TimePREBA(weeks))*6
SLDdiffBAFFU = ((((SLDFollow-up – SLDBaseline)/SLDBaseline))*100)/TimeBAFFU(weeks))*6
SLDdifference = SLDBAFFU - SLDPREBA
TGR was calculated across the same clinically relevant treatment periods (and if relevant 
between follow up scans thereafter). Tumor size was expressed in the same way, using 
SLD. Let t be the time expressed in months for the period between CT-scans. The tumor 
volume at time t is equal to Vt = V0 exp(TG*t), assuming the tumor growth follows an 
exponential law. V0 is the volume at baseline and TG is a measure of tumor growth. We 
approximated the tumor volume (V) by V = 4 π R3 /3, where R, the radius of the sphere is 
equal to SLD/2[25]. TG is than equal to TG = 3 Log(SLDt/SLD0)/t. To report the TGR results 
in a clinically meaningful way, we expressed TGR as a percentage increase in tumor 
volume during 1 month using the following transformation: TGR ¼ 100 [exp(TG) 1], where 
exp(TG) represents the exponential of TG. TG and TGR were calculated using the following 
transformation: 




For patients who had disease progression with new lesions, the SLDdifference and TGR 
were computed on the target lesions only (new lesions were not included in the SLD). 
Hyperprogressive disease was defined as a 2-fold or greater increase in TGR from baseline. 
True hyperprogressive disease (True-HPD) was defined as a 2-fold or greater increase 
in TGR from baseline and PD as defined by RECIST v1.1 at the first follow up evaluation, 
according to the definition of Champiat et al.[16].
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Statistical analysis
Overall survival (OS) was determined as the time between the first administration of 
nivolumab and the time of death by any cause, patients with loss to follow up were 
censored. OS was estimated and presented graphically using the Kaplan-Meier method. 
Survival curves were compared using the Log-rank test. Hazard ratios (HR) were estimated 
from Cox proportional hazard models. Statistical comparisons were performed using the 
X2 or Fisher’s exact test for categorical data, t-test were used for continuous variables. All 
the tests were 2-sided and significance was assumed if P < 0.05. All the analyses were done 
using IBM SPSS statistics version 23.
RESULTS
The majority of the 58 patients included for analysis were male (59%) and the mean age 
was 63 (range 35-79). Ten percent of patients were non-smokers, 83% were either current 
or an ex-smokers and for 7%, this was unknown. Histological types were: adenocarcinoma 
(71%), squamous cell carcinoma (22%), Large cell in (2%), NSCLC NOS (2%), and unknown 
(3%) (Suppl. table 1).  
All patients received prior chemotherapy with a median of 4.1 months between the 
last administration of chemotherapy and the administration of CPI, ranging from 0.7 to 
24.6 months in the 53 patients with the exact stop date known. Thirty-nine percent of 
56 patients received prior radiotherapy to the chest with a median time of 9.6 months 
between the last radiation dose and the first administration of CPI, ranging from -2.1 to 
24.6 months. In two patients this was not recorded. 
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Figure 2.
RECIST categories at first follow up A. Tumor growth in SLD difference between baseline and first 
follow-up. B. SLD difference before and after baseline. C. Tumor growth in TGR before and after 
baseline. D. Tumor growth in SLD difference with patients showing hyperprogressive disease. E. 
Overall survival (OS) when differentiated according to RECIST response categories (Log Rank P= 
0.004). F. OS according to HPD (Log Rank P= 0.041).True-HPD (black) =  hyperprogressive disease 
defined as PD at the first evaluation with a 2-fold or greater increase in tumor growth rate (TGR) from 
baseline; No hyperprogressive disease (yellow) = patients not showing HPD at fist follow up. PREBA 
= Pre-baseline period; BAFFU = period from baseline to first follow-up.
The median OS was 11.5 ± 2.8 months. The median number of months on treatment was 
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10.5 ± 5.1 weeks. And  the mean time from baseline to first follow up (TimeBAFFU) was 5.8 
± 1.7 weeks. At first follow-up CT scan, patients were categorized by RECIST v1.1 into: 
CR 0 (0%), PR 7 (12%), SD 41 (71%), and PD 10 (17%) patients. Figure 2A shows how 
follow-up CT’s are classically evaluated, taking the baseline CT as the zero point, 
and categorizing tumor growth at follow-up according to RECIST. Lines ending above 
zero represent tumor growth, with a 20% increase in total tumor size being the cut-
off for PD. Lines ending below zero represent tumor shrinkage, with -30% being the 
cut-off for partial response. 
Next, we compared the above change in sum of the diameters according to RECIST after 
start of treatment to the change in sum of the diameters before the start of treatment 
(Figure 2B). Of the 10 patients showing PD at first follow up, CPI caused a decrease in 
growth rate in 4 patients (40%), an increase in tumor growth rate in 5 patients (50%) and 
in 1 patient (10%) the tumor growth did not significantly change (defined as a change of 
≤5%). Of the 41 patients showing SD at first follow up, CPI caused a decrease in growth 
rate in 26 patients (63%), an increase in tumor growth rate in 11 patients (27%) and in 4 
patients (10%) the tumor growth did not significantly change. In all 7 patients showing PR 
at first follow up, CPI caused a decrease in tumor growth.
 Tumor growth rate (TGR) is derived from the SLD but accounts for an assumption for 
tumor volume. In Figure 2C the TGR before and after initiation of CPI therapy is shown. 
and although this gives a similar representation of the changes in growth pattern it is 
harder to correlate with the RECIST criteria than Figure 2B. 
In total 11 patients (19%) fulfill the definition of HPD based on TGR alone defined as a 
>50% increase in TGR between PREBA and BAFFU. Four patients (7%), were defined as 
having True-HPD, because they showed PD according to RECIST at the first follow up on 
top of the >50% increase in TGR. In figure 2D, these patients with True-HPD are visualized 
within the RECIST categories. 
OS was differentiated according to RECIST v1.1 response categories: PR 25.3 ± 5.3 months, 
SD 10.3 ± 2.5 months and PD 6.0 ± 2.6 months. (Log Rank P= 0.004) (Figure 2E). When 
differentiating according to HPD status an OS of: no True-HPD 12.3 ± 4.3 months versus 
True-HPD 2.3 ± 2.7 months was observed. (Log Rank P= 0.041) (Figure 2F)
The distribution of TGR across the 2 periods is as follows; PREBA period: median 28.0 
(range: -48.6 to 293.7) and BAFFU period: median 6.9 (range: -83.8 to 142.6). The group was 
divided into patients showing tumor growth acceleration (TGR/SLDdiff at BAFFU > PREBA) 
16 (27%) and patients showing tumor growth deceleration and/or shrinkage (TGR/SLDdiff 
at BAFFU < PREBA) 37 (64%) after the initiation of therapy, excluding patients with stable 
TGR 5(9%) (<5% difference in TGR per month) (Figure 3A). Comparison of acceleration in 
TGR with deceleration in TGR provided a significant difference in median OS of 6.0 ± 0.6 
vs 18.0 ± 4.4  months, Log Rank P= 0.002. (Figure 3C). Deceleration of TGR reduced the 
risk of early death with a HR of  0.35; 95% CI of 0.18 to 0.71.  By only taking into account 
the 48 patients showing tumor growth before the start of CPI, the TGR could be further 
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divided into a group that showed tumor shrinkage after initiation of therapy (N=21, 44%), 
tumors that kept growing but with a decreased growth rate (N=14, 29%) and tumors that 
kept growing but increased their growth rate (N=13, 27%). (Figure 3B) This provided a 
significant difference in median OS of 25.3 ± 3.6 vs 8.9 ± 2.5 vs 5.5 ± 0.7  months, Log Rank 
P<0.001. (Figure 3D). When plotting OS against growth rate in SLDdifference at 6 weeks 
after baseline, the effect of these growth patterns can be appreciated. Figure 4.
Figure 3.
A. TGR acceleration versus deceleration after start of therapy. B. Patients showing growth before 
the start of therapy grouped according to change in growth pattern after start of therapy. C OS 
according to increase versus decreased TGR after start of therapy (Log Rank: P= 0.002). D. OS 
according to change in TGR after initiation of therapy (Log Rank: P< 0.001). TGR = Tumor growth 
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Figure 4.
Overall survival plotted against the SLDdifference at six weeks after the start of CPI in the patients 
that showed tumor growth before the start of therapy. The patients were divided into groups 
according to tumor growth rate change. Patients showing tumor growth with an increased growth 
rate (red) as well as with a decreased growth rate (yellow) go over the 20% growth line, defining 
progressive disease at first follow up.
No correlation between TGR or SLDdifference during PREBA and during BAFFU was 
found. No significant correlations were observed in gender, age, histology, smoking and 
previous radiotherapy for patients showing tumor growth acceleration when compared to 
patients showing growth deceleration.  For the patients showing True-HPD no significant 
correlations were observed in gender, age, histology, smoking and previous radiotherapy 
when compared to the rest of the studied population. 3 out of 4 patients with True-HPD 
were ≥65 years, the fourth patient was 46 years old. 
DISCUSSION
This study explores the dynamics of tumor growth in patients treated with CPI for NSCLC. 
We confirm the presence and incidence of HPD but we also describe a novel phenomenon 
that in those tumors that keep growing, a decrease in tumor growth rate induced by CPI 
is associated with improved survival. The division of the group into patients showing 
deceleration in TGR versus acceleration in TGR at first follow up after the start of CPI 
therapy, provided a significant and clinically relevant difference in OS of 12 months. 
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This is relevant as the patients in each group fall into different RECIST categories. For 
example, patients with a decrease in TGR on CPI might still be growing fast enough to be 
categorized as having PD at the first response assessment. However, these patients have a 
significant better OS than a patient with a tumor that responded with an increase in TGR. 
Of the patients showing PD according to RECIST criteria by an increase of SLD of ≥ 20%, 
40% actually had a decrease in tumor growth. In these patients, after determination of PD, 
in general the immune therapy will be withheld, potentially deteriorating the outcome 
of the patient. In this particular group, treatment beyond progression was given when a 
patient was in good clinical condition, given the option of pseudo-progression. This may 
also (partly) explain why we did find this increase in OS, but a further treatment may be 
beneficial for these patients. As far as the authors are aware, only Lahmar et al.[15] recently 
presented an abstract describing a similar analysis in 58 NSCLC patients treated with 
CPIs and categorized their response patterns according to increasing or decreasing TGR 
after the initiation of therapy[15]. In line with our findings, they also found a significant 
relationship between treatment TGR and OS after immunotherapy.
When the growth patterns were further divided into three groups, (i.e. a group that showed 
tumor shrinkage after initiation of therapy; tumors that kept growing but with a decreased 
TGR; and tumors that kept growing but with an increased TGR), significant differences in 
median OS of respectively 25.3, 8.9 and 5.5 months were found. When comparing just the 
two groups that kept growing, only a tendency towards significance was found, P=0.065, 
possibly due to the small number of patients. No significant differences for the patients 
showing TGR acceleration were observed in gender, histology, smoking and previous 
radiotherapy when compared to the patients showing deceleration. 
Of the 58 patients found eligible for inclusion in this study, four (7%) were having True-
HPD defined as showing PD according to RECIST at the first evaluation with a 2-fold or 
larger increase in TGR between the period prior to treatment (PREBA) and upon therapy 
(BAFFU). This is a comparable range as found by Champiat et al.[16] who used the same 
definition for HPD[16]. In a recent review incidences of HPD up to 21% were described 
in NSCLC patients specifically[8]. In other histologies incidences up to 29%[17–19] were 
found but these used different, and often less strict, definitions. Comparable to the study 
by Champiat et al.[16] we only included patients that had a follow up CT scan, and excluded 
the patients who became too ill to be scanned or who died before the first follow-up CT 
scan. True-HPD was, in this study, a significant negative predictive value for OS. Patients 
showing True-HPD had a median OS of only 2.3 while the other patients had an OS of 
more than one year. This result is, again, in line with the observations  by Champiat et al. 
and Ferrera et al.[16, 19]. 
Many patients in the available patient cohort were not eligible for inclusion due to the 
relatively long time of more than two weeks between the baseline scan and the start of 
CPI treatment. To be able to use TGR in a more standardized way we recommend stricter 
follow up protocols with the baseline CT scan and start of therapy ideally being on the 
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same day. In the case of this study, up to 47% extra patients could have been included 
if this stricter follow up protocol would have been implemented. Another limitation of 
the current study is that it is a retrospective analysis. The selection of target lesions may 
not perfectly reflect the evolution of the whole tumor burden and new lesions were not 
accounted for. Moreover, we assumed that tumors do grow as spheres, while we know 
this is not always the case[26]. It remains to be determined whether response assessment 
using RECIST is the optimal basis to determine the TGR in immunotherapy. To differentiate 
early HPD from pseudo-progression is another pitfall in this treatment type, further 
underlining the importance of imaging at defined intervals, close monitoring and clear 
definitions. 
To date, there is no definition of TGR for growth assessment in treatment with 
immunotherapeutic agents and it is still unclear which factors influence TGR. Tumor growth 
rate integrates the time interval between CT-scans allowing a quantitative assessment of 
the dynamics and kinetics of the tumor. But, as can be seen in figures 2B and C, TGR is 
more difficult to correlate with the RECIST criteria because the percentage in which TGR 
is expressed does not match the RECIST thresholds. To make TGR more related to the 
way tumor evaluation takes place using RECIST, the factor time was integrated into the 
SLD measurements, resulting in a SLDdifference in percentage over 6 weeks. This could 
possibly be a more accessible expression in everyday practice for tumor growth kinetics 
when used only to evaluate if tumor growth is increasing, decreasing or if it is shrinking. To 
find the predictors and to understand the biological mechanisms underlying the variable 
therapeutic effects, prospective studies with close monitoring and biopsies are necessary. 
But, by starting to visualize and monitor tumor growth kinetics before and after onset of 
therapy, insight into the response patterns in immunotherapy treatment can already be 
improved. In current clinical practice, we are already calculating the SLDdifference of the 
target lesion to evaluate RECIST response between two CT-scans at a certain treatment 
point. If these results are put in a graph from the first available scan, a visual representation 
of the growth rate changes over time and how treatments are influencing these, will 
be obtained. Because TGR is calculated from the same measurements that determine 
RECIST, extra work for the radiologist would be avoided. Ideally, an integrated software 
application or a web page would be developed in which the SLD is entered, after which 
it visualizes the tumor growth kinetics in a graph that represents the evolution over the 
different follow up moments. When more widely used, and more data becomes available, 
graphs could be validated and cut off  values for treatment planning could be determined.
In summary, in this study, tumor growth dynamics provide clinically relevant information 
and additional information about response to using RECIST alone. In the current computer 
driven medical world, calculating and visualizing tumor growth kinetics before and during 
treatment can potentially improve treatment planning, and might help to decide early 
which patients might, and might not benefit from their treatment with CPI.
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Introduction: A minority of NSCLC patients benefit from anti-PD1 immune 
checkpoint inhibitors. A rational combination of biomarkers is needed. The objective 
was to determine the predictive value of tumor mutational load (TML), CD8+ T cell 
infiltration, HLA class-I and PD-L1 expression in the tumor.
Materials and Methods: Metastatic NSCLC patients were prospectively included 
in an immune-monitoring trial (NTR7015) between April 2016-August 2017, 
retrospectively analyzed in FFPE tissue for TML (NGS: 409 cancer-related-genes) and 
by IHC staining to score PD-L1, CD8+ T cell infiltration, HLA class-I. PFS (RECISTv1.1) 
and OS were analyzed by Kaplan-Meier methodology. 
Results: 30 patients with adenocarcinoma (67%) or squamous cell carcinoma (33%) 
were included. High TML was associated with better PFS (p=0.004) and OS (p=0.025). 
Interaction analyses revealed that patients with both high TML and high total CD8+ 
T cell infiltrate (p=0.023) or no loss of HLA class-I (p=0.026), patients with high total 
CD8+ T cell infiltrate and no loss of HLA class-I (p=0.041) or patients with both high 
PD-L1 and high TML (p=0.003) or no loss of HLA class-I (p=0.032) were significantly 
associated with better PFS. Unsupervised cluster analysis based on these markers 
revealed three sub-clusters, of which cluster-1A was overrepresented by patients 
with progressive disease (15 out of 16), with significant effect on PFS (p=0.007).
Discussion: This proof-of-concept study suggests that a combination of PD-L1 
expression, TML, CD8+ T cell infiltration and HLA class-I functions as a better predictive 
biomarker for response to anti-PD-1 immunotherapy. Consequently, refinement of 
this set of biomarkers and validation in a larger set of patients is warranted.
Précis
The findings suggest that a rational combination of biomarkers – PD-L1, TML, CD8+ T 
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INTRODUCTION
Tumors evade T-cell mediated destruction by exploiting inhibitory immune checkpoints 
such as the PD-1/ PD-L1 pathway. The efficacy of treatment with immune checkpoint 
inhibitors (ICIs) targeting this pathway in non–small-cell lung cancer (NSCLC) is limited, 
and better use of biomarkers is needed to predict response to treatment 1. 
The currently most widely used biomarker is PD-L1 expression in the tumor, as assessed 
by the PD-L1 tumor proportion score (TPS), which is positively associated with a response 
to ICI treatment in metastatic NSCLC patients 2. However, the performance of the PD-L1 
assay to predict clinical response remains poor 3. 
The presence of tumor infiltrating CD8+ T cells which recognize tumor antigens, when 
presented at the tumor cell surface in the context of HLA class I, is a prerequisite for 
successful ICI treatment. A surrogate marker for recognition of tumor antigens is tumor 
mutational load (TML), a measurement of the frequency of mutations in tumor cells, that 
correlates with the number of neoantigens that can be recognized by CD8+ T cells 4. Next-
generation genome sequencing (NGS) panels composed of about 300-600 cancer-related 
genes are designed to predict the TML with similar accuracy as whole exome sequencing 
5. A strong CD8+ type 1 T cell infiltration of tumors critically contributes to a better clinical 
outcome in cancer, including NSCLC 4. Conversely, (partial) loss of HLA occurs in a sizeable 
fraction of NSCLC tumors, as well as HLA diversity modulate the prognostic impact of 
tumor-infiltrating CD8+ T cells, and thus survival after checkpoint blockade 6-9. While TML 
is an emerging biomarker, CD8+ T cell infiltration and HLA expression have not been 
considered as predictive biomarkers in NSCLC.
Therefore, this study is the first to determine the predictive value of the TML, CD8+ T cells 




Patients with stage IV NSCLC who started nivolumab monotherapy between April 2016 
and August 2017 at the Erasmus University Medical Center, Rotterdam, The Netherlands, 
were included prospectively in the MULTOMAB study (Dutch Trial Registry NTR7015/
NL6828). The study was approved by the independent ethics committee (Medical 
Research Ethics Committee Erasmus MC; MEC 16-011) and all patients provided written 
informed consent. Patients were randomly selected and assessed for eligibility. Patients 
with NSCLC stage IV were included who had been treated with nivolumab monotherapy 
(weight-based dosing: 3mg/kg i.v., Q2W) and who were evaluable by RECIST v1.1. Patients 
who were treated with a prior line of immunotherapy were excluded. The median follow-
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up time was 27 weeks (interquartile range: 14-46 weeks) and the median time between 
diagnostic biopsy and first administration of nivolumab was 5 weeks (interquartile range: 
1-41 weeks). The use of archival formalin-fixed, paraffin-embedded (FFPE) samples was 
in accordance with guidelines from the Dutch Federation of Medical Research and was 
approved by the independent ethics committee (Medical Research Ethics Committee 
Erasmus MC; MEC 17-1186). Specimen handling and all biomarker assay analyses were 
undertaken blinded; a unique code was assigned for each patient, with a separate list 
linking these codes with the patient characteristics and outcomes.
TML assay
Mutational load was determined by the Oncomine TML assay (ThermoFisher Scientific, 
Waltham, MA) according to manufacturer’s protocol on an Ion Torrent S5 XL next-
generation sequencing platform (Gilford, NH). Mutational load is defined as the number 
of somatic nonsynonymous variants (missense and nonsense single nucleotide variants 
plus insertions and deletions) detected per megabase of exonic sequence with sufficient 
coverage. Germline variants were filtered out using the Mutation Load Calculation Filter 
Chain in Ion Reporter software 5.10 (ThermoFisher Scientific, Waltham, MA). A TML cut-off 
of 11 mut/Mb was used to differentiate between tumors with low or high TML.
Immunohistochemistry on FFPE samples
Expression patterns of classical HLA (HLA-A and HLA-B/C) were assessed according to the 
Ruiter scoring system 10 as described before 8. The intensity and percentage of cells in the 
tumor were determined based on the sum of the intensity of staining (ranging from 0-3) 
and percentage positive cells (ranging from 0-5). Loss of HLA class I was defined by a low 
Ruiter score (0-3) of both HLA-A and HLA-B/C. Patients were dichotomized for low or high 
total CD8+ T cell infiltration based on the mean CD8+ T cell infiltration for all patients, and 
for low (<50%) or high (>50%) PD-L1 TPS (using the ready-to-use SP263 Ab clone on a 
Ventana Benchmark Ultra (both form Roche Diagnostics, Tucson, AZ) system according to 
the manufacturer’s instructions. Mouse monoclonal Abs HCA-2 and HC-10 (tissue culture 
supernatant respectively anti HLA-A, 1:500, and anti HLA-B/-C, 1:750; a generous gift from 
Prof. dr. J. Neefjes, Department of Cell and Chemical Biology, LUMC) were used to detect 
the free heavy chain of the classical HLA-A and HLA- B/-C molecule). The detection of 
CD8+ T-cells was done by using mouse monoclonal CD8 Ab (clone IA5, Leica Biosystems, 
Germany, 1:500). PD-L1 TPS was determined by using clone SP263 (Ventana PD-L1 assay, 
Roche, Switzerland).
Statistical analysis
Best overall response (BOR) was assessed according to RECIST v1.1 for complete response 
(CR), partial response (PR), stable disease (SD) and progressive disease (PD): minimum 
duration of 90 days for SD was required, confirmation of CR or PR was not necessary. PFS 
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was defined as the time between the first administration of nivolumab until PD or death 
due to any cause, and OS until death due to any case. Survival was compared by log-
rank test using Kaplan-Meier methodology. Group comparisons of categorical data were 
performed by 2-tailed χ2 or Fisher’s Exact test. Differences with two-sided P values <0.05 
were considered significant. No power analysis was performed in this proof-of-concept 
study. R version 1.1.453 (R-project, www.rproject.org) was used for hierarchical cluster 
analysis with complete linkage by Manhattan distance measure, using the mean for 
missing values, statistical software package SPSS v24.0.0.1 (SPSS, Chicago, USA) was used 
for further statistical analysis. 
RESULTS
A total of 99 patients were assessed for eligibility, of whom 69 patients were excluded 
because of either insufficient or poor quality of samples (n=33), or failure to obtain FFPE 
material from referring hospitals (n=36). 30 patients were analyzed (Table 1). The mean 
duration of nivolumab treatment was 5.4 months (SD: 4.6). Two patients (6%) developed 
severe immune-related toxicity (grade 3/4, according to CTCAE 4.03). All patients had at 
least one prior line of chemotherapy, consisting of platinum-based doublet chemotherapy, 
and three patients were also treated with an EGFR tyrosine kinase inhibitor. The mean 
duration of response to first line chemotherapy was 7.2 months (SD: 4.7). Examples of two 
representative patients are shown in Fig. 1a, displaying TML and IHC staining of classical 
HLA, CD8+ T cells and PD-L1. 
First, the prognostic effect of each parameter on PFS (Fig. 2a-d) and OS (Fig. S1a-d) was 
determined. High TML was significantly associated with better PFS (p=0.004) and OS 
(p=0.025). PD-L1 was associated with improved PFS (p=0.027), but not with OS (p=0.121). 
CD8+ T cells and HLA as individual biomarkers were not significantly associated with 
better OS or PFS, which was expected 8, although normal expression of HLA class I resulted 
in the better OS and PFS when compared to complete or partial loss of HLA expression. 
Complete loss was defined by a low score (0-2), partial loss by an intermediate score (3-6), 
and normal expression by a high score (7-8). Patients with complete loss had impaired PFS 
compared to patients with partial loss or normal expression of HLA class I (Fig. S2). 
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Table 1: Patient characteristics, TML and IHC patterns at baseline. 
Patient characteristics number mean (SD)




























Neg (0%) 11 (40.7)
Pos (>1%) 16 (59.3)
From a total of 99 eligible patients, 69 were non-evaluable for this analysis, because either there 
was no sufficient archived FFPE tissue (n=31), FFPE tissue could not be obtained from the referring 
hospital (n=36) or the tissue was of poor quality (n=2). The expression patterns of HLA-A and HLA-
B/C as well as the total CD8+ T cell infiltration in these patients were similar to what we reported 
before in a comparable group of NSCLC patients (10). 
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However, interaction analyses between these two markers and the other markers revealed 
that each combination of two markers was significantly associated with better PFS (Fig. 
2e-j), except for PD-L1 with CD8+ T cells due to low power. Specifically, 1) high TML and 
either high total CD8+ T cell infiltration (p=0.023) or no loss of HLA class I (p=0.026), 2) high 
total CD8+ T cell infiltration and no loss of HLA class I (p=0.041),  and 3) high PD-L1 and 
either high TML (p=0.003) or no loss of HLA class I (p=0.032) was associated with better 
PFS.
Next, the patients were divided into two groups on the basis of a clinical response (CR/PR/
SD) or failure to respond (PD) to nivolumab treatment (Table S1). This revealed a significant 
overrepresentation of patients with a high TML (p=0.043) and/or more profound total 
CD8+ T cell infiltration (p=0.005) among clinical responders. This association was not 
found for HLA class I expression or PD-L1 (TPS >1% or >50%). 
A comparison of the absolute values for all these parameters confirmed that the mean 
TML (p=0.001) and mean total CD8+ T cell infiltrate (p=0.004) were higher in the group 
of patients with a treatment response (Table S2). Notably, the TML was not directly 
correlated with CD8+ T-cell infiltration or HLA expression, but was positively associated 
with PD-L1 (p=0.035; Table S3).
Lastly, an unsupervised cluster analysis based on the four parameters was performed. 
This revealed two major clusters and a total of three sub-clusters (Fig. 1b). Cluster 1A was 
overrepresented by patients with PD (15 out of 16) of which the tumors were negative for 
2-3 of the 4 biomarkers. Cluster 2 almost exclusively comprised patients with SD of which 
the tumor was positive for 2-3 biomarkers but did not express PD-L1. Survival analyses of 
the 3 different clusters (Fig. 2k and Fig. S1k) indicate a significant effect on PFS (p=0.007), 
while the OS (p=0.74) was significant in a post-hoc comparison of cluster 1A with 1B 
(p=0.048).
DISCUSSION
The present proof-of-concept study suggests that in addition to PD-L1 expression also 
TML, CD8+ T cell infiltration and HLA class I expression are associated with PFS and predict 
the response to anti-PD-1 immunotherapy. Interestingly, unsupervised cluster analysis of 
the patients based on all four markers revealed one cluster pattern that almost exclusively 
identified non-responders (cluster 1A). In the current real-life setting, only a small amount 
of archival material could be used for TML determination and IHC staining, derived 
from routine biopsy specimens from the primary tumor and following initial diagnostic 
procedures (including routine NGS testing for driver mutations in some cases). We were 
able to demonstrate the clinical value of TML analysis in this immuno-oncology setting, 
and we believe this is the first study to do so in combination with a range of IHC biomarkers 
in small, realistic biopsy specimens. 
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Our findings are consistent with previous studies in different settings, although those 
studies cannot be generalized. Associations between TMB and immune signatures are 
generally cancer type dependent 11, and it can be assumed that they are also tumor stage 
dependent. In addition, a prospective study in early-stage untreated NSCLC patients 
demonstrated a significant and independent association of low immune-evasion capacity 
(defined as tumors with no immune editing potential, no HLA loss and no antigen 
processing machinery [APM] defects) and high number of neoantigens with increased 
disease-free survival 12.
Moreover, release of checkpoint blockade by nivolumab may result in a series of dynamic 
changes in the composition of the tumor microenvironment 13 which override the current 
prediction (false negatives), but this was not taken into account as we were limited to the 
use of archival material prior to ICI therapy. Notably, a significant correlation between PD-
L1 expression and TML was determined, which may contradict accumulating evidence 
from clinical trials 14. This may be related to the limited number of patients, but may also 
result from the use of continuous covariates rather than stratified data in clinical trials 
where true correlations may easily be overlooked. Based on our findings, it could not be 
established that TML and PD-L1 serve as an independent biomarker for clinical outcome. 
An interesting finding of this study is the added value of expression of HLA class I molecules 
on cancer cells, which is known to be crucial for the recognition of tumor cells by CD8+ 
TCs. In our opinion, the actual detection of HLA class I expression is more valuable as a 
future biomarker for ICIs than genetic, epigenetic, transcriptional, post-transcriptional or 
post-translational aberrations, such as loss of heterozygosity in HLA or B2M mutations, 
since protein expression is the ultimate outcome of all those changes. For instance, 
genetic studies have revealed that NLRC5, an HLA class I transactivator, is an important 
target for cancer immune evasion. The expression of NLRC5 correlated with that of HLA 
class I and negatively correlated with OS in stage III NSCLC 15. We focused primarily on the 
expression of HLA class I and did not determine selective APM defects, while this could 
also affect the recognition of tumor antigens by the immune system. For HLA peptides 
to be presented to CD8+ T cells, peptides must be processed by proteolysis, trimmed 
by enzymes to fit into the groove of HLA molecules, and transported intracellularly by 
peptide transporters, endoplasmic reticulum chaperones and the Golgi apparatus. The 
antigen presenting pathway often is altered in cancer, including lung cancer 16,17. Further 
studies should be directed at investigating the impact of the APM defects on response 
to ICIs. Last but not least, due to the relatively low patient numbers, we decided to take 
complete loss defined as a low score (0-3) of both HLA-A and HLA-B/C, but not partial HLA 
class I loss into consideration. However, a subgroup analysis showed that patients with 
complete loss have impaired OS and PFS compared to patients with no loss of HLA class 
I. The PFS of patients with partial loss was comparable to that of patients with no loss of 
HLA class I.
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Taken together, the findings support the hypothesis that a rational combination of 
biomarkers – based on the biological requirements for the ICIs to work –  may contribute 
to a more adequate response prediction of ICI treatment in NSCLC. Consequently, 
refinement of this proposed set of biomarkers and validation in a greater set of patients 
is warranted. 
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SUPPLEMENTARY INFORMATION
Supplementary Table 1. Best overall response analysis.
Response No response
Number (%) Number (%) p-value
TML 0.043
Low (<11 mut/Mb) 5 (45.5%) 12 (85.7%)
High (>11 mut/Mb) 6 (54.5%) 2 (14.3%)
HLA-A 0.4
Low 4 (40.0%) 10 (52.6%)
High 6 (60.0%) 9 (47.4%)
HLA-B/C 0.615
Low 4 (40.0%) 8 (42.1%)
High 6 (60.0%) 11 (57.9%)
Total CD8+ 0.005
Low 2 (20.0%) 14 (77.8%)
High 8 (80.0%) 4 (22.2%)
PD-L1 (TPS) 0.492
Neg (0%) 5 (45.5%) 6 (37.5%)
Pos (>1%) 6 (54.5%) 10 (62.5%)
PD-L1 (TPS) 0.279
Low (<50%) 7 (63.6%) 13 (81.3%)
High (>50%) 4 (36.4%) 3 (18.8%)
Patient grouping by response to anti-PD1 ICI therapy, comparing TML low vs. high, HLA-A low vs. 
high, HLA-B/C low vs. high, total CD8+ low vs. high, PD-L1 negative (neg) vs. positive (pos), PD-L1 
low (<50%) vs. high (>50%). P-values (1-tailed) by Fisher’s Exact test.
Supplementary Table 2. Test of between-subjects effects
Response Non-response
Mean (SE) Mean (SE) p-value
TML 10.2 (1.0) 5.2 (0.9) 0.001
HLA-A 5.2 (0.9) 3.2 (0.8) 0.098
HLA-B/C 4.8 (0.8) 3.9 (0.7) 0.407
Total CD8+ 58.5 (9.2) 18.5 (8.4) 0.004
PD-L1 (TPS) 23.0 (10.0) 16.3 (9.1) 0.629
Tests of Between-Subjects Effects (n=22) of response comparing individual predictive absolute 
values of: TML (mut/Mb), HLA-A and HLA-B/C (Ruiter scoring), total CD8+ (cells/mm2), PD-L1 (TPS; 
%). P-values (1-tailed) by Multivariate testing, excluding patients with missing values.
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Supplementary Table 3. Correlation matrix





0.022 ,440* -0.184 -0.227
Sig. (2-tailed) 0.916 0.035 0.240 0.147





0.022 0.067 0.163 0.086
Sig. (2-tailed) 0.916 0.754 0.249 0.546





,440* 0.067 0.064 -0.035
Sig. (2-tailed) 0.035 0.754 0.682 0.820





-0.184 0.163 0.064 ,623**
Sig. (2-tailed) 0.240 0.249 0.682 0.000





-0.227 0.086 -0.035 ,623**
Sig. (2-tailed) 0.147 0.546 0.820 0.000
Number 26 28 24 29
Correlation matrix of PD-L1 tumor proportional score (TPS; %), total CD8+ T cell infiltration (cells/
mm2), TML (mutations/Mb), HLA-A and HLA-B/C (Ruiter Score). Parametric correlations were 
performed by Pearson correlation coefficient, non-parametric correlations by Kendall’s Tau. TML 
was significantly correlated with PD-L1 (r2=0.440, p=0.035), HLA-A was significantly correlated with 
HLA-B/C (r2=0.623, p=0.000001).
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Supplementary Figure 2. Kaplan-Meier curves based on HLA class I expression
Kaplan-Meier curves showing the a OS en b PFS of patients based on the HLA class I expression: 
complete loss vs. partial loss vs. no loss of HLA class I. Here, complete loss was defined as 0-2, partial 
loss as 3-6, and no loss as 7-8. This resulted in a separate score for HLA-A and HLA-B/C. These scores 
were combined into a single score for HLA class I expression. Statistical tests were non-significant for 
OS (log rank p=0.055) and PFS (log-rank p=0.298).
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Introduction: A minority of advanced non-small-cell lung cancer (NSCLC) patients 
benefit from treatment with immune checkpoint inhibitors (ICIs). Ineffective effector 
function of activated T and NK cells may lead to reduced tumor cell death, even 
when these activated effector cells are released from their immune checkpoint 
brake. Hence, in this study we aimed to assess the association of baseline serum 
granzyme B, as well as germline variation of the GZMB gene, with clinical outcome 
to PD-1 blockade.
Materials and Methods: A total of 347 stage IV NSCLC patients who started 
nivolumab treatment between June 2013 and June 2017 were prospectively 
included. Baseline serum and whole blood was available, allowing for protein 
quantification and targeted DNA sequencing. Clinical outcome was based on best 
overall response (BOR) according to RECIST v1.1, PFS, and OS.
Results: Patients with low serum levels of granzyme B had worse PFS (HR 1.96; 95%CI 
1.12-3.43; p=0.018) and worse OS (HR 2.08; 95%CI 1.12-3.87; p=0.021) than patients 
with high baseline serum levels. To validate the findings, germline variation of GZMB 
rs8192917 was assessed. Patients with homozygous and heterozygous variants of 
GZMB rs8192917 had worse BOR (OR:1.60; 95%CI:1.01-2.52; p=0.044) and worse PFS 
(HR:1.38; 95%CI:1.02-1.87; p=0.036) than wild types. 
Discussion: A low baseline serum level of granzyme B and germline variation 
of GZMB was associated with worse clinical outcome in NSCLC, emphasizing the 
relevance and additional value of monitoring germline genetic variations which 
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INTRODUCTION
Immune checkpoint inhibitors (ICIs) target immune effector cells, predominantly T cells, 
which may lead to an effective immune response towards tumor cells 1,2. Although ICIs 
have shown to significantly improve overall survival (OS) in advanced non-small-cell lung 
cancer (NSCLC), only a minority of patients benefits from treatment, with an objective 
response in about one out of five patients 3,4. 
The molecular mechanisms underlying resistance to ICI therapy are only partly explained. 
It is postulated that a combination of factors contribute to response, involving tumor 
biology, tumor microenvironment, the peripheral immune system, as well as germline 
genetics 5,6. PD-1-mediated inhibition targets signalling downstream of the T cell receptor 
via its downstream phosphatase SHP-2, as well as co-stimulatory molecules 7,8. Importantly, 
distorted effector function of activated T and NK cells may lead to reduced tumor cell 
death, even when these activated effector cells are released from their PD-1 brake. 
Previously, it has been demonstrated that immunohistochemical staining and in vivo 
imaging, using positron emission tomography (PET), of intratumoral granzyme B may 
serve as a predictive biomarker for PD-1 blockade in melanoma 9. Granzyme B is a key 
serine protease that is secreted to induce apoptosis, primarily by activated T cells and 
NK cells 10. Distortion of granzyme B activity could be linked to reduced entry, trafficking, 
and accumulation within the cytoplasm of target cells (e.g. tumor cells), and/or linked 
to reduced enzymatic activity, and hence decreased cleavage of intracellular substrates, 
such as caspase-3 11-13. 
Taken together, we hypothesise that low baseline serum levels of granzyme B, and 
consequently alterations of the GZMB locus, may contribute to resistance mechanisms 
of PD-1 blockade. The primary objectives of the current analysis were to assess the 
association of baseline serum granzyme B levels with progression-free survival (PFS) 
and overall survival (OS) after PD-1 blockade in NSCLC patients. As a validation, genetic 
variants of the GZMB gene were related with PFS, OS and best overall response (BOR). 
Secondary objectives were to assess the relationship between serum granzyme B as well 
as genetic variations of GZMB and cytotoxic immune cell populations in blood.
MATERIALS AND METHODS
Study design and data collection
Patients with advanced NSCLC who were treated with PD-1 ICIs between June 2013 and 
June 2017 at the Erasmus University MC (Rotterdam, The Netherlands) and the Amphia 
Hospital (Breda, The Netherlands) were prospectively included. Patients with NSCLC 
stage IV were included who had been treated with nivolumab monotherapy (3mg/kg 
i.v., Q2W), patients were excluded who were treated with a prior line of immunotherapy. 
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The study was approved by the independent ethics committee board (MEC 02-1002 
and MEC 16-011) and all patients provided written informed consent. Whole blood and 
baseline serum were available for DNA analysis and protein quantification, respectively. 
All assays were performed blinded to study endpoints; patients were assigned to a 
subject number. Patient characteristics included demographic and clinical data. BOR 
was assessed according to the Response Evaluation Criteria in Solid Tumors version 1.1 
(RECIST v1.1) 14. A minimum duration of 90 days for stable disease (SD) was required. 
Confirmation of partial response (PR) or complete response (CR) was not required. After 
treatment initiation, radiological evaluation by computed tomography (CT) was usually 
performed every 6 weeks. Progression-free survival (PFS) was defined as the time from 
the first administration of nivolumab until progressive disease (PD), or death due to any 
cause, whichever occurred first. OS was defined as the time from the first administration 
of nivolumab until death due to any cause. 
Quantitative protein measurement and DNA analysis
Quantitative analysis of granzyme B in serum was performed by a magnetic bead-based 
assay, using a 1x96-well microplate and magnetic anti-granzyme-B-coated beads (Human 
Magnetic Luminex Assay, R&D Systems Inc., MN). GZMB c.128T>C (rs8192917) was selected 
primarily based on its presumed contribution to resistance mechanisms of ICIs 9. A total of 
twelve single-nucleotide polymorphisms (SNPs) were selected in eight genes based on their 
contribution to T cell immunity and their correlation with overt T cell responses, such as 
the autoimmune diseases (AIDs) systemic lupus erythematosus and rheumatoid arthritis. A 
summary of the correlation of selected SNPs with overt T cell responses is displayed in suppl. 
table 1. SNPs with a minor allele frequency (MAF) of <5% were excluded from the analysis. 
Linkage disequilibrium was tested using the application LDmatrix of LDlink version 5 (https://
ldlink.nci.nih.gov/). Distribution of genotypes was tested for Hardy-Weinberg equilibrium 
(HWE) using the χ2 test. Deviations from HWE may reflect genotyping errors, though, may also 
be a signal of disease association15, e.g. mutation of tumor suppressor genes. DNA isolation 
and genotyping for GZMB rs8192917, HLA-A rs60131261, IL10 rs3024493, IL2RA rs3024493, 
IFNG rs2430561/rs2069705/rs2069718, PDCD1 rs2227981/rs10204525/rs2227982, PTPN11 
rs2301756 and ZAP70 rs13420683 has been performed using TaqMan analysis as previously 
described 16. Whole-blood specimens was used for extraction of DNA. Genotyping was 
performed using predesigned Taqman allelic discrimination assays, consisting of two allele-
specific minor groove binding probes. Polymerase chain reactions (PCR) were performed 
in a reaction volume containing DNA, primers, and the specific probes were labelled with 
fluorescent dye.
Flow cytometry
Peripheral blood samples were analysed multiplex flow cytometry as previously described 
by Kunert et al.6. In short, absolute cell counts of immune cell populations were determined 
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on whole blood after lysis of red blood cells, and frequencies of particular subsets were 
determined in more detail on cryopreserved peripheral blood mononuclear cell samples 
that were stained with a mix of antibodies.
Mutational burden and expression of PD-L1 in tumor tissue
Expression of PD-L1 and tumor mutational burden (TMB) have previously been 
determined in a subset of patients of cohort 1 (n=26; stage IV NSCLC patients) using 
archival formalin-fixed, paraffin-embedded tissue samples17. Baseline expression of PD-
L1 has been determined using antibody clone SP263 (Roche Diagnostics, Tucson, AZ), 
whereas TMB has been measured using the Oncomine TML assay (Thermofisher Scientific, 
Waltham, MA).
Statistical analysis
To study the relationship between baseline protein levels or SNPs and survival (PFS and 
OS), Cox regression analysis was used. Patient survival was visualised by the Kaplan-
Meier approach. Patients were dichotomized for low or high granzyme B serum levels 
based on the median value of all patients. Dominant, recessive, and additive models 18 
were used to test associations between SNPs and clinical outcomes including BOR, PFS 
and OS. Hazard ratios (HR) and 95% CIs were calculated. For the association of SNPs with 
radiological response, BOR was utilized as an ordered categorical variable with three 
levels, namely: CR/PR (pooled), SD and PD, by means of ordinal logistic regression analysis. 
This method assumes that the relationship between each pair of outcome groups is the 
same. The proportional odds assumption was checked for all analyses. Univariate ordinal 
logistic regression was applied for both SNPs and patient factors, and odds ratio (OR) and 
95% confidence intervals (CI) were calculated. Multivariable ordinal logistic analysis was 
performed including both single SNPs and patient factors, with p < 0.1 according to the 
univariate analyses. All analyses with a significant relation (p < 0.05) between SNP and 
clinical outcome, were internally validated by bootstrapping19, where 1,000 bootstrap 
samples were generated (with replacement) and 95% CIs were calculated for either ORs or 
HRs. Furthermore, bias and bias-corrected 95% CIs were calculated. In general, a p-value 
< 0.05 was considered to be statistically significant. Analyses were performed using IBM 
SPSS Statistics version 24.0.0.1 (Chicago, IL) and STATA version 15.1 (StataCorp LP, TX). 
RESULTS
Patient characteristics
Baseline serum from a total of 78 (cohort 1) and DNA from a total of 322 stage IV NSCLC 
patients (cohort 2) was available for analysis (table 1). There was a 16.5% subject overlap 
between the patient cohorts. All patients were treated with at least one dose of nivolumab 
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at 3 mg/kg Q2W. Overall, median absolute starting dose was 222 mg (interquartile range 
[IQR] 192 - 263 mg). The objective response rate (ORR) was similar in cohort 1 and cohort 
2, respectively 19.2% and 16.6%. A minority of all patients (7%) could not be evaluated 
for response by RECIST v1.1 due to early death, loss to follow-up or incomplete or absent 
follow-up tumor assessments. In the univariate analysis of cohort 2, WHO performance 
status (0 vs. >1) and sex (male vs. female) were significantly associated with PFS (HR 0.66; 
95%CI 0.46-0.95; p=0.027 and HR 1.38; 95%CI 1.06-1.80; p=0.18, respectively) and OS (HR 
0.52; 95%CI 0.34-0.77; p=0.001 and HR 1.40; 95%CI 1.05-1.86; p=0.023, respectively). In the 
multivariable analysis, only WHO performance status and primary tumor type remained 
significant for their association with respectively PFS or OS and BOR.
Serum levels of granzyme B are associated with clinical outcome
Serum levels of granzyme B were determined in cohort 1 (Suppl. Fig. 1), having a median 
concentration of 1.27 pg/mL, which was used as the cut-off to dichotomize patients with 
low and high levels of serum granzyme B (as described in the method section). Patients 
with low baseline serum levels of granzyme B had a significant worse PFS (HR 1.96; 95%CI 
1.12-3.43; p=0.018, figure 1a) than patients with high levels of baseline serum granzyme 
B. Likewise, low levels of granzyme B were significantly associated with worse OS (HR 2.08; 
95%CI 1.12-3.87; p=0.021, figure 1b) compared to high levels of granzyme B.
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Table 1. Patient characteristics
Cohort 1 (n=78) Cohort 2 (n=322)
Age at start Mean (range in years) 63.6(35-78) 64.7(29-85)
n % n %
Sex
Male 48 61.5 202 62.7
Female 30 38.5 120 37.3
Primary tumor
Adenocarcinoma 52 66.7 200 62.1
Squamous cell carcinoma 17 21.8 96 29.8
Large cell carcinoma - - 22 6.8
Lung cancer with unknown 
pathology
9 11.5 4 1.2
WHO PS
0 18 23.1 54 16.8
1 39 50.0 188 58.4
2 1 1.3 7 2.2
3 - - 1 0.3
Unknown 20 25.6 72 22.4
Prior lines
0 2 2.6 1 0.3
1 60 76.9 217 67.4
2 13 16.7 82 25.5
3 2 2.6 15 4.7
4 1 1.3 6 1.9
5 - - 1 0.3
Smoking status
History or current smoker 56 71.8 238 73.9
Never smoker 8 10.3 20 6.2
Unknown 14 17.9 64 19.9
Ethnicity
Caucasian 74 94.9 308 95
Other 4 5.1 5 2
Unknown 0 - 9 3
Baseline characteristics of NSCLC cohort 1 and cohort 2. 16.5% of the patients (n=53) from cohort 
2 were overlapping with cohort 2. Abbreviations: number (n) WHO performance status (WHO PS).
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Figure 1. Association of serum granzyme b and GZMB genotype with survival
A) Kaplan-Meier plots showing the A) progression-free survival (PFS; in days) and B) overall survival 
(OS; in days) of patients in cohort 2 (n=78) with low (in blue) vs. high (in red) baseline serum levels of 
granzyme B. The C) PFS and D) OS of patients in cohort 2 (n=322) with wild type (in red) vs. variant 
germline GZMB (in blue). Numbers at risk shown below the graph.
Germline variation of GZMB is associated with clinical outcome
To validate the findings in a second cohort by a different approach 20, genetic alterations 
of GZMB c.128T>C (rs8192917), together with a mechanism-of-action based panel of 
other SNPs, were related to PFS, OS and BOR in cohort 2. Investigated SNPs with the 
corresponding haplotype frequencies, MAF and HWE statistics are shown in suppl. table 
2. After correction for WHO performance status and sex in multivariable analysis, patients 
with homozygous and heterozygous variants of GZMB rs8192917 had worse PFS (HR 1.38; 
95%CI 1.02-1.87; p=0.036; table 2; figure 1c). This finding could be internally validated 
(HR 95%CI 1.02-1.87; bias 0.003; bias-corrected 95%CI 1.03-1.88; p=0.036; suppl. table 3). 
Remaining SNPs were not associated with PFS after correction for patient factors (table 3). 
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No significant association of SNPs with OS was observed after correction of patient factors 
(table 3). Of note, homozygous and heterozygous variants of GZMB rs8192917 were not 
significantly associated with OS (HR 1.19; 95%CI 0.91-1.57; p=0.212; table 2; figure 1d). 
Homozygous and heterozygous variants of GZMB rs8192917 were significantly associated 
with worse BOR (OR 1.60; 95%CI 1.01-2.52; p=0.044; table 2) and could be internally 
validated for the association with BOR (OR 95%CI 1.05-2.55, bias 0.007; bias-corrected 
95%CI 1.09-2.57; p=0.030, suppl. table 3). All the results from both univariate (p < 0.1) and 
multivariate analyses of the association with PFS, OS or BOR are shown in table 3. Results 
from the internal validation of factors that were significantly associated after correction 
for patient factors (p-value < 0.05) are shown in suppl. table 3. For a subset of patients, 
both serum levels of granzyme B and germline variation of GZMB c.128T>C (rs8192917) 
were available for analysis. Patients with homozygous and heterozygous variants of GZMB 
rs8192917 (n=19) had significant lower serum levels of granzyme B compared to patients 
with wild type GZMB (n=34; mean difference 8.6 pg/mL, 95% CI 1.77-15.38, p=0.015).
Table 2. Association between GZMB genotype and clinical outcome
PFS Univariate analysis Multivariate analysis
Parameter Test variables HR (95%CI) P-value HR (95%CI) P-value
GZMB c.128T>C CC+CT vs. TT 1.39(1.07-1.80) 0.013* 1.38(1.02-1.87) 0.036*
WHO 0 vs. >1 0.66(0.46-0.95) 0.027* 0.61(0.42-0.89) 0.01*
Sex Male vs. female 1.38(1.06-1.80) 0.018* 1.29(0.95-1.76) 0.103
OS Univariate analysis
Parameter Test variables HR (95%CI) P-value
GZMB c.128T>C CC+CT vs. TT 1.19(0.91-1.57) 0.212
WHO 0 vs. >1 0.52(0.35-0.77) 0.001*
Sex Male vs. female 1.40(1.05-1.86) 0.023*
BOR Univariate analysis Multivariate analysis 
Parameter Test variables OR (95%CI) P-value OR (95% CI) P-value
GZMB c.128T>C CC + CT vs. TT 1.63 (1.04-2.57) 0.033* 1.60 (1.01-2.52) 0.044*
Primary tumor Other vs. 
adeno
0.63 (0.40-0.98) 0.041* 0.63 (0.41-0.99) 0.045*
Univariate and multivariate analysis of the association of germline variation of GZMB and 
progression-free survival (PFS), overall survival (OS) or best overall response (BOR). Patient factors 
associated with OS/PFS (p-value < 0.1) were included in the multivariate analysis. Significance is 
marked by *. Abbreviations: hazard ratio (HR), 95% confidence interval (95%CI), WHO performance 
status (WHO).
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Table 3. Association between investigated SNPs and clinical outcome
Univariate analysis (PFS)
Parameter Test variables HR (95%CI) P-value
IFNG c.874T>A AA+AT vs. TT 0.76(0.58-0.99) 0.045
IL2RA c.64+5006T>C  CC+CT vs. TT 0.80(0.62-1.04) 0.098
WHO performance status 0 vs. >1 0.66(0.46-0.95) 0.027
Sex Male vs. female 1.38(1.06-1.80) 0.018
Multivariate analysis (PFS)
Parameter Test variables HR (95% CI) P-value
IFNG c.874T>A AA+AT vs. TT 0.79(0.58-1.07) 0.131
WHO performance status 0 vs. >1 0.66(0.45-0.95) 0.024 
Sex Male vs. female 1.26(0.92-1.71) 0.148
IL2RA c.64+5006T>C  CC+CT vs. TT 0.81(0.60-1.10) 0.177
WHO performance status 0 vs. >1 0.65(0.45-0.93) 0.019
Sex Male vs. female 1.29(0.95-1.76) 0.101
IFNG c.874T>A  AA+AT vs. TT 0.76(0.55-1.05) 0.093
WHO performance status 0 vs. >1 0.52(0.34-0.77) 0.001
Sex Male vs. female 1.45(1.03-2.02) 0.32
Univariate analysis (OS)
Parameter Test variables HR (95% CI) P-value
IFNG c.874T>A  AA+AT vs. TT 0.72(0.55-0.95) 0.021
WHO performance status 0 vs. >1 0.52(0.35-0.77) 0.001
Sex Male vs. female 1.40(1.05-1.86) 0.023
Multivariate analysis (OS)
Parameter Test variables HR (95% CI) P-value
IFNG c.874T>A  AA+AT vs. TT 0.76(0.55-1.05) 0.093
WHO performance status 0 vs. >1 0.52(0.34-0.77) 0.001
Sex Male vs. female 1.45(1.03-2.02) 0.32
Univariate analysis (BOR)
Parameter Test variables OR (95%CI) P-value
IL10 c.387+284C>A AA vs. AA +AC 0.25 (0.07-0.89) 0.033
ZAP70 -21-4127C>A AA vs. CC+AC 0.50 (0.25-0.98) 0.045
Primary tumor Other vs. adeno 0.63 (0.40-0.98) 0.041
Multivariate analysis (BOR)
Parameter Test variables OR (95% CI) P-value
IL10 c.387+284C>A AA vs. AA +AC 0.24 (0.07-0.84) 0.026
Primary tumor Other vs. adeno 0.61 (0.39-0.96) 0.031
ZAP70 -21-4127C>A AA vs. CC+AC 0.49 (0.24-0.97) 0.042
Primary tumor Other vs. adeno 0.61 (0.39-0.96) 0.033
Univariate and multivariate analysis of the association between germline SNPs (except those related 
to GZMB variation; those are shown in table 2) and progression-free survival (PFS), overall survival 
(OS) or best overall response (BOR). Only SNPs that were associated with OS/PFS/BOR (p-value < 
0.1) are shown and included in the multivariate analysis. Significance is marked by *. Abbreviations: 
hazard ratio (HR), 95% confidence interval (95%CI), WHO performance status (WHO).
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Serum levels of granzyme B are accompanied by presence of T cells with 
terminal differentiation and exhausted phenotype
Next, we assessed the relationship between serum granzyme B as well as genetic variations 
of GZMB and cytotoxic immune cell populations in blood. Overall, there was a tendency that 
patients with lower serum granzyme B levels had lower absolute numbers of peripheral 
CD56+NK cells (mean 141 vs. 205 cells/µL, p=0.16; suppl. fig. 2) and CD8+ T cells (346 vs. 463 
cells/µL, p=0.41; figure 2a) when compared to patients with higher serum granzyme B levels. 
In fact, patients with homozygous or heterozygous variants of GZMB rs8192917 had a higher 
number of CD8+ T cells but not CD56+ NK cells than patients with wild type GZMB (figure 
2b and suppl. fig. 2b). Further, we studied whether granzyme B levels or GZMB genotypes 
correlate with frequencies of those immune cell phenotypes that correspond to either terminal 
differentiation (CCR7-CD45RA+) or exhaustion (PD1+ and TIM3+) of CD8+ T cells, as signs 
Figure 2. Association between serum granzyme B and T cell populations with phenotypes 
that correspond to functional responses
Associations are shown between A) serum granzyme B levels or B) GZMB genotype and T cell 
populations in blood. CD8+ T cells is considered as a subset of T lymphocytes with cytotoxic functions. 
CCR7-CD45RA+ cytotoxic T cells correspond with terminal differentiation, and PD1+TIM3+ cytotoxic 
T cells correspond with exhaustion, both signs of T cell activation or cytotoxicity. Abbreviations: wild 
type (WT), heterozygous variant (HET) and homozygous variant (HVAR).
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of T cell cytotoxicity. Interestingly, patients with lower serum granzyme B levels had a 
lower proportion of CCR7-CD45RA+CD8+ T cells (mean 44 vs. 54 %, p=0.040) as well as 
PD1+TIM3+CD8+ T cells (mean 4.5 vs. 7.8 %, p=0.001; figure 2a). No significant association 
nor trend could be observed between GZMB genotype and frequencies of T cells with 
these phenotypes (figure 2b).
Relationship between serum granzyme B, expression of PD-L1 and TMB
Interaction analysis for PFS and OS was performed between serum granzyme B, and PD-L1 
and TMB in a subset of evaluable patients. In the univariate analysis, TMB (HR 7.31; 95%CI: 
1.5-34.7; p=0.01) was significantly correlated with PFS, while expression of PD-L1 (HR 4.30; 
95%CI: 0.9-19.8; p=0.06) or serum granzyme B (HR 2.34; 95%CI: 0.9-5.9; p=0.07) did not 
meet the threshold for significance (suppl. table 4). Moreover, only serum granzyme B 
was significantly correlated with OS (HR: 2.95; 95%CI: 1.09-7.93; p=0.03; suppl. table 5). 
Multivariate analysis of these biomarkers (namely: serum granzyme B, PD-L1 and TMB) for 
PFS and OS did not meet significance. Of note, the hazard ratios were in favor of higher 
levels of PD-L1 (>50%), TMB (>10 mut/Mb) and serum granzyme B (>1.27 pg/mL), yet 
expression of PD-L1 (%), TMB (mut/Mb) and serum granzyme B levels (pg/mL) were not 
significantly correlated with each other (suppl. table 6). 
DISCUSSION
The present study demonstrates that serum levels of granzyme B and alterations of the 
GZMB locus may contribute to resistance mechanisms of PD-1 blockade. This concept 
(figure 3) is based on our findings that 1) low serum levels of granzyme B and 2) a common 
germline polymorphism of the GZMB gene were associated with worse clinical outcome 
after PD-1 blockade in metastatic NSCLC patients. Moreover, serum levels of granzyme 
B were positively correlated with peripheral abundance of T cell populations that were 
highly differentiated or were expressing the immune checkpoints PD1 and TIM3. The 
results are in line with our hypothesis that cytotoxic effector functions of lymphocytes 
(i.e., through granzymes) are critical for the anti-PD-1 antibody-mediated immune effects. 
Granzyme B levels were determined at baseline in stage IV NSCLC patients prior to start 
with PD-1 ICIs. The median granzyme B level in this cohort was 1.27 pg/mL (range 0 – 88 
pg/mL), which was lower than reported levels in healthy controls, e.g. a median plasma 
granzyme B of 5.7 pg/mL (IQR 3.7 – 7.1 pg/mL; n=38) 21 or 11.5 pg/mL (range 1 – 130 pg/mL; 
n=54) 22. Measurements of granzyme B in serum were consistent with measurements in 
plasma 22. Our findings confirm the hypothesis that lower granzyme B levels in metastatic 
cancer patients mirrors the immune micro-environment of tumors favoring tumor growth 
by halting the anti-tumor response of cytotoxic immune cells. This may be a result of those 
germline variations that impact cytotoxic functions of lymphocytes.
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Figure 3. Mechanism of action 
Schematic overview of the proposed mechanism of action of the GZMB SNP. Presence of the GZMB 
c.128T>C SNP indicates the expression of variant granzyme B isotypes (indicated as pink granzyme 
B molecules) that might lead to impaired cytotoxic effector functions of T cells, resulting in impaired 
apoptosis of tumor cells and partial resistance to anti-PD-1 blockade. The molecular mechanism of 
the PD-1 antibody nivolumab is shown in the white box. This figure was created by DH in BioRender.
com.
Besides germline polymorphisms in the GZMB gene, polymorphisms in other genes 
have been investigated as well for their association with clinical outcome. Interestingly, 
these germline variations were not consistently found to correlate with PFS, OS or 
BOR. Interpretation of these findings are challenging, and do not necessarily implicate 
an absence of effects of non-GZMB SNPs. Although SNPs were rationally selected by 
their correlations with autoimmunity (suppl. table 2), we cannot exclude that SNPs in 
the investigated genes contribute to therapy resistance, as well as epigenetic or post-
transcriptional regulation of gene expression or function. For example, PD-1 ICIs are 
suggested to only minimally target responses mediated by T cell receptors (involving 
ZAP70) and their primary method of action is most likely explained by relieving SHP-2 
inhibition of the CD28 co-stimulatory pathway 8. Genomic alterations in tumors may 
involve loss of tumor antigens that are recognized by T cells, loss of antigen-presenting 
machinery components, tumor-induced inactivation of T cell signalling and insensitivity 
to effector functions of lymphocytes, death receptors or interferons 23.
The nonsynonymous substitution of GZMB c.128T>C (rs8192917) was found to be in strong 
linkage disequilibrium with other common (MAF>15%) exonic variants, representing 
a haplotype block (data publicly available from The Single Nucleotide Polymorphism 
Database (https://www.ncbi.nlm.nih.gov/snp/; suppl. figure 3). This indicates that 
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two predominant isoforms of granzyme B are expressed in the European population, 
defining two predominant isoforms, and is consistent with previous reports that genetic 
variation of GZMB leads to change of three amino acids of the mature protein (Q48P88Y245 
to R48A88H245) 24,25. Interestingly, the two isoforms have a similar expression, stability and 
proteolytic activity, however, the variant granzyme B isotype was observed to be incapable 
of inducing apoptosis in tumor cell lines in contrast to the functional effects of the more 
common isotype 26. 
Interaction analysis between granzyme B, expression of PD-L1 in tumor and TMB showed 
that these markers were not inter-correlated, which suggests their value as independent 
biomarkers for clinical outcome after PD-1 ICIs. Although our findings in regard to serum 
granzyme B and GZMB germline variation are confirmed in a large patient cohort and 
by internal validation, further investigations need to be performed to determine the 
clinical value as a predictive or prognostic biomarker of response to PD-1 blockade. 
These investigations include comparative analysis with these currently used biomarkers 
in an extended patient cohort, and evaluation of the diagnostic accuracy and mapping 
of the sensitivity of serum granzyme B in a prospective clinical trial. The results may not 
be directly applicable to other ethnic groups, as the study was performed in a European 
population.
An important aspect of our results is that germline genetics related to cytotoxic effector 
functions of lymphocytes contribute to mechanisms of resistance to ICI therapy. Previously, 
it has been shown that germline variations in regard to the antigen presentation 
machinery are related to response to ICIs, i.e. HLA-1 heterozygosity 27. Considering the 
urgent need to understand how genetic variation affects response to ICIs, as reviewed by 
Havel et al. 5, further work is warranted to identify novel genetic loci. We believe that apart 
from genes that are involved in antigen presentation, other immune-modulating genes 
may also contribute to response and resistance mechanisms of ICIs, of which granzyme 
B is an example. Determination of germline variations of cancer patients contributing 
to response to ICIs may well be performed by future genome wide association studies 
(GWAS). 
CONCLUSIONS
While the immune-oncology field rapidly advances, our understanding of ICI resistance 
mechanisms is limited and effective patient selection is lacking. Our data demonstrate 
that granzyme B is an important player in the antitumor immunity, as a consequence of 
the finding that low serum levels of granzyme B and germline variation of the GZMB gene 
contributes to resistance to PD-1 blockade in advanced NSCLC. As recent clinical trial 
results underline effective biomarker-based patient selection, future trials that incorporate 
granzyme B into diagnostics is considered as a promising step in this direction.
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SUPPLEMENTARY INFORMATION
Supplementary Figure 1. Frequency histogram 
 
Frequency histogram of granzyme B measurements in serum. In total, baseline measurements were 
performed in 78 stage IV NSCLC patients. Almost half of the patients had undetectable levels of 
granzyme B in serum.
Supplementary Figure 2. Lack of association between serum granzyme B or GZMB genotypes 
and NK cell numbers
Association is shown between A) serum granzyme B levels or B) GZMB genotype and the number 
of CD56+ NK cells in blood. Abbreviations: wild type (WT), heterozygous variant (HET) and 
homozygous variant (HVAR).
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Supplementary Figure 3. LD statistics for all common GZMB SNPs
Heatmap matrix of pairwise linkage disequilibrium statistics of common SNPs of GZMB (MAF > 15%; 
dbSNP database). Exon germline variants (rs-numbers) are marked with the red boxes. Note that all 
common germline variants present in GZMB exones are in strong linkage disequilibrium, defining 
two predominant GZMB isoforms in the European population (~70% common GZMB allele). Data 
derived from publicly available reference haplotypes are used from the 1000 Genomes Project. 
The R squared as a measure of linkage disequilibrium are shown, red indicates high correlation. 


























Granzyme B is correlated with clinical outcome in NSCLC   |   199 
9
Supplementary Table 1. Association of SNPs with AIDs
Gene Rs-number Disease Effect Key references
HLA-A rs60131261 Vitiligo Higher susceptibility (OR 1.53) for 
AID and associated with elevated 
expression of HLA-A
Jin, 201615




IL10 rs3024493 SLE, T1D, 
CD, UC, 
BeD
Higher susceptibility (OR 1.26) for 
AIDs
Ramos, 201117 
IL2RA rs2104286 RA, MS Lower susceptibility (OR 0.81) for RA, 













AS Higher susceptibility for AID Chen, 201622
Liu, 201123
PTPN11 rs2301756 UC Higher susceptibility (OR 1.81) for AID Narumi, 200924
ZAP70 rs13420683 CD Higher susceptibility (OR 2.25) for AID Bouzid, 201325
Germline variations of genes that are implicated in the etiopathogenesis of autoimmune diseases 
(AIDs). These variants are indicated by gene and rs-number. Abbreviations: Type 1 diabetes (T1D), 
Crohn’s disease (CD), ulcerative colitis (UC), alkylosing spondyloditis (AS), Behcet’s disease (BeD), 
rheumatoid arthritis (RA), multiple sclerosis (MS), systemic lupus erythematosus (SLE).
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Supplementary Table 2. Investigated single-nucleotide polymorphisms
Protein Gene rs-number Variant WT HET HVAR Undet. MAF HWE (χ2)
Granzyme 
B
GZMB rs8192917 c.128T>C 205 104 13 0 20% <0.01
HLA-A HLA-A rs60131261 delTTTA 178 116 28 0 27% 2.05
IL-10 IL10 rs3024493 c.387+284C>A 231 81 10 0 16% 0.77
CD25 IL2RA rs2104286 c.64+5006T>C 180 118 22 2 25% 0.2
IFN-γ IFNG rs2430561 c.874T>A 105 153 63 1 43% 0.29
rs2069705 −1616T>C 145 135 42 0 34% 1.4
rs2069718 367–895C>T 112 148 60 2 42% 0.8
PD-1 PDCD1 rs2227981 804C>T 94 154 73 1 47% 0.42
rs10204525 889G>A 271 47 4 0 9% 1.39
rs2227982 644C>T 320 2 0 0 0.3% -
SHP-2 PTPN11 rs2301756 333–223A>G 259 60 3 0 10% 0.05
ZAP-70 ZAP70 rs13420683 −21–4127C>A 177 106 33 6 27% 7.42*
Overview of investigated SNPs. *If χ2>3.84 (p-value <0.05) then SNP is not consistent with HWE. 
ZAP70 -32-4127C>A (rs13420683) was not consistent with HWE (χ2 7.42; p < 0.01) but remained 
in the analysis after excluding the likelihood of a type I error. As PDCD1 644C>T (rs2227982) had 
a MAF of 0.3% (<5%) in the study cohort, it was excluded from further analyses. All other SNPs 
were considered suitable for analysis. Abbreviations: wild-type (WT), heterozygote variant (HET), 
homozygote variant (HVAR), minor allele frequency (MAF), Hardy-Weinberg equilibrium (HWE).
Supplementary Table 3. Internal validation
Multivariate analysis (BOR)
Factor Comparison OR (95%CI) P-value Bias Bias-corrected 95%CI
GZMB c.128T>C CC + CT vs. TT 1.019-2.509 0.041 0.006 1.052-2.548
Primary tumor Other vs. adeno 0.410-0.981 0.041 -0.005 0.425-1.009
IL-10 c.387+284C>A AA vs. AA +AC 0.010-5.420 0.367 -0.128 0.033-0.908
Primary tumor Other vs. adeno 0.398-0.946 0.027 -0.006 0.405-0.979
ZAP70 -21-4127C>A AA vs. CC+AC 0.236-1.019 0.056 0.005 0.246-1.014
Primary tumor Other vs. adeno 0.395-0.953 0.030 -0.006 0.398-0.987
Multivariate analysis (PFS)
Factor Comparison HR (95%CI) P-value Bias Bias-corrected 95%CI
GZMB c.128T>C CC+CT vs. TT 1.022-1.867 0.036 0.003 1.027-1.879
WHO performance 0 vs. >1 0.418-0.898 0.012 <-0.001 0.408-0.876
Sex Male vs. female 0.943-1.771 0.111 <0.001 0.943-1.780
Bootstrap results of the association between SNPs and clinical outcome. Bias measure, bias-corrected 
95%CI and p-value of the multivariate analysis are shown in the table for each factor. SNPs associated 
with BOR, PFS or OS (p<0.1; multivariate analysis) were included. Remaining SNPs and patient factors 
are not shown.* Abbreviations: hazard ratio (HR), odds ratio (OR), 95% confidence interval (95%CI).
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Supplementary Table 6. Correlation matrix of PD-L1, TMB and granzyme B
Tumor mutational burden Pearson Correlation 0,13
p-value (2-tailed) 0,56
n 22
Granzyme B Pearson Correlation -0,20 -0,18









Correlation matrix showing the Pearson correlation test outcomes of tumor mutational burden, 
granzyme B levels and PD-L1 expression in tumor tissue obtained prior to start of PD-1 ICIs in a 
subset of patients from cohort 1. Abbreviations: number of patients (n).
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Introduction: Non-small-cell lung cancer exhibits a range of transcriptional and 
epigenetic patterns that not only define distinct phenotypes, but may also govern 
immune related genes, which have a major impact on survival. 
Materials and Methods: We used open-source RNA expression and DNA 
methylation data of the Cancer Genome Atlas with matched non-cancerous tissue 
to evaluate whether these pretreatment molecular patterns also influenced genes 
related to the immune system and overall survival. 
Results: The distinction between lung adenocarcinoma and squamous cell 
carcinoma are determined by 1,083 conserved methylation loci and RNA expression 
of 203 genes which differ for  >80% of patients between the two subtypes. 
Using the RNA expression profiles of 6 genes, more than 95% of patients could 
be correctly classified as having either adeno or squamous cell lung cancer. 
Comparing tumor tissue with matched normal tissue, no differences in RNA 
expression were found for costimulatory and co-inhibitory genes, nor genes 
involved in cytokine release. However, genes involved in antigen presentation had a 
lower expression and a wider distribution in tumor tissue. 
Discussion: Only a small number of genes, influenced by DNA methylation, 
determine the lung cancer subtype. The antigen presentation of cancer cells is 
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INTRODUCTION
Smoking induced lung cancer has a large number of DNA mutations while other 
environmental factors such as air pollution may cause a different distribution in DNA 
mutations, often observed in non-smokers in genes like EGFR, BRAF, HER2 and ALK [1]. 
Lung cancer is traditionally subdivided into small-cell lung cancer and non-small-cell lung 
cancer (NSCLC) with the latter being divided into two main subtypes, adenocarcinoma 
and squamous cell carcinoma (SCC). 
It is known that DNA methylation is affected by age, smoking, emphysema and histological 
subtype [2]. Changes in the methylation pattern affects RNA expression, leading not only 
to different phenotypes, but also to a different effect on the immune activation. This may 
not only be reflected in the expression of human leukocyte antigen (HLA) or PD-L1 on 
tumor cells, but also in the tumor microenvironment. The Cancer Genome Atlas group 
(TCGA) performed molecular studies on lung adenocarcinoma and SCC identifying driver 
oncogenes and loss-of-function mutations in the HLA-A class I major histocompatibility 
gene [3,4]. Molecular classification approaches were made by clustering phenotypes on 
different platforms [5]. In a more recent study, a “cluster-of-clusters” analytic approach 
on differential DNA expression showed three distinct subtypes within SCC and six within 
adenocarcinomas [6]. Three of the adenocarcinoma subtypes had high expression of 
several immune related genes including PD-L1, PD-L2, CD3 and CD8. 
To date, the role of epigenetic modifications in relation to tumor responses in NSCLC 
remains to be clarified. Global DNA hypomethylation at repeated sequences has been 
identified in tumor cells in combination with DNA hypermethylation at specific loci [7]. 
CpG dinucleotides are highly represented in repeated sequences of the genome (LINE, 
SINE) and in the promotor regions of about 65% of the human genome and it is suggested 
that these play a role in regulation of gene expression. Biopsies of both adenocarcinoma 
and SCC show differences in methylation and in immune infiltrate [8]. Although their tumor 
response to checkpoint inhibitors is similar (1 year progression-free survival of 21% and 
19% for respectively SCC and non-SCC in the Checkmate studies), different determinants 
driving tumor response and resistance may be involved [9].
We hypothesized firstly, that a clear separation based on DNA methylation and RNA 
expression can be made between the NSCLC subtypes, and secondly, that methylation 
controls immune modulating genes in the tumor DNA and tumor-intrinsic defects must 
be present. 
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MATERIALS AND METHODS
Study cohort and data acquisition
Patients with treatment naive NSCLC, adenocarcinoma and SCC, whose DNA methylation 
and RNA expression data from the resected tumor was available in the public domain, 
were selected from two different profiling platforms (RNA sequencing resulting in 
60,483 mRNA expression values and methylation profiling by Infinium HM450 platform 
resulting in 485,577 DNA methylation β-values) at the TCGA Research Network (http://
cancergenome.nih.gov/). Details on methods and data generation of the RNA sequencing 
and DNA methylation can be found in the original TCGA landmark papers [3,4] Duplicate 
samples, those with missing histological diagnosis, and those with disease recurrences 
were removed. In total, 1,024 unique NSCLC patients with tumor tissue were selected 
of whom 154 patients provided additional normal tissue. Patients with normal tissue 
provided 108 samples for the normal RNA expression dataset and 74 samples for the 
normal DNA methylation dataset; 28 patients provided samples for both methods. The 
tumor RNA expression dataset consisted of 1,014 tumor samples (513 adenocarcinoma 
and 501 SCC) and the tumor methylation dataset consisted of 828 tumor samples (458 
adenocarcinoma and 370 SCC). We extracted clinical and pathological data on age, 
gender, histology, stage of disease, tumor cell percentage and survival calculated from 
time of diagnosis to time of death or last follow-up (Extended Data Table 4). The dataset 
was analyzed during a hackathon session, in which data scientists in collaboration with 
physicians competed to create a “functioning” product by the end of the 3-day event.
Data curation and statistical methods
All datasets were filtered and curated for non-significantly associated features after 
preprocessing of the files. ComBat, an empirical Bayes location/scaling method was 
applied to rule out potential cohort bias in the RNA expression data as a consequence of 
different study sites and laboratories, whereas BEclear was used in the DNA methylation 
data (Supplementary Information). As co-variant we used gender, because this 
factor has a high variance over the batches and its value is known for all samples. 
We started with principal component analysis (PCA) to discern underlying structure of 
the database, e.g. the total gene expression versus the immune modulating gene groups 
expressions.
For RNA expression and DNA methylation data we used non-parametric tests. The 
separation of the cancer types was compared before and after bias correction with both 
the Kolmogorov-Smirnov test and Mann-Whitney U test. The Kolmogorov-Smirnov tests 
provides a ks-score, which determines whether the given distributions of two groups are 
the same or different with a probability of 1-ks-score (Supplementary Information).
After we determined differences in distributions of methylation probes, an algorithm 
was developed using separate cut-off values for DNA methylation and RNA expression to 
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identify the most predictive genes to classify the NSCLC subtypes. This best split analysis 
determined whether a cut-off value could provide a split of at least 85% of patients into 
the correct subtype with a certainty of more than 80%, starting with probes or genes that 
had the highest differences (fold change). Differences between tumor subtypes based on 
DNA methylation β value had to be at least 0.1 to increase the probability of biological 
relevance. Loci with the largest differences for both DNA methylation and RNA expression 
respectively were determined after the annotating the probes into corresponding genes, 
an overlap in genes of both lists was established for biological interpretation.
Different immune modulatory genes were selected and grouped according to their 
function (Extended Data Table 5). These include co-stimulatory genes (COSTIM), co-
inhibitory genes (COINHIB), antigen presenting genes (AGPRES) and immune modulatory/ 
inflammatory cytokines and chemokines (CYTCHEM). The co-stimulatory immune 
modulatory gene group included genes that are known to be expressed in tumor cells 
(e.g. ICOSL, OX40L, SLAM), as reviewed by Chen and Flies [30]. Similarly, co-inhibitory 
genes were included in the analysis (e.g. VTCN1, CD113, CD48). HLAE was included for its 
protein function as inhibitor ligand for immunocompetent (NK) cells [31,32]. For antigen 
presentation, genes were selected involved in antigen presentation (e.g. classical HLA) and 
genes involved in antigen processing (e.g. TAP1, CIITA, HLAA) were selected for inclusion in 
the antigen presentation genes group [33]. Genes coding for cytokines and chemokines 
(e.g. IL10, IDO, IFNG) were selected based on their implication in immune tolerance of 
cancer through pleiotropic effects in immune regulation and inflammation [34–36]. 
Gene densities of all AGPRES genes were calculated within R using a kernel density 
estimate from the distribution of RNA expression of NSCLC and non-cancerous tissue.
To study the relationship between expression of immune related gene groups (AGPRES, 
COSTIM, COINHIB, CYTCHEM) and overall survival, a multivariate Cox regression analysis 
was used with age, gender, smoking (pack years), tumor type and stage of disease as 
covariates (patient factors with p<0.1 from univariate analysis included). The expression 
of pretreatment immune related gene groups was used as a categorical variable with 
two levels divided by the median (high and low overall expression of all involved genes). 
Hazard ratios (HR) and 95% confidence intervals (CI) are reported. 
To investigate the biological pathways, Ingenuity Pathway Analysis (Qiagen, Hilden, 
Germany) was used to perform gene enrichment analyses on these gene lists. 
RESULTS
Methylation in NSCLC
We used 1,024 unique patients from NSCLC TCGA datasets. Based on DNA methylation 
a PCA analysis appeared to be capable of separating adenocarcinoma and SCC (Fig. 1a). 
The prediction model based on the PCA outcomes correctly identified all but one of the 
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included patients as either adenocarcinoma or SCC. Importantly, stratification for high and 
low purity (indicated as the proportion of tumor cell content) of the processed samples did 
not influence the findings. Remarkably, of all methylation probes with a ks-score ≥0.95, the 
mean corrected differences ranged from +0.02 to +0.15 (scale -1 - +1), implicating a very 
small variation in methylation for these highly conserved loci in both phenotypes and a 
consistent stronger methylation of adenocarcinoma compared to SCC (Fig. 2). 
Figure 1. Clustering of main lung cancer phenotypes based on DNA methylation and RNA 
expression
A) Pulmonary adenocarcinoma is distinguished from squamous cell carcinoma by DNA methylation 
and B) to a slightly lesser extent by RNA expression.
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Figure 2. Higher DNA methylation in adenocarcinoma compared to squamous cell carcinoma
A) Adenocarcinoma contains consistently higher methylated DNA than squamous cell lung 
carcinoma mainly due to a relative small number of probes at conserved loci compared to B) 
a theoretical at random model. Overall difference in methylation is 0.017 (positive values on the 
y-axis indicate higher DNA methylation of adenocarcinoma, negative values indicate higher DNA 
methylation of squamous cell carcinoma). X-axis ranks the probes according to the ks-score for 
differentiation between both histological subtypes. Y-axis is the difference between the mean 
methylation (0 is low methylation and 1 is high methylation) between both subtypes.
 
After we observed significant differences in methylation probe distribution between 
the subtypes, we continued with a best split analysis. The algorithm identified 1083 
methylation probes (out of a total of 485,577 probes) which individually could be used 
to correctly classify at least 85% of patients. Next, we looked into the chromosomal 
position of the different methylated probes. An even distribution along the genome was 
determined at increasingly stringent ks-scores (Fig. 3a,b and Extended Data Table 1). 
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Figure 3. Location of methylation probes along 23 chromosomes that separates 
adenocarcinoma from squamous cell lung carcinoma at ks ≥ 0.95 and ks ≥ 0.97 level
Methylation pattern for each chromosome characterized by their individual probes A) with ks-score 
for separability between histologic subtypes over 95 % are evenly distributed over chromosomes 
with an exception for the x-chromosome. B) Probes with ks-score over 97 % show the conserved 
methylated areas that preserve the difference between subtypes. Mostly they are related to CpG 
islands located along chromosomes. X-axis and y-axis refer to respectively the chromosome number 
and individual probe localization on the chromosome according to ks-score for separability. Green 
dots represent differential probes. Antigen presentation and costimulation genes are flagged for 
chromosome location. (For interpretation of the references to colour in this figure legend, the reader 
is referred to the web version of this article).
 
The higher ks-score indicates a better separability between histologic subtypes 
(Supplementary Information). The methylation pattern for each chromosome characterized 
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by individual probes with ks-score ≥ 95% was distributed over all chromosomes except 
the X-chromosome. Probes with a high ks-score over 97% for separability represented 
conserved methylated loci that preserve the difference between phenotypes.
To address morphological differences between adenocarcinoma and SCC based on DNA 
methylation, an enrichment analysis was performed on the gene level based on the 
methylation probes that are most distinct for phenotype (ks-score >0.95; n=2,101 mapped 
genes). Remarkably, these and other genes showed a low methylation rate compared to 
normal tissue. The main canonical pathways that are most distinct for NSCLC subtypes are 
DNA repair pathways (Extended Data Fig. 1). However, based on the relative methylation 
of these genes, mechanisms involved in response to the category “viral infections” (z-score 
10.7, p<0.001;) were more activated in SCC compared to adenocarcinoma, whereas 
mechanisms involved in cell death (z-score -17.8, p<0.001) were inhibited. Central 
genes involved in “viral infection” that are found to be differential in SCC compared to 
adenocarcinoma include IRF3, NFKB1, RELA (also known as NFKB3), STAT3, SRPK1 and TRIM. 
Expression in NSCLC
We next aimed to investigate to what extent methylation influences RNA expression 
levels. We observed that DNA methylation explains approximately 40 - 55% of the 
inversely correlated variation in the RNA expression. This percentage, however, is not 
only dependent on the β-value level that would biologically lead to effective epigenetic 
gene suppression, but also on the correlation between gene expression and methylation 
(Fig. 4e). Approximately 60% of methylation probes (different to the random 50%) are 
inversely correlated with RNA expression by selecting only those methylation probes that 
are assumed to have an epigenetic suppressive effect (average β-value > 0.25) on DNA 
transcription and with a significant correlation (correlation coefficient >0.5 or <-0.5). Of 
note, methylation probes with a negative, positive, or no relationship with gene expression 
could be determined as illustrated in Fig. 4b-d (Supplementary information, sub 5). In 
general, genes that were heavily methylated showed a lower RNA expression than genes 
that had a moderate or low methylation rate. 
Unsupervised principal component analysis of the transcriptome led to a slightly less 
accurate separation of NSCLC phenotypes (Fig. 1b) than that based on DNA methylation 
data (Fig. 1a). Comparing tumor with non-cancerous tissue confirms that the RNA 
expression pattern is specific for NSCLC (Fig. 1b). The best split analysis on RNA data 
identified 203 genes, of which the expression was different in 85% of cases between 
SCC and adenocarcinoma. Of these, differences in RNA expression of five genes (KRT5, 
DSC3, DSG3, TP63, CALML3), and one miRNA (MIR205HG) combined could separate both 
subtypes with an accuracy of 95%. 
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Figure 4. Relation between DNA methylation for immune modulating genes determined by 
one probe and gene expression at four quartile levels
A) Immune modulating genes identified by probes with ks-score ≥ 70 % (adenocarcinoma vs. SCC) 
show an inverse relationship between expression and methylation for most genes. In this example, 
LAG3 and B3GAT1 show the opposite expression effect at low and moderate methylation, respectively. 
Examples are shown of probes with B) the highest negative correlation, C) highest positive correlation 
and D) no correlation between DNA methylation and RNA expression. E) The percentage of methylation 
probes that are inversely correlated with RNA expression depends on the cut-off of the correlation 
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Bilevel molecular analysis in NSCLC
We selected the top 500 methylation probes with their corresponding genes and the top 
500 genes based on RNA expression and found an overlap of 41 genes related to the 
separation of the NSCLC phenotypes based on both DNA methylation and RNA expression 
(Extended Data Table 2). Gene enrichment analysis by Ingenuity Pathway Analysis 
revealed that TP63 was an important upstream regulator, with elevated expression in SCC 
compared to adenocarcinoma. Target molecules of TP63 in the list of 41 genes included 
CSTA, SNAI2, DST, ACTL6A, KRT7 and the miRNA MIR205HG, and their expression was in the 
same predicted direction as the TP63 activation in SCC.
Figure 5.  Four immune modulatory gene groups as compared with all gene expressions in 
non-small cell lung cancers shows two clusters of increase (PC3 and PC6-9)
Four main immune modulatory gene groups were distinguished, involved in T cell antigen 
presentation (AGPRES), T cell co-inhibitory (COINHIB), T cell co-stimulator (COSTIM) and T cell 
cytokines/chemokines (CYTOCHEM). The influence of these gene groups were investigated on the 
individual principle components. The y-axis represents the loading of a gene in the DNA expression 
dataset to a principle component. The red boxes indicate all genes in the DNA expression dataset, 
whereas the other boxes represent the genes of selected immune modulating gene groups. All 
immune modulating gene groups are most pronounced in PC7, PC8 and PC9. The midline in the 
boxplot is the median of data in that component, with the lower and upper limits of the box being 
the first and third quartile, respectively. By default, the whiskers will extend up to 1.5 times the 
interquartile range from the top (bottom) of the box. If there are any data beyond that distance, they 
are represented individually as black dots (‘outliers’). (For interpretation of the references to colour 
in this figure legend, the reader is referred to the web version of this article).
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Immune modulating genes and methylation
As expected, methylation was inversely correlated for most methylation probes, e.g. higher 
level of HLA-B, TAP1, CD2 methylation leads to lower RNA expression (Fig. 4a). Of note, 
none of the 1083 methylation probes identified by the best split analysis for histological 
subtype included any of the selected immune related genes.  
We performed a principal component analysis including all RNA expressing genes and 
determined the weight of each component of immune modulatory gene groups: T 
cell co-inhibitory (COINHIB), T cell co-stimulator (COSTIM), T cell antigen presentation 
(AGPRES) and T cell cytokines/chemokines (CYTOCHEM) (Fig. 5 and Extended Data Fig. 
2). Genes in the immune related groups were gathered in two clusters, in PC3 and PC6-9. 
Antigen presenting gene expression was positively associated with co-stimulatory gene 
expression, not only in tumor but also in non-cancerous tissue (Extended Data Fig. 2b, c).
Genes involved in the immune response towards endogenous retroviral sequences were 
also more methylated in adenocarcinoma compared to SCC, but we did not study the 
repetitive DNA areas with high versus low methylation. 
Antigen presenting gene expression in tumor 
Average RNA expression of genes in the antigen presenting gene group was lower in 
tumor than in non-cancerous tissue and showed a larger variation (SD) in expression 
(Fig. 6). HLAA, HLAB and TAP2 RNA expression showed a decreased density, suggesting 
suppression of antigen presentation and processing. The other immune related gene 
groups in tumors also showed variation, but median values were not significantly different 
from non-cancerous tissue. At last, we asked ourselves what impact the different immune 
components have on survival. Interestingly, we were unable to identify survival benefit in 
an adjusted Cox regression for high expression of genes involved in antigen presentation 
or costimulatory function (Extended Data Table 3). Genes involved in the inhibition of 
the immune system also were not associated with survival. 
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Figure 6. RNA expression of immune modulating genes in tumor and their matched non-
cancerous tissue
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Density distribution of immune modulating gene expressions in 106 NSCLC tumors and their 
matched non-cancerous tissue. The antigen presenting gene expressions show a different 
density distribution compared to non-cancerous expressions, while the density of coinhibitory, 
costimulatory, and cyto- and chemokine gene expressions were largely similar.
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DISCUSSION
We identified epigenetic and RNA expression patterns in tumor tissue from NSCLC 
patients, that distinguished squamous cell lung cancer from adenocarcinoma. Especially 
the conserved loci with hardly variation in DNA methylation between hundreds of 
patients were responsible for the distinction between the subtypes. Adenocarcinoma was 
globally more methylated than squamous cell carcinoma. Immune adaptive mechanisms 
have also been described such as gene hypermethylation targeting the interleukin-6/
Stat3 pathway [10].
Not only methylation but also the differences in the expression values of only six genes 
could explain the difference between the subtypes in 97% of patients. Involved genes 
were keratine 5 (KRT5), tumor protein p63 (TP63), DSC3, desmoglein 3 (DSG3), calmodulin 
like 3 (CALML3), and the miRNA MIR205HG. All are directly or indirectly involved in tissue 
morphogenesis, differentiation cell adhesion, and proliferation. The predominant isoform 
ΔNp63α is overexpressed in SCC and may influence tissue microenvironment by recruiting 
proinflammatory cells. TP63 is commonly used in immunohistochemistry to differentiate 
SCC from adenocarcinoma, which supports the robustness of our analysis [11–13]. 
Next, we have shown that immune regulatory genes were included in regions marked 
by methylation probes with a ks-score >95%; these methylation profiles were associated 
with differential expression in immune modulatory genes before therapy. These genes 
were located in methylation regions distinguishing pretreatment NSCLC phenotypes 
by distribution, but were not identified by the best split analysis, indicating that 
genes involved in subtype morphology and immune regulation are both regulated by 
methylation but belong to completely distinct gene groups.
Now we have established the relation between methylation and immune expression 
status, we asked ourselves whether the pretreatment expression of the immune 
modulating gene groups of early NSCLC patients had survival consequences. We were 
unable to identify any survival benefit. Compared to non-cancerous tissue we observed 
a much broader distribution of the expression of immune modulating genes in NSCLC, 
while the median expression of T cell co-inhibitory, co-stimulatory, and cyto- and 
chemokine genes remained similar. Only the antigen presenting gene expression in 
NSCLC was decreased. This group consisted not only of the classical HLAA, HLAB and HLAC 
whose expression depend on methylation but also B2M and TAP genes. By multiplexed 
quantitative immunofluorescence loss of expression of B2M, HLA-I heavy chains and HLA-
II was observed in less than 23% of NSCLC patients [14]. Loss of B2M expression resulted 
in decreased or no cell surface expression of MHC class I, which impairs antigen 
presentation to cytotoxic T cells [15,16]. In melanoma loss of B2M and TAP1 expression 
reduced overall survival when treated with ipilimumab [17]. Limiting the expression of 
genes involved in antigen presentation is an important mechanism of tumor cells to evade 
the immune system [18]. In early NSCLC tumors that have an activated immune system, 
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extensive immune editing is present in order to fit with the tumor microenvironment, as 
indicated by the relative depletion of neoantigens in tumors and loss of heterozygosity 
in HLA genes [19]. This allele-specific HLA loss may occur in about 40% of NSCLC patients 
[18]. We observed that in tumor and non-cancerous tissue antigen presenting and 
co-stimulatory gene expression was positively associated, suggesting that a higher 
expression of antigen presenting genes is associated with more inflammation. Although 
our analysis does not provide information on cell types, it suggests that the higher dosage 
of antigen presenting gene expression in (any) tissue associates with more co-stimulatory 
gene expressions from T cells. Overall, it may be concluded that the antigen presenting 
gene group harbors the main immune related defect in NSCLC patients.
Finally, our analysis revealed that higher methylation was observed in genes involved 
in the immune response towards endogenous retroviral sequences in adenocarcinoma 
compared to SCC. Disruption of methylation in both subtypes leads to different retroviral 
expressions. Moreover, analyzing a wide spectrum of over 2,000 involved genes with the 
highest subtype separability revealed viral involvement, likely retroviral or transposon 
loci. As we know, human endogenous retroviruses are under epigenetic control and rarely 
expressed in normal tissue [20,21]. Hypomethylation of the LINE family member L1 occurs 
in multiple solid cancers and cell lines [22,23]. Lung squamous cell carcinoma has elevated 
ERVH-5 and other RNA derived endogenous retrovirus expression that were associated 
with low cytolytic activity [24]. We observed that IRF3, NF-κB and STAT pathways are critical 
in the production of type I interferons downstream of pathogen recognition receptors. 
They detect viral RNA and DNA [25]. The genes SRPK1 and TRIM4 are found to regulate 
these virus-induced IFN induction pathways [26,27]. This provides further molecular 
evidence of the presumed importance of (retro)viral infection in predominantly squamous 
cell carcinoma as previously observed in squamous cell carcinomas that contained viral 
DNA [28]. Importantly, a significant proportion of the differentiating methylation probes 
suppresses viral and retroviral associated genes. Further investigation is needed into the 
exact nature of those repetitive areas that are hyper- or hypomethylated.
All studies have limitations. Importantly, the tumor samples have varying tumor content 
(at least 40%) tough, as shown by stratification, this had no consequences for our findings. 
In order to perform our enrichment analysis of the epigenetic background across NSCLC 
phenotypes on a gene level methylation signals were averaged. Although this approach 
resulted in relevant and consistent findings, it may lead to inevitable loss of information 
as its effect varies across different gene regions. For instance, hypermethylation of high 
density CpG regions has been recognized to strongly associate with gene expression 
regulation [29]. Lastly, splicing variants and small cumulative effects within several genes 
in the same pathway have not taken into consideration in the RNA expression analysis. 
Alternative splicing may have a functional impact and is increased in cancer compared to 
normal tissue [29].
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Together these results show that NSCLC phenotypes are largely determined by epigenetic 
regulation of a small conserved group of genes, involved in extracellular matrix and 
cell structure. Methylation controls immune related genes – also those involved in 
endogenous retroviral sequences - that show a larger expression diversity in tumor than 
in non-cancerous tissue. Decreased expression of genes involved in antigen presentation 
are the main immune related defect in NSCLC, highlighting their importance for immune 
invasion by the tumor. 
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During the three days of the hackathon sessions, data preparation was performed. 
Before analysis, a few steps were taken to make data clean and ready for analyses. For the 
methylation dataset, 89.000 probe IDs with missing methylation value for every patient 
were removed. For the probe IDs that have missing values for some patients, an imputation 
method was used. To be specific, the missing values were replaced by the median value of 
methylation for the corresponding probe IDs on all patients. 
For gene expression dataset, gene name and chromosome number and start position are 
concatenated together to create unique “probe IDs”. Duplicated probe IDs are removed 
from the dataset (25 probe IDs). Similar method as for the methylation dataset was used to 
handle missing values. Further in the cleaning process, probe IDs with all gene expression 
values of 0 or with no variance are removed (2.123 probe IDs in total).
2. Cohort bias correction
ComBat, an empirical Bayes location/scaling method, was applied for cohort bias correction. 
No significant decrease in phenotype separation was observed. However, for the DNA 
methylation data ComBat correction qualitatively altered the probe wise distributions; 
basically by removing the bimodality and reducing the differential expression (1). This 
is further motivated by the fact that the means of the first principal components over 
the cohorts are approximately centered around the origin for adenocarcinoma and SCC, 
also the median and mean shift with respect to the median/mean of the entire set is 
centered around the origin (2). Applying the same statistical tests to separate groups of 
batches with either only adenocarcinoma or only SCC, a non-significant decrease in batch 
separation was observed. When looking to the main oncogene drivers in NSCLC and the 
top six genes that differentiate adenocarcinoma from squamous cell lung cancer, both 
were unaffected by ComBat correction (Fig. 1,2)
BEclear uses inter-batch ks-scores to decide which probes should be corrected and 
subsequently uses a matrix factorization method to produce the new probe values. 
Although one loses signal in cohorts with between-array and within-array corrections, 
the results for DNA expression data are very limited. If we look into the corrected data 
dimensions, the number of methylation probes reduced by 8% and gene expression data 
by 23%.
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Figure 1. Top cancer genes of NSCLC are unaffected by ComBat correction.
Similarly, for the top 1% percentile of genes with a p-value <0.001, the six genes were 
found, which are slightly shifted for the non-parametric corrected data.
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Figure 2. Six top-genes KRT5, DSC3, DSG3, TP63, MIR205HG, CALML3 from DNA expression 
are non-significantly shifted after ComBat correction tested by Kolmogorov-Smirnov test.
In conclusion, our corrections were performed in such a way that important biological 
signals are not eliminated by batch and cohort corrections.
3. Principal component analysis (PCA)
PCA is a statistical method, that will reduce the number of dimensions within a dataset. 
The extracted features, or principle components, have the following properties:
1. For p-dimensional data (x1,…,xp), a principle component PC is a linear 
 combination of the original variables, hence PC=a1.x1+a2.x2+…+ap.xp, where 
 |a|=1.
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2. For principle component PCk, the loadings vector ak=a1,…,apk is obtained 
 by finding the linear projection that maximizes the total amount of variance 
 within the dataset.
3. Each new generated principle component is orthogonal to all of the previous 
 principle components. Hence, for the kth principle component, we have ak.aj=0 
 for each j<k.
By definition of these properties, from a p-dimensional dataset that consist of n 
observations, at most (n, p) principle components can be extracted. 
The optimal number of principle components to select for the analysis is subjective to 
the application. We have used 10 dimensions. As, by definition of point 2 and 3 above, all 
principle components are both independent of each other and decreasingly ordered in 
amount of variance they explain.
4. Separability of adenocarcinoma and squamous cell lung  
 carcinoma 
a. by ks-score
The Kolmogorov-Smirnov test (ks test) is a nonparametric test that compares two data 
samples. The goal of the ks test is to determine whether two data samples come from the 
same distribution, noting that it is not specified what that common distribution is. The ks-
score quantifies a distance between the empirical distribution functions of two samples. 
The ks-score is mathematically defined by:
 Dn,m=|F1,nx-F1,mx| ,
where F1,n and F2,m are the empirical distribution functions of the first and the second 
sample respectively, and the supremum function. If both samples comes from the same 
distribution, then Dn,m converges to 0 almost surely in the limit. To conclude, the ks score 
lays in the interval [0,1], where a score closer to zero indicates that both samples are more 
likely to be drawn from the same distribution.
We determined the ks-score for each gene by methylation probes. 
ks-score  = 
The ks-score indicates the ability to separate between the subtypes of NSCLC 
(adenocarcinoma or squamous cell lung carcinoma), where 1 indicates high separability 
and 0 no separability. 
b. Best Split method
To approximate the best split for histological subtypes we used the median for the global 
distributions for each methylation probe. A more sophisticated method for determining an 
approximation for the best split is Hartigan’s dip test but we found no qualitative difference 
when applied to a subset of probes. We also applied differential evolution to optimize the 
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accuracy of the best RNA expression split, but this approach did not noticeably increase the 
accuracy. Because of the balanced presence of the subtypes adenocarcinoma and squamous 
cell carcinoma we used the medians of the methylation and RNA expressions distributions. 
Given the approximate split, we established for each split the accuracy and recall in separating 
the two subtypes. We required a minimum precision of 85% for both subtypes. This operation 
was performed over the probes, ordered by descending fold change, until the number of 
successive failures to meet the minimum precision exceeded a threshold (in this case 50). 
5. Bridge between DNA methylation and RNA expression
Methylation values of the genes (β-value for a probe per sample ranged from 0 to 1(0: 
unmethylated, 1: methylated) and the total RNA expression in tumor samples were 
studied. Methylation influences a change in gene expression. Samples in quantile 1 have 
the lowest RNA expression and samples in quantile 4 have the highest RNA expression. 
For each quantile and probe_ID the corresponding methylation distribution out of the 
methylation dataset is visualized by a boxplot.
For combining DNA methylation and RNA expression data we obtained a list of overlapping 
differential genes and used the Wasserstein distance metric, a way to compare the 
probability distributions, where one variable is derived from the other by small, non-
uniform random or deterministic perturbations. We defined three metrics that combine 
the statistical separability and the actual separation of the two subtype distributions. 
These metrics were first Wasserstein distance* ks score, second Wasserstein distance* ks 
score, and median fold change*ks score on the intersection of the top-500 probes for RNA 
expression and methylation that leads to 41 genes. Second, we merged  the data for RNA 
expression and methylation probes on the genes level and took the multiplications of the 
aggregated values for the three metrics; the overlap of the top-100  gave 28 gene.
6. Survival analysis
Univariate and multivariate survival analysis were performed between the expression 
profiles of immune modulating gene groups (high vs. low expression), patient and tumor 
characteristics. Patient factors associated with overall survival (p<0.1) were included in the 
multivariate analysis. Age and the TNM tumor-stage (T1, T2 or T3) reached the significance 
threshold (p<0.05) in the multivariate analysis. The hazards ratios and 95% confidence 
intervals were used to estimate the pretreatment gene group contribution on predicting 
overall survival.
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Extended Data Table 1. Top 41 gene list for best separation of NSCLC subtypes
Chromosome Gene Start Stop Strand Fold change
chr15 BNC1 83255903 83284716 - 15.04
chr10 CALML3 5524009 5526771 + 13.32
chr5 IRX4 1877413 1887236 - 12.64
chr18 DSC3 30990008 31042815 - 10.34
chr1 MIR205HG 209428820 209432838 + 4.79
chr3 TP63 189631416 189897279 + 3.89
chr2 DQX1 74518131 74526336 - 3.13
chr11 TRIM29 120111275 120185529 - 2.73
chr9 CEL 133061978 133087355 + 2.70
chr14 TGM1 24249114 24264432 - 2.47
chr7 SOSTDC1 16461481 16530580 - 2.42
chr3 CSTA 122325244 122341972 + 1.46
chr7 AKR1B10 134527592 134541408 + 1.37
chr17 RAPGEFL1 40177010 40195656 + 1.14
chr1 SLC16A1 112911847 112957013 - 0.98
chr18 KCTD1 26454910 26657401 - 0.97
chr8 SNAI2 48917690 48921740 - 0.89
chr1 VANGL2 160400586 160428678 + 0.84
chr14 FRMD6 51489100 51730727 + 0.82
chr6 DST 56457987 56954628 - 0.73
chrX EFNB1 68828997 68842147 + 0.51
chr7 FSCN1 5592823 5606655 + 0.45
chr19 FXYD3 35115879 35124324 + 0.44
chr3 DLG1 197042560 197299300 - 0.38
chr16 ABCC1 15949577 16143074 + 0.37
chr12 ZNF385A 54369133 54391298 - 0.36
chr3 ACTL6A 179562880 179588408 + 0.30
chr17 JUP 41754604 41786931 - 0.20
chrX ZDHHC9 129803288 129843909 - -0.22
chr12 DRAM1 101877351 102012130 + -0.28
chr12 KRT7 52232520 52252186 + -0.43
chr21 CLIC6 34669389 34718227 + -0.43
chr13 ATP11A 112690329 112887168 + -0.43
chr4 HOPX 56647988 56681899 - -0.46
chr6 SLC44A4 31863192 31879046 - -0.56
chr1 PLEKHA6 204218851 204377665 - -0.57
chr15 ALPK3 84816680 84873482 + -0.61
chr4 SLC4A4 71187286 71572087 + -0.67
chr14 NKX2-1 36516392 36521149 - -0.68
chr14 SFTA3 36473288 36513829 - -0.71
chr17 HNF1B 37686432 37745247 - -0.84
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Extended Data Table 3. Patient characteristics
Age at tumor biopsy (years)
Median (range) 67 (33 - 90)
Gender, M/F 614/410
Smoking status, n (%)
Never smoker 93 (9)
Former smoker > 15 years 219 (21)
Former smoker ≤ 15 years 421 (41)
Former smoker, unspecified duration 9 (1)
Current smoker 256 (25)
Unknown 26 (3)
Total 1024 (100)
Follow-up (of censored patients; months)
Median (range) 23 (0 - 242)




























Abbreviations: number (n), squamous cell lung cancer (SCC). 
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Extended Data Table 4. Immune modulating gene groups
COSTIMULATORY COINHIBITORY AGPRES CYTOCHEM
Receptor       Ligand Receptor         Ligand
CD28 CD80, CD86 CD272 VTCN1 HLAA TGFB1
CD134 OX40L CD279 PDCD1LG1, 
PDCD1LG2
HLAB TNF
CD137 4-1BBL CD94, NKG2A HLAE HLAC IL6
CD40L CD40 CTLA4 CD80, CD86 CIITA IL10
CD278 ICOSL TIGIT CD155, CD112, 
CD113
LMP2 IFNG
CD27 CD70 CD160 HVEM TAP1 IDO
HVEM LIGHT PD1HR PD1H LMP7
LIGHT HVEM 2B4 CD48 TAPBP







Four known clusters of genes involved in stimulating and inhibiting T lymphocyte responses, 
antigen presentation (AGPRES), and cyto- and chemokines (CYTOCHEM).
Extended Data Figure 1. Main canonical pathways based on DNA methylation.
Main canonical pathways of 2,101 mapped genes with at least one probe and with ks-score ≥ 0.95 

























234   |   Chapter 10
Extended Data Figure 2. Gene groups involved in antigen presentation and co-stimulation
 (A) Principal component analysis of gene expression can distinguish antigen presentation and 
costimulatory genes from other genes. (B) In both NSCLC subtypes, the higher expression of antigen 
presenting genes is associated with higher expression of costimulatory genes; (C) and similar in 
non-small cell lung cancer tissue and non-cancerous tissue.
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Introduction: Checkpoint inhibitors have become standard care of treatment 
for non-small cell lung cancer (NSCLC), yet only a limited fraction of patients 
experiences durable clinical benefit, highlighting the need for markers to stratify 
patient populations.
Materials and Methods: To prospectively identify patients showing response 
to therapy, we have stained peripheral blood samples of NSCLC patients treated 
with 2nd line nivolumab (n = 71), as well as healthy controls, with multiplex flow 
cytometry. By doing so, we enumerated 18 immune cell subsets and assessed 
expression for 28 T cell markers, which was followed by dimensionality reduction as 
well as rationale-based analyses.
Results: In patients with a partial response (PR), representing best overall response 
(BOR) according to RECIST v1.1, the number of CD8 T cells at baseline and during 
treatment is similar to those of healthy controls, but 2-fold higher than in patients 
with progressive and stable disease (PD and SD). CD8 T cell populations in PR 
patients show enhanced frequencies of T effector memory re-expressing CD45RA 
(TEMRA) cells, as well as T cells that express markers of terminal differentiation 
(CD95+) and egression from tumor tissue (CD69-). In PR patients, the fraction of CD8 T 
cells that lacks co-stimulatory receptors (CD28, ICOS, CD40L, 4-1BB, OX40) correlates 
significantly with the total numbers and differentiated phenotype of CD8 T cells.
Discussion: This study demonstrates that high numbers of peripheral CD8 T cells 
expressing differentiation markers and lacking co-stimulatory receptors at baseline 
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INTRODUCTION
The onset of T cell activation and differentiation, generally a consequence of the T cell 
receptor (TCR) recognizing its cognate antigen, is usually accompanied by up-regulated 
expression of co-inhibitory receptors such as programmed-death 1 (PD-1), proving a 
negative feedback mechanism to keep T cell activity ‘in check’ [1, 2]. Many types of cancer 
exploit this adaptive immunity and demonstrate high expression levels of co-inhibitory 
ligands such as PD-L1 to resist anti-tumor T cell responses. Clinical use of nivolumab, a 
monoclonal antibody targeting PD-1, showed promising results in metastatic melanoma 
[3], NSCLC [4, 5] as well as various other types of cancer [6]. Collectively, however, study 
results reveal that only a limited subset of patients experiences durable clinical benefit [7]. 
This highlights the need for markers that would identify patients prone to responding to 
treatment at an early time point and select these patients for extended treatment, thereby 
avoiding further exposure of patients with limited benefit to a potentially toxic and costly 
treatment.
Initial searches for predictive markers focused on the expression of PD-L1 [8, 9], but despite 
FDA approval for patient stratification based on PD-L1 expression in primary tumor tissue 
of NSCLC patients, interpretation of such immune stainings with respect to cell type and 
optimal cut off percentage remains challenging [10, 11]. Similarly, investigations assessing 
tumor mutational burden (TMB), mismatch repair deficiency (dMMR) and microsatellite 
instability (MSI) reveal that a high score on each of these markers correlates with enhanced 
responsiveness to anti-PD-1 therapy [12, 13], but on their own these markers may not 
be sufficiently discriminative to predict clinical response. Also, CD8 T cell density within 
tumor biopsies has been shown to predict anti-PD-1 response in patients diagnosed 
with advanced melanoma [14]. Interestingly, local CD8 T cell immunity is affected by 
escape mechanisms [15], and profiles based on multiple immune parameters, such as 
the presence of effector cells, MHC molecules, suppressor cells, as well as immune and 
metabolic checkpoints provide predictive value exceeding that of single markers such as 
PD-L1 or mutational load [16,17,18]. However, limited availability of biopsy tissue and its 
invasiveness, especially in case of visceral tumors, often limits in situ determination of such 
markers. Multi-parameter analysis of immune cell subsets in blood is an easily employable 
screening method anticipated to reveal surrogate markers for clinical responses. Indeed, 
the absolute number of lymphocytes in blood samples correlates with clinical outcome 
in melanoma patients treated with ipilimumab, a monoclonal antibody targeting the co-
inhibitory receptor CTLA-4 [19]. And more recently, Ki67 expression in a subset of PD-1+ 
CD8+ T cells has been reported as a measure of effector T cell invigoration in patients with 
advanced melanoma and NSCLC who were treated with antibodies targeting the PD-1/
PD-L1 axis [20,21,22].
In the current study, we have enumerated 18 immune cell populations and performed 
both cluster and selected analyses to assess differential frequencies of multiple T cell 
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subsets using 28 markers of T cell activation, maturation, co-signaling and chemotaxis in 
NSCLC patients treated with 2nd line nivolumab in order to obtain prospective immune 
markers identifying those patients showing a clear response to therapy.
MATERIALS AND METHODS
Study design
The MULTOMAB study (local ethics board study number MEC16–011) was originally 
designed by the Laboratory of Translational Pharmacology, Dept Medical Oncology at the 
Erasmus MC Cancer Institute (PIs: R. Mathijssen; J. Aerts and R. Debets). Patients asked to 
participate in the reported analysis are suffering from NSCLC and receiving treatment in 
the form of nivolumab (BMS936558, Opdivo®). Written informed consent was obtained 
from all participants prior to inclusion into the study.
Patients and collection of specimens
Data was prospectively collected from NSCLC patients treated with 3 mg/kg of nivolumab 
(intravenously every 2 weeks) between May 5th 2016 and November 1st 2017, with a 
minimum follow-up of three months. Patient characteristics are provided in Additional 
file 1: Table S1. Blood was drawn at 3 time points (pre-treatment (“baseline”) and prior to 
2nd and 3rd administration of nivolumab (visits (V) 1 and 2). For an overview of patient 
treatment and sample acquisition, see Additional file 1: Figure S1. Freshly obtained, whole 
blood was used to enumerate immune cell populations, whereas PBMCs were isolated 
using ficoll gradient and stored using standard protocols and thawed at later time points 
to assess frequencies of T cell subsets. Healthy control samples were obtained from 15 
donors that were matched with patients for age and gender-distribution (median age: 
65 years (60–69); 6 female (40%) and 9 male (60%) donors) (Sanquin, Amsterdam, The 
Netherlands).
Assessment of tumor volume and clinical response
Baseline tumor burden was defined as the sum of the longest diameter of all target lesions. 
Best overall response (BOR) was assessed according to RECIST v1.1. Partial response (PR) 
was defined as a minimal decrease of 30% in the sum of diameters of the target lesions, 
taking as reference the sum of diameters at baseline, while progressive disease (PD) 
was defined as a minimal increase of 20% in the sum of diameters of the target lesions, 
taking as reference the smallest sum of diameters while on study and a minimal absolute 
increase of 5 mm. Stable disease (SD) was defined as insufficient change in tumor sizes to 
qualify for either PR or PD and if duration of SD was 90 days or more. Patients with non-
measurable lesions were excluded from analysis. All three BOR response groups displayed 
similar medians and ranges with regard to age, sex and histology of primary lung tumor.
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Flow cytometry
Whole blood was stained and after lysis of red blood cells analyzed by multi-color FCM 
on a BD 3-laser Celesta flow cytometer using FACSDIVA 8.x software. Absolute cell counts 
were determined using Flow-Count Fluorospheres (Beckman Coulter). Cryopreserved 
PBMC samples were thawed and stained with a master mix of antibodies. Please refer 
to Additional file 1: Table S2 for an overview of staining panels and utilized markers; all 
panels were optimized, compensated using Fluorescence minus one (FMO) controls and 
measurements were corrected for background fluorescence; a detailed list of antibodies is 
available upon request. Data were gated and analyzed using FlowJo software (Tree Star). 
Please refer to Additional file 1: Table S3 for an overview of our data analysis work scheme, 
in which dimensionality reduction analysis (tSNE, see below) preceded two-dimension 
(2D) analysis of selected markers. The latter analysis of large datasets was conducted using 
R.
T-distributed stochastic neighbor embedding (tSNE) analysis
tSNE analysis was performed using the Cytosplore software, with an interactive graphical 
user interface. CD8 T cell populations were extracted as individual .fcs files and imported 
into Cytosplore [23], where they were down-sampled to at most 1000 cells per sample, and 
tSNE analysis was performed on these 211,000 ± 6000 data points (cells from 71 patients, 
3 time points each). Clustering was carried out with gradients of density plots, where 
first a threshold (sigma) of 26 was used, which provided 22 ± 8 clusters per combination 
of markers (see Additional file 1: Table S2, panels 2–6). This threshold was iteratively 
increased to a lower number of clusters in such a way that differential marker intensities 
were not compromised, providing a total of 12 ± 4 clusters per combination of markers. 
A total of 58 clusters was identified across all markers. The marker intensity profiles and 
contributions of individual BORs in these clusters were extracted from Cytosplore to excel 
sheets (Microsoft) for visualization.
Statistics
tSNE-identified clusters were tested for differential abundance among BOR groups and 
time points using the Student’s T-test of the scipy stats package in python, while 2D 
analysis of selected markers was conducted using the Kruskal Wallis test. Descriptive 
statistics included median, standard deviation and range for continuous variables. For 
comparison of median differences between individual BOR groups the Mann–Whitney U 
test was used. For normally distributed data, significant changes of median cell numbers 
or frequencies within BOR groups over time were determined using two-sided, paired 
Student’s T-test. Correlations between continuous variables were determined by Pearson’s 
r coefficient. Differences were considered significant with a p-value below 0.05.
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Data reporting
In this discovery study, experiments were not randomized and the investigators were not 
blinded to patient sample allocation during experiments and outcome assessment.
RESULTS
NSCLC patients with PR to nivolumab harbor normal, non-decreased numbers of CD8 T cell 
numbers in blood in contrast to PD and SD
Availability of freshly obtained, peripheral blood of 32 of the 71 NSCLC patients enrolled in 
this study allowed us to conduct enumeration of 18 major immune cell populations prior 
to and following nivolumab treatment (for treatment and patient details, please refer to 
Additional file 1: Figure S1 and Additional file 1: Table S1). Patients were assessed for their 
best overall response (BOR) according to RECIST v1.1 within a follow-up time of at least 
90 days (except for patients experiencing progressive disease (PD) within that timeframe) 
and categorized into patients with partial response (PR; n = 7), stable disease (SD; n = 10) or 
PD (n = 15). For reference purposes, the same immune cell populations were enumerated 
in a control group of age and gender-matched healthy individuals (n = 15). Figure 1 
depicts the numbers of immune cells detected per μl of peripheral blood at baseline, 
after the 1st treatment cycle (2 weeks after baseline, visit (V)1) and 2nd treatment cycle 
(4 weeks after baseline, V2). Numbers remained unchanged after onset of therapy for the 
majority of immune cell populations, except for eosinophils, which increased in numbers, 
independent of BOR, and T cells, which differed significantly between PR and PD patients 
after onset of therapy (see below). When compared to healthy reference values at baseline 
(see Additional file 1: Figure S2), numbers of granulocytic and myeloid cell populations 
were enhanced in all BOR groups, i.e., mature neutrophils, monocytes and M-MDSCs, while 
numbers of lymphocytes (i.e. B and NK cells), were decreased. At baseline, SD patients 
displayed an enhanced number of immature neutrophils compared to PR patients, who 
in turn displayed significantly lowered numbers of these cells compared to healthy 
controls samples. On the other hand, compared to these healthy reference values, median 
numbers of T cells at baseline were significantly decreased only in PD and SD, but not in PR 
patients (see Additional file 1: Figure S2). When assessing the major T cell populations, we 
observed that αβ-T cells, but in particular their CD8-positive subset represented the T cell 
population that attributed to the difference among the BOR groups (Fig. 2). In example, 
at baseline we measured a median of 500 CD8 T cells/μl (range: 80–1450) in PR patients, 
while in SD and PD patients we measured 210 CD8 T cells/μl (30–900) (p = 0.061) and 250 
CD8 T cells/μl (60–1250) (p = 0.057), respectively. This difference increased after onset of 
therapy. Namely, at time point V1 we measured a median of 560 CD8 T cells/μl (170–1900) 
in PR patients, while PD and SD patients showed medians of 220 CD8 T cells/μl (90–1070) 
(p = 0.032) and 230 CD8 T cells/μl (10–550) (p = 0.01), respectively. Neither γδ-T cells, nor 
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the CD4-positive αβ-T cell subset displayed significant differences between the three BOR 
groups.
Figure 1. Nivolumab treatment does not result in changed numbers of peripheral immune cell 
populations, except eosinophils and T cells 
Figure 1. Nivolumab treatment does not result in changed numbers of peripheral immune cell 
populations, except eosinophils and T cells  
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Blood samples taken from patients at baseline, V1 and V2 were stained, ery-lysed and subsequently 
analyzed by multi-color FCM. Immune cell populations that were enumerated and markers used 
are listed in Additional file 1: Table S2, panel 1. Median numbers of immune cell populations of 
healthy controls are indicated by a dark grey, dotted line, and upper and lower quartile ranges are 
indicated by light grey dotted lines. Statistically significant differences between BOR groups were 
determined using Mann–Whitney U test. * p < 0.05; ** p < 0.01. BOR = best overall response, PR = 
partial response, SD = stable disease, PD = progressive disease, HC = healthy control.
Blood samples taken from patients at baseline, V1 and V2 were stained, ery-lysed and subsequently analyzed by multi-color 
FCM. Immune cell 
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Figure 2. Patients responding to nivolumab show high numbers of CD8 T cells
Graphs show numbers of αβ and γδ T cells in peripheral blood and the respective CD4+ and CD8+ 
subsets of αβ T cells. See legend to Fig. 1 for details, abbreviations and statistical testing.
PR patients show enriched frequencies of CD8 T cells with a phenotype that corresponds to 
enhanced T cell differentiation
As numbers of CD8 T cells differed between patients in the different BOR groups, we 
further investigated their particular subsets in more detail. To this end, we stained 
peripheral blood mononuclear cell (PBMC) samples of a total of 71 NSCLC patients (PR: 
n = 14; SD: n = 25; PD: n = 32) for 28 markers (Additional file 1: Tables S2 and S3), followed by 
dimensionality reduction as well as rationale-based analysis to identify (combinations of ) 
markers from each of our flow cytometry panels that would reveal significant differences 
between BOR groups and time points within the CD8 T cell subset (identical analysis was 
conducted in CD4 T cells; data not shown). Starting with T cell maturation markers, and 
taking into account all patients and time points, density plots revealed 9 distinct clusters 
of which 5 were differently abundant between BOR groups and time points (Fig. 3a). In 
example, clusters 3 and 8 displayed higher densities in PR patients when compared to 
PD patients (significantly different clusters are highlighted by red lines in Fig. 3a; see 
also Additional file 1: Figure S3A). Zooming in on density plots of markers (Fig. 3b) and 
expression intensities of those markers within individual clusters (Fig. 3c), we observed 
that differences in above-mentioned clusters were mostly attributed to CD45RA, CCR7, 
CD95 and CD69. Instructed by these cluster analyses as well as reported combinations of 
T cell maturation markers, we observed that frequencies of CD8 T cells expressing single 
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maturation markers were not different (Fig. 3d, upper row), whereas frequencies of CD8 T 
cells expressing CD45RA and lacking CCR7 as well as those expressing CD95 and lacking 
CD69 were different among BOR groups (Fig. 3d, lower row). In fact, PR patients showed 
an enhanced frequency of CD45RA+CCR7− CD8 T cells at baseline (median: 43.1%) when 
compared to PD patients (29.7%). Moreover, PR but not PD patients showed a trend of 
increased frequency of CD45RA+CCR7− CD8 T cells during nivolumab treatment (52 and 
31% at V1 for PR and PD, respectively). Additionally, PR, SD and PD patients showed 60, 53 
and 46% of CD95+CD69− CD8 T cells at baseline, respectively (Fig. 3d; p = 0.033 PR v. PD). 
Furthermore, CD4 T cells displayed no differences between BOR groups with regard to 
maturation and differentiation markers (data not shown).
When assessing CD8 T cell frequencies according to markers of proliferation and regulatory 
T cells in an identical manner (Additional file 1: Figures S3B and S4), we identified 
clusters with significant, albeit low intensity differences between BOR groups. However, 
neither frequencies of CD8 T cells expressing individual markers nor those expressing 
combinations of markers, such as CD25 and FOXP3, were differently present among BOR 
groups. Notably, frequency of CD4 regulatory T cells showed no difference between BOR 
groups (data not shown). Frequencies of CD8 T cells expressing the proliferation marker 
Ki67 either as a single marker or in combination with PD-1 did not show significant 
differences between BOR groups either. It is noteworthy, however, that we did observe a 
significant increase in frequency of Ki67+ CD8 T cells expressing PD-1 after onset of therapy 
in all BOR groups (Additional file 1: Figure S5) and that there was a positive correlation 
between frequency of Ki67+ within PD1+CD8 T cells and pre-treatment tumor volume of 
target lesions in NSCLC patient. This correlation, however, was not predictive of response 
to therapy.
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PR patients show decreased frequencies of CD28+CD40L+ and 
CD28+ICOS+ CD8 T cells
When looking into expression of co-inhibitory receptors, we identified several density 
clusters that showed significant differences between BOR groups and time points (Fig. 
4a and Additional file 1: Figure S3C). Differences in the majority of these clusters were 
attributed to CD57 and PD-1 (Fig. 4b and c). In addition to these findings, we have assessed 
the sum of different co-inhibitory receptors expressed by CD8 T cells (i.e., BTLA, PD-1, 
TIM3, LAG3), and noted that PR patients have a trend of expressing higher frequencies of 
CD8 T cells with 2 or more different co-inhibitory receptors when compared to PD patients 
at baseline (Fig. 4d). Instructed by these analyses, we observed that frequencies of CD8 
T cells expressing a single type of co-inhibitory receptors were not different, whereas 
frequencies of CD8 T cells co-expressing PD-1 and TIM3 were more frequent in PR patients 
when compared to PD patients at baseline (Fig. 4e). This finding extends the observation 
that the frequency of highly differentiated CD8 T cells is enhanced in PR patients. Using 
our panel of co-stimulatory receptors, we again identified density clusters that are 
differentially abundant among BOR groups and time points (Fig. 5a, Additional file 1: 
Figure S3D). Interestingly, clusters that were more abundant in PR patients were marked by 
a decreased presence of CD28, ICOS and CD40L (clusters 3 and 8 in Fig. 5b and c), whereas 
clusters that were more abundant in PD patients were marked by an increased presence 
of CD28 and CD40L (clusters 4 and 7). When assessing the sum of different receptors 
expressed by CD8 T cells, we noted that PR patients were marked by a higher frequency 
of CD8 T cells devoid of all five co-stimulatory receptors (i.e., CD28, ICOS, CD40L, 4-1BB 
and OX40). PR patients had lower frequencies of CD8 T cells with 2 or more different co-
stimulatory receptors when compared to PD patients at baseline (Fig. 5d). Frequencies of 
CD8 T cells expressing a single type of co-stimulatory receptors, except a lower frequency 
of CD40L+ CD8 T cells, were not different among BOR groups nor time points (Fig. 4e). 
In contrast, analysis of frequencies of CD8 T cells expressing 2 co-stimulatory receptors 
revealed that T cells expressing CD28 combined with another receptor, particularly CD40L 
or ICOS, were lowest in PR and significantly higher in PD patients (Fig. 5e).
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Figure 4. Patients with PR display enhanced frequency of PD-1+ TIM3+ CD8 T cells at baseline
(a) Density plots of all data points (ALL: cells from 71 patients, 3 time points each) and split up 
according to BOR and time points. Plot with 10 clusters (lower left) is the result of gradients of density 
plots and iterative testing (see Materials and Methods for details). Individual clusters were assessed 
for significant differences between BOR groups and time points, and highlighted by red lines (see also 
Additional file 1: Figure S3C). (b) Density plots of individual markers and (c) expressions of markers 
within individual clusters according to relative intensities; clusters showing different abundance (from 
panel A) are highlighted by red rectangles. (d) Sum of different types of co-inhibitory receptors that 
are expressed by CD8 T cells (excluding CD57) at baseline. Green circles visualize fraction of CD8 T 
cells expressing 0 or 1 type of co-inhibitory receptors. (e) Frequencies of CD8 T cells positive for single 
markers or combinations of two markers showing significant differences. Markers used are listed in 
Additional file 1: Table S2, panel 4. Statistically significant differences between BOR groups and time 
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Figure 5. Patients with PR display reduced frequencies of CD8 T cells co-expressing CD28 and 
CD40L or CD28 and ICOS
(a) Density plots of all data points (ALL: cells from 71 patients, 3 time points each) and split up 
according to BOR and time points. Plot with 8 clusters (lower left) is the result of gradients of 
252   |   Chapter 11
density plots and iterative testing (see Materials and Methods for details). Individual clusters 
were assessed for significant differences between BOR groups and time points, and highlighted 
by red lines (see also Additional file 1: Figure S3D). (b) Density plots of individual markers and (c) 
expressions of markers within individual clusters according to relative intensities; clusters showing 
different abundance (from panel A) are highlighted by red rectangles. (d) Sum of different types 
of co-stimulatory receptors that are expressed by CD8 T cells at baseline. Orange circles visualize 
fraction of CD8 T cells expressing 0 or 1 type of co-stimulatory receptors. (e) Frequencies of CD8 T 
cells positive for single markers or combinations of two markers with significant differences. Markers 
used are listed in Additional file 1: Table S2, panel 5. Statistically significant differences between BOR 
groups and time points were determined using Mann–Whitney U test. * p < 0.05.
Figure 6. Number of CD8 T cells in PR patients correlate with CD8 T cell maturation phenotypes
Correlation matrix depicts CD8 T cell phenotypes that were selected according to statistically 
significant differences between BOR groups (p values < 0.001) as well as extent of correlations with 
number of CD8 T cells and frequency of T cell phenotypes (r values < − 0.5 and > 0.5). Correlations 
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In PR patients, the CD8 T cell differentiation phenotype coincides with a 
complete lack of co-stimulatory receptors
To study whether and how the differential numbers of CD8 T cells as well as the differential 
frequencies of defined CD8 T cell phenotypes among BOR groups were inter-related, 
we conducted extensive correlation studies with all immune markers measured in this 
study. Figure 6 displays the resulting matrix of immune parameters with the highest 
correlations (r values < − 0.5 or > 0.5 and p values < 0.001) with number of CD8 T cells 
and the CD8 phenotypes. Enhanced numbers of CD8 T cells in PR patients relate most 
clearly to frequencies of CD45RA+CCR7− CD8 T cells as well as CD8 T cells with no co-
stimulatory receptors. In turn, frequencies of CD45RA+CCR7− CD8 T cells predominantly 
relate to frequencies of CD95+ CD8 T cells, CD57+ CD8 T cells, PD-1+ CD8 T cells and again 
CD8 T cells with no co-stimulatory receptors.
DISCUSSION
In this explorative study, we set out to discover potential immune markers in NSCLC 
patients that correspond with response to nivolumab therapy. The distribution of BOR 
in this prospective study of 71 patients is reflective of clinical outcome in large clinical 
trials with NSCLC patients [4, 5] with about 20% of treated patients showing response. 
Using our prospectively collected cohort of patients, we have enumerated immune cell 
populations and assessed clusters of T cell markers and frequencies of T cells subsets in 
blood samples drawn prior to and during therapy, using reference values from age- and 
gender-matched healthy controls.
Most studies evaluating systemic immune profiles generally rely on frozen PBMC samples, 
resulting in a bias towards immune cell populations that show high stability throughout 
the freeze/thaw procedure [24]. To address this issue, we have determined numbers of 
18 different immune cell populations in freshly obtained blood. Amongst the significant 
differences in numbers of major immune cell populations between the three BOR groups, 
we detected a general increase in numbers of eosinophils during nivolumab therapy. Such 
an increase in peripheral eosinophils has previously been identified as a prognostic marker 
for survival in metastatic melanoma patients treated with various types of immune therapy 
[25]. However, increase in eosinophils was not associated with BOR in our NSCLC cohort 
as this increase occurred irrespective of BOR. At baseline, only immature neutrophils and 
T cells, in particularly CD8 T cells, showed differences among BOR groups. The increased 
number of immature neutrophils in SD patients is interpreted with caution since this 
finding may have been the result of exclusion of several outliers in this particular BOR 
group at baseline, part of our downstream analysis, which may have reduced the spread in 
this immune cell subset. The reduced number of CD8 T cells in SD and PD patients prior to 
therapy on the other hand shows a relatively low spread and is consistent over time. The 
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latter observation may explain the lack of responsiveness to therapy and is supported by 
previous findings of reduced numbers of T cells (CD45+CD3+) during immune checkpoint 
inhibition [19]. Besides therapy-induced changes, we also observed changed numbers 
of immune cell populations at baseline when compared with healthy controls. Increased 
numbers of mature neutrophils and monocytes correspond with an inflamed tumor 
microenvironment that may drive the proliferation of these cells and their detection in 
the periphery [26]. Also, our finding of increased numbers of M-MDSCs is in line with 
multiple reports, and may be of interest since these cells have been described as main 
suppressors of immune responses [27, 28]. The role of activated NK cells (expressing MIP-
1β and CD69) in the context of anti PD-1 therapy of melanoma patients has recently been 
highlighted by Hodi and colleagues [29]. These authors observed increased frequencies 
of these cells as well as NK cells in patients showing response to therapy. Important to 
note that numbers of neutrophils, M-MDSCs, B or NK cells, neither by themselves nor in 
combination with other immune cell populations, did correlate with BOR in the present 
study, indicating that immune response in NSCLC patients may be mostly driven by T cells, 
rather than NK, B or other effector cells.
To follow-up on the different CD8 T cell numbers, we conducted a dimensionality reduction 
as well as 2D analyses to identify marker combinations and T cell subsets. Notably, we 
observed that reduced numbers of CD8 T cells in SD and PD patients were not due to 
changed frequencies of CD8 regulatory T cells nor a general lack of T cell proliferation 
(Additional file 1: Figure S4). Although the presence of CD4 Treg cells within the tumor 
microenvironment has been described as a potential driver of tumor immune escape 
(reviewed in [30]), peripheral frequencies of this subset may not be sufficiently reflective 
of local conditions. An increase in the frequency of PD-1+ CD8 T cells and an enhanced 
frequency of PD-1+ CD8 T cells that express Ki67 has previously been observed in NSCLC 
patients undergoing anti-PD-1/anti-PD-L1 therapy [20, 31]. Similar to this study, we 
found an increase in PD-1+ CD8 T cells expressing Ki67, yet no correlation between their 
frequencies after onset of therapy and the clinical response according to RECIST1.1 (see 
Additional file 1: Figure S5). Huang and colleagues demonstrated that the ratio between 
Ki67+PD-1+ CD8 T cells and pre-therapy tumor burden was indicative of a clinical response 
of melanoma patients to pembrolizumab [21]. While we observed a similar correlation 
between 1D tumor measurements and frequencies of Ki67+PD-1+ CD8 T cells, albeit to 
a lower degree (see Additional file 1: Figure S5C), we were unable to demonstrate this 
ratio to be of discriminatory value among BORs in our NSCLC patient cohort. Although 
we cannot exclude that increased frequencies of Ki67+PD-1+CD8 T cells depend on tumor 
type, mutational load and/or certain patient subgroups, our findings do argue that further 
studies are required to better define how the Ki67 marker relates to clinical response to 
checkpoint inhibition. When conducting similar tSNE and 2D analysis of chemo-attractant 
receptors, we observed that the frequency of CD8 T cells expressing such receptors did 
not yield differences between BOR groups or time points (Additional file 1: Figure S6).
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When looking into maturation states of T cells, we detected significantly higher frequencies 
of CD45RA+CCR7− CD8 T cells, a phenotype often related to terminal T cell differentiation 
[32], in PR patients compared to PD patients at baseline and during treatment. Moreover, 
in PR patients we observed higher frequencies of CD95+CD69− CD8 T cells. While CD95 
has been recognized for FAS-mediated apoptosis, there is evidence for FAS-mediated 
T cell proliferation and differentiation as well [33]. High numbers of CD95+ CD8+ tumor 
infiltrating lymphocytes have previously been demonstrated to have predictive value in 
breast cancer patients [34] and an enhanced frequency of CD95+ T cells in blood of stage 
IV melanoma patients has been reported to associate with clinical response upon anti-
PD-1 treatment [22]. CD69 is an early activation marker that shows a rapid and transient 
upregulated expression upon TCR-mediated activation of CD8 T cells. Additionally, 
CD69 has been described as a tissue retention marker, indicating that down-regulated 
expression of CD69 coincides with egress of T cells into the blood flow [35]. Therefore, 
the observed changes, with respect to both CD45RA+CCR7− and CD95+CD69− CD8 T cell 
phenotypes, may be a consequence of local antigen encounter, T cell differentiation, and 
tissue egression of CD8 T cells in PR patients. Interestingly, these findings are nicely in 
line with recent observations by Gide and colleagues showing that differentiated effector 
memory T cells are more abundant in melanoma patients who respond to PD1 and CTLA-
4 antibody treatment [36]. Further evidence for enhanced T cell differentiation in PR 
patients comes from the observation that the frequency of the mentioned phenotypes 
highly correlates with the frequency of CD8 T cells expressing CD57, another marker of 
terminal exhaustion upon antigen encounter [37]. Lastly, other CD8 T cell phenotypes that 
have been reported to relate to late T cell differentiation, such as lack of the co-stimulatory 
receptor CD28 and co-expression of PD-1 and TIM3, also show enhanced frequencies 
in PR patients (discussed below). Analysis of co-signaling receptors revealed that clear 
differences between BOR groups are particularly related to a CD8 T cell subset lacking the 
co-stimulatory receptors CD28, ICOS, CD40L, 4-1BB and OX40. Interestingly, PR patients 
show an increased frequency of CD8 T cells lacking co-stimulatory receptors, in particular 
CD28 and CD40L or CD28 and ICOS. Moreover, the frequency of CD28+ CD8 T cells showed 
a high and inverse correlation with the frequency of CD8 T cells lacking co-stimulatory 
receptors (Fig. 6). While expression of CD28 is a pre-requisite for proper activation of T 
cells, the absence of this receptor has been described as part of a negative feedback loop 
following long-term antigen stimulation [38], and fits the above-described phenotype 
of antigen-exposed and differentiated CD8 T cells. Further substantiating the premise 
that a higher frequency of CD8 T cells in PR patients have encountered antigen, is our 
observation that these patients contain higher frequencies of PD-1+TIM3+ CD8 T cells at 
baseline (see Fig. 5c). The combination of these two receptors has been well described as 
a sign of activation-mediated T cell differentiation and potentially exhaustion [39,40,41]. 
Moreover, in patients with squamous cell carcinoma of the head and neck, recent studies 
showed that PD-1+TIM3+ CD8 T cells that lack CD28 and CD27 were able to suppress 
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proliferation of autologous peripheral blood T cells ex vivo [42]. Of interest, the presence 
of intra-tumoral PD-1+ CD8 T cells expressing the transcription factor Tcf has been related 
to tumor control in response to immunotherapy [43, 44] and these T cells may harbor 
stemness and yield T cells that are more differentiated. Since PD-1 primarily intervenes 
with CD28 co-signaling, rather than TCR signaling itself [20, 45], we cannot exclude that 
the frequency of CD28+ T cells that co-express Ki67 and PD-1 becomes enhanced upon 
treatment with checkpoint inhibitor. Along these lines, it is striking that the frequency 
of CD8 T cells devoid of multiple co-stimulatory receptors is highest in PR patients at 
baseline and throughout therapy, and correlates with the total number of CD8 T cells as 
well as frequencies of CD8 T cells showing a CD45RA+CCR7− phenotype.
CONCLUSIONS
In conclusion, we found that NSCLC patients with a PR upon treatment with nivolumab 
demonstrate enhanced numbers of CD8 T cells and a phenotype corresponding with late 
differentiation at baseline. Collectively, our findings argue that a large fraction of CD8 T 
cells in PR patients has been exposed to tumor antigen and subsequently matured and 
egressed into the bloodstream. This enhanced CD8 T cell differentiation was accompanied 
by a higher frequency of PD-1 and TIM3 and a complete loss of co-stimulatory receptors. 
We propose that a panel comprising the markers CD45RA, CCR7, CD95, CD69, CD57, PD-1 
as well as CD28, CD40L, and ICOS should be validated in larger cohorts of patients and 
used to develop a model aiding in the identification of NSCLC patients prone to show 
tumor regression upon anti-PD-1 therapy. While novel approaches are emerging that 
include assessment of tumor material with regard to T cell exclusion and exhaustion [18], 
to our knowledge this is the first description of peripheral immune markers able to identify 
NSCLC patients showing response to nivolumab treatment prior to onset of therapy (see 
Additional file 1: Figure S7 for a schematic overview of our findings).
Enhanced frequencies of T cell subsets in patients with clinical benefit   |   257 
11
REFERENCES
1. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. 
Annu Rev Immunol. 2008;26:677–704.
2. Wherry EJ. T cell exhaustion. Nat Immunol. 2011;12(6):492–9.
3. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously 
untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320–30.
4. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel 
in advanced nonsquamous non-small-cell lung Cancer. N Engl J Med. 2015;373(17):1627–39.
5. Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, et al. Nivolumab 
versus docetaxel in advanced squamous-cell non-small-cell lung Cancer. N Engl J Med. 
2015;373(2):123–35.
6. Callahan MK, Postow MA, Wolchok JD. Targeting T cell co-receptors for Cancer therapy. 
Immunity. 2016;44(5):1069–78.
7. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator 
approach to cancer therapy. Cancer Cell. 2015;27(4):450–61.
8. Gettinger S, Herbst RS. B7-H1/PD-1 blockade therapy in non-small cell lung cancer: current 
status and future direction. Cancer J. 2014;20(4):281–9.
9. Sundar R, Cho BC, Brahmer JR, Soo RA. Nivolumab in NSCLC: latest evidence and clinical 
potential. Ther Adv Med Oncol. 2015;7(2):85–96.
10. Ribas A, Hu-Lieskovan S. What does PD-L1 positive or negative mean? J Exp Med. 
2016;213(13):2835–40.
11. Rijnders M, van der Veldt AAM, Zuiverloon TCM, Grunberg K, Thunnissen E, de Wit R, et al. PD-L1 
antibody comparison in urothelial carcinoma. Eur Urol. 2018.
12. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors 
with mismatch-repair deficiency. N Engl J Med. 2015; 372(26):2509–20.
13. Zhu J, Armstrong AJ, Friedlander TW, Kim W, Pal SK, George DJ, et al. Biomarkers of 
immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and 
beyond. J Immunother Cancer. 2018;6(1):4.
14. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD1 blockade induces 
responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568–71.
15. Debets R, Donnadieu E, Chouaib S, Coukos G. TCR-engineered T cells to treat tumors: seeing but 
not touching? Semin Immunol. 2016;28(1):10–21.
16. Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D, et al. Pan-cancer 
Immunogenomic analyses reveal genotypeImmunophenotype relationships and predictors of 
response to checkpoint blockade. Cell Rep. 2017;18(1):248–62.
17. Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, et al. The immune landscape 
of Cancer. Immunity. 2018;48(4):812–30 e14.
18. Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, et al. Signatures of T cell dysfunction and exclusion 
predict cancer immunotherapy response. Nat Med. 2018;24(10):1550–8.
258   |   Chapter 11
19. Weide B, Martens A, Hassel JC, Berking C, Postow MA, Bisschop K, et al. Baseline biomarkers for 
outcome of melanoma patients treated with Pembrolizumab. Clin Cancer Res. 2016;22(22):5487–96.
20. Kamphorst AO, Pillai RN, Yang S, Nasti TH, Akondy RS, Wieland A, et al. Proliferation of PD-1+ 
CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients. Proc Natl 
Acad Sci U S A. 2017;114(19):4993–8.
21. Huang AC, Postow MA, Orlowski RJ, Mick R, Bengsch B, Manne S, et al. T-cell invigoration to 
tumour burden ratio associated with anti-PD-1 response. Nature. 2017;545(7652):60–5.
22. Krieg C, Nowicka M, Guglietta S, Schindler S, Hartmann FJ, Weber LM, et al. High-dimensional 
single-cell analysis predicts response to anti-PD-1 immunotherapy. Nat Med. 2018;24(2):144–53.
23. van Unen V, Hollt T, Pezzotti N, Li N, Reinders MJT, Eisemann E, et al. Visual analysis of mass 
cytometry data by hierarchical stochastic neighbor embedding reveals rare cell types. Nat 
Commun. 2017;8(1):1740.
24. Kadic E, Moniz RJ, Huo Y, Chi A, Kariv I. Effect of cryopreservation on delineation of immune 
cell subpopulations in tumor specimens as determinated by multiparametric single cell mass 
cytometry analysis. BMC Immunol. 2017;18(1):6.
25. Moreira A, Leisgang W, Schuler G, Heinzerling L. Eosinophilic count as a biomarker for prognosis 
of melanoma patients and its importance in the response to immunotherapy. Immunotherapy. 
2017;9(2):115–21.
26. Uribe-Querol E, Rosales C. Neutrophils in Cancer: two sides of the same coin. J Immunol Res. 
2015;2015:983698.
27. Pogoda K, Pyszniak M, Rybojad P, Tabarkiewicz J. Monocytic myeloidderived suppressor cells as a 
potent suppressor of tumor immunity in nonsmall cell lung cancer. Oncol Lett. 2016;12(6):4785–94.
28. de Goeje PL, Bezemer K, Heuvers ME, Dingemans AC, Groen HJ, Smit EF, et al. Immunoglobulin-
like transcript 3 is expressed by myeloid-derived suppressor cells and correlates with survival in 
patients with non-small cell lung cancer. Oncoimmunology. 2015;4(7):e1014242.
29. Subrahmanyam PB, Dong Z, Gusenleitner D, Giobbie-Hurder A, Severgnini M, Zhou J, et 
al. Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 
immunotherapy in melanoma patients. J Immunother Cancer. 2018;6(1):18.
30. Chaudhary B, Elkord E. Regulatory T cells in the tumor microenvironment and Cancer 
progression: role and therapeutic targeting. Vaccines (Basel). 2016;4(3).
31. Mazzaschi G, Facchinetti F, Missale G, Canetti D, Madeddu D, Zecca A, et al. The circulating pool 
of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in 
advanced NSCLC. Lung Cancer. 2019; 127:153–63.
32. Thome JJ, Farber DL. Emerging concepts in tissue-resident T cells: lessons from humans. Trends 
Immunol. 2015;36(7):428 –35.
33. Paulsen M, Janssen O. Pro- and anti-apoptotic CD95 signaling in T cells. Cell Commun Signal. 
2011;9:7.
34. Blok EJ, van den Bulk J, Dekker-Ensink NG, Derr R, Kanters C, Bastiaannet E, et al. Combined 
evaluation of the FAS cell surface death receptor and CD8+ tumor infiltrating lymphocytes as a 
prognostic biomarker in breast cancer. Oncotarget. 2017;8(9):15610 –20.
Enhanced frequencies of T cell subsets in patients with clinical benefit   |   259 
11
35. Mackay LK, Braun A, Macleod BL, Collins N, Tebartz C, Bedoui S, et al. Cutting edge: CD69 
interference with sphingosine-1-phosphate receptor function regulates peripheral T cell 
retention. J Immunol. 2015;194(5):2059–63.
36. Gide TN, Quek C, Menzies AM, Tasker AT, Shang P, Holst J, et al. Distinct immune cell populations 
define response to anti-PD-1 monotherapy and anti-PD-1/anti-CTLA-4 combined therapy. 
Cancer Cell. 2019;35(2):238–55 e6.
37. Verma K, Ogonek J, Varanasi PR, Luther S, Bunting I, Thomay K, et al. Human CD8+ CD57- TEMRA 
cells: too young to be called “old”. PLoS One. 2017; 12(5):e0177405.
38. Weng NP, Akbar AN, Goronzy J. CD28(−) T cells: their role in the ageassociated decline of 
immune function. Trends Immunol. 2009;30(7):306–12.
39. Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. Targeting Tim-3 and 
PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med. 
2010;207(10):2187–94.
40. Severson JJ, Serracino HS, Mateescu V, Raeburn CD, McIntyre RC Jr, Sams SB, et al. PD-1+Tim-3+ 
CD8+ T lymphocytes display varied degrees of functional exhaustion in patients with regionally 
metastatic differentiated thyroid Cancer. Cancer Immunol Res. 2015;3(6):620–30.
41. Kim JE, Patel MA, Mangraviti A, Kim ES, Theodros D, Velarde E, et al. Combination therapy with 
anti-PD-1, anti-TIM-3, and focal radiation results in regression of murine gliomas. Clin Cancer 
Res. 2017;23(1):124–36.
42. Pfannenstiel LW, Diaz-Montero M, Tian YF, Scharpf J, Ko J, Gastman B. Immune-checkpoint blockade 
opposes CD8+ T-cell suppression in human and murine Cancer. Cancer Immunol Res. 2019.
43. Siddiqui I, Schaeuble K, Chennupati V, Fuertes Marraco SA, Calderon-Copete S, Pais Ferreira D, et 
al. Intratumoral Tcf1(+)PD-1(+)CD8(+) T cells with stemlike properties promote tumor control in 
response to vaccination and checkpoint blockade immunotherapy. Immunity. 2019;50(1):195–
211 e10.
44. Kurtulus S, Madi A, Escobar G, Klapholz M, Nyman J, Christian E, et al. Checkpoint blockade 
immunotherapy induces dynamic changes in PD1(−)CD8(+) tumor-infiltrating T cells. Immunity. 
2019;50(1):181–94 e6.
45. Hui E, Cheung J, Zhu J, Su X, Taylor MJ, Wallweber HA, et al. T cell costimulatory receptor CD28 
is a primary target for PD-1-mediated inhibition. Science. 2017;355(6332):1428–33.
260   |   Chapter 11
SUPPLEMENTARY INFORMATION
Figure S1. 
For immune monitoring, 20 ml of peripheral blood was taken at three time points: prior to therapy 
(baseline), prior to the second therapy cycle (V1, 2 weeks after baseline) and prior to the third 
therapy cycle (V2, 4 weeks after baseline). Blood was stained, ery-lysed and 18 different immune 
cell populations were enumerated by multiplex flow cytometry. PBMCs were isolated and 
cryopreserved, and stained for 28 markers (for a detailed panel overview, please refer to Table S2) 
followed by dimensionality reduction as well as rationale-based analyses. 
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Figure S2. 
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Blood samples were taken from NSCLC patients at baseline as well as from healthy controls (HC), 
and were stained, ery-lysed and subsequently analyzed by multi-color FCM. See legend to Figure 
S1 and Table S2 for details. Statistically significant differences between BOR groups and HC were 
determined using Mann–Whitney U test. * * p < 0.05, ** p < 0.01, *** p < 0.005.
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Figure S3. 
Graphs depict % of CD8 T cells (mean + SD) present in tSNE clusters according to BOR groups and 
time points and categorized by panels of markers (as described in Table S2), namely: (A) T cell 
maturation, (B) proliferation/regulatory T cell markers, (C) co-inhibitory receptors, (D) costimulatory 
receptors and (E) chemo-attractant receptors. See legends to Figs. 3, 4, 5, S4 and S6 for details. Red 
lines indicate differences between BOR groups within the same time point, black lines indicate 
differences within the same BOR group but between time points. Statistically significant differences 
were determined using Student’s T test. * p < 0.05; ** p < 0.01; *** p < 0.005.
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Figure S4. 
(A) Density plots of all data points (ALL: cells from 71 patients, 3 time points each) and split up 
according to BOR and time points. Plot with 14 clusters (lower left) is the result of gradients of 
density plots and iterative testing (see Materials and Methods for details). Individual clusters were 
assessed for significant differences between BOR groups and time points, and highlighted by red 
lines (see also Figure S3B). (B) Density plots of individual markers and (C) expressions of markers 
within individual clusters according to relative intensities; clusters showing different abundance 
(from panel A) are highlighted by red rectangles. (D) Frequencies of CD8 T cells positive for single 
markers or combinations of two markers. Markers used are listed in Table S2, panel 3. Statistically 
significant differences between BOR groups and time points were determined using Mann–Whitney 
U test. * p < 0.05.
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Figure S5. 
Graph in (A) shows frequency of Ki67+ cells within PD-1+CD8 T cells. Graph (B) presents the 
difference in frequency of Ki67+ within PD1+CD8 T cells between BOR groups. Graph in (C)  depicts 
correlation between 1D tumor burden at baseline according to radiology (see methods for details) 
and maximum change in frequency of Ki67+ within PD1+CD8 T cells (delta between either V1 or 
V2 and baseline). Correlations were statistically assessed via Spearman’s test. Statistically significant 
differences between BOR groups and time points were determined using Mann–Whitney U test and 
paired Student’s T-test, respectively. * p < 0.05, ** p < 0.01, *** p < 0.005.
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Figure S6. 
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(A) Density plots of all data points (ALL: cells from 71 patients, 3 time points each) and split up 
according to BOR and time points. Plot with 17 clusters (lower left) is the result of gradients of 
density plots and iterative testing (see Materials and Methods for details). Individual clusters were 
assessed for significant differences between BOR groups and time points, and highlighted by red 
lines (see also Figure S3E). (B) Density plots of individual markers and (C) expressions of markers 
within individual clusters according to relative intensities; clusters showing different abundance 
(from panel A) are highlighted by red rectangles. (D) Frequencies of CD8 T cells positive for single 
markers or combinations of two markers. Markers used are listed in Table S2, panel 6. Statistically 
significant differences between BOR groups and time points were determined using Mann–Whitney 
U test. *p < 0.05.
Figure S7. 
This figure depicts main findings of this study, indicating that patients responding to therapy (PR) 
prior to start of therapy display higher numbers of peripheral CD8 T cells, with enhanced frequencies 
of the phenotypes CD45RA+CCR7−, CD95+CD69− and lack of CD28, ICOS, CD40L, 4-1BB and OX40.
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Supplementary Table I. Patient characteristics
Tumor type: NSCLC
Treatmenta: Nivolumab, Q2W, 3mg/kg





WHO performance status:     
                                   







Histology of primary lung tumor:   






2   (2.8%)
BOR:  
           
           
progressive disease (PD)





    15 (46.9%) c
    10 (31.2%)
    7   (21.9%)
Median follow-up (days, range) 242 (35-544)
a all patients received platinum-containing pre-treatment  
b all patients enrolled in this study (71 in total) underwent staining for 28 T cell markers in frozen 
PBMC samples  
c 32 of these 71 patients underwent enumeration of immune cell populations in fresh blood samples
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Supplementary Table II. Multiplex flow cytometry panels
1
a
  markers      markers














































lymphocytes CD45+ SSC B cells
NK cells
T cells 
      αβ - T cells 






























T cell maturation markers CCR7(CD197), CD45RA, CD95, CD69, CD27, CD103
3
b
T cell proliferation/ regulatory T cell 
markers
Ki67, CD25, FOXP3, PD-1(CD279)
4
b








T cell chemoattractant receptors CXCR3(CD183), CXCR4(CD184), CCR1(CD191), 
CCR4(CD194), CCR5(CD195)
a enumeration of immune cell populations in fresh blood sample
b assessment of T cell subset frequencies in PBMC samples
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Supplementary Table III. Analysis work scheme
clinical 
parameters
best overall response (SD/PR/PD)a
time points baseline, V1 (2 weeks after baseline), V2 (4 weeks after baseline)
change Δbaseline-V1, Δbaseline-V2, Δmax
b
Order of analysis










CD4/CD8 T cells subsets 












a  see Methods for details on response assessment
b defined as maximal change from baseline measurement
c testing of specific marker combinations was guided by significance and was only conducted when 
markers yielded p<0.05 comparing all three BOR groups (Kruskal-Wallis).
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Background: Immune checkpoint inhibitors that target the PD-1 receptor induce 
a response in only a subgroup of metastatic melanoma patients. Previous research 
suggests that TGF-β signaling and a collagen-rich peritumoral stroma (tumor 
fibrosis), may negatively interfere with the interaction between T cells and tumor 
cells and thereby contribute to resistance mechanisms by immune-exclusion, while 
increased tumor infiltration of M1-like macrophages enhances T cell activity. Hence, 
the current study aimed to assess the relationship between blood-based markers 
of collagen or vimentin turnover (reflecting M1 macrophage activity) and clinical 
outcome in metastatic melanoma patients after PD-1 inhibition. 
Methods: Metastatic melanoma patients who were treated with anti-PD-1 
monotherapy between May 2016 and March 2019 were included in a prospective 
observational study. Type III collagen formation (PRO-C3) and cross-linking (PC3X), 
matrix metalloprotease (MMP)-degraded type III (C3M) and IV collagen (C4M), 
granzyme B degraded type IV collagen (C4G), and citrullinated and MMP-degraded 
vimentin (VICM) were measured with immunoassays in serum before (n=107), and 
six weeks after the first administration of immunotherapy (n=94). Biomarker levels 
were associated with overall survival (OS) and progression-free survival (PFS).    
Results: Multivariate Cox regression analysis identified high baseline PRO-C3 (Q4) 
as a predictor of worse PFS (HR=1.81, 95%CI=1.06-3.10, p=0.030) and OS (HR=2.08, 
95%CI=1.06-4.09, p=0.035), after correction for lactate dehydrogenase (LDH). High 
PC3X also independently predicted worse PFS (HR=1.86, 95%CI= 1.09-3.18, p=0.023), 
whereas a high C3M/PRO-C3 ratio was associated with improved OS (HR=0.42, 
95%CI=0.20-0.90, p=0.025) after correction for LDH. An increase in VICM (p<0.0001; 
in 56% of the patients) was observed after six weeks of treatment, and an increase 
in VICM was associated with better OS when adjusted for WHO performance status 
and brain metastases (HR=0.28, 95%CI=0.10-0.76, p=0.013) and LDH (HR=0.42, 
95%CI=0.20-0.91, p=0.028).   
Conclusions: Blood-based biomarkers reflecting excessive type III collagen 
turnover were associated with worse OS and PFS after PD-1 inhibition in metastatic 
melanoma. Moreover, an increase in VICM levels after six weeks of treatment was 
associated with improved OS. These findings suggest that type III collagen and 
vimentin turnover contribute to resistance/response mechanisms of PD-1 inhibitors 
and hold promise of assessing extracellular matrix- and stroma derived components 
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INTRODUCTION
Over the last decade, immune checkpoint inhibitors (ICIs) have improved the overall 
survival (OS) of patients with metastatic cancer. Monoclonal antibodies directed to the 
programmed cell death protein 1 (PD-1) receptor have emerged as frontline therapies for 
cancers such as metastatic melanoma. However, there is an unmet need for biomarkers 
to guide treatment decisions, as the efficacy of ICIs is highly variable across individual 
patients. Although the expression of its ligand programmed death-ligand 1 (PD-L1) has 
been positively associated with clinical outcome in metastatic melanoma, the predictive 
performance remains limited, which may partly be explained by tumor heterogeneity [1]. 
Similarly, other biomarkers, such as CD8+ T cell infiltration and tumor mutational burden, 
individually or combined, have been considered as biomarkers [2,3]. Interestingly, recent 
evidence suggests that transforming growth factor beta (TGF-β), cancer associated 
fibroblasts (CAFs) and immune-exclusion in tumor tissue are associated with worse clinical 
outcome after PD-L1 or PD-1 inhibition in solid cancer [4–6]. Those immune-excluded 
tumors are characterized by a collagen-rich peritumoral stroma (tumor fibrosis) that blocks 
the interaction between CD8+ T cells and tumor cells [4–6]. The main collagens of the 
interstitial matrix (type I and III collagen) and the basement membrane (type IV collagen) 
are upregulated in immune-excluded tumors that are accompanied by a peritumoral 
location of CD8+ T cells [7]. Moreover, components of proteolytic extracellular matrix 
(ECM) turnover appear to affect the response mechanisms to ICIs by regulating steps in 
the cancer-immunity cycle [8]. Melanoma is characterized by a highly reactive and fibrotic 
tumor stroma [9,10]. Increased stroma activity leads to increased matrix metalloproteinase 
(MMP)-mediated collagen degradation resulting in the generation and release of small 
protein fragments into the blood circulation [11,12]. These ECM protein fragments can be 
used as non-invasive biomarkers measured in blood, and may be used to assess processes 
such as MMP-mediated collagen degradation and collagen formation and cross-linking 
by evaluating its blood-based signature [12]. This has been demonstrated by our previous 
study showing that biomarkers measuring type III collagen formation (PRO-C3) or MMP-
degraded type IV collagen (C4M) are associated with worse clinical outcome after CTLA-4 
ICIs in metastatic melanoma patients [13]. The two collagen derived biomarkers assess 
different components of the ECM in the tumor microenvironment (TME) by reflecting 
a dense stromal interstitial matrix and fibrotic activity (PRO-C3) and degradation of the 
basement membrane (C4M) [14].  
The current study aimed to investigate the relationship of tissue-derived biomarkers 
and clinical outcome after PD-1 inhibition in patients with metastatic melanoma. Protein 
fragments reflecting type III collagen formation (PRO-C3) and cross-linking (PC3X), MMP-
degraded type III (C3M) and IV collagen (C4M), granzyme B degraded type IV collagen 
(C4G), and citrullinated and MMP-degraded vimentin (VICM) were measured in serum 
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obtained before and six weeks after the first administration of PD-1 ICIs. Moreover, the 
dynamics of collagen turnover and VICM during treatment were assessed.
MATERIALS AND METHODS
Study design and data collection
Patients with metastatic melanoma who were treated with anti-PD-1 monotherapy 
(pembrolizumab  or nivolumab) at the Erasmus MC Cancer Institute (Rotterdam, The 
Netherlands) were prospectively included in the MULTOMAB immune-monitoring trial 
(Dutch Trial Registry number NL6828) between May 2016 and March 2019. Pembrolizumab 
was administered as a three-weekly infusion of 2 mg/kg, and nivolumab as a two-weekly 
infusion of 3 mg/kg. Patients who were treated with a prior line of immunotherapy or 
who received combination ICI therapy were excluded. The study was approved by the 
independent ethics committee board (reference number: MEC 16-011; Medical Ethical 
Board Erasmus MC, Rotterdam, The Netherlands) and all patients provided written 
informed consent. Serum samples drawn at baseline and after six weeks (median: 6, IQR 
6-9 weeks) of treatment and were available for the assessment of selected ECM biomarkers. 
All biomarker assays were performed blinded to clinical outcome and patients were 
assigned to a subject number. Progression-free survival (PFS) was defined as the time 
from the first administration of PD-1 ICI until progressive disease (PD; based on Response 
Evaluation Criteria in Solid Tumors version 1.1 [RECIST v1.1]) [15] or death, whichever 
occurred first. OS was defined as the time from the first administration of PD-1 ICI until 
death. After treatment initiation, radiological evaluation by computed tomography was 
usually performed every 3 months. For the determination of the best overall response 
(BOR) by RECIST v1.1, a minimum duration of 90 days for stable disease (SD) was required. 
Confirmation of partial response (PR) or complete response (CR) was not required. 
Assessment of biomarkers of extracellular matrix turnover in serum
Levels of ECM biomarkers were assessed in duplicates in serum samples using 
immunoassays (Nordic Bioscience, Herlev, Denmark) as previously described 1. In 
short, type III collagen formation were measured with a competitive enzyme-linked 
immunosorbent assay (ELISA) targeting the N-terminal pro-peptide of type III collagen 
(PRO-C3). Moreover, type III collagen formation and cross-linking were measured with 
a sandwich ELISA targeting cross-linked N-terminal pro-peptides of type III collagen. 
Granzyme B-mediated degradation of type IV collagen was measured with a competitive 
electro-chemiluminescence assay (C4G). Lastly, MMP-degraded type III collagen (C3M), 
MMP-degraded type IV collagen (C4M), and MMP-degraded and citrullinated vimentin 
(VICM) were measured with competitive ELISAs. 
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Statistical analysis
Firstly, patient survival (PFS and OS) was visualized by the Kaplan-Meier approach and 
log-rank tests were used to determine differences between the curves after stratification 
of patients into quartile groups based on biomarker levels. Kaplan-Meier survival curves 
were also used to analyze survival outcomes in patients with a low type III collagen 
degradation to formation (C3M/PRO-C3) ratio (<1) compared to a high C3M/PRO-C3 ratio 
(>1). Moreover, survival outcomes were analyzed in patients with an evident increase 
in biomarkers (>20%) at week 6 compared to baseline versus the rest of the patients. 
The association with survival (PFS and OS) was further analyzed using univariate and 
multivariate Cox regression analysis. Correction for potential confounding factors was 
performed, variables with a p-value of ≤ 0.05 were considered for multivariate analyses. Test 
variables (ECM biomarkers) were included as continuous variable and stratified by the 75th 
percentile cutoff. Secondly, to study the association of baseline ECM biomarker levels with 
BOR: patients with PD were compared to patients with SD/PR/CR and analyzed using the 
Mann-Whitney test. Lastly, the dynamics of ECM biomarkers were studied by determining 
the difference over time of individual ECM biomarkers, indicating an increase or decrease 
comparing baseline levels to levels during therapy using the Wilcoxon matched-pairs 
rank test. A Pearson correlation was used to examine biomarker correlations. Analyses 
were performed using MedCalc (v16.8.4), IBM SPSS Statistics version 24.0.0.1 (Chicago, IL) 
and Graphpad Prism 8.3.0 (Graphpad Software, LLC). A p-value of p<0.05 was considered 
statistically significant.
RESULTS
Serum from a total of 107 metastatic melanoma patients at baseline and paired serum 
from 94 patients (88% of all patients) that was obtained six weeks (median: 6, IQR 6-9 
weeks) after PD-1 ICI therapy was available for analysis. The baseline patient characteristics 
including demographic and clinical data are shown in Table 1. All 107 patients were 
evaluable for the OS analysis, with a median OS of 36.2 months. Three patients (3%) were 
not evaluable for determination of BOR, i.e. because of early clinical progression, resulting 
in a disease control rate (the proportion of patients with a BOR of SD, PR or CR) of 63.5%. 
The serum levels of the six different ECM biomarkers were evaluated at baseline: PRO-C3, 
PC3X, C4G, C3M, C4M and VICM. The distribution of those baseline measurements is 
shown in Suppl. Fig. 1. For all six ECM biomarkers, there was a right-skewed distribution 
of data. 
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Table 1. Patient characteristics



















Present at baseline 18 (17%)
Absent at baseline 48 (45%)






Not evaluable 3 (3%)
Continuous variables Median (IQR)
Age 66 (55-73)
LDH at baseline 216 (183-306)
Abbreviations: Best overall response (BOR), complete response (CR), partial response (PD), stable 
disease (SD), progressive disease (PD), lactate dehydrogenase (LDH).  
Baseline levels of PRO-C3 and PC3X are negatively associated with survi-
val outcomes
Firstly, the relationship between ECM-derived biomarkers at baseline and clinical outcome 
after PD-1 inhibition in patients with metastatic melanoma were investigated. For 
PRO-C3 and PC3X, statistically significant differences among PFS curves were observed 
across the quartiles of biomarker levels (median PFS of PRO-C3 Q1: 28.4 months, Q2: 
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not reached, Q3: 12.9 months and Q4: 2.6 months, p=0.028 and median PFS of PC3X Q1: 
26.9 months, Q2: 9.1 months, Q3: 23.3 months and Q4: 3.2 months, p=0.035; Fig. 1a,b). 
Similarly, the association of ECM biomarkers with OS was assessed (Fig. 2a-f), resulting in 
a corresponding trend for PRO-C3 and PC3X (median OS of PRO-C3 Q1: 42.3 months, Q2: 
not reached, Q3: 36.2 months and Q4: 13.9 months, p=0.056 and median OS PC3X Q1: not 
reached, Q2: 29.7 months, Q3: not reached and Q4: 17.0 months, p=0.064; Fig. 2a,b). The 
baseline levels of C4G, C3M, C4M or VICM were not significantly associated with PFS or 
OS (Fig. 1a-f and Fig. 2a-f). Of note, PRO-C3 and PC3X levels were moderately correlated 
with each other at baseline (Pearson r=0.60, p<0.0001), while C3M and C4M were strongly 
correlated at baseline (Pearson r=0.86, p<0.0001; Suppl. Table 1). Interestingly, patients 
with a high C3M/PRO-C3 ratio (>1) at baseline had improved PFS (median PFS: 15.5 vs. 2.8 
months, p=0.020) and OS (median OS: 42.3 vs. 4.6 months, p<0.001) compared to patients 
with a low C3M/PRO-C3 ratio (<1; Fig. 3a,b). 
Figure 1. Association of ECM biomarkers measured at baseline and progression free survival


















































































































































Kaplan-Meier plots demonstrating the association of ECM biomarkers with progression free survival 
(PFS) for metastatic melanoma patients. A) PRO-C3, B) PC3X, C) C4G, D) C3M, E) C4M and F) VICM 
were dichotomized into quartiles (Q4, representing the highest levels of the biomarker). P-values 
are based on the log-rank test.
Excessive type III collagen turnover are independent predictors of worse 
outcome 
Univariate and multivariate Cox regression analyses were performed of all ECM 
biomarkers corrected for common (prognostic) baseline patient risk factors. In the 
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univariate analysis, PRO-C3, PC3X, C4G and C3M levels as continuous test variables were 
negatively correlated with PFS (Table 2). Additionally, the predictive value was evaluated 
by using the 75th percentile cut-point (Q4), based on the observation that patients with 
high biomarker levels (Q4) had worse survival outcomes compared to patients with low 
biomarker levels (Q1-3; Fig. 1a-d and Fig. 2a,b). Here, higher baseline levels of PRO-C3 
(HR=1.96, 95%CI=1.17-3.30, p=0.011), PC3X (HR=2.05, 95%CI=1.23-3.43, p=0.006), C4G 
(HR=1.93, 95%CI=1.15-3.26, p=0.014) and C3M (HR=1.75, 95%CI=1.04-2.93, p=0.036) 
were significantly associated with worse PFS compared to lower levels (Table 2). For OS, 
the results were comparable for PRO-C3 and PC3X. In the univariate analysis, PRO-C3 
and PC3X as continuous test variables were negatively associated with OS, while higher 
PRO-C3 (HR=2.41, 95%CI=1.26-4.60, p=0.008) and PC3X (HR=2.21, 95%CI=1.14-4.28, 
p=0.019) was associated with worse OS compared to lower levels (Table 3). Again, a high 
C3M/PRO-C3 ratio (>1) was associated with improved PFS (HR=0.51, 95%CI=0.29-0.91, 
p=0.023) and OS (HR=0.33, 95%CI=0.16-0.65, p=0.001) compared to a low ratio (Table 
3). Importantly, baseline lactate dehydrogenase (LDH) had a significant impact on PFS 
(HR=1.00, 95%CI=1.00-1.00, p=0.014) and OS (HR= 1.00, 95%CI=1.00-1.00, p<0.0001). In 
the multivariate analysis, PRO-C3 and PC3X levels were both independently associated 
to worse PFS after correction for LDH (HR=1.81, 95%CI=1.06-3.10, p=0.030 and HR=1.86, 
95%CI=1.09-3.18, p=0.023, respectively; Table 2), although baseline PRO-C3 and PC3X 
were moderately correlated with baseline LDH (p<0.0001; Suppl. Table 1). Importantly, 
PRO-C3 remained significantly associated to worse OS after adjustment for LDH 
(HR=2.08, 95%CI=1.06-4.09, p=0.035), with a similar trend for PC3X that did not however 
meet statistical significance (HR=1.78, 95%CI=0.88-3.60, p=0.106; Table 3). The WHO 
performance score of patients (HR=3.10, 95%CI=1.64-5.86, p<0.001) and the presence 
of cerebral metastases before start of treatment (HR=2.39, 95%CI=1.01-5.68, p=0.049) 
were also associated with OS in the univariate analysis, attenuating the association of all 
biomarkers and OS (data not shown). 
In line with previous findings, a high C3M/PRO-C3 ratio had a positive relationship with OS 
when adjusted for LDH (HR=0.42, 95%CI=0.20-0.90, p=0.025; Table 3).
Baseline levels of PRO-C3 are associated with progressive disease
The relationship between baseline levels of the ECM biomarkers and the BOR was assessed. 
When comparing patients with PD to patients achieving disease control (BOR of SD, PR or 
CR), baseline PRO-C3 levels were significantly elevated in PD patients (median 10.5 ng/
ml; 95%CI=8.3-12.7 vs. 8.8 ng/ml; 95%CI=7.6-9.9, p=0.046; Suppl. Fig 2a). No significant 
differences were observed for the remaining five biomarkers (Suppl. Fig. 2b-f).
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Figure 2. Association of ECM biomarkers measured at baseline and overall survival 











































































































































Kaplan-Meier plots demonstrating the association of ECM biomarkers with overall survival (OS) 
for metastatic melanoma patients. A) PRO-C3, B) PC3X, C) C4G, D) C3M, E) C4M and F) VICM were 
dichotomized into quartiles (Q4, representing the highest levels of the biomarker). P-values are 
based on the log-rank test. 
An increase of VICM levels during treatment was positively associated 
with clinical outcome
The dynamics of collagen and VICM turnover were assessed during PD-1 inhibition by 
comparing the baseline biomarker levels to the levels after PD-1 ICI therapy. For PRO-C3, 
PC3X and VICM, an increase of serum levels was observed after six weeks of therapy 
compared to baseline (PRO-C3: 10.2 ng/ml; 95%CI=9.4-12.1 vs. 9.0 ng/ml; 95%CI=8.3-
9.9; p<0.0001, PC3X: 5.7 ng/ml; 95%CI=5.2-6.3 vs. 4.9 ng/ml; 95%CI=4.4-5.6; p=0.003 and 
VICM: 21.4 ng/ml; 95%CI=17.0-25.7 vs. 15.0 ng/ml 95%CI=12.6-18.1; p<0.0001; Suppl. 
Fig 3). Neither C4G, C3M or C4M changed significantly after treatment. Of note, the 
levels of all six biomarkers were highly correlated before and after 6 weeks of treatment 
(Suppl. Table 2). Biomarker levels during therapy were associated to PFS and OS. By 
the Kaplan-Meier approach, moderate significant differences of PFS were observed for 
quartile groups of PRO-C3 (p=0.011), C4G (p=0.017) and C4M (p=0.046) levels (Suppl. Fig. 
4). The levels of the ECM biomarkers after six weeks of treatment were not significantly 
associated to OS (Suppl. Fig. 5). Next, stratification was performed into patients who 
had an evident increase of the ECM biomarker during therapy (of more than 20% from 
baseline) and patients who did not have an evident increase (the remaining patients). 
Patients with an increase of VICM during therapy seemed to have, although not significant, 
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an improved PFS (median PFS: 28.4 vs. 8.4 months, HR=0.59, 95%CI=0.35-1.01, p=0.056). 
The OS in these patients was significantly improved (median OS: 42.3 vs. 36.2 months, 
HR=0.39, 95%CI=0.19-0.86, p=0.018). VICM remained significant after correction for WHO 
performance status and brain metastases (HR=0.28, 95%CI=0.10-0.76, p=0.013) and LDH 
(HR=0.42, 95%CI=0.20-0.91, p=0.028; Fig. 4c,f). No significant differences were observed 
for PRO-C3 or PC3X (Fig. 4a,b,d,e), although a trend could be observed for PRO-C3 and 
PC3X levels and worse PFS.   
Table 2. Univariate and multivariate Cox regression analysis of the association of patient 
factors and ECM biomarkers with progression-free survival (PFS)
Univariate Multivariate
Factor Test variable HR (95% CI) P-value HR (95% CI) P-value
Gender Male vs. Female 1.14 (0.69-1.86) 0.611    
Age Continuous (yr) 1.00 (0.99-1.02) 0.744    
WHO  >1 vs 0 1.60 (0.98-2.62) 0.061
Brain metastasis Present vs. absent 1.00 (0.52-1.94) 0.997    













































C4M Continuous (ng/ml) 1.01 (1.00-1.03) 0.158    
VICM Continuous (ng/ml) 1.01 (1.00-1.02) 0.121    
C3M/PRO-C3 >1 vs <1 0.51 (0.29-0.91) 0.023*
Adjusted for LDH
0.59 (0.32-1.11) 0.102
HR were calculated by univariate and multivariate cox regression analysis. By the multivariate analysis, 
the individual biomarkers were adjusted for LDH. Abbreviations: WHO performance score (WHO), 
lactate dehydrogenase (LDH), 95% confidence interval (95% CI), hazard ratio (HR). Significance is 
marked with stars.
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Table 3. Univariate and multivariate Cox regression analysis of the association of patient 
factors and ECM biomarkers with overall survival (OS)
Univariate Multivariate
Factor Test variable HR (95% CI) P-value HR (95% CI) P-value
Gender Male vs. Female 1.31 (0.68-2.51) 0.426    
Age Continuous (yrs) 1.01 (0.99-1.03) 0.410    
WHO >1 vs 0 3.10 (1.64-5.86) <0.001***
Brain metastases Present vs. absent 2.39 (1.01-5.68) 0.049*
LDH Continuous (U/L) 1.00 (1.00-1.00) <0.0001****
PRO-C3 Continuous (ng/ml)
4.0-12.6 ng/ml, Q1-Q3
























C4G Continuous (ng/ml) 1.00 (0.98-1.02) 0.693    
C3M Continuous (ng/ml) 1.02 (0.96-1.08) 0.484    
C4M Continuous (ng/ml) 1.01 (0.99-1.04) 0.237    
VICM Continuous (ng/ml) 1.01 (0.99-1.02) 0.344    





HR were calculated by univariate and multivariate cox regression analysis. By the multivariate 
analysis, the individual biomarkers were adjusted for LDH (indicated by #) or adjusted for WHO 
and brain metastases (indicated by ¤). Abbreviations: WHO performance score (WHO), lactate 
dehydrogenase (LDH), 95% confidence interval (95% CI), hazard ratio (HR). Significance is marked 
with stars.
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Figure 4. Increase in VICM after anti-PD-1 treatment associates with PFS and OS
A B C
D E F




































































































































Kaplan-Meier plots demonstrating the association of change in PRO-C3 (A, D), PC3X (B, E) and VICM 
(C, F) with progression-free survival (PFS) and overall survival (OS) six weeks after start of anti-PD-1 
ICI therapy after stratification of patients based on an increase of more than 20% from baseline 
versus <20% increase.  P-values are based on the log-rank test.
DISCUSSION
The present study demonstrates that blood-based biomarkers of protease-generated 
neo-epitopes on protein fragments reflecting altered ECM turnover are associated with 
clinical outcome after PD-1 ICI therapy in metastatic melanoma. Baseline serum levels of 
ECM protein fragments PRO-C3 and PC3X, indicating a collagen-rich peritumoral stroma, 
were associated with resistance to PD-1 inhibition. Moreover, upregulation of VICM during 
therapy, reflecting M1 macrophage activity, was associated with improved survival. 
Patients with higher PRO-C3 and PC3X levels had worse clinical outcome after PD-1 
inhibition compared to patients with lower levels. Interestingly, as PRO-C3 and PC3X are 
released to the blood circulation during excessive collagen formation and cross-linking 
[16], the findings suggest that those markers identify tumors with an immune-excluded 
phenotype. Immune-exclusion is characterized by dense collagen stroma that limits the 
entry of tumor infiltrating lymphocytes into the TME, which is considered as an important 
biological mechanism of therapy resistance [4,17]. Cytotoxic T cell activity towards cancer 
cells in the TME is suggested to be an independent factor of the PD-L1 tumor proportion 
score and tumor mutation burden [2,18]. 
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Although these protease-generated protein fragments were significantly correlated to 
LDH levels, we demonstrated that higher PRO-C3 independent of LDH was associated 
with worse PFS and OS and that higher PC3X was associated with worse PFS. LDH is 
known as a marker of tumor burden and a clinically significant adverse prognostic factor 
for metastatic melanoma, which is also confirmed in this immune-oncology setting 
[19]. Elevated LDH levels is integrated as a suffix to the M1 subcategories in recent TNM 
cancer staging protocols[20], providing additional prognostic value. Interestingly, similar 
observations for PRO-C3 were previously seen in metastatic melanoma patients who were 
treated with CTLA-4 ICI therapy [13], suggesting that the non-invasive biomarker may be 
considered across different ICIs.
Dense collagen stroma may also affect the diffusion and distribution of the therapeutic 
antibodies [21], in addition to its effect in limiting the entry of tumor infiltrating 
lymphocytes into the TME. Previous work by Jensen et al. demonstrated additional 
prognostic value of the ratio of type III collagen degradation to formation (C3M/PRO-C3) 
after CTLA-4 inhibition in metastatic melanoma [13]. The present findings confirm that 
patients with a high C3M/PRO-C3 ratio (>1) are linked to better clinical outcome after PD-1 
inhibition, thereby providing additional evidence for the hypothesis that patients with 
relatively low net fibrosis/collagen deposition are more likely to respond to ICIs. PRO-C3 
and PC3X are associated with a higher activity of CAFs. In addition to the desmoplastic, 
collagen rich TME related to immune-exclusion, CAFs have also shown to contribute to a 
diminished immune function by expressing TGF-β, PD-L1/PD-L2 and by inducing immune 
checkpoints on T cells [6,22–24].
We demonstrated that patients with an increase in VICM during treatment had improved 
clinical outcome. VICM is released from activated inflammatory M1 macrophages [25], 
which may be an important factor for response to ICIs compared to the immune-suppressive 
M2 macrophage phenotype. For example, PD-L1 inhibition was demonstrated to polarize 
macrophages into a more pro-inflammatory phenotype, which was associated with 
enhanced T cell activity [26]. In mice, PD-1 inhibition was found to increase macrophage 
phagocytosis, and was associated with better survival in a macrophage dependent fashion 
[27]. Our results support these findings and additionally suggest that blood-based VICM 
levels has potential value for monitoring early response to PD-1 inhibition. 
Whereas higher C4M levels at baseline were previously demonstrated to be associated 
with worse clinical outcome after CTLA-4 inhibition in metastatic melanoma [13], we could 
not confirm this observation after PD-1 inhibition. C4M mirrors basement membrane 
remodeling, which is strongly associated with malignant progression of cancer [28]. These 
inconsistent results may be explained either by the difference of mechanism of action of 
CTLA-4 and PD-1 inhibition or by the higher efficacy of PD-1 inhibition in this immune-
oncology setting [13].   
Interestingly, C4G levels were previously associated with improved OS after CTLA-4 
inhibition in metastatic melanoma (Jensen et al., AACR abstract 2020, in press). This C4G 
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biomarker measures a neo-epitope of granzyme B mediated degradation of type IV 
collagen that may reflect cytotoxic T-cell infiltration in the TME [29]. Nevertheless, we could 
not observe a relationship between C4G levels and clinical outcome after PD-1. Granzyme 
B is a key serine protease that is secreted by activated T and NK cells to induce apoptosis 
[30]. While it is suggested to contribute to response mechanisms of PD-1 inhibition in 
metastatic lung cancer, illustrated by an inverse relationship of both granzyme B levels as 
well as germline variation of GZMB and clinical outcome (Hurkmans JITC 2020, in press), 
further research is needed to elaborate on the differences between ICIs and tumor types 
[31].
Despite the interesting findings, this study also has some limitations. Patients were treated 
with two different ICIs (nivolumab or pembrolizumab) and not designed/powered to 
differentiate between the two. Although these are highly similar monoclonal antibodies 
directed to the PD-1 receptor, this may have an impact on the results. Furthermore, the 
sample size was too small to correct for multiple testing or for splitting the patients into 
a discovery and validation group. Nevertheless, in the current analysis we were able to 
demonstrate strong associations with survival outcomes for a selection of ECM biomarkers. 
Though, ECM turnover is a physiological process taking place throughout the body, the 
assessments of specific post-translational modifications (neo-epitopes) may reduce the 
systemic background of healthy turnover and instead increase the specificity of ECM 
turnover in the TME [12,32]. Lastly, even though our main objective was to investigate the 
association of markers with clinical outcome, the findings do not address the predictive 
performance of the biomarkers, for which prospective external validation is needed in 
cohorts randomized to different modalities.
CONCLUSIONS
In conclusion, we demonstrated that the ECM protein fragments PRO-C3 and PC3X in 
baseline serum, representing a dense collagen stroma, were associated with worse clinical 
outcome after PD-1 inhibition in metastatic melanoma. Moreover, increasing VICM levels 
early during therapy was associated with improved survival. VICM levels correspond 
with M1 macrophage activity by its specific release of MMP-degraded and citrullinated 
vimentin in the blood circulation. After validation, these biomarkers may provide a robust 
non-invasive tool for patient stratification and therapeutic decision-making in immuno-
oncology.   
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SUPPLEMENTARY INFORMATION
Supplementary Figure 1. Histograms showing the distribution of serum levels of ECM 
biomarkers


















































































Histograms showing the distribution of serum levels of the studied ECM biomarkers at baseline A) 
PRO-C3, B) PC3X, C) C4G, D) C3M, E) C4M and F) VICM. The distribution of levels is generally skewed 
to the right.
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Relationship between the ECM biomarkers A) PRO-C3, B) PC3X, C) C4G, D) C3M, E) C4M and F) VICM 
with therapy response. Therapy response was based on RECIST v1.1. Patients with progressive 
disease (PD) were compared to patients with stable disease (SD), partial response (PR) or complete 
response (CR) with Mann-Whitney test. 









































































The graphs show the serum levels of ECM biomarkers at baseline and 6 weeks after start of PD-1 
ICI therapy: A) PRO-C3, B) PC3X, C) C4G, D) C3M, E) C4M and F) VICM. The black lines represent the 
median value of patients. Serum levels were compared using Wilcoxon matched-pairs test. 
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Supplementary Figure 4. Association of ECM biomarkers measured at week six and 
progression free survival


















































































































































Kaplan-Meier plots demonstrating the association of ECM biomarkers with progression free survival 
(PFS) for metastatic melanoma patients. A) PRO-C3, B) PC3X, C) C4G, D) C3M, E) C4M and F) VICM 
were dichotomized into quartiles (Q4, representing the highest levels of the biomarker). P-values 
are based on the log-rank test.
Supplementary Figure 5. Association of ECM biomarkers measured at week six and overall survival


















































































































































Kaplan-Meier plots demonstrating the association of ECM biomarkers with overall survival (OS) 
for metastatic melanoma patients. A) PRO-C3, B) PC3X, C) C4G, D) C3M, E) C4M and F) VICM were 
dichotomized into quartiles (Q4, representing the highest levels of the biomarker). P-values are 
based on the log-rank test.
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Supplementary Table 2. Correlation matrix showing the association of baseline and week six 
measurements of the ECM biomarkers
PRO-C3 PC3X C4G C3M C4M VICM
Pearson 
Correlation 0.68 0.67 0.83 0.72 0.70 0.45
Sig. (2-tailed) <0.0001**** <0.0001**** <0.0001**** <0.0001**** <0.0001**** <0.0001****
N 94 94 93 94 94 94
Pearson correlation was used. Abbreviations: Sig significance (sig.), number (N).
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Background: Many cancer patients do not obtain clinical benefit from immune 
checkpoint inhibition. Checkpoint blockade targets T-cells, suggesting that tyrosine 
kinase activity profiling of baseline peripheral blood mononuclear cells may predict 
clinical outcome. 
Methods: Here a total of 160 patients with advanced melanoma or non-small-
cell lung cancer (NSCLC), treated with anti-CTLA-4 or anti-PD-1, were divided in 5 
discovery and cross-validation cohorts. The kinase activity profile was generated 
by analyzing phosphorylation of PBMC lysates in a micro-array comprising of 144 
peptides derived from sites that are substrates for protein tyrosine kinases. Binary 
grouping into patients with or without clinical benefit was based on RECISTv1.1. 
Predictive models were trained using partial least square discriminant analysis 
(PLS-DA), performance of the models was evaluated by estimating the Correct 
Classification Rate (CCR) using cross-validation.
Results: The kinase phosphorylation signatures segregated responders from non-
responders by differences in canonical pathways associated with governing T-cell 
migration, infiltration and co-stimulation. PLS-DA resulted in a CCR of 100% and 
93% in the anti-CTLA-4 and anti-PD1 melanoma discovery cohorts, respectively. 
Cross-validation cohorts to estimate the accuracy of the predictive models showed 
CCRs of 83% for anti-CTLA-4 and 78% or 68% for anti-PD-1 in melanoma or NSCLC, 
respectively. 
Conclusions: Blood-based kinase activity profiling for response prediction to ICIs in 
melanoma and NSCLC revealed increased kinase activity in pathways associated with 
T cell function and lead to a classification model with a highly accurate classification 
rate in cross-validation groups. The predictive value of kinase activity profiling is 
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INTRODUCTION
Tumors can evade T cell-mediated destruction via the expression of immune checkpoints, 
including the programmed cell death ligand-1 (PD-L1) and CD80 or CD86, that inhibit T 
cells that express programmed cell death 1 (PD-1) or cytotoxic T lymphocyte antigen 4 
(CTLA-4), respectively. Immune checkpoint inhibitors (ICIs) against  these receptors have 
been approved for a variety of malignancies and revolutionized their clinical management, 
in particular that of melanoma and non-small cell lung cancer (NSCLC)1-4. However, durable 
responses are only obtained in a minority of patients, whereas ICIs are associated with 
considerable side effects and costs. Therefore, robust and reliable predictive biomarkers 
to predict treatment response are urgently needed. 
The cognate interaction between T cells and antigen presenting cells (APCs) via 
interaction of the T cell receptor (TCR) with antigen presented in the context of HLA, 
results in activation of T cells after which T cells quickly upregulate CTLA-4 and/or PD-1 
as part of a negative feedback loop. As a result, T cells may display a reduced capacity to 
become activated, proliferate and exert specific effector functions. Currently, CTLA-4 is 
thought to play a major role during priming of a T cell response in the lymph node where 
it directly prevents co-stimulation of T cells via interaction of CD28 with its ligand CD80/86 
on APCs. Moreover, CTLA-4 is constitutively expressed on regulatory T cells (Tregs), 
and Tregs can reduce expression of CD80/86 by trans-endocytosis thereby preventing 
activation of effector T cells5. PD-1 inhibits activation of pre-existing tumor-specific 
T cells during the effector phase and is thought to dampen an immune response after 
antigen eradication in order to prevent immune pathology. Eventually, tumor eradication 
by T cells relies on TCR-mediated activation and downstream co-stimulatory signaling, 
which is tightly regulated by different tyrosine kinase mediated signaling pathways. For 
instance, activation of PI3K and deactivation of PTEN results in recruitment and activation 
of downstream signaling molecules like AKT, enhancing T cell survival, proliferation and 
effector functions6. Under normal conditions, ligation of the inhibitory receptors CTLA-
4 and PD-1 results in recruitment of SHP2 phosphatases that dampens TCR signaling as 
well as CD28 signaling7-9. As such, kinase activity may reflect anti-tumor T cell activity 
and consequently could act as a predictor for clinical outcome after ICI therapy. In fact, 
peptide micro-array technology to evaluate global kinase activities in tumor or blood 
has recently been applied as a biomarker strategy for response prediction to chemo- or 
targeted-therapy in several cancer types.6,10-13 
Previous efforts to predict the clinical response to ICI therapy yielded various biomarkers, 
including tumor mutational burden (TMB) and PD-L1 expression in tumor tissue for 
NSCLC14,15.  The predictive performance of these biomarkers may be sufficient in some 
studies16,17, yet are complicated by both the availability of tissue and both inter- and 
intra-tumoral heterogeneity. Interestingly, a number of blood parameters have been 
associated with response to CTLA-4 and PD-1/PD-L1. For example, the total number and 
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composition of circulating leukocytes were associated with clinical outcome, amongst 
which high lymphocyte and eosinophil counts, low monocyte count and low neutrophil 
to lymphocyte ratio (NLR). In addition, the absence of myeloid-derived suppressor cells 
and presence of classical monocytes or previously activated T cells was associated with 
better response rates or survival after ICI.18-28 Collectively, these studies indicate that the 
activation status and number of several immune cells in blood may provide minimally 
invasive predictive biomarkers that are suitable for routine clinical use.
Whereas commonly used methods, including transcriptomics and high-dimensional 
flowcytometry may reveal the outcome of certain incoming signals, they do not reveal 
the whole network of signal transduction pathways activated in cells, nor show at which 
point they are deregulated in certain patients. Protein kinases are a large family of highly 
influential proteins which modify the activity, affinity and location of many cellular proteins 
in order to regulate cellular processes, in particular signal transduction. Here, we argued 
that if some of the complex biological tumor-immune cell interactions determining the 
response to ICIs are also reflected in the plethora of immune cells in the blood, then kinase 
activity profiling of peripheral blood mononuclear cells (PBMCs) may be able to capture 
this. Therefore, we have explored the predictive performance of kinase activity profiling 
in PBMCs from advanced melanoma and NSCLC patients treated with anti-PD-1 or anti-
CTLA-4 monotherapy.
MATERIALS AND METHODS
Patient population and study workflow
Patients with irresectable stage III/IV advanced melanoma or stage IV NSCLC were 
included if they had received intravenous monotherapy with either ipilimumab (anti-
CTLA4; 3 mg/kg every 3 weeks for 4 courses), nivolumab (anti-PD-1; 3 mg/kg every 2 
weeks until a maximum of 2 years) or pembrolizumab (anti-PD1; 2 mg/kg every 3 weeks 
until a maximum of 2 years) as standard of care at the Erasmus University Medical Center 
(Rotterdam, The Netherlands), Leiden University Medical Center (Leiden, The Netherlands) 
or University Hospital Zürich (Zürich, Switzerland), all being  referral hospitals. Patients 
who received ICI combination therapy or who were treated with a prior line of any form 
of immunotherapy were excluded, pretreatment of corticosteroids was not considered. 
The study was approved by the independent ethics committee board (reference numbers: 
MEC 16-011, P11-016, and MEC 14-0425, respectively) and in accordance with the revised 
WMA Declaration of Helsinki on human rights. Following written informed consent of the 
patients, blood samples were collected before the first administration of ICIs and after the 
last administration of any previous treatment if applicable . 
Blood-based kinase activity profiling   |   331 
14
Data collection
Binary grouping was performed according to patients with (responders) or without (non-
responders) clinical benefit based on response evaluation criteria in solid tumors (RECIST) 
version 1.1. For determination of best overall response (BOR), confirmation of a complete 
or partial response (CR/PR) was not required, but a minimum duration of 90 days was 
required for stable disease (SD). Patients with a CR, PR or SD as BOR were considered to 
have obtained clinical benefit after ICIs and were defined as responders. Patients with 
progressive disease (PD) were defined as non-responders. Additionally, binary grouping 
was performed according to progression-free survival (PFS), measured from start of 
treatment to death or the first evaluation time point that PD is detected; the two groups 
included late (> 140 days) or no progression (responders) versus patients with early 
progression within 140 days (non-responders). Clinical parameters and chemistry or blood 
parameters were evaluated at baseline and included age, gender, WHO performance score, 
pathological tumor type, presence of brain metastases and serum lactate dehydrogenase 
(LDH) levels.
Preparation of PBMC lysate
Venous blood of patients was collected at baseline using either sodium-heparin or EDTA 
as anticoagulant, and isolation of PBMCs was done within 4 hours or within 24 hours 
depending on the local study protocol (Suppl. Table 1). PBMC were isolated by density 
gradient centrifugation and cryopreserved until further use. Erythrocyte lysis was only 
performed in the Mel-CTLA4-B cohort if PBMC still contained considerable erythrocyte 
contamination after isolation. Importantly, kinase activity was affected by erythrocyte 
lysis during PBMC isolation (Suppl. Fig. 1a). Moreover, overall reduced kinase activity 
was observed in PBMCs that were isolated after 24 hour from blood collected in EDTA 
anticoagulated tubes (Suppl. Fig. 1b). 
Cryopreserved cells were thawed, washed with phosphate buffered saline, and lysed 
using ice-cold M-PER lysis buffer (Mammalian Protein Extraction Reagent, Thermo 
Fisher Scientific, MA, USA) containing 1:100 Protease Inhibitor Cocktail (Thermo Fisher 
Scientific). Cell lysate was obtained by centrifugation at 14.000 × g for 10 min at 4°C. 
After centrifugation the supernatant was snap-frozen in aliquots and stored at -80°C. The 
protein concentration was determined using the Bradford Assay (Thermo Fisher Scientific) 
with bovine serum albumin (BSA) as the standard. 
Kinase activity profiling
PBMC kinomic activity was measured using protein tyrosine kinase (PTK) PamChip-96 
microarrays (catalog # 86311, PamGene International BV, ’s-Hertogenbosch, The 
Netherlands) using standard manufacturer protocol. In short, the microarrays were 
blocked with 2% BSA (Calbiochem # 126609) to prevent non-specific binding. After 
blocking the arrays were washed three times with 1x PK buffer (50 mM Tris-HCl pH 7.5, 
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10 mM MgCl2, 0.01% Brij35, 2 mM DTT). For kinomic profiling 2 µg PBMC lysate protein 
was used in 40 µl PTK assay buffer (1x PK buffer, 10mM DTT, 400 µM ATP, 1x PTK additive 
(PamGene International BV), 1:400 Halt Phosphatase Inhibitors (Thermo Fisher Scientific, 
MA, USA), 0.01% BSA (Calbiochem), and fluorescein isothiocyanate (FITC)-labeled 
antiphosphotyrosine antibody (PamGene). During incubation the reaction mixture was 
pumped up and down through the porous membrane for 60 cycles at 2 cycles/min. 
Incubation and read-out of the microarrays was performed with 96 arrays in parallel 
on a PamStation-96. Typically, 3-4 technical replicates of each sample were measured 
in the same run. Time courses of peptide phosphorylation were followed by recording 
fluorescent images which were quantified by automated image analysis in Bionavigator 
6.3.67 (PamGene). Analysis of signals was performed after local background subtraction 
in Bionavigator 6.3.67 interfaced to the open source statistical program R 3.3.1 (R-project, 
www.rproject.org). 
Analysis was specifically performed per cohort and comprised a quality check, removal 
of outlier replicates, data transformation and averaging of the kinase signal replicates. 
To check data quality, the first step was exclusion of a low portion of arrays that showed 
clear visual defects (e.g. broken membrane, large stains) or technical replicates clearly 
deviating from the other replicates of the same samples. In the second step, data is log-
transformed (CTLA-4 cohorts: Mel-CTLA4-A, Mel-CTLA4-B) or normalized using the VSN 
method (PD-1 cohorts: Mel-PD1-A,  Mel-PD1-B, NSCLC-PD1). Prior to log-transformation, 
a small fraction of negative values in the (background corrected) signals was handled by 
setting all signals <1 or equal to 1. Signal-positive spots were required to show a positive 
trend in the recorded phosphorylation time course. Peptides for which such a trend could 
not be detected in > 75% of the samples were excluded from further analysis. Effectively, 
88-113 peptides were included for further analysis. Technical replicates of each patient 
sample were averaged resulting in a single kinase activity profile per included patient for 
subsequent analysis.
Principal Component Analysis (PCA) was performed on the transformed and filtered data 
and PCA scores were used to identify systematic variation, e.g. as a result of different sub-
cohorts and/or the use of different PamStation-96 microarray plates. Systematic variation 
was handled by applying ComBat29 batch correction, and outlier patient samples were 
removed. For the small Mel-CTLA4-A cohort no such correction was necessary. For the 
Mel-CTLA4-B cohort a batch effect was observed and corrected for the batches in which 
samples were lysed together. A small number (ranging from 1 to 8) of outlier samples 
according to PCA scores or heat map visualizations of the transformed profiles were 
removed. In most cases these were samples showing low overall kinase activity. Other 
reasons for removing measured patient samples from the analysis was unavailability of 
clinical data or if, after reevaluation, patients were observed not to fulfill the selection 
criteria. 
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Statistical analysis and bioinformatics
Kinase activity profiles were correlated to the clinical response to ICIs. Univariate (per 
peptide) analysis was performed using a two-sided two sample t-test with binary 
grouping as a covariate (responders versus non-responders). Peptides with p < 0.05 were 
regarded as significant, in addition, the proportion of false discoveries in a set of significant 
peptides was estimated using the False Discovery Rate (FDR) method of Benjamini & 
Hochberg. Classification analysis was performed using Partial Least Squares Discriminant 
Analysis (PLS-DA) with patients divided in binary groups as previously described13. In 
short, a classification model is trained using all tested peptides, i.e., without prior peptide 
selection based on responder and non-responder differences. The resulting model is a set 
of coefficients (one for each peptide + an offset) that can be applied to new observations 
to obtain a score that predicts classification in either groups. For each cohort, the Correct 
Classification Rate (CCR) was estimated using cross validation. Approximately 90% 
binomial confidence intervals (CI90) for the CCR estimates were obtained using the exact 
method (note that a CI90 implies with 95% confidence that the CCR is higher than the lower 
limit). Prediction of kinases responsible for the changes in peptide phosphorylation in the 
kinomic profiles were obtained using the Upstream Kinase Analysis tool in Bionavigator 
6.3.67 (PamGene). Results were visualized by annotation to a kinase phylogenetic tree 
using the web-based Coral tool (http://phanstiel-lab.med.unc.edu)30. Additionally, 
Ingenuity Pathway Analysis (Qiagen, Hilden, Germany) was used to perform gene set 
enrichment analyses utilizing the delta and unadjusted p-value of each peptide (two-
sided two sample t-tests). Pathway activation or inhibition were predicted by the z-score 
statistic, and further explored by the MAP tool (Qiagen, Hilden, Germany). Full access 
of the datasets generated during the current study is provided in the supplementary 
materials (Suppl. Tables 2-6).
RESULTS
A total of 174 advanced cancer patients were enrolled and 160 patients were evaluable for 
analysis (Fig. 1) because in 14 cases (8%) the patient samples had to be removed as they 
did not comply with the quality check (Suppl. Fig. 2). The study protocols between the 
centers were different with regard to the PBMC isolation protocol and the anti-coagulant 
used for blood collection. As a consequence, the different patient cohorts were not pooled 
for analysis, resulting in five distinct cohorts (Fig. 1), and protocol differences could 
be assessed for their effect on kinase activities. The baseline patient characteristics are 
provided in Table 1. Patient cohort Mel-CTLA4-A was used as a discovery cohort for anti-
CTLA-4 and consists of 10 melanoma patients selected based on an equal distribution 
of responders and non-responders. All responders in this cohort had SD >90 days, thus 
precluding selection bias based on exceptionally good and worse responders, only. 
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The patients had a baseline blood LDH level that was not above 2x the upper limit of 
normal (ULN, i.e. < 250 U/ml) to avoid bias towards a known independent prognostic 
factor. The 29 patients in cohort Mel-PD1-A functioned as discovery cohort for anti-PD-1 
and had an almost equal distribution of responders (n=14) and non-responders (n=15). 
The mean baseline blood LDH level was not elevated above 2x ULN in the Mel-PD1-A 
discovery cohort, although some individual patients did have an elevated LDH above this 
threshold. The patients in the three other cohorts were used for cross-validation to assess 
the performance of response prediction by kinase activity profiling. Because of the lower 
response rate, patients in the MEL-CTL-B cohort were selected on equal distribution of 
responsers and non-responders, but again not based on patients with an exceptionally 
good or bad response. Patients in the other cohorts were not selected, apart from the 
exclusion criteria that they should not have received prior immunotherapy or combination 
checkpoint blockade. The mean baseline blood LDH level was higher and the range of 
values of individual patients larger in the cross-validation cohorts when compared to the 
discovery cohorts (Table 1).
Kinase activity profiles in PBMC of patients responding to checkpoint 
blockade
The correlation of kinase activity profiles with treatment response is visualized for the 
discovery cohort Mel-CTLA4-A using a heat map (Fig. 2a). A profound difference in 
kinase activity was observed between the responder and non-responders. Generally, 
the phosphorylation signal of peptides was higher in responders compared to non-
responders. For 83% of the target peptides, a significantly higher signal was found in 
responders compared to non-responders (two-sided two sample t-test, p-value < 0.05; FDR 
< 5%). This overall increase in kinase activity was confirmed in the cross-validation cohort 
Mel-CTLA4-B (Fig. 2b), although less pronounced since only 23% of the target peptides 
displayed a significantly higher signal in responders compared to non-responders (two-
sided two sample t-test, p-value < 0.05, FDR = 18%). In addition, the relative increase in 
signal was higher in the Mel-CTLA4-A cohort (median Log2 Fold Change= 0.84; SD = 0.15; 
~ 80% increase) compared to the Mel-CTLA4-B cohort (median Log2 Fold Change = 0.40; 
SD = 0.17; ~ 30% increase). This increase in signal appears to reflect systemic, non-specific 
signaling in the responders compared to the non-responders.
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Figure 1. Schematic overview of the study.
A) Work flow showing that kinase activity was measured in baseline PBMC samples using a peptide 
microarray system consisting of identical arrays, each containing 144 unique protein tyrosine kinase 
phosphorylation sites. PBMC samples were isolated from blood collected before onset of immune 
checkpoint inhibitor therapy. The kinase activity profile is analyzed using BioNavigator (PamGene), 
Coral tool (Courtesy Cell Signaling Technologies) to annotate kinases onto a phylogenetic tree and 
Ingenuity Pathway Analysis software (Qiagen) to perform gene set enrichment analyses. B) Flow 
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Table 1. Baseline patient characteristics
Mel-CTLA4-A Mel-CTLA4-B Mel-PD1-A Mel-PD1-B NSCLC-PD1
Total, n 10 29 29 36 56
Age, median (range) 59.3 (26-79) 58.3(35-86) 64.0 (39-84) 61.6 (31-83) 63.1 (35-81)
Gender, n
Male 4 13 16 21 36
Female 6 16 13 15 20
Primary tumor, n
Melanoma 10 29 29 36 0
NSCLC 0 0 0 0 56
   Adenocarcinoma 0 0 0 0 37
   SCC 0 0 0 0 17
   Large cell carcinoma 0 0 0 0 2
Treatment regimen, n
Anti-PD1 0 0 29 36 56
   Nivolumab 0 0 1 14 50
   Pembrolizumab 0 0 28 22 6
Anti-CTLA4
   Ipilimumab 10 29 0 0 0
Prior therapy lines, n (%)
0 4 (40%) - 20 (69%) 30 (83%) 1 (2%)
1 4 (40%) - 9 (31%) 6 (17%) 46 (82%)
2 2 (20%) - 0 (0%) 0 (0%) 7 (12%)
>2 0 (0%) - 0 (0%) 0 (0%) 2 (4%)
Prior immunotherapy, n
No 10 29 29 36 56
Yes 0 0 0 0 0
Cerebral metastasis, n (%)
No 6 (60%) - 17 (59%) 15 (42%) 0 (0%)
Yes 2 (20%) - 11 (38%) 2 (5%) 0 (0%)
Unknown 2 (20%) - 1 (3%) 19 (53%) 56 (100%)










All patients received immune checkpoint inhibitor monotherapy and did not receive any prior line 
of immunotherapy. Abbreviations: lactate dehydrogenase (LDH), squamous cell carcinoma (SCC).
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Figure 2. Baseline kinase activity profiles and response classification of patients treated with 
CTLA-4 blockade
Heat maps showing kinase activity of separate cohorts of melanoma patients who were treated with 
CTLA-4 ICIs: A) discovery cohort Mel-CTLA4-A and B) cross-validation cohort Mel-CTLA4-B. Binary 
grouping of patients that either benefited or not from treatment (responders and non-responders, 
respectively)are shown . The columns represent patients sorted from left to right according 
to treatment response; the rows represent peptides sorted according to Pearsons correlation 
coefficient with treatment response, such that the peptides with a relatively higher phosphorylation 
signal in the non-responders are shown at the top of the map and the peptides with a relatively 
high signal in the responders are shown at the bottom of the map. The values are scaled per row 
to zero mean and unit variance. Furthermore, classification analyses of these cohorts are shown: C) 
discovery cohort Mel-CTLA4-A and D) cross-validation cohort Mel-CTLA4-B. The bar graphs show 
for each patient the prediction index obtained by cross validation of a PLS-DA model (see methods 
section). If the prediction index > 0 the patient is predicted to be a responder. The color of the bars 
indicates the actual clinical response class.
Discovery cohort Mel-PD1-A included melanoma patients who were treated with anti-
PD-1. The profound higher kinase activities as observed in the responders in the two 
anti-CTLA-4 cohorts was not observed in the three anti-PD-1 cohorts. Therefore, the data 
was normalized for overall kinase activity using the VSN method. As a consequence, the 
data reflects differences in the ratio between peptides on the array rather than the overall 
differences. Responder patients showed a different kinase activity profile when compared 
to non-responders (Fig. 3a). For 17% of the peptides in cohort Mel-PD1-A, a significant 
different signal was found in responders compared to non-responders (two-sided 
two sample t-test, p < 0.05; FDR = 29%). These differentially phosphorylated peptides 
represented both higher and lower signals in responders compared to non-responders. 
Likewise, differential peptide phosphorylation was observed in the cross-validation 
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cohorts Mel-PD1-B and NSCLC-PD1 (Fig. 3b-c). In Mel-PD1-B, 16 peptides (18%) displayed 
significantly differential signals for response (two-sided two sample t-test, p < 0.05, FDR = 
25%) whereas NSCLC-PD1, 18 peptides (19%) were significantly differently phosphorylated 
in responders compared to non-responders (two-sided two sample t-test, p < 0.05, FDR 
= 24%). The specific differences in kinase activities differentiating responders and non-
responders varied between cohorts. 
A high percentage of patients is correctly classified for response by their 
kinase activity profile
To investigate the potential use of kinase activity profiling as a biomarker for response to 
ICI therapy, classification analysis was performed using the binary grouping of responders 
and non-responders. Because of the kinase profile variation between the CTLA-4 and 
PD-1 ICIs cohorts, a separate PLS-DA classification model was trained for each cohort and 
predictive scores for each patient were obtained using cross-validation. This resulted in 
a correct classification rate (CCR) of 100% (90%CI 74-100%) in  the discovery cohort Mel-
CTLA4-A and 83% (64-93%) in cross-validation cohort Mel-CTLA4-B (Fig. 2c,d). The CCR was 
93% (80-99%) in the discovery cohort Mel-PD1-A, 78% (63-88%) in cross-validation cohort 
Mel-PD1-B, and 68% (56-78%) in the second cross-validation cohort NSCLC-PD1 (Fig. 3d-f). 
Upstream kinase and canonical pathway analysis identify kinases asso-
ciated with T cell function
Bioinformatics was applied to interrogate the biological processes underlying response or 
resistance to ICIs. Here, we have zoomed in on the anti-PD-1 cohorts as the overall increase 
of kinase activity in anti-CTLA-4 responders hampered proper identification of relevant 
and recognized peptide targets. Identified kinases were annotated to a phylogenetic 
tree for protein tyrosine kinases (Fig. 4). In the discovery cohort Mel-PD1-A, predictions 
revealed that the VEGF family kinases and FES/FER have relatively higher activity in 
responders compared to non-responders. Similarly, but less pronounced, the activity 
of TYRO-3, AXL and MER kinases of the TAM-family and the TRK-family were positively 
correlated with response in this cohort. In the cross-validation cohort Mel-PD1-B, however, 
the activity of several kinases, including the SRC family kinases, were negatively correlated 
with response. Interestingly, the above observations were corroborated in the second 
cross-validation cohort NSCLC-PD1, where VEGF kinases were found to have higher 
activity and the SRC family kinases to have lower kinase activity in responders compared 
to non-responders. Canonical pathway analysis using Mel-PD1-A and NSCLC-PD1 cohorts 
revealed the importance of peptide targets involved in immune cell migration/leukocyte 
extravasation and co-stimulation of T helper cells. Finally, increased kinase activity in the 
STAT3-, ERBB-, VEGF- and EGF-signaling pathways were found to be related to response to 
anti-PD-1, whereas the PTEN activation was associated with resistance to anti-PD-1 (Fig. 
5 and Suppl. Fig. 3). 
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Figure 3. Baseline kinase activity profiles and response classification of patients 
treated with PD-1 blockade
Heat maps showing the kinase activity of separate cohorts of melanoma patients who were treated 
with PD-1 ICIs: A) disovery cohort Mel-PD1-A, B) cross-validation cohort Mel-PD1-B and C) second 
cross-validation cohort NSCLC-PD1. See legend to Figure 2 for details. Furthermore, the classification 
analysis of these cohorts are shown: D) discovery cohort Mel-PD1-A, E) cross-validation cohort Mel-
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Figure 4. Identification of involved kinase families by phylogenetic tree analysis
Kinase activities that were measured for the anti-PD1 treated cohorts, Mel-PD1-A (A), Mel-PD1-B (B), 
and NSCLC-PD1 (C) were exposed to the Coral tool to annotate kinases onto a phylogenetic tree 
(Courtesy Cell Signaling Technologies Inc.). The coloring indicates the effect size (purple: increased 
phosphorylation; and orange: decreased phosphorylation in responders compared to non-
responders), and the size of the circle indicates the specificity score of the corresponding kinase (a 
higher score indicates a higher likelihood to contribute to the observed phosphorylation changes).
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Figure 5. Differential kinase activity involves canonical pathways associated with T cell 
function  analysis
Top canonical pathways according to kinase activities are schematically shown for cohort A) Mel-
PD1-A and B) NSCLC-PD1. Orange (positive z-score) indicates a predicted upregulation of the 
pathway in patients who benefit from treatment (responders), blue (negative z-score) indicates 
a predicted downregulation of the pathway in responders. Gray represents canonical pathways 
without a predicted activity pattern. The significance value indicates the probability that involved 
kinases are associated with the canonical pathway by random chance alone, cutoff was set at a B-H 
p-value >12. Ranking was based on the trend and z-score.
DISCUSSION
In this study we have investigated whether the clinical response to ICIs is reflected by the 
kinase activity profile in PBMC. We observed differential kinase activity profiles between 
patients with and without clinical benefit, which were subsequently used to develop a 
predictive model with a high correct classification rate (68 to 100%) in metastatic cancer 
patients who were treated with ICI monotherapy. 
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The predictive power of kinase activity profiling positively compares to currently 
recognized biomarkers for response to ICIs. For instance, PD-L1 expression in the tumor 
has a sensitivity and specificity ranging from 58 to 85% and 49 to 60%, respectively, 
depending on the tumor type, applied cutoff or type of anti-PD-1 antibody31. A similar 
predictive performance has been reported for TMB32. The kinase activity profile, reported 
here, demonstrated a lower predictive performance for response to PD-1 inhibitors in 
NSCLC compared to melanoma. Potentially this is due to prior systemic treatments since 
nearly all (98%) NSCLC but not (28%) melanoma patients included in this study were 
pretreated, this may have impacted the outcomes of the kinase profiles. 
Responsiveness to CTLA-4 ICIs in melanoma was associated with higher overall kinase 
activity at baseline in responders when compared to non-responders, suggesting a 
generally more active immune system in responder patients. Indeed, higher pre-existing 
T cell activity has been associated with a better response to CTLA-4 blockade in mouse 
models33,34. In line with reports on circulating immune-suppressive cells in metastasized 
patients35, our findings may implicate that immune suppression is less pronounced in 
responder patients. 
The  melanoma or NSCLC patients showing a clinical response to PD-1 blockade displayed 
a more restricted kinase profile. Upstream and canonical pathway analysis of differentially 
activated peptide targets extend earlier reports on the mechanism of action of PD-1 ICIs. 
First, high activity of TAM-family kinases, such as TYRO-3, AXL and MERTK, in responders 
fits findings by others that MERTK becomes activated in CD4+ and CD8+ T cells downstream 
of TCR signaling36. Secondly, identification of pathways, such as extravasation and CD28 
costimulation, extends outcomes of studies demonstrating the key importance of T cell 
recruitment and T cell co-stimulation in anti-PD-1 responses7,37,38. Thirdly, higher activity 
in the VEGF pathway in responding patients with melanoma and NSCLC was in line with 
the finding that VEGF-A enhances the expression of PD-1 by cytotoxic lymphocytes in the 
tumor microenvironment in a mouse model30. Also, in cancer patients, VEGF is implicated 
to (in)directly enhance PD-1 expression by intra-tumoral T cells, which may be reflected 
by higher PD-1 expression on circulating CD4+ cells and its association with better clinical 
outcome after ICI in melanoma20. Finally, we also observed lower activity of the PTEN 
pathway in responding patients with melanoma or NSCLC. This may seem counterintuitive 
as loss of PTEN in tumor cells was associated to anti-PD-1 therapy resistance39,40. However, 
in T cells PTEN functions as a negative regulator of TCR-signaling. In the absence of PTEN, 
TCR-mediated activation of T cells is strongly enhanced and thresholds for T cell activation 
become less dependent on CD28-costimulation41. Taken together, the above four lines 
of evidence argue that kinase acivities and pathways that are differentially present in 
melanoma and NSCLC patients who respond to anti-PD1 reflect the presence of circulating 
tumor-specific T cells38. 
Recently, the serine threonine kinase (STK) activity profiles in PBMCs from a small group of 
28 metastatic NSCLC patients treated with nivolumab as well as healthy individuals were 
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reported10. Baseline activity of the CAMK-family and AGC-family was higher in the group 
of patients with relatively lower survival after PD-1 blockade when compared to patients 
with longer survival or healthy individuals. The authors suggested that this probably 
reflects multiple lines of prior systemic treatment (including tyrosine kinase inhibitors 
[14%] or bevacizumab [39%]). We did not observe differences in these kinase families 
because we determined the PTK instead of STK activity profiles in PBMC lysates.
Our study has some limitations. Although cross-validation led to correct classification rates 
that varied from 68% to 100% in separate patient cohorts, the underlying kinase activity 
profiles were not fully consistent. This may be due to differences in the study populations. 
For instance, the baseline serum LDH levels showed a greater heterogeneity between 
patients of cohort Mel-PD1-B (median LDH 315 U/L; range 128-1523) when compared to 
cohort Mel-PD1-A (median 229 U/L; range 124-359).  Serum LDH is considered  a clinically 
significant prognostic factor for metastatic melanoma26 and is incorporated in the M1 
subcategory of current TNM cancer staging protocols42. More importantly, differences in 
the kinase activity profiles may also be affected by the fact that for this exploratory study 
we did not apply standardized protocols for PBMC isolation across the patient cohorts, 
neither was pretreatment of patients with corticosteroids or systemic treatment other 
than immunotherapy taken into account. We did notice that the overall kinase activity 
was affected by erythrocyte lysis during PBMC isolation and by the timespan between 
PBMC isolation and blood collection when EDTA was used as an anticoagulant. Indeed, 
EDTA by capturing Ca2+ may negatively influence PTK activity43. Moreover, considering 
the relatively large number of kinase spots that were determined in modest patient 
cohorts, prospective validation with sufficient power is needed before it may be clinically 
applicable for treatment selection. Finally, the kinase activities point at major involvement 
of T cell pathways governing migration, tissue infiltration and co-stimulation. In this study, 
we used PBMC lysates for kinase activity profiling of individual patients, yet, kinase activity 
profiling of specific immune subsets may further improve the response prediction and 
provide more detailed insights in the biological mechanisms of response and resistance 
to ICIs. 
In conclusion, we have demonstrated the potential of kinase activity profiling of PBMCs for 
response prediction after ICI in separate cross-validation patient cohorts. In a first attempt 
to address the remaining challenges, the standardization of PBMC isolation protocols and 
the interrogation of kinase activity in subsets of immune cells has been incorporated in 
a currently ongoing prospective study to validate the predictive value of kinase activity 
profiles in PBMCs for ICI response. 
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SUPPLEMENTARY INFORMATION
Supplementary Figure 1. Effect of anticoagulant for blood collection on PTK activity
Erythrocyte lysis, anti-coagulant and time prior to PBMC isolation affect overall kinase activity. The 
overall kinase activity is depicted as relative kinase activity (%) compared to controls which were set 
at 100 % (blue bars). A) The kinase activity was determined after erythrocyte lysis for 10 or 30 minutes 
during PBMC processing and is compared to PBMC prepared without  erythrocyte lysis (none, blue 
bars). B) Blood of healthy donors (n=4) was collected in EDTA or sodium heparin collection tubes 
and PBMCs were isolated either within 4 or 24h following collection of blood, depicted in blue and 
orange bars, respectively. Paired t-tests were used to compare different experimental conditions; 
error bars indicate the SD. Abbreviations: ethylenediaminetetraacetic acid collection tube (EDTA), 
sodium heparin collection tube (heparin).






         Erythrolysis                 Anti-coagulant and time span prior to PBMC isolation 
 
 
  p=0.011                                          
348   |   Chapter 14
Supplementary Figure 2. Detailed flow chart
The extended flow chart of the patient selection process is shown. 174 patients were assessed 
for eligibility, and 14 technical outliers were removed (8%). As described in the supplementary 
text, signal-positive spots required a positive trend in the recorded phosphorylation time course. 
Peptides for which such a trend could not be detected in > 75% of the samples were removed, 
which yielded 88-113 peptides (depending on cohort) for further analysis. Abbreviations: kinase 
profile (KP), cross-validation (cross-val.).
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Supplementary Figure 3. Comparison analysis of two anti-PD-1 cohorts
A) Comparison analysis of cohort Mel-PD1-A and NSCLC-PD1. Orange (positive z-score) indicates a 
predicted upregulation of the pathway in responders, blue (negative z-score) indicates a predicted 
downregulation of the pathway in responders. Gray represents canonical pathways without an 
expected activity pattern. B) CD28 signaling in Th cells as well as C) immune cell extravasation have 
predicted upregulated activity in responders. 
  





































350   |   Chapter 14
Supplementary Table 1. Site-specific study protocols
Cohort ICI Study site Anticoagulant PBMC isolation within Erythrolysis
Mel-CTLA4-A CTLA-4 Center A Na-Hep 4 h no
Mel-CTLA4-B CTLA-4 Center B EDTA 24 h yes
Mel-PD1-A PD-1 Center A Na-Hep 4 h no
Mel-PD1-B PD-1 Center C EDTA 24 h no
NSCLC-PD1 PD-1 Center C EDTA 24 h no
Five patient cohorts were evaluated in this study. The cohorts are based on the malignancy 
(melanoma or NSCLC patients), the type of ICI therapy administered and the center were the 
samples were collected. Patient number per cohort and anticoagulant used for blood collection 
are listed. An erythrocyte lysis step was performed during PBMC isolation for cohort Mel-CTLA4-B. 
Abbreviations: ethylenediaminetetraacetic acid collection tube (EDTA), sodium heparin (Na-Hep).
Supplementary Tables 2-6. Datasets generated by kinase activity profiling
Included as separate online .txt files (http://jitc.biomedcentral.com)
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Introduction: Thyroid dysfunction is among the most common adverse effects 
during anti-PD-1 immunotherapy, and alongside correlations with elevated anti-
thyroid antibodies (ATAb), studies have found correlations with survival. However, 
the exact relations remain to be clarified. We therefore aimed to clarify the 
relationship between thyroid dysfunction, ATAbs and survival in anti-PD-1 treated 
cancer patients.
Materials and Methods: We included 168 patients with non-small-cell lung 
carcinoma, renal cell carcinoma, and metastatic melanoma treated with nivolumab 
or pembrolizumab. TSH and free T4 (FT4) levels were measured before each anti-
PD-1 infusion. ATAb levels (anti-thyroid peroxidase (TPO) and anti-thyroglobulin 
(Tg)) were measured at baseline and after 2 months of treatment. Although the vast 
majority of patients had detectable levels of ATABs, only few patients had positive 
ATAbs when using conventional cut-offs. To study the consequences of detectable 
ATABs, the cut-off levels were a priori set at the median concentrations at baseline 
in the study population. Tumor progression was classified according to RECIST v1.1.
Results: Patients who acquired overt thyroid dysfunction during treatment had 
significantly higher overall survival (OS) (HR=0.18 [95%CI: 0.04-0.76]; p=0.020) and 
progression free survival (PFS) (HR=0.39 [0.15-0.998]; p=0.050) than patients without 
thyroid dysfunction with one-year OS rates of 94% vs 59% and one-year PFS rates 
of 64% vs 34%. During treatment, patients with ATAb levels  above the median had 
a higher OS (HR=0.39 [0.21-0.72]; p=0.003) and PFS (HR=0.52 [0.33-0.81]; p=0.004) 
than patients with ATAb levels below the median, with one-year OS rates of 83% 
vs 49% and PFS rates of 54% vs 20%, respectively. When analyzing ATAb levels 
over time, patients with a persistent ATAb level above the median had a higher OS 
(HR=0.41 [0.19-0.89], p=0.025) and PFS (HR=0.54 [0.31-0.95], p=0.032) compared to 
patients with a persistent ATAb level below the median. Patients whose ATAb levels 
increased above the median during treatment had an improved OS (HR=0.27 [0.06-
1.22], p=0.088) and PFS (HR=0.24 [0.07-0.77], p=0.017) compared to patients whose 
ATAb levels decreased below the median.
Discussion: Acquired overt thyroid toxicity and above median ATAb levels during 
anti-PD-1 treatment are associated with improved PFS and OS. Additionally, our 
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INTRODUCTION
Immunotherapies against immune checkpoints that inhibit T cell activation (cytotoxic T 
lymphocyte antigen 4 (CTLA-4) and programmed cell death 1 (PD-1)) are rapidly emerging 
treatments in oncology. While these treatments have impressively improved survival for 
various metastatic malignancies, they are associated with many immune related adverse 
events (1-3). Thyroid toxicity is among the most common (5-15%) immune related adverse 
events during anti-PD-1 immunotherapy.1-3 In most cases, it presents itself as a transient 
thyrotoxicosis followed by hypothyroidism, thereby resembling the course of a classical 
thyroiditis, but its exact cause remains unclear.4,5 Previous studies have suggested that 
thyroid toxicity during anti-PD-1 treatment may be associated with improved overall 
survival (OS), but these studies were limited by small sample sizes, included only patients 
with non-small-cell lung carcinoma (NSCLC), and showed inconsistent effects on 
progression-free survival (PFS).6,7 While thyroid autoimmunity, the presence of anti-thyroid 
antibodies (ATAbs), prior to immunotherapy has been related to the development of 
thyroid toxicity during immunotherapy,8,9 the ATAb status at baseline showed no relation 
with improved survival.10 We therefore hypothesized that the occurrence of thyroid 
toxicity during anti-PD-1 treatment and thyroid antibody status may predict treatment 
outcomes in anti-PD-1 treated patients. This hypothesis was investigated in patients with 
various cancer  types in a large prospective cohort study.  
MATERIALS AND METHODS
A total of 168 patients with metastatic melanoma, NSCLC, and renal cell carcinoma (RCC) 
who started anti-PD-1 treatment, nivolumab (every 2 weeks) or pembrolizumab (every 
3 weeks), between April 2016 and July 2017 at the Erasmus Medical Center (Rotterdam, 
the Netherlands) were eligible for the MULTOMAB-trial11-13 (Dutch Trial Registry 
#NL6828). The goal of the MULTOMAB-trial was to set up a biobank of prospectively 
collected blood samples for pharmacokinetic analyses of monoclonal antibodies and 
immunophenotyping. All adult patients beginning anti-PD-1 treatment were eligible for 
the MULTOMAB-trial, in which we serially collected serum samples and isolated peripheral 
blood mononuclear cells. Therapy was terminated in case of complete response, disease 
progression, severe side effects, or patients’ wish. The study was approved by the local 
ethics board committee.
OS was defined as the period between the start of therapy until death, while PFS was 
calculated until tumor progression, based on standard Response Evaluation Criteria In 
Solid Tumors (RECIST) v1.1, or death. Patients who were lost to follow-up were censored. 
Serum was collected prior to each drug administration (every 2 or 3 weeks) in order to 
determine TSH and free T4 (FT4) levels. Serum TSH and FT4 levels were measured via 
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immunoassays on Siemens Immulite 2000XPi (reference range: 0.4-4.3 mU/L) and Ortho 
Vitros ECiQ (reference range: 11-25 pmol/L), respectively. Thyroid toxicity was scored as 
‘subclinical’ when TSH levels were increased (subclinical hypothyroidism) or decreased 
(subclinical hyperthyroidism) and FT4 levels were normal. Thyroid toxicity was scored as 
‘overt’ when TSH levels were increased and FT4 levels decreased (overt hypothyroidism), or 
vice versa (overt hyperthyroidism). Patients who acquired overt thyroid toxicity after they 
had acquired subclinical thyroid toxicity were scored as ‘overt’. Patients were monitored for 
thyroid toxicity until tumor progression. This was done because this research investigates 
possible prospective markers for which events occurring after tumor progression are not 
of any predictive value. Patients with abnormal TSH levels or receiving thyroid medication 
within 3 months before the start of immunotherapy were categorized as having a pre-
existing thyroid disorder. 
Antibodies directed against thyroid peroxidase (anti-TPO) and thyroglobulin (anti-Tg) 
were measured on a Phadia 250 at baseline and 2 months after start of treatment, or the 
last available sample in case of death. The lower limit of quantification (LLoQ) for anti-TPO 
was 33 IU/mL and for anti-Tg it was 244 IU/mL, as reported by the supplier. The lower 
limit of detection (LLoD) for both values was 1 IU/mL. The vast majority of patients had 
detectable levels of ATAbs, only 7 patients at baseline and 14 patients during follow-
up had positive antibodies when using conventional cut-offs for anti-TPO  and anti-Tg 
positivity as provided by the assay manufacturers (60 and 280 IU/mL, respectively). To 
avoid underpowered analyses and to study the consequences of detectable ATAbs- as a 
reflection of an auto-immune reaction, the cut-off levels were a priori set at the median 
concentrations at baseline in the study population (anti-TPO: 3.05 IU/mL, anti-Tg: 22.35 
IU/mL). Patients with any antibody level above these cut-offs were categorized as patients 
with ‘above median’ ATAb levels and patients with anti-TPO and anti-Tg levels below these 
cut-offs were categorized as patients with ‘below median’ ATAb levels.
Categorical variables were tested using X2 tests (or Fisher’s exact test when X2 test 
assumptions were not valid). Age distribution between groups was analyzed using one-
way ANOVA. To study relationships between thyroid toxicity and PFS or OS, Cox regression 
analysis was used where thyroid toxicity was added to the model as a time-dependent 
covariate. This method takes into account the fact that thyroid toxicity emerges during 
the follow-up period and can only emerge when the patient survives long enough to 
develop the toxicity. Hence, false positive results due to immortal time bias are prevented. 
Conventional Cox regression was used for relationships between ATAb status and PFS or 
OS. Patients using glucocorticoids were excluded in sensitivity analyses, as these could 
both interfere with thyroid toxicity and ATAb.   
All analyses were corrected for cancer type, as it was a confounder in the relationship 
between thyroid toxicity and survival. A p-value <0.05 was considered statistically 
significant and STATA (v15.1 StataCorp. College Station, TX) was used for all statistical 
analyses. 
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RESULTS
Baseline characteristics of all patients (n=168) are shown in Table 1. The median follow-
up time of patients still alive was 14.9 (IQR:9.2-18.4) months. During the study period, 
34 patients (20%) developed subclinical thyroid dysfunction and 20 patients (12%) 
developed overt thyroid dysfunction. Twenty-seven patients (16%) had pre-existing 
thyroid dysfunction, consisting of 9 cases with hyperthyroidism and 18 cases with 
hypothyroidism. Twenty-two of those patients only had subclinical thyroid disease. 
Eighty patients (48%) developed no thyroid dysfunction during the study period. For 
7 patients (4%) it was impossible to determine thyroid dysfunction due to missing TSH 
values. Median time to development of all types of thyroid dysfunction was 2.8 (IQR: 1.3-
4.2) months, whereas for overt thyroid dysfunction it was 2.1 (IQR: 1.2-3.7) months. There 
were no differences in age, sex, cancer type, and drug administered between patients 
who developed thyroid dysfunction and those who did not (Table 2). Patients with above 
median ATAb levels at baseline (p=0.374) or acquired above median ATAb levels during 
therapy (p=0.349) did not have a different risk of acquired thyroid toxicity than patients 
with below median baseline ATAb levels.
Table 1. Baseline characteristics of study cohort
Patients (n=168)
Sex (number (%))
Male  103 (61%)
Female  65 (39%)
Age at start of treatment (years)
Median (IQR)  65 (58-70)
Cancer type (number (%))
Non-small-cell lung carcinoma 93 (55%)
Melanoma 63 (38%)
Renal cell carcinoma 12 (7%)
Drug treatment (number (%))
Nivolumab  118 (70%)
Pembrolizumab  50 (30%)
Follow-up time (months)a
Median (IQR) 14.9 (9.2-18.4)
aFollow-up time for patients who were alive at end of study
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Table 2. Patient characteristics by thyroid toxicity groups
P-value









Sex (number (%)) 0.17
Male 53 (67%) 23 (63%) 11 (53%) 12 (46%)
Female 27 (33%) 11 (37%) 9 (47%) 15 (54%)
Age at start  of 
treatment(years)
0.18
Mean (IQR) 64.5 (58-71) 64 (56-70) 67.5 (60-72.25) 69 (62.5-73.5)
Cancer type (number (%)) 0.08
Non-small-cell lung 
carcinoma
40 (53%) 23 (67%) 11 (53%) 14 (50%)
Melanoma 37 (43%) 6 (19%) 8 (41%) 10 (38%)
Renal cell carcinoma 3 (4%) 5 (15%) 1 (6%) 4 (12%)
Drug (number (%)) 0.53
Nivolumab 53 (68%) 26 (74%) 13 (65%) 21 (77%)
Pembrolizumab 27 (32%) 8 (26%) 7 (35%) 6 (23%)
One-year survival rate (%)
Overall survival 64% 54% 94% 68%
Progression free survivala 33% 34% 64% 45%
a PFS could not be calculated for 3 patients
Patients who acquired overt thyroid dysfunction had longer OS (HR=0.18 [CI-95%: 0.04-
0.76], p=0.020) as well as PFS (HR=0.39 [0.15-0.998], p=0.050) than patients without 
thyroid dysfunction. No difference was found in OS (HR=1.54 [0.79-2.98], p=0.201) and 
PFS HR=0.99 [0.52-1.91], p=0.998) in patients with subclinical thyroid dysfunction or 
with pre-existing thyroid dysfunction (OS: HR=0.92 [0.44-1.90], p=0.816; PFS: HR=0.71 
[0.40-1.26], p=0.243) when compared to patients without thyroid dysfunction (Figure 1). 
These effects remained significant after excluding patients using glucocorticoids for PFS 
(p=0.020). For OS, a trend to significance was observed (p=0.078). 
Median time to the measurement of ATAbs during treatment was 2.1 (IQR:2.0-2.3) 
months. ATAb level distributions are described in Supplementary Table 1. Age and sex 
were divided proportionally over the ATAb status groups, in contrast to cancer type and 
drugs administered (Table 3). Within this cohort, patients with NSCLC and RCC were 
predominantly treated with nivolumab, while patients with metastatic melanoma were 
predominantly treated with pembrolizumab. Patients with ATAb levels above the median 
did not differ in OS (HR=0.97 [0.55-1.72], p=0.930) and PFS (HR=0.99 [0.64-1.54], p=0.981) 
when compared to patients with ATAb levels below the median (Figure 2). However, 
during treatment, patients with ATAb levels above the median had improved OS (HR=0.39 
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[0.21-0.72], p=0.003) and PFS (HR=0.52 [0.33-0.81], p=0.004) when compared to patients 
with ATAb levels below the median with one-year survival rates of 83% vs 49% for OS 
and 54% vs 20% for PFS, respectively. These effects remained significant after excluding 
patients treated with glucocorticoids for OS (p=0.010) and PFS (p=0.010).
Furthermore, we analyzed the changes of ATAbs over time (Figure 3). In 84% of patients, 
the ATAb status did not change from baseline until the end of treatment. We found that 
the 70 patients (48%) with a persistent ATAb level above the median, had a significantly 
improved OS (HR=0.41 [0.19-0.89], p=0.025) and PFS (HR=0.54 [0.31-0.95], p=0.032) 
compared to the 53 patients (36%) with a persistent ATAb level below the median. The 
15 patients (10%) whose ATAb levels increased above the median during treatment had 
an improved OS (HR=0.27 [0.06-1.22], p=0.088) and PFS (HR=0.24 [0.07-0.77], p=0.017) 
compared to the 9 patients (6%) whose ATAb levels decreased below the median (Figure 
3).
Finally, Supplementary Figure 1 provides the thyroid toxicity courses in patients 
experiencing thyroid toxicity. This swimmers plot shows a variety of patterns. In many 
cases a hyperthyroid phase was followed by a hypothyroid phase which is classical for a 
thyroiditis, while only rarely a hypothyroid phase was followed by a hyperthyroid phase.
Figure 1. Thyroid toxicity and survival
Kaplan-Meier curves of patients with acquired overt thyroid toxicity (in green), acquired subclinical 
thyroid toxicity (in blue), pre-existing thyroid dysfunction (in black), or without thyroid dysfunction 
(in red). a) OS and b) PFS. OS: Overt vs without: HR=0.18 (CI-95%: 0.04-0.76), p=0.020; Subclinical 
vs without: HR=1.54 (0.79-2.98), p=0.201; Pre-existing vs without: HR=0.92 (0.44-1.90), p=0.816. 
PFS: Overt vs without: HR=0.39 (0.15-0.998), p=0.050; Subclinical vs without: HR=0.99 (0.52-1.91), 
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Figure 2. Anti-thyroid antibodies and survival
Kaplan-Meier curves of patients with anti-thyroid antibodies above median (in green) or below 
median (in red). a) OS for antibody status at baseline (HR=0.97 (0.55-1.72), p=0.930), b) PFS for 
antibody status at baseline (HR=0.99 (0.64-1.54), p=0.981), c) OS for antibody status during 
treatment (HR=0.39 (0.21-0.72), p=0.003), and d) PFS for antibody status during treatment (HR=0.52 
(0.33-0.81), p=0.004).
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Figure 3. Changes in anti-thyroid antibody status and survival
Kaplan-Meier curves of patients with acquired anti-thyroid antibodies above median (in green), 
acquired anti-thyroid antibodies below median (in red), continued anti-thyroid antibodies above 
median (in blue), or continued anti-thyroid antibodies below median (in black).  a) OS and b) PFS. OS: 
Acquired above median vs acquired below median: HR=0.27 (0.06-1.22), p=0.088; Persistentabove 
median vs persistentbelow median: HR=0.41 (0.19-0.89), p=0.025. PFS: Acquired above median vs 
acquired below median: HR=0.24 (0.07-0.77), p=0.017; Persistent above median vs Persistentbelow 
median: HR=0.54 (0.31-0.95), p=0.032
DISCUSSION
Anti-PD-1 treated patients with metastatic melanoma, NSCLC, and RCC and  acquired 
overt thyroid toxicity   and/or higher ATAb levels during treatment have clinically relevant 
prolonged OS and PFS compared to patients without thyroid toxicity and/or low ATAbs. 
We hypothesize that these patients represent a group with a higher susceptibility 
to autoimmunity, which in turn could be beneficial in the anti-cancer treatment via 
autoimmune dependent pathways, leading to longer survival. This is supported by 
various studies in recent years showing that the occurrence of immune related adverse 
events in anti-PD-1 treated patients is associated with improved response and survival.14-25 
However, most of these studies were limited by their retrospective study design and/or 
small sample size, while in the current large prospective study we observed effect sizes for 
thyroid toxicity on OS which are much stronger compared to published associations with 
other immune related adverse events.14-25  
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Our finding that ATAb status at baseline is not correlated with OS or PFS is in line with 
the results of Toi et al.10 However, we found that a very large portion of patients did not 
change in ATAb status from baseline until end of treatment and significantly improved OS 
and PFS were observed for patients with persistent ATAb levels above the median when 
compared to patients with persistent ATAb levels below the median.  Finally, patients 
whose ATAb levels rose above the median during treatment had significantly improved 
survival compared to patients whose ATAb levels decreased below the median, leading to 
the observed difference in survival between patients with ATAb levels above and below 
the median during treatment. These results suggests that a predisposition for higher 
susceptibility to autoimmunity could already exist at baseline, but may be influenced 
during --and possibly by-- the treatment, which is a new finding. 
An important finding in our study is that only a few patients had positive ATAbs when 
using conventional cut-off thresholds. As these thresholds are specifically used for 
diagnosing Hashimoto’s thyroiditis, rather than detecting autoimmunity, the cut-off 
levels in our study were a priori set at the median concentrations at baseline in the study 
population. The fact that these lower cut-off thresholds can serve as a strong predictive 
marker suggest that more subtle increases in ATAb levels are involved and relevant in this 
setting when compared to diagnosing Hashimoto’s hypothyroidism.
Alternative models are available to describe response in patients treated with 
immunotherapy, like iRECIST (immune related response criteria). However, we used 
RECIST v1.1 since this is currently still standard in the oncology field for patients treated 
with immunotherapy.26,27 The scoring of thyroid toxicity in our study was purely based on 
the interpretation of serum TSH and FT4 levels to determine the presence of subclinical or 
overt thyroid dysfunction. This is because the decision to treat thyroid toxicity in practice is 
predominantly guided by this endocrine classification and therefore has clinical relevance. 
This in contrast to Common Terminology Criteria for Adverse Events (CTCAE), a common 
method used within oncology, which describes the severity of organ toxicity for patients 
receiving cancer therapy, with a score ranging from 0 (no adverse event) up to 5 (death). 
Another important advantage of the current analysis is that we adjusted our results for 
time dependent effects, while others did not, thereby preventing misinterpretation of the 
effects of thyroid toxicity on survival. It may be possible that patients with a longer follow-
up time are more likely to develop thyroid toxicity. However, median duration to overt 
thyroid toxicity was 2.1 months, whereas the median follow-up time in our study was 14.9 
months, well exceeding the median duration to thyroid toxicity.
The number of patients with pre-existing thyroid dysfunction in our cohort was high 
(16%), which is likely explained by our definition of thyroid dysfunction. Out of 27 patients 
with pre-existing thyroid disease, 22 patients were classified as having subclinical thyroid 
dysfunction, which we classified as such when having one aberrant TSH value prior start 
with immunotherapy. We intentionally used these very strict criteria to define pre-existing 
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thyroid disease to avoid including any patient with pre-existing mild thyroid dysfunction 
which could interfere with our study aim .
The presence of non-thyroidal illness (NTI) may complicate the interpretation of thyroid 
function tests in severely ill patients. NTI is more common among intensive care patients, 
but none of our patients were hospitalized in the intensive care unit. Moreover, the most 
important associations in our cohort were found in patients with overt thyroid toxicity, 
the biochemical fingerprint of which does not resemble NTI, and was also supported by 
the observed thyroid toxicity courses (Supplementary Figure 1). Therefore, it is unlikely 
that the potential presence of NTI among study participants substantially influenced the 
study results. When evaluating the course of thyroid dysfunction over time, a variety of 
patterns was observed, an important part of which resembled a thyroiditis. The fact that 
a hypothyroid phase was not always preceded by a hyperthyroid phase might be due to 
the fact that the hyperthyroid phase was short and occurred between the time of thyroid 
function testing.
Despite correlations between ATAb status and  and thyroid toxicity and OS, no associations 
were found between ATAb status and thyroid toxicity in our cohort. This could be explained 
by the fact that the number of patients with thyroid toxicity in the separate ATAb status 
groups were low. Therefore, further studies should investigate this relationship in larger 
groups of patients. 
In conclusion, this study shows that acquired overt thyroid toxicity and higher ATAbs 
during treatment are strong predictive markers for response to anti-PD-1 treatment in 
three cancer types studied.  If validated in an independent study, these parameters may 
serve as novel predictive markers.
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Thyroid toxicity patterns in patients with acquired thyroid toxicity (euthyroidism in green; subclinical 
hypothyroidism in light blue; subclinical hyperthyroidism in yellow; overt hypothyroidism in dark 
blue; overt hyperthyroidism in red). →: Patient did not die nor was lost to follow-up. †: Patient died 
or was lost to follow-up.
Supplementary Table 1. Distribution of anti-TPO and anti-Tg levels
Baseline (n=156) Follow-up (n=158)
Anti-TPO (IU/ml) Anti-Tg (IU/ml) Anti-TPO (IU/ml) Anti-Tg (IU/ml)
Median (IQR) 3.1 (0-7.9) 22.4 (0-46.5) 3.4 (0-8.3) 23.1 (0-49.5)
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Background: In solid organ transplant (SOT) recipients, transplant rejection during 
immune checkpoint inhibitor (ICI) treatment for cancer is a clinical problem. Donor-
derived cell-free DNA (dd-cfDNA) can be detected in blood and is a sensitive 
biomarker for diagnosis of acute rejection in SOT recipients. To our best knowledge, 
this is the first case report of a kidney transplant  recipient with advanced cancer 
treated with ICI who was monitored with dd-cfDNA.
Case presentation: A 72-year old female with a long-standing renal transplant was 
diagnosed with advanced melanoma in 2018 and was treated with the anti-PD1 
antibody nivolumab. Within 12 days after the first administration of nivolumab, dd-
cfDNA ratio increased to 23%, suggesting allograft rejection. Her kidney transplant 
function deteriorated and acute rejection was confirmed by renal transplant 
biopsy. As the rejection could not be controlled despite immunosuppressive 
treatment, a transplant nephrectomy was necessary and haemodialysis was started. 
Immunological analysis of the renal explant showed infiltration of alloreactive, 
nivolumab-saturated, PD1+ cytotoxic T cells. After transplant nephrectomy, she 
experienced nivolumab-related toxicity and rapid disease progression. 
Conclusion: Clinicians prescribing ICIs should be aware that SOT recipients are at 
risk of transplant rejection as a result of T cell activation. Dd-cfDNA is a sensitive 
biomarker and should be further studied for early detection of transplant rejection. 
Immunological analysis of the kidney explant showed marked graft infiltration with 
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INTRODUCTION
Immune checkpoint inhibitors (ICIs) have significantly improved the overall survival 
of patients with advanced malignancies, including advanced stage melanoma 1. The 
monoclonal antibody nivolumab blocks the inhibitory immune checkpoint receptor 
programmed death-1 (PD-1), thereby promoting the anti-tumor immune response 2. This is 
particularly hazardous for solid organ transplant (SOT) recipients who may develop acute 
rejection as a result of enhanced T cell activation 3. As SOT recipients have an increased risk 
to develop ICI-responsive malignancies, including melanoma and cutaneous squamous 
cell carcinoma 4,5, ICI-induced SOT rejection is a clinical problem. For adequate patient 
counselling and early intervention during ICI treatment, biomarkers for early detection of 
acute rejection are needed. However, conventional biomarkers to monitor SOT integrity 
have a low sensitivity and specificity 6.
Donor-derived cell-free DNA (dd-cfDNA) can be detected in blood and urine of SOT 
recipients and has been shown to be a potentially useful  biomarker for the early diagnosis 
of acute rejection of kidney transplants 7. In kidney transplant recipients, dd-cfDNA levels 
of <1% of total cfDNA appear to reflect the absence of active rejection whereas levels >1% 
seem to indicate active rejection 7. However, many questions regarding the clinical utility 
of dd-cfDNA monitoring following SOT remain and this is not standard practice (reviewed 
in Verhoeven et al.). Here, a kidney transplant recipient is described who experienced 
severe acute allograft rejection during ICI therapy for metastatic melanoma. In the 
current analysis, dd-cfDNA was evaluated as a potential sensitive biomarker for detection 
of transplant rejection in a cancer patient treated with ICIs. Second, to understand the 
pathophysiology of this ICI-induced rejection, graft-infiltrating leucocytes were isolated 
and characterized.
MATERIALS AND METHODS
Genotyping, isolation and measurement of dd-cfDNA
Peripheral blood mononuclear cells of the recipient and spleen cells of the donor were 
used for automated purification of DNA (Maxwell, Promega, Leiden, the Netherlands). 
Donor and recipient were genotyped and discriminated by using a panel of 10 
preselected different single-nucleotide polymorphisms (SNP). Blood samples for dd-
cfDNA were collected in CellSave BCT tubes (Menarini, San Diego, CA). Blood collection 
tubes were stored at 4°C within 3 hours after collection, and within 2 days post draw, 
plasma was separated by centrifugation at 1,600 × g for 20 minutes and stored at -80°C. 
Post thaw, plasma was centrifuged for a second time at 16,000 × g for 10 minutes and 
cfDNA was extracted immediately using the Circulating Nucleic Acid kit (Qiagen, Venlo, 
The Netherlands)). For the droplet digital PCR (ddPCR), droplets were manually generated 
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with the QX200 Droplet Generator (Bio-Rad, Lunteren, The Netherlands). The samples were 
run on a the T100TM Thermal Cycler (Biorad, Lunteren, The Netherlands). Dd-cfDNA was 
quantified based on differences in SNPs between donor and recipient (3 different SNPs 
that were able to distinguish between ddcfDNA and cfDNA) using the QX200TM Droplet 
Reader (Biorad, Lunteren, The Netherlands). Analysis was performed with QuantaSoft 
Analysis Pro (Bio-Rad, Lunteren, The Netherlands).
Immunohistochemical stainings
Four μm sections of Formalin-Fixed Paraffin-Embedded (FFPE) tissue were mounted 
serially on adhesive glass slides and deparaffinized. Antigen retrieval was performed by 
CC1 antigen retrieval solution (ref. 950-124, Ventana Medical Systems, Inc., Oro Valley, 
Arizona). Specimens were incubated with the primary antibody. The following antibodies 
were used; CD3 (ref. 790-4341, Ventana Medical Systems, Inc., Oro Valley, Arizona), CD4 
(ref. 790-4423, Ventana Medical Systems, Inc., Oro Valley, Arizona), CD8 (ref. 790-4460, 
Ventana Medical Systems), CD20 (790-2531 Ventana Medical Systems), Granzyme B 
(262R-18, Cell Marque Corporation, Rocklin, California), Ki-67 (ref. 790-4286 Ventana 
Medical Systems) and PD-1 (ref. 760-4895, Cell Marque). Detection was performed with 
OptiView DAB (ref. 760-700, Ventana Medical Systems, Inc.) or UltraView-DAB (ref. 760-500, 
Ventana Medical Systems, Inc) and amplification was done with the Amplification Kit (ref: 
760-080 or OptiView Amplification Kit ref: 760-099, Ventana Medical Systems, Inc.). Next, 
the specimens were counterstained with haematoxylin II (ref: 790-2208, Ventana Medical 
Systems, Inc.) and cover-slipped in order to keep the specimens pressed flat. Each slide 
contained a positive control. All stainings were performed on the VENTANA BenchMark 
ULTRA (Ventana Medical Systems, Inc.).
Flow cytometric phenotyping of graft infiltrating lymphocytes (GILs)
GILs were stained with the following monoclonal antibodies (MoAb) in order to determine 
their phenotype: CD3, CD4, CD8, and PD-1. In order to measure the capacity of the cells 
to produce pro-inflammatory cytokines, the GILs were stimulated for 4 hours with 0.5 μg/
mL phorbol myristate acetate (PMA) and 10 μg/mL ionomycin (Sigma-Aldrich, St. Louis, 
MO) at 37°C. Intracellular accumulation of cytokines was enhanced by the addition of 
monensin and brefeldin A. The reaction was stopped by the addition of ethylene-diamine-
tetra-acetic acid. Subsequently, cells were stained with CD3 brilliant violet 510 (BV510; 
Biolegend, San Diego, CA), CD4 brilliant violet 421 (BV421; Biolegend), CD8 phycoerythrin-
cyanine7 (Pe-Cy7; BD), PD-1 allophycocyanin-Cy7 (APC-Cy7; Biolegend), and the viability 
marker 7-aminoactinomycin (7-AAD; Biolegend). After surface staining, the cells were 
immediately fixed with FACS lysing solution (BD) and permeabilized with PERM II (BD). 
Intracellular staining was performed with the following MoAb: TNFα PE (Biolegend), IFNγ 
fluorescein isothiocyanate (FITC; BD) and IL-2 APC (BD). Samples were measured on the 
FACSCanto II (BD). 
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In order to determine free binding places of nivolumab (Bristol-Myers Squibb, New 
York, NY), was labelled with the SiteClickTM R-PE Antibody Labeling Kit (ThermoFisher, 
Waltham, MA). The GILs from the patient and the control patient were not stimulated. 
Cells were phenotyped with the following monoclonal antibodies: CD3 brilliant violet 
510 (Biolegend), CD4 brilliant violet 421 (Biolegend), CD8 phycoerythrin-cyanine7 (BD), 
Nivolumab-PE, and the viability marker 7-aminoactinomycin (Biolegend). After surface 
staining, the cells were measured on the FACSCanto II (BD). Analysis was performed with 
Kaluza 1.5a software (Beckman Coulter, Brea, CA).
CASE PRESENTATION
In 2018, a 72-year-old female with a long-standing renal transplant was diagnosed with 
metastatic BRAF-wildtype melanoma, five years after a cutaneous melanoma (Breslow 
thickness 0.8 mm) had been radically excised. She presented with a solitary large left 
axillary metastasis of 6 cm which encased the axillary artery and the plexus brachialis, 
resulting in edema and paralysis of her left arm. The patient had received a deceased 
donor kidney transplant in 2013 due to end-stage renal disease caused by hypertensive 
nephropathy and a unilateral nephrectomy because of renal cell carcinoma (T2N0M0) in 
2006. Apart from the development of post-transplantation diabetes mellitus, the clinical 
course after her transplantation had been uneventful. At the time of melanoma diagnosis, 
she had a stable renal function with limited proteinuria (urinary protein to creatinine ratio 
of 33 g/mol) and a serum creatinine concentration of 150 umol/L, corresponding to an 
eGFR of 30 mL/min per 1.73 m2 (CKD-EPI formula) 8. 
The large left axillary mass was considered unresectable. After radiotherapy combined 
with hyperthermia, she had progressive disease with pulmonary and distant lymph node 
metastases. She was carefully counselled about ICI-associated side effects, specifically 
about the possibility of renal allograft rejection. Progressive axillary metastasis with 
severe vascular and neurologic complications led to the shared decision to start first-line 
nivolumab (3 mg/kg Q2W). The immunosuppressive regimen consisting of tacrolimus (1.5 
mg q.d.) and mycophenolate mofetil (500 mg b.i.d.) was switched to prednisolone (20 mg 
q.d.) and nivolumab was administered one week thereafter. 
Twelve days after first nivolumab administration, the patient presented with nausea, 
vomiting, loose stools and abdominal pain located at the site of her transplant. Laboratory 
investigation demonstrated severe renal insufficiency with a serum creatinine of 549 
umol/L. A kidney transplant biopsy was performed and demonstrated extensive acute 
ischemic changes with capillary endothelial necrosis, tubular epithelial degeneration, 
edema and haemorrhage, consistent with infarction (Figure 3A). These findings were 
interpreted as acute kidney transplant rejection and methylprednisolone pulse therapy 
(1000 mg intravenously for 3 consecutive days) and haemodialysis were initiated. 
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Because of ongoing rejection despite methylprednisolone treatment, prednisolone 
was discontinued and transplant nephrectomy was performed. Because of advanced 
malignancy, T lymphocyte-depleting antibodies were not administered.
After transplant nephrectomy, nivolumab was continued for a period of 8 weeks. As 
she experienced immune-related adverse events, including pneumonitis grade 2 and 
colonoscopy-conformed colitis grade 2 (common terminology criteria for adverse events 
version 4.03), nivolumab was discontinued and prednisolone was initiated. Three months 
after the start of nivolumab, 18F-FDG PET-CT revealed progressive disease with new lung 
and lymph node metastases (Figure 1). The patient decided to stop haemodialysis and 
died five months after the start of nivolumab.
Figure 1. 
Three months after the start of nivolumab, 18F-FDG PET-CT revealed progressive disease with new 
lung and lymph node metastases. Pleural effusion was present.
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Dd-cfDNA reveals acute allograft rejection 
The patient participated in the MULTOMAB clinical trial, (see Dutch Trial Register number 
NTR7015), in which blood is collected prospectively for translational purposes. After 
kidney transplant rejection, previously obtained blood samples were analyzed for dd-
cfDNA. Dd-cfDNA was expressed as a percentage of total cfDNA (see methods section 
below). Prior to administration of nivolumab, dd-cfDNA was low (0.9%; Figure 2). One 
week after administration of nivolumab, dd-cfDNA increased to 2.9%, indicating active 
rejection of the allograft. At the time of rejection, 12 days after first administration of 
nivolumab, dd-cfDNA increased to a maximum of 23.1%. Dd-cfDNA levels declined to 
8.8%, 0.1% and 0.0% at 3-5 hours, 22 days and 77 days after transplant explantation, 
respectively, corresponding with the half-life of dd-cfDNA 9.
Figure 2.
Time course of the percentage plasma dd-cfDNA (green) and serum creatinine concentration (red), 
in relation to important clinical events. During the hospital admission, hemodialysis (HD; day 17) 
was initiated. Dd-cfDNA levels declined from 23% to 8.8% 3-5 hours after kidney explantation. 
Dotted lines are added to connect separate measurements of creatinine and dd-cfDNA. Of note, no 
comparative serum creatinine measurement was performed at 7 days after the first administration 
of nivolumab.
Acute vascular rejection with viable graft infiltrating lymphocytes
Histopathological examination of the explanted kidney allograft demonstrated severe 
vascular, acute T-cell mediated rejection with an almost entirely necrotic kidney 
parenchyma with hemorrhage and moderate endothelialitis with focal fibrin deposition 
(Figure 3B). CD3+ T lymphocytes were found subendothelially (Figure 3C) and included 
both CD4+ (Figure 3D) and CD8+ T cells (Figure 3E). No CD20+ B lymphocytes were 
identified (Figure 3F). The cytotoxic CD8+ T cells were active and viable, as evidenced by 
the presence of intracellular granzyme B (Figure 3G) and Ki-67 (Figure 3H), reflecting 
their cytotoxic potential and proliferation, respectively. PD-1+ staining was also seen in 
the vessel wall (Figure 3I).
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Despite the necrotic status of the renal explant, viable lymphocytes were revealed, 
which mainly consisted of CD3+ T cells (59%). Within the total CD3+ T cell population, the 
CD4+:CD8+ ratio was approximately 1:3 (22% CD4+ and 73% CD8+, Figure 4A). Cytokines, 
such as IFN-y, TNF and IL-2, play an important role in the immune response that mediate 
allograft rejection. The amount of these pro-inflammatory cytokines, produced by T-cells, 
indicates whether these cells are activated. After polyclonal stimulation, the capacity of 
the T cells to produce  IFN-γ, TNFα and IL-2 was measured 10. CD8+ T cells had a higher 
capacity than CD4+ T cells to produce IFN-γ (91% vs. 37%; Figure 4B) and TNFα (66% vs. 
34%), whereas CD4+ T cells showed a higher capacity for IL-2 production (5% vs. 17%).  
Nivolumab PD-1 occupancy on graft infiltrating lymphocytes
Further immunological analysis was performed to examine whether nivolumab was 
successfully bound to the graft infiltrating lymphocytes (GILs), which were considered to 
have caused rejection. Among the GILs, PD-1 was expressed on both the CD4+ and CD8+ 
T cells (31% and 34%, respectively; Figure 4C), indicating that the receptor for nivolumab 
was present on the surface of these cells. To determine the amount of free PD-1 binding 
places on the GILs in the explant, conjugated nivolumab was added to the explant of both 
the current and a control patient, who experienced an acute rejection without ICI. In the 
renal explant of the control patient, nivolumab binding capacity was 49% of CD4+ and 
37% CD8+ T-cells (Figure 4D), whereas conjugated nivolumab was not able to bind CD4+ 
and CD8+ T-cells (0% and 0%, respectively) in the nivolumab-treated patient.
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Figure 3. 
Histology of the renal graft at the time of the kidney transplant biopsy and the explantation 
under nivolumab treatment (250 μm scale bar). Immunohistochemistry of the explanted kidney. 
A: HE staining of the kidney biopsy shows diffuse cortical necrosis, hemorrhage and glomerular 
congestion. B: HE staining of the renal explant shows moderate endothelialitis with focal fibrin 
deposition. C-I: immunohistochemistry of the explanted kidney. C-E: CD3+, CD4+ and CD8+ T-cells 
are present. F: no CD20+ B-cells are present. G and H: indicates the presence granzyme producing 
cells and proliferating cells (Ki-67) cells. Overall, there is influx of PD-1+ granzyme B-producing CD8+ 
T-cells in the vascular wall with endothelialitis. Magnification: 10x.
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Figure 4.
Phenotyping of the graft infiltrating lymphocytes isolated from the explanted kidney during 
nivolumab treatment. A: Unstimulated graft infiltrating-lymphocytes were gated by size and 
granularity in the forward and side scatter. CD4+ and CD8+ T cells were gated within total CD3+ cells. 
B: Intracellular IFN-γ, TNFα and IL-2 was determined in CD3+CD8- (representing the CD4+ population) 
and CD8+ T cells at 3 hours of stimulation with PMA/ionomycin. C: Presence of the presence of PD-1 
in CD4+ and CD8+ T-cells was also determined.  D: Blockade of the PD-1 receptor by nivolumab 
was demonstrated by adding conjugated nivolumab to these cells and was compared with graft 
infiltrating lymphocytes of a rejected kidney from a patient who was not treated with nivolumab.
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DISCUSSION
Here a melanoma patient with a kidney transplant is reported who developed a fulminant 
acute kidney allograft rejection two weeks after the start of nivolumab treatment. Dd-
cfDNA was measured in this cancer patient to monitor allograft integrity and detect 
potential allograft rejection at an early stage during treatment with an ICI. Previously, 
it has been reported that quantification of so called dd-cfDNA can be useful to detect 
allograft rejection. Cell-free DNA is degraded into non-encapsulated DNA and released 
after cell death, or by active secretion of cells. During SOT rejection, the cells of donor 
origin are damaged and their content is released into the bloodstream. 7 Detection of 
dd-cfDNA is based on chimerism: donor cells are genetically distinct from that of the 
transplant recipient 6. 
Immunological analysis of the kidney explant showed marked graft infiltration with 
alloreactive PD-1+ cytotoxic T cells that were saturated with nivolumab, demonstrating 
nivolumab-mediated inhibition of PD-1. This indicated that nivolumab was bound to the 
T cells which likely caused allograft rejection. The graft infiltrating T cell population had 
the capacity to mount an effector response.
As indications of ICIs are expected to expand and SOT recipients have an increased risk 
to develop malignancies, e.g. advanced hepatocellular carcinoma in liver transplant 
patients, the use of ICIs in SOT recipients is a clinical problem, the magnitude of which is 
likely to increase in the near future 11. However, clinical trials of ICIs excluded SOT patients. 
Apart from case reports and case series 12-16, the efficacy and toxicity of ICI in transplanted 
patients with malignancies have not been studied extensively but do indicate the high 
risk of allograft rejection. Serum creatinine, which estimates the glomerular filtration rate, 
is not specific nor sensitive for kidney transplant rejection 17. 
The findings of the present case study suggest that dd-cfDNA may be a valuable biomarker 
for early detection of ICI-induced transplant rejection. It remains unclear at this stage if 
this novel biomarker outperforms conventional biomarkers such as serum creatinine. The 
first serum creatinine measurement in this case was only performed 12 days after the first 
administration of nivolumab and not at the same time of the dd-cfDNA measurement.
In conclusion, physicians prescribing ICIs should be aware of the increased risk of allograft 
rejection as a result of T cell activation. We believe that a combined measurement of dd-
cfDNA and conventional biomarkers may assist physicians to diagnose transplant rejection 
in this particular setting at an early stage but this should be studied prospectively. The 
transplant rejection was caused by alloreactive cytotoxic T cells that were positive for PD-1 
and were saturated with nivolumab, which is in line with the anti-tumor effect of this drug.
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PHARMACOLOGY OF IMMUNE CHECKPOINT INHIBITORS
The pharmacokinetics (PK) of immune checkpoint inhibitors (ICIs) were studied in Part I of 
this thesis. In the studies described in this thesis, an association was found between drug 
exposure and PD-1 ICI response for non-small-cell lung cancer (NSCLC; Chapter 2), while 
earlier phase I studies established that a relationship was lacking between drug dose and 
therapy response1. This was an unexpected finding as drug dosing is usually positively 
correlated with drug exposure, and has been the motif for subsequent PK studies.
Cancer cachexia pathways may lead to higher drug clearance
We presume that the association between drug exposure and therapy response might 
be the result of inter-patient variability of drug clearance. This hypothesis was confirmed 
by Turner et al. for a PD-1 ICI (pembrolizumab) in solid tumors2. Here, drug clearance 
was negatively correlated with drug exposure and this correlation was equivalent across 
different dose levels.2 Hence, patients with rapid disease progression or unfavorable 
prognostic characteristics were found to have a higher elimination rate of the drug and 
consequently have worse survival outcome regardless of the dose they received.
For clarification, Table 1 shows the paradoxical association between exposure and 
response in two hypothetical patients with variation in dosing and drug clearance. Higher 
drug clearance of patient B (0.45 L/day) results in lower exposure (156 vs. 467 mg/L*day 
for a 70 mg dose; 1560 vs. 4670 mg/L*day for a 700 mg dose) and represents a patient with 
a more advanced disease status or reflects disease progression during immunotherapy. 
Even though the absolute drug exposure of patient B for the 700 mg dose is higher than 
patient A’s systemic exposure for the 70 mg dose, patient B does not benefit of treatment. 
This is irrespective of the dosage (70 or 700 mg). For that reason, an exposure-response 
relationship may be observed within dose levels. 
Table 1. Hypothetical patients with distinct levels of drug clearance
CL (L/day) Dose (mg) AUC (mg/L*day) BOR Dose (mg) AUC (mg/L*day) BOR
Patient A 0.15 70 467 PR 700 4670 PR
Patient B 0.45 70 156 PD 700 1560 PD
Table 1. Two hypothetical patients (patient A and B) with respectively lower and higher drug 
clearance, who were treated with low or high dose immune checkpoint inhibitors. Patient B had 
impaired response irrespective of exposure. Table adapted from Badawi et al.3 Abbreviations: 
drug clearance (CL), area under the curve (AUC), best overall response (BOR), partial response (PR), 
progressive disease (PD).
Next, we explored patient characteristics that predominantly impact the rate of drug 
clearance. In Chapter 3 and 4, we described the first real-world population PK model 
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for nivolumab and pembrolizumab. Here, we found that the relationship between 
drug clearance and therapy response was most profound in stage IV NSCLC treated 
with nivolumab, which could be confirmed for pembrolizumab. Furthermore, baseline 
albumin levels were negatively associated with drug clearance, suggesting a key role of 
cancer cachexia in the PK of ICIs. Elimination of ICIs primarily occurs through metabolic 
breakdown into amino acids4, while the extended half-life time is the result of recycling 
mechanisms, similar to endogenous immunoglobulins. Potentially, higher drug clearance 
may represent a more advanced disease status, which may result in cancer cachexia and 
induces catabolism of immunoglobulins. Hence, we propose that cachexia pathways as a 
result of cancer progression may lead to higher target elimination of ICIs. Based on these 
findings, we postulate that the observed association between drug exposure or clearance 
with therapy response is a reflection of the patients’ metabolism (Figure 1; upper part of 
the figure).
TREATMENT SELECTION OF NSCLC
A serum profile involved in the acute phase response may reflect cancer 
cachexia and is associated with resistance to ICIs
In the second part of the thesis (Part II), we focused on treatment selection of ICIs 
in NSCLC. The role of cancer cachexia in NSCLC was also underlined by studying the 
serum proteome (Chapter 5). Enrichment analysis of the serum proteome, consisting of 
more than one thousand different proteins, identified IL-6 as a key upstream regulator 
of therapy resistance. Higher IL-6 was associated with worse clinical outcome, which 
was known to be strongly correlated as an acute phase protein to cancer cachexia. 
Interestingly, further evidence that emphasizes the role of the general metabolism was 
provided by a serum protein signature by mass spectrometry that stratified outcomes 
in patients with advanced NSCLC with second-line PD-1 ICIs (Chapter 6). A potential 
biological mechanism supporting the test was determined using protein set enrichment 
analyses methods. Consistently, patients were primarily stratified based on proteins 
involved in the acute phase response, acute inflammatory response, wound healing and 
complement activation, which was upregulated in patients with a worse clinical outcome 
after PD-1 inhibition. No significant association with progression-free survival (PFS) or 
overall survival (OS) was observed in a comparable cohort of advanced NSCLC patients 
treated with docetaxel. This demonstrates a predictive value of this specific serum protein 
signature, while previous research that showed the involvement of these mechanisms 
of resistance refrained from demonstrating predictive value5,6. Hence, although cancer 
cachexia is considered a prognostic factor, cancer cachexia related pathways have also 
been suggested to be specific for immunotherapeutic response.
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Figure 1. Pharmacokinetics and the tumor-immune interaction impacts tumor response after 
ICIs
The following model was proposed in this thesis, in which the therapy response to immune 
checkpoint inhibitors or tumor-immune factors direct the metabolic state of patients (progressive 
disease or malignant grade are associated with catabolism). Cancer cachexia is suggested to lead 
to higher drug clearance and lower drug exposure, which may also be a result of lower dosing. The 
association between drug exposure or drug clearance is the result of differences in the metabolic 
state of patients. As a consequence, we propose that there is no causal relationship between drug 
exposure or drug clearance and therapy response, despite our findings that indicate an exposure-
response relationship at the start of this thesis. Moreover, there is no true dose-response relationship 
in patients that are treated with ICIs as standard of care (either fixed or weight based dosing 
strategies). Of note, other factors rather than the tumor-immune interaction may also contribute to 
patients’ general metabolism, such as intrinsic, genetic or physiologic features.
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Tumor growth rate as tool for better evaluation of tumor response after 
ICIs
The clinical outcome after ICIs is generally based on the patient’s survival or radiological 
evaluation of tumor lesions over time. Radiological evaluation allows classification into 
patients who have progressive disease, stable disease or partial/complete response. 
Classically, this is done according to the Response Evaluation Criteria in Solid Tumors 
(RECIST v1.1)7. However, new methods of radiological evaluation have been studied, 
as cancer patients that are treated with immunotherapy sometimes show initial tumor 
growth with subsequent tumor shrinkage, defined as pseudo-progression. Treatment past 
progression is needed to recognize these tumor growth dynamics. Therefore, tools such as 
immune-related RECIST have been proposed by Nishino et al.8 to evaluate patients in this 
immune-oncology setting, but also experimental biomarkers might contribute to identify 
pseudo-progression during treatment. Circulating tumor DNA (ctDNA) is proposed to be 
a useful biomarker for this purpose: melanoma patients with pseudo-progression have 
demonstrated to have a profound decrease of ctDNA, which was not observed in patients 
with true progression9. 
In addition, considerable tumor growth acceleration may occur, that could be 
characterized as hyper-progressive disease (HPD; Figure 2)10. The growth patterns are 
very specific for immunotherapy, in contrast to other regimens such as chemotherapy or 
targeted therapies, and can only be determined by assessment of the tumor growth rate 
before in relation to after start of ICIs. We determined the volumetric growth rate before 
and after start of treatment in NSCLC patients (Chapter 7) to study the significance of 
these growth patterns after ICI treatment. Here, a significant relationship between tumor 
growth rate and OS could be determined, and a minority of patients (7%) had HPD. HPD 
was correlated with worse OS of only 2 months, which was in line with the observations 
by Champiat et al.11 
Different strategies for response evaluation have thus been considered, as RECIST v1.1. 
does not adequately reflect response to ICIs. Tumor growth dynamics seem to provide 
additional information, particularly to distinguish patients with the poorest prognosis, 
compared to alternatively used evaluation methods. 
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Figure 2. Hyper-progressive disease
A           B     C
Patient with stage IV NSCLC showing hyper-progressive disease. CT scans were performed A) 10 
weeks before start, B) at baseline and C) at first disease evaluation 3 weeks after start of PD-1 ICIs. 
The blue arrow indicates the prominent tumor lesion. Figure adapted from Champiat et al.10.
A combination of tumor-immune markers improves prediction
The importance of the tumor-immune interaction in patient stratification was determined 
in Chapter 8, where we combined several factors that were considered to have predictive 
value. This combination involved tumor intrinsic factors (tumor mutation burden 
[TMB], PD-L1 expression, expression of classical HLA) and information about the tumor 
microenvironment (TME; cytotoxic tumor infiltrating lymphocytes [TILs]). Strikingly, 
cluster analysis based on all markers revealed one cluster pattern that almost exclusively 
identified patients that did not benefit from ICIs. Here, patients with lower rates of cytotoxic 
TILs had worse OS than patients with higher rates, which was only in patients with either 
higher TMB, higher PD-L1 expression or strong classical HLA expression. Hence, a rational 
combination of markers improved response prediction.
Distorted function of cytotoxic TIL is associated with resistance to ICIs
Distorted effector function of cytotoxic TILs lead to reduced tumor cell death after ICIs, 
even when these cells are activated. Cytotoxic TILs are generally known to represent CD8+ 
T cells that have been primed by antigen presenting cells to recognize tumor antigens 
and to subsequently induce apoptosis of tumor cells. Because granzyme B is a key serine 
protease secreted by cytotoxic TILs, we hypothesized that a common germline variant of 
the GZMB gene (occurring in approximately one third of the European population) could 
lead to ICI resistance resulting from an incapability of TILs to induce tumor lysis12. Here, we 
showed that both germline variation of the GZMB gene and lower serum levels of granzyme 
B are associated with therapy resistance in NSCLC (Chapter 9). Moreover, GZMB variation 
was associated with serum levels: patients with the heterozygous or homozygous variant 
of GZMB had lower serum levels than patients with the wild type. Notably, we determined 
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that germline variation of GZMB was also significantly associated with impaired PFS and 
OS in metastatic melanoma (Chapter 12), which will be further discussed in the third part 
of the summary: Treatment selection of melanoma, and across other tumor types. Taken 
together, we demonstrated that germline genetics may significantly impact immune 
response mechanisms after ICIs in NSCLC and melanoma. The work indicates that the host 
genetics may significantly impact immune responses after ICIs.
Molecular characterization of NSCLC phenotypes demonstrates diffe-
rent mechanisms of immune evasion
The complexity of the tumor-immune interaction was further underlined in Chapter 
10. We performed a genome-wide molecular characterization of lung adenocarcinoma 
and squamous cell carcinoma based on DNA methylation and RNA expression. While 
differences could be determined in the modulation and expression of key immune 
modulating genes, the differences were mainly regulated by a group of genes that were 
not involved in immune modulation. Decreased expression of genes involved in antigen 
presentation were observed to be the main immune related defect13.
Characterization of pre-treatment peripheral immune cells in relation to 
tumor response after ICIs
The association of the peripheral immune status with therapy response was studied in 
Chapter 11. A large fraction of cytotoxic T cells of patients who benefit from treatment 
were found to be exposed to tumor antigen and matured and egressed in the bloodstream. 
NSCLC patients with higher numbers of T cells expressing differentiation markers and 
lacking co-stimulatory receptors were associated with therapy response. Moreover, the 
intracellular kinase activity profile of peripheral immune cells was determined in stage 
IV NSCLC and metastatic melanoma (Chapter 14). Interestingly, reduced activity in the 
phosphatase and tensin homolog (PTEN) pathway in peripheral immune cells before start 
of treatment was associated with therapy response. Loss of PTEN in cancer was found 
to be associated with therapy resistance of ICIs14,15. However, an inverse effect may be 
achieved when PTEN is downregulated in immune cells by becoming less dependent on 
activating co-stimulatory receptors for the recognition and elimination of tumor cells16. 
Reduced phosphorylation in the PTEN pathway may decrease the activation threshold 
and increase the clonal expansion of CD8+ T cells after presentation of tumor-antigens by 
antigen-presenting cells, facilitating apoptosis of tumor cells. The findings demonstrate 
the potential of studying immune cell subsets in blood prior to onset of ICIs, which may 
provide a broader view of the host immune system and local tumor-immune interactions.
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TREATMENT SELECTION OF MELANOMA, AND ACROSS TUMORS
We assume that the model for therapy response after ICIs (Figure 1) is applicable across 
tumors. Nevertheless, the factors that determine tumor-immune interactions may vary 
between tumors, primarily because of differences of intrinsic tumor characteristics and 
its preferred niche. Therefore, we have also studied the pharmacokinetics of PD-1 ICIs in 
metastatic melanoma, renal cell carcinoma, urothelial cell carcinoma and mesothelioma 
(Chapter 3 and 4), as well as treatment selection of PD-1 ICIs in metastatic melanoma.
Distorted function or exclusion of cytotoxic TIL associates to ICI resistance
We determined that germline variation of GZMB was associated with impaired clinical 
outcome in both NSCLC (Chapter 9) and metastatic melanoma (Chapter 12), although the 
association of GZMB variation in metastatic melanoma was much weaker than in NSCLC. 
The associations in metastatic melanoma did not retain significance after correction for 
baseline patient characteristics. On the other hand, a common germline variant in PDCD1, 
the gene encoding for PD-1, was strongly associated with impaired OS. Reduced fractions 
of peripheral PD-1+ CD4+ T cells were observed in patients with this specific germline 
variant in PDCD1, suggesting that it may affect ICI response by decreasing transcriptional 
initiation and PD-1 expression. Once more, the findings indicate that host genetics may 
impact immune responses after ICIs, but also indicate differences between NSCLC and 
melanoma. 
Importantly, distorted function of effector T cells may not only result from an incapability 
of TILs to induce tumor lysis, for instance as a consequence of germline variation of 
GZMB, but is also heavily affected by the architecture of the TME11. Tumors that are 
excluded of cytotoxic TILs are characterized by collagen-rich stroma that blocks the 
tumor-immune interaction. An immune-excluded phenotype has been associated with 
therapy resistance11, and specific pro-peptides of type III collagen are suggested to reflect 
the immune-excluded tumor type. In metastatic melanoma patients, we demonstrated 
that two main components of desmoplasia (pro-C3 and PC3X; pro-peptides of type III 
collagen) measured in blood were associated with resistance of ICIs (Chapter 13). The 
findings display the possibility to predict response after ICIs by assessment of stroma 
derived components in blood. 
Immune-related toxicity and solid organ transplant rejection after ICI 
therapy
After initiation of ICI therapy, also self-tolerant immune cells may become activated 
that may result in immune-related toxicity or adverse effects. In fact, the occurrence of 
immune-related toxicity has been suggested to be related to tumor response after ICI. 
The relationship between ICI response and the occurrence of immune-related toxicity, 
thyroid autoimmune phenomena, was studied in patients with various solid tumors 
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(Chapter 15). Here, we could observe that acquired thyroid toxicity during treatment were 
associated with therapy response. Interestingly, elevated thyroid specific antibodies prior 
to initiation of ICIs were correlated with response. The findings suggest additional value 
for treatment selection or early screening in these patients for on-treatment autoimmune 
thyroid toxicity, and suggests the importance of the host immune system on response 
mechanisms after ICIs.
Likewise, in solid organ transplant recipients, transplant rejection may be triggered during 
ICI therapy. A patient example of a kidney recipient with metastatic melanoma who was 
treated with immunotherapy was described in Chapter 16. Given that donor cells are 
genetically distinct from that of the transplant recipient, this patient was closely monitored 
by determining the levels of donor-derived cell-free DNA. Although it remains unclear 
whether this cell-free DNA outperforms conventional markers (e.g. serum creatinine) in 
this setting, the findings suggest that it has potential for early detection of transplant 
rejection induced by ICIs.
PERSPECTIVES ON THE PHARMACOKINETICS
To date, fixed and less frequent dosing of ICIs have been established for the treatment 
of stage IV NSCLC, among other tumor types. These new dosing strategies have been 
conducted in silico through the use of population PK modeling and simulation17,18, which 
results in overall similar drug exposure. Fixed dosing is usually preferred compared to 
weight-based dosing since it would reduce costs associated with drug preparation and 
administration. Also, less frequent dosing means that patients may reduce their visits to 
daycare units in medical centers. With this intention, new dosing strategies should be 
investigated. 
Improving dosing strategies by dose de-escalation, dose personalization 
or applying a loading dose
Lower dosage of ICIs leads to cost savings by decreasing the demand of resources. Different 
strategies may be implemented for this purpose. Generally, dose de-escalation can be 
conducted by lowering the dose of each drug administration, less frequent dosing while 
establishing the dose of each drug administration, or a combination of these options. A 
shorter duration of therapy, especially when its early therapeutic effect has been shown, 
might also be considered for certain tumor types. Currently, the minimum effective 
concentration is unknown, so we need prospective data to validate such strategies. 
Personalized dosing may be considered given the large inter-patient variability of ICIs. We 
provided understanding in the patient factors that are responsible for the interpatient 
variability (Chapters 3 and 4). For nivolumab, men had a 20% higher drug clearance 
than women and important variables that explain variability included body surface area 
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(BSA) and serum albumin. A possible methodology would be to calculate an optimal 
dose and interval for each individual based on gender, BSA and blood chemistry (e.g. 
serum albumin). Personalized dosing would be challenging as disease dynamics may 
influence the patients’ metabolism in such way that patients with progressive disease had 
significantly higher drug clearance. 
Moreover, a loading dose may be applied to further optimize the dosing scheme, as the 
drug is generally well-tolerated19. We have presented in Chapter 3 that biological half-life 
time of nivolumab is approximately 25 days, which results in an estimated time to reach 
steady state of 12 weeks (a rule of thumb is that 87.5% of the steady state concentration 
will be achieved after five half-lives). This has already been applied for other therapeutic 
monoclonal antibodies (such as cetuximab or trastuzumab20,21), and would reduce the 
time before the rate of drug input is equal to the rate of drug clearance.
Figure 3. Body distribution of PD-1 ICIs
A) 18F-FDG PET demonstrated high glucose metabolism of tumors in both lungs and mediastinal 
lymph nodes. B) 89Zr-labeled nivolumab PET demonstrate heterogeneous tracer uptake within 
and between tumors  7 days after infusion of radio-labeled nivolumab. High accumulation can be 
observed in the liver, spleen and gastrointestinal tract. C) the kinetics of 89Zr-labeled nivolumab on 
day 0, 3, 5 and 7, showing increasing tissue accumulation and decreasing concentration in the blood 
circulation over time. Figure adapted from Niemeijer et al.23. Abbreviations: spleen (S).
Importance of further understanding the pharmacology of ICIs
Unfortunately, biological understanding of the relationship between PK and the immune-
modulating activity in the tumor and TME remains incomplete. Current evidence from 
studies suggests that peripheral pharmacodynamics markers such as PD-1 receptor 
occupancy was not associated with therapy response. A saturation of the PD-1 receptor 
(>80%) was reached at very low exposures of ICIs (corresponding to an approximate 
nivolumab dose of 0.3 mg/kg Q2W)22. However, the receptor occupancy in blood may 
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not represent its activity in the TME, as it may not necessarily mean that the drug would 
reach the tumor. Recently, understanding of the distribution was expanded by positron 
emission tomography (PET) studies with radio-labeled nivolumab23. Nivolumab seemed 
gradually cleared from the circulation by the liver, spleen and gastro-intestinal tract and 
specifically accumulate at the target site (Figure 3). Non-invasive, whole body visualization 
may contribute to our understanding of the pharmacokinetics of ICIs. 
In conclusion, we presume that future research should prospectively study the efficacy 
of dose de-escalation strategies of ICIs, because costs continue to be a problem for 
both patients and society. Importantly, profound differences between tumor types are 
expected, illustrated by a strong inverse drug clearance-OS relationship for patients with 
advanced-stage NSCLC, which was not apparent  for metastatic melanoma (Chapter 3 
and 4). The underlying biological mechanism is not yet understood. We propose that 
surrogate markers for faster catabolism of (endogenous) immunoglobulins and relevant 
patient factors might be convenient for selecting patients for dose de-escalation. Ideally, 
this may be accompanied by PK monitoring to determine the minimal effective drug 
concentration. Further insights in context of the exact distribution of ICIs through the 
body and its immune-modulating activity in the TME is warranted, because it is unlikely 
that the pharmacologic response solely depends on drug binding to its target. As the 
relationships connecting drug elimination and cancer cachexia may be the key to our 
understanding of the ICI pharmacokinetics, it would be interesting to relate PK to cancer 
cachexia pathways.
PERSPECTIVES ON TREATMENT SELECTION
In addition to PD-L1 expression in tumor tissue, many predictive biomarkers have been 
considered in clinical trials for ICIs. PD-L1 expression in tumor tissue was shown to have 
a sensitivity and specificity ranging from 58–85% and 49–60%, respectively, depending 
on the tumor type or ICI24. In the Introduction, an overview was provided of the research 
that has been done up to the start of this thesis. In the following, we provide an updated 
literature overview (summarized in Table 2), and discuss future perspectives of treatment 
selection.
Potential for the early on-treatment assessment of the immunological 
response after ICIs
To date, ICIs directed towards the PD-1 receptor or its ligand PD-L1 are now standard of 
care for many types of cancer, whether or not combined with chemotherapy or CTLA-4 
inhibitors. In murine melanoma cell line and models, checkpoint blockade targets only 
specific subsets of TIL populations, with major differences between PD-1 and CTLA-4 
ICIs. Here, anti-PD-1 predominantly induces the proliferation of exhausted-like CD8+ 
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T cells, while anti-CTL-4 also induces the expansion of CD4+ T cells.25 In patients with 
advanced NSCLC, Kamphorst et al. focused on the peripheral immunological response 
after PD-1 ICIs. Here, an increase of peripheral PD1+ CD8+ T cells early on-treatment was 
observed in patients with a radiological response. These peripheral cells had an effector-
like phenotype, expressed costimulatory molecules and CTLA-4.26 The findings were 
confirmed by the same group and specific peripheral CD8+ T cell clones were found to 
be activated in patients with melanoma27.  Although differentiated CD8+ T cells (Chapter 
11) and the absolute numbers or ratios of a wide variety of immune subsets have been 
suggested to be predictive for response28-35, of which most findings were confirmed in 
independent patient cohorts, the predictive performance remains limited. Attempts to 
increase the predictive value of blood biomarkers with the combination of apparent 
prognostic markers, such as the ratio between T cell reinvigoration with tumor load 
reported by Huang et al.36, should not be considered for future treatment selection. Such 
combination biomarkers with information on the likely course of disease (irrespective of 
treatment type) should be avoided because this dilutes the predictive value. 
Although patterns of the peripheral immunological response after treatment start 
in patients are generally specific for reactive tumors - with differences across ICIs but 
similarities across tumor types (NSCLC or melanoma) – previous reports about pre-
treatment patterns in peripheral blood are less consistent. Early on-treatment assessment 
of the immunological response have been shown to be more predictive.
Response to ICIs relies on tumor-immune interactions
The number of TILs, their spatial distribution and the state of effector T cells are found to 
be essential for an adequate immunological response after PD-1 inhibition65,71. A general 
increase in TILs could be determined with identified transcriptome signatures related 
to IFN-γ72,73, but this was determined by investigation of mixed immune and tumor cells 
together, which complicates correct interpretation. Therefore, single-cell techniques have 
been developed to further differentiate immune subsets with tumor or stroma tissue. 
Actually, tumor reactivity after PD-1 ICIs seems to be restricted to TIL subsets with high 
expression levels of PD-1 in NSCLC. These TIL subsets are highly distinctive based on its 
transcriptional signature, with the capacity of tumor recognition.64 In metastatic melanoma, 
two major phenotypes of CD8+ T cells were identified by single-cell transcriptomic 
analysis, of which the ratio of memory-like and exhausted CD8+ T cells was suggested to 
be related with response after PD-1 ICIs65.  Nevertheless, it was incompletely understood 
whether the T cell response to ICIs relies on pre-existing TILs, or on recruitment of TILs. 
And so, longitudinal single-cell transcriptome analysis of tumor samples were performed. 
In patients with advanced skin basal and squamous cell carcinoma, it was demonstrated 
that response to PD-1 inhibition depends on recruitment of novel T cell populations.74
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Table 2. Literature overview (updated) of proposed biomarkers for immune checkpoint 
inhibitors
Agent Tumor Marker Association Reference
Peripheral blood cells
PD-1 inhibitors NSCLC CD8+ T cellsa Positive Kamphorst et al., Proc Nal Acad Sci 
USA 201726
PD-1 inhibitors MM Tex/TB
b Positive Huang et al., Nature 201736




Tanizaki et al., J Thorac Oncol 
201828
PD-1 MM CD8+ T cellsc Positive Wieland et al., Cancer Immunol 
Immunother 201827
PD-1 MM Classical monocytes Positive Krieg et al., Nat Med 201837
Blood-based molecules
PD-1 or CTLA-4 
inhibitors
MM sPD-1/sPD-L1 Negative Zhou et al., Cancer Immunol Res 
201738
PD-1 inhibitors NSCLC sPD-L1 Negative Costantini et al., Oncoimmunology 
201839
PD-1 inhibitors MM IFN-γ, IL-6, IL-10 Positive Yamazaki et al., Cancer Sci 20176
PD-(L)1 inhibitors NSCLC dNLR/LDHd Negative* Mezquita et al., JAMA Oncol. 
201829
PD-1 inhibitors MM Exosomal PD-L1 Negative Chen et al., Nature 201840
PD-1 inhibitors NSCLC Exosomal PD-1 mRNA Positive Del Re et al., Br J Cancer 201841
ICIs (meta 
analysis)
NSCLC LDH Negative* Zhang et al., Cancer Med 201942
Chemo, ICIs NSCLC dNLR/LDH Negative* Kazandjian et al., JAMA Oncol 
201943
Tumor genome
PD-(L)1 inhibitors NSCLC EGFR or ALK mutation Negative Lee et al., J Thor Oncol 201744
PD-1 inhibitors MM and 
NSCLC
B2M mutation Negative Gettinger et al., Cancer Discov 
201745
PD-1 inhibitors MM and 
NSCLC
B2M mutation Negative Sade-Feldman et al., Nat Commun 
201746
PD-1 inhibitors Solid tumors MMR deficiency Positive Le et al., Science 201747
PD-1 and in 
combination with 
CTLA-4 inhibitors
NSCLC TMB Positive Hellman et al., N Engl J Med 201848
PD-1 and CTLA-4 
inhibitors
NSCLC TMB Positive Hellmann et al., Cancer Cell 201849
PD-(L)1 inhibitors NSCLC TMB Positive Rizvi et al., J Clin Oncol 201850
PD-L1 inhibitors NSCLC bTMB Positive Gandara et al., Nat Med 201851
PD-L1 inhibitors NSCLC bTMB Positive Rizvi et al., Ann Oncol 201852






Hellmann et al., Cancer Cell 201853
PD-(L)1 inhibitors NSCLC EGFR or ALK mutation Negative Rizvi et al., J Clin Oncol 201850
PD-(L)1 and/or 
CTLA-4 inhibitors
NSCLC MET mutation Negative Sabari et al., Ann Oncol 201854
PD-1 inhibitors NSCLC STK11 mutation Negative Skoulidis et al., Cancer Discov 
201855
PD-(L)1 inhibitors NSCLC bTMB Positive Wang et al., JAMA Oncol 201956
PD-(L)1 inhibitors NSCLC bTMB Positive Wang et al., J Thorac Oncol 202057
PD-(L)1 and/or 
CTLA-4 inhibitors
NSCLC NOTCH mutation Positive Zhang et al., Clin Cancer Res 
202058
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Tumor microenvironment
PD-L1 inhibitors NSCLC PD-L1 Positive Rittmeyer et al., Lancet 201759
CTLA-4 inhibitors MM PD-L1 on T cells Positive Jacquelot et al., Nat Commun 
201760
PD-1 or CTLA-4 
inhibitors
MM CD8+ TIL Positive Tietze et al. Eur J Cancer 201761
CTLA-4 inhibitors MM FOXP3+ and CD8+ Tcells 
in lymph nodes
Positive Balatoni et al., Cancer Immunol 
Immunother 201862




Duruisseaux et al. Lancet Respir 
Med 201863
PD-1 inhibitors NSCLC PD-1high TIL Positive Thommen et al., Nat Med 201864
PD-1 inhibitors MM TCF7+/TCF7- CD8+ TILf Positive Sade-Feldman et al., Cell 201865





Positive Gide et al., Cancer Cell 201966
CTLA-4 inhibitors MM and RCC CD20+ TILh Positive Helmink et al., Nature 202067
Commensal microbiotica
PD-1 inhibitors MM B longum, C aerofaciens, 
E faecium
Positive Matson et al., Science 201868
CTLA-4 inhibitors MM Faecalibacterium family Positive Chaput et al., Ann Oncol 201969
PD-1 inhibitors MM Ruminococcaceae family Positive Gopalakrishnan et al., Science 
201870
Updated overview from March 2017 of biomarkers with probable predictive value after immune 
checkpoint inhibitors for metastatic melanoma (MM) or non-small cell lung cancer (NSCLC). 
Abbreviations: absolute lymphocyte count (ALC), absolute neutrophil count (ANC), absolute 
eosinophil count (AEC), tumor infiltrating lymphocyte (TIL), soluble PD-1 or PD-L1 (sPD-1 or sPD-L1), 
interferon-γ (IFN-γ), mismatch repair (MMR), tumor mutation burden (TMB), blood TMB (bTMB). 
*Likely prognostic biomarkers. aProliferating CD8+ T cells early on-treatment, bthe ratio between 
peripheral exhausted-phenotype CD8+ T cells (Tex) and pretreatment tumor burden (TB) defined 
by the sum of diameters according to RECIST v1.1, cproliferating CD8+ T cells with an effector-like-
phenotype and co-stimulation CD28/CD27 was required for ICI response, dthe ratio between derived 
neutrophils/leukocytes minus neutrophils (dNLR) to lactate dehydrogenase (LDH), eEPIMMUNE 
DNA methylation profile of tumor tissue, fthe ratio between memory-like and exhausted CD8+ T 
cells based on TCF7 marker, geffector memory-phenotype T cells and activated T cell signatures 
(interferon-related genes) and htumor infiltrating B cells, presence of tertiary lymphoid structures 
and related exosomes.
While the role of T cell invigoration is well-studied and fairly established, other immune 
cell populations may also contribute to mechanisms of response or resistance of ICIs. 
Recently, higher expression of B cell markers have been determined in patients with 
melanoma or RCC who benefit from CTLA-4 ICIs. Histological examination demonstrated 
the localization of B cells within organized lymphoid aggregates.67 Interestingly, T cells 
with high expression levels of PD-1, reported to be essential for immunological response 
after PD-1 ICIs, are found to be in close proximity with B cell infiltrates and primarily 
produce CXCL1364. CXCL13 is a cytokine that mediates the formation of organized 
lymphoid aggregates in tumor75. These lines of evidence suggest that specific tumor-
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associated T cells initiate the formation of organized lymphoid aggregates in patients with 
immunological response after ICIs. However, its precise role remains to be elucidated.
Need for prospective evidence and further biological understanding of 
blood-based molecules such as exosomes
Serum LDH was suggested to be a negative predictive biomarker for survival after ICIs 
in NSCLC42. However, this relationship has also been determined for chemotherapy, and 
is likely prognostic35,76-78, as discussed for melanoma in the Introduction of this thesis. 
Accumulating evidence taking LDH and the neutrophil-to-lymphocyte ratio (NLR) into 
account demonstrate only prognostic value. Here, a pre-treatment index of NLR and 
LDH was significantly associated with better survival in patients with NSCLC who were 
treated with ICIs, irrespective of treatment type28,43,79-81. On the other hand, blood-based 
molecules in the PD-1 pathway have also been related to ICI efficacy. Patients with 
higher levels of serum soluble PD-L1 are associated with poorer response to PD-1 and 
CTLA-4 ICIs38,39, which was preliminarily suggested to be derived from alternate splicing 
activities and tumor cell death. Moreover, a subtype of extracellular vesicles, known as 
exosomes, are suggested to play a role in intercellular communication82. Higher protein 
levels of PD-L1 in exosomes are proposed to be associated with response to PD-1 ICIs in 
metastatic melanoma40, while a decrease of exosomal PD-1 mRNA was demonstrated to 
be associated to therapy response in NSCLC. Although these markers are closely linked 
to known immunotherapy pathways, the source and role in cancer of soluble/exosomal 
PD-L1 are largely unknown. 
The prospect of the tumor (epi)genetics to predict response after ICIs
Advances have been made in further understanding the role of tumor genetics in 
response and resistance mechanisms of ICIs. After March 2017, TMB has been of interest 
in particular. TMB was reported to have a similar test performance as PD-L183 and may 
independently predict response to ICIs, which has the potential to combine with other 
biomarkers improve prediction (Chapter 7). Although the application of TMB as predictive 
biomarker is debated because of some negative prospective trials, most clinical studies 
demonstrate that tumor or blood-based TMB are positively associated with better clinical 
outcome after PD-(L)1 ICIs in NSCLC and melanoma48-52,56,57,84, which may be explained by 
its association with tumor immunogenicity.
Retrospective work has shown that TP53/KRAS co-mutation is related with better clinical 
outcome after ICIs85,86. KRAS-mutated NSCLC is generally smoking-related, effects DNA 
damage repair (DDR) mechanisms and correlate with higher TMB87, and may explain the 
positive relationship of KRAS mutations with ICI response. On the contrary, mutations 
related to reduced antigen presentation were consistently related to ICI resistance45,46. The 
effect of specific genetic alterations in EGFR or ALK  have been related to worse clinical 
outcome after ICIs in NSCLC44,50, particularly when compared with alternative treatment 
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options such as tyrosine kinase inhibitors with superior survival outcomes. Data about 
other targetable mutations is insufficiently available but suggests that these patients are 
generally less likely to respond to ICIs. For example, patients with MET exon 14 mutated 
NSCLC express PD-L1 but have significant lower TMB compared to unselected patients54. 
Tumors with EGFR, ALK or MET oncogenic drivers are generally associated with younger 
age of cancer onset and with never-smoking88. Hence, these tumors have co-occurrence 
of lower TMB and are probably related to lower number of tumor antigens that can be 
recognized by cytotoxic T cells, which are considered as less immunogenic tumors. 
Recently, STK11 or KEAP1 mutated NSCLC was associated with worse clinical outcome 
after PD-155 or PD-1/CTLA-4 ICIs53, which was initially suggested to reflect ICI resistance 
mechanisms. However, a significant proportion of NSCLC patients with STK11 or KEAP1 
mutations do benefit from PD-1 inhibition (AACR Annual Meeting 2020)89 and those 
genetic alterations have been proposed to be prognostic, not predictive, in advanced 
NSCLC90. 
NOTCH mutations were reported as a robust predictive biomarker of ICIs in NSCLC. Here, 
deleterious NOTCH mutations were related with better clinical outcome after ICIs in 
four independent NSCLC cohorts (EGFR/ALK wild types), compared to non-deleterious 
mutations or wild type, which could not be determined after chemotherapy58. Although 
TMB was higher in both non- and deleterious NOTCH mutations, the predictive value seems 
to rely on higher transcription of genes related to DDR, suggesting more mutagenesis in 
tumors with deleterious NOTCH mutations. 
Interestingly, genome-wide epigenetic profiling can be used for the development of 
predictive biomarkers of complex traits, such as smoking behaviour91. Here, a DNA 
methylation signature has been developed and validated to predict survival after 
PD-1 ICIs in NSCLC, which could not be determined in patients who did not receive 
immunotherapy63. 
Taken together, determination of the TMB, as well as specific genetic defects, hold great 
promise for prediction of response after ICIs. While STK11 or KEAP1 mutations may only 
have prognostic value, the exact mechanism need to clarified of other mutations that have 
predictive value. A crucial role is speculated for DDR pathway, but it is unknown whether 
the reported relationship of genetic alterations in KRAS, EGFR, ALK or MET  are linked 
to distinct mechanisms of ICI response or can just be explained by their link with TMB. 
Importantly, novel insights in tumor epigenetics do not only demonstrate the feasibility 
of a DNA methylation signature as a predictive biomarker, but also provides insight in the 
epigenetic landscape which may serve as a target for novel therapies. 
Commensal gut microbiome relate to response after ICIs
The potential of fecal microbial transplantation to affect the antitumor effects of ICIs has 
determined in mice models92, however, former research in human has only determined 
associations between variable commensal microbiome and clinical outcome of ICIs68-70. 
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Even more, a retrospective analysis of two randomized trials demonstrates reduced OS 
of ICIs when antibiotics are used at time of initiation in advanced NSCLC, which was less 
pronounced in the docetaxel group93. As antibiotic use is known to impact distinct gut 
bacteria, the findings suggest a causal relationship, but remain to be clarified in future 
studies.
Towards robust treatment selection
For robust treatment selection, we believe that several key factors, affecting the immune 
response after ICIs, should be combined in a prediction model. Such a predictive model 
would outperform individual biomarkers (e.g. PD-L1 expression in tumor tissue or TMB) and 
add to current prognostic tools (e.g. TNM cancer staging94). Importantly, the integration 
of blood-based biomarkers, patient characteristics and imaging, being minimal-invasive, 
has advantages over tissue-based biomarkers. However, considerable hurdles must be 
overcome for implementation of rapid guidance for physicians in clinical decision making. 
Firstly, a predictive model requires a continuous process of model update and re-
evaluating as knowledge increases, and would have profound implications in the clinics. 
Although randomized controlled trials with sufficient power would still be needed to 
endorse the efficacy of novel (combination) treatments, the continuous evaluation and 
updating of a prediction model would be performed in the real-world setting, requiring 
larger trials with appropriate size, ideally being cluster-randomized studies known as 
impact studies95. Academic and peripheral medical centers should collaborate closely to 
collect and share patient data to re-evaluate the prediction model in the immunotherapy 
setting, particularly because the field is rapidly moving with the registration of novel 
(combination) treatments or treatment sequences. Secondly, particularly in real-world 
clinical setting, patients are more likely to lack one or more markers. Therefore, solutions 
to handle with missing data should be implicated. Thirdly, while prediction models may 
be useful to aid in the treatment decisions, we should prevent that treatment algorithms 
emerge that define subgroup indications for very similar monoclonal antibodies. This 
has previously led to less rational treatment algorithms for the second line ICI treatment 
of patients with advanced NSCLC, with different subgroup indications for monoclonal 
antibodies directed to the same immune checkpoint (e.g. pembrolizumab or nivolumab 
as second line treatment for advanced-stage IV NSCLC in palliative setting). Instead, it 
should assist the physician to select the right (combination) treatment or treatment 
sequence for the right patient. Lastly, as examined by Kappen et al.95, it is essential that 
physicians are informed about the underlying assumptions of the model. In this immune-
oncology setting, questions should be addressed, such as what parameters are included 
in the model and the underlying rationale. In that way, physicians prescribing ICIs would 
understand better how it may affect their patients.
Hence, a future predictive model for ICI response may meet the requirements as described 
above. Importantly, the development of a predictive model should rely on OS or robust 
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response evaluation, which can be supported by dynamic early on-treatment biomarkers 
or tumor growth dynamics. The inclusion of parameters that reflect the likely course of 
disease should be avoided, as it dilutes the predictive value. Based on our own findings 
and previous research, it should include information about tumor intrinsic factors, the 
TME and the host immunity apart from the PK of ICIs. Although several knowledge gaps 
are still present, precise and accurate treatment selection for ICIs is within reach for the 
clinic.
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NEDERLANDSE SAMENVATTING
Immunotherapie is een nieuwe methode van anti-kanker behandeling en neemt de 
laatste jaren een steeds belangrijkere plek in bij de behandeling van verschillende 
soorten tumoren. Immuun checkpoint remmers zijn een vorm van immunotherapie 
en hebben als doel om de tolerantie van het immuunsysteem (afweersysteem) naar 
tumorcellen te doorbreken. Hierdoor worden tumorcellen weer herkend en opgeruimd 
door het eigen lichaam. Hoewel de geregistreerde immuun checkpoint remmers een 
overlevingsvoordeel oplevert vergeleken met alternatieve therapie zoals chemotherapie, 
reageert maar een deel van de patiënten goed op deze vorm van therapie. Daarnaast 
heeft helaas een deel van de patiënten bijwerkingen, welke het resultaat zijn van een 
overactief en ontremd immuunsysteem. De centrale vraagstelling in dit proefschrift is 
om de anti-kanker behandeling met immuun checkpoint remmers te personaliseren. 
Oftewel, om de juiste patiënt op de juiste manier te behandelen. Hierbij is er ten eerste 
gekeken naar de farmacokinetiek van patiënten met gemetastaseerde (uitgezaaide) 
kanker. De farmacokinetiek omschrijft hoe een geneesmiddel zich in patiënten gedraagt 
en hoe het verschil tussen patiënten kan worden verklaard. Daarnaast beschrijft dit 
proefschrift verschillende onderzoeken naar de gerichte behandeling bij patiënten met 
gemetastaseerde longkanker en melanoom, dus hoe de juiste patiënt geselecteerd kan 
worden voor de juiste behandeling. Hierbij wordt ook een literatuuroverzicht gegeven 
over de belangrijkste ontwikkelingen (Hoofdstuk 1 en 17).
Immuun checkpoint remmers worden gegeven via een intraveneus infuus, waarna het 
middel in de bloedcirculatie terecht komt en langzaam de bloedspiegel in de tijd zal 
dalen tot een opvolgende gift. Aanvankelijk werd dit gedoseerd op basis van gewicht 
van de patiënt, en tegenwoordig wordt ook een vaste dosering gegeven. Bij de eerste 
registratiestudies werd gezien dat het geneesmiddel al bij een lage dosering in staat is 
om effectief te zijn, en dat het niet uitmaakt of een hogere dosis wordt gegeven. Ook 
blijken bijwerkingen niet vaker op te treden bij een hoge dosering dan bij een lagere 
dosering. Omdat de kosten van dit geneesmiddel niet gering zijn, zijn er bij een groot 
aantal patiënten die regulier worden behandeld opeenvolgende spiegelbepalingen 
gedaan om de farmacokinetiek te onderzoeken. In een eerste onderzoek werd er een 
relatie gevonden tussen de blootstelling (hoogte van de bloedspiegel) en de effectiviteit 
van immuun checkpoint remmers (Hoofdstuk 2), hoewel in registratiestudies nooit 
een dosis-respons relatie werd beschreven. We stellen dat dit mogelijk het gevolg is 
van veranderde afbraak van het geneesmiddel, waarvoor overtuigende bewijslast 
kwam bij patiënten die behandeld waren met verschillende doseringen. Om beter te 
snappen waar de verschillen tussen patiënten kunnen worden verklaard, hebben we 
een farmacokinetiek model ontwikkeld op basis van opeenvolgende spiegelbepalingen 
in honderden patiënten. De afbraak van het geneesmiddel bleek afhankelijk te zijn van 
specifieke patiëntkarakteristieken, mogelijk verwant aan kanker cachexie – een metabole 
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staat van afbraak door gevorderde ziekte (Hoofdstuk 3 en 4). Deze kennis kan worden 
gebruikt voor het optimaliseren van huidige dosis strategieën.  
Hoewel de invloed en oorzaak van kanker cachexie vooral gerelateerd zal zijn aan 
het natuurlijk beloop van de ziekte, zijn de vereiste onderdelen voor effectiviteit van 
immunotherapie waarschijnlijk 1) de eigenschappen van de tumorcellen, 2) zijn interactie 
met de omgeving en 3) de staat van het immuunsysteem van de patiënt. In dit proefschrift 
dragen we bij aan de groeiende kennis over de verschillende mechanismen die een 
rol spelen bij het wel of niet reageren op immunotherapie. Specifieke eiwitprofielen 
kunnen worden herkend in bloed van patiënten met gemetastaseerd longkanker die 
niet reageren op immunotherapie, welke gerelateerd lijken te zijn aan kanker cachexie 
(Hoofdstuk 5) en acute ontsteking (Hoofdstuk 6). Daarnaast leidt het combineren van 
verschillende eigenschappen van tumorcellen en zijn interactie met de omgeving, tot 
een betere voorspelling van de effectiviteit bij patiënten met longkanker (Hoofdstuk 
8). Wij combineerden hier een in de kliniek gebruikte voorspeller van effectiviteit na 
immunotherapie. Deze voorspeller combineert het percentage tumorcellen die positief 
zijn voor het eiwit (PD-L1) dat bindt aan de immuun checkpoint (PD-1) met de hoeveelheid 
mutaties van de tumorcellen, het vermogen om tumoreiwitten te presenteren (klassiek 
HLA) en de aanwezigheid van immuuncellen (CD8+ T cellen). In een bijkomende 
moleculaire analyse wordt het belang van verminderde werkzaamheid of afwezigheid 
van presentatie van eiwitten aan immuun cellen onderstreept, wat essentieel lijkt te zijn 
voor beide subtypes van longkanker (Hoofdstuk 10). Belangrijk hierbij is dat de interactie 
tussen tumorcellen en immuun cellen fysiek moet kunnen plaatsvinden. Deze interactie 
zou kunnen worden belemmerd door bindweefselvorming in de tumor, ook wel immuun-
exclusie genoemd. We zien dat dit proces gerelateerd is aan verminderde werkzaamheid 
van immunotherapie bij patiënten met gemetastaseerd melanoom, waarbij componenten 
hiervan in het bloed eenvoudig te meten zijn (Hoofdstuk 13). Bijdragend is ook de staat 
van het immuunsysteem in bloed (Hoofdstuk 11 en 14), en ook erfelijke eigenschappen 
van de patiënt (Hoofdstuk 9 en 12). Deze erfelijke eigenschappen lijken voor een groot 
deel overlappend te zijn voor de immuunrespons van verschillende tumortypes zoals 
longkanker of melanoom, maar er zijn ook zeker verschillen in de factoren die bepalend 
zijn voor het wel of niet reageren van immunotherapie. Wij zagen dat variaties in het DNA 
van patiënten in een gen, welke codeert voor een eiwit dat wordt uitgescheiden door 
immuun cellen om tumorcellen te doden (granzyme B), bepalend is voor de immuun 
respons bij zowel longkanker als melanoom na immunotherapie. Echter, de variatie in het 
DNA binnen een gen die codeert voor de immuun checkpoint PD-1 lijkt vooral een rol te 
spelen bij melanoom. 
Aanvullend vonden wij dat radiologische evaluatie van tumoren wordt bemoeilijkt door 
verschillende groei patronen welke kenmerkend zijn voor immunotherapie, vergeleken 
met alternatieve therapieën. Bij patiënten met gemetastaseerd longkanker is de 
ruimtelijke groei van tumoren voorafgaand en na start van de behandeling met immuun 
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checkpoint remmers bepaald (Hoofdstuk 7). Groeipatronen van tumoren rond de start 
blijken sterk gerelateerd aan overleving van patiënten na immunotherapie, met name 
bij de patiënten met sterk versnelde tumorgroei (hyperprogressie), en dragen bij aan de 
huidige methoden van responsevaluatie. Daarnaast constateerden wij dat het optreden 
van bijwerkingen van de schildklier na immunotherapie geassocieerd is met de vorming 
van antistoffen en de effectiviteit (Hoofdstuk 15). Het gevaar van een overactief en 
ontremd immuunsysteem na starten van immunotherapie is daarnaast vooral ook een 
bedreiging bij patiënten met een orgaantransplantatie. In een casus bespreking van 
een patiënt na niertransplantatie met gemetastaseerd melanoom beschreven we dit 
fenomeen en het meten van DNA van de donor in bloed leek hierbij geschikt voor vroege 
detectie van afstoting van de niertransplantatie (Hoofdstuk 16). 
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CURRICULUM VITAE
Daniël (Daan) Petrus Hurkmans werd geboren op 1 mei 1988 
in Castricum, Nederland. In 2006 voltooide hij de middelbare 
school, richting natuur en gezondheid, natuur en techniek, 
gymnasium met Latijn als klassieke taal aan het Bonhoeffer 
college te Castricum. In 2015 behaalde Daan de master 
Geneeskunde en Biomedische Wetenschappen (Cum Laude) 
aan Universiteit Leiden te Leiden, waarvan hij een jaar van 
zijn Biomedische Wetenschappen heeft volbracht aan 
het Karolinska Instituut en het Centrum voor Moleculaire 
Geneeskunde te Stockholm, Zweden. Aansluitend werkte hij 
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Geneeskunde, waarbij hij tevens werkzaam was voor de afdelingen Longgeneeskunde en 
Cardiologie. Er werd in 2017 gestart met het huidige promotieonderzoek aan de afdeling 
Interne Oncologie en de afdeling Longgeneeskunde en in het Erasmus Universitair MC, 
onder supervisie van prof. dr. A.H.J. Mathijssen en prof. dr. J.G.J.V. Aerts. Zijn onderzoek 
heeft zich gefocust op de farmacologie en personalisatie van immuun checkpoint 
remmers bij uitgezaaide vormen van kanker (m.n. melanoom, niet-kleincellig longkanker 
en niercelkanker). In 2019 ontving Daan een Merit Award van de European Society for 
Medical Oncology (ESMO) tijdens de jaarlijkse ESMO meeting in Barcelona, voor een 
studie binnen zijn proefschrift.
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